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ABSTRACT 
 
John Doyle Beard: Military Service, Deployments, and Exposures in Relation to Amyotrophic Lateral 
Sclerosis Etiology and Survival 
(Under the direction of Lawrence S. Engel) 
 
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease. Its importance as 
a public health problem lies in its generally rapid progression and often fatal outcome. ALS rates have 
been reported to be higher among U.S. military veterans, of which there are currently more than 21 
million, but the causal agents related to military service have not been identified. Previous studies were 
limited by reliance on mortality as a surrogate for incidence, a dearth of survival analyses, lack of clinical 
data, low statistical power, and limited exposure assessment. 
We used information from Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis, a study of 630 veteran ALS cases and 975 frequency-matched veteran controls to 1) 
evaluate associations between aspects of military service, deployments, and 40 exposures and ALS 
etiology; and 2) evaluate associations between aspects of military service, deployments, and 40 exposures 
and ALS survival. We used inverse probability weighting to evaluate and adjust for potential selection 
bias resulting from studying cases who likely represent long survivors and controls who may be different 
from U.S. military veterans at large. 
We observed several inverse associations between ALS and military service and deployment 
variables, but these may be because the control group was comprised of many career military veterans. 
We found lower odds of ALS among officers and higher odds among veterans whose longest deployment 
was World War II or the Korean War. There was no difference in the odds of ALS among veterans of the 
Air Force, Army, Marines, and Navy. ALS was more common among veterans who had direct contact 
iii 
with eight exposures incurred during deployment to four major wars. We did not find strong evidence that 
military-related factors were associated with shorter ALS survival. 
While we cannot exclude the effects of uncontrolled selection bias or confounding by non-
military exposures on our results, they provide clues to potential causal factors underlying the apparent 
increase of ALS among military veterans and, therefore, require replication and further study. 
Furthermore, the null association we found between military-related factors and ALS survival may be 
comforting to ALS cases who are military veterans.
iv 
To the veterans of the United States of America  
and to all those who grapple with amyotrophic lateral sclerosis every day.
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CHAPTER ONE: BACKGROUND1 
 
AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic lateral sclerosis (ALS), often called Lou Gehrig’s disease, is a debilitating 
neurodegenerative disease that involves motor neuron loss in the central nervous system (1-3). 
Specifically, motor neurons die in the brain stem and spinal cord (lower motor neurons) and in the 
cerebral cortex (upper motor neurons) (1-3). Individuals with ALS comprise more than 90% of 
individuals with motor neuron disease (MND); in the United Kingdom the term MND is used for ALS (1-
3). A diagnosis of ALS requires both upper and lower motor neuron involvement (1-3). About two-thirds 
of individuals with ALS have a spinal form, symptoms of which include muscle wasting and spasticity, 
progressive weakness, motor dysfunction, and paralysis (1-3). Most remaining individuals with ALS have 
a bulbar form, symptoms of which include difficulty speaking or swallowing, excessive drooling, and 
facial weakness, although limb symptoms usually appear within one to two years of bulbar symptoms in 
these individuals (1-3). Some forms of ALS also involve cognitive changes that resemble frontotemporal 
dementia (1-3). 
ALS is rare in the general population; incidence is about two per 100,000 per year and prevalence 
is about six per 100,000 population (1-3). Nevertheless, 2.7 of every 1,000 deaths in the United States 
(U.S.) were due to ALS in 2011 (4). In addition, the effect of motor neuron loss in the daily lives of 
individuals with ALS is dramatic and may include an inability to move, eat, talk, or complete other 
activities of daily living (1). ALS cases are unable to work, have expensive health bills, require intensive 
care, and are often depressed (2, 3). 
1Except for the addition of the section titled “Specific exposures and ALS in non-military populations”, this chapter 
is an almost verbatim copy of Beard JD, Kamel F. Military service, deployments, and exposures in relation to 
amyotrophic lateral sclerosis etiology and survival. Epidemiol Rev. 2015;37(1):55-70, and appears by permission of 
the Society for Epidemiologic Research. 
1 
                                                          
Half of individuals with ALS die within three years of diagnosis, but 4% survive at least ten years 
after diagnosis (1-3). The most common cause of death among ALS cases is respiratory failure (2). 
Riluzole is the only ALS therapy approved by the U.S. Food and Drug Administration, but a recent meta-
analysis found it extends survival by only two to three months (5). Treatments including physical therapy 
can relieve ALS symptoms (2, 3), but explanations for the extremely variable survival of ALS cases, 
particularly explanations that could lead to interventions or therapies, are sorely needed. 
About 90-95% of ALS is classified as sporadic and 5-10% is classified as familial (1-3), based on 
family history. Most familial forms are due to polymorphisms in genes for Cu/Zn superoxide dismutase-1 
(SOD1), TAR DNA binding protein 43 (TARDP), fused in sarcoma (FUS), or ubiquilin 2 (UBQLN2) or 
an expansion of the intronic hexanucleotide repeat sequence in chromosome 9 open reading frame 72 
(C9ORF72) (1, 6-11). Established risk factors for sporadic ALS incidence include increasing age, male 
gender, and cigarette smoking (1-3, 12). Other possible risk factors have been investigated (1-3, 13-15), 
but none has been consistently associated with sporadic ALS. 
Factors consistently associated with shorter survival after ALS diagnosis include older age at 
diagnosis (16-24), bulbar onset (17-22, 24-26), clinical features (e.g., disease progression/disability status, 
respiratory function) (17-19, 21, 23, 27, 28), time between symptom onset and diagnosis (17-19, 24-26, 
29) and diagnosis category (definite, probable, etc.) (17). 
MILITARY-RELATED FACTORS AND ALS 
More than 21 million Americans, or about one in 11 of those at least 18 years-old, have served in 
the military in their lifetimes (30). Among American men, who comprise 92% of U.S. military veterans 
(31), this number jumps to about one in six (30). U.S. military personnel are exposed to a number of 
factors encountered in the unique circumstances of their jobs that may lead to health problems later in life 
(32). For example, U.S. military personnel are exposed to intensive physical activity, lifestyle factors 
(cigarette smoking, alcohol consumption), physical trauma (combat-related, fractures), emotional trauma 
(psychological), transmissible agents (viruses), toxic substances (lead, pesticides), and other 
environmental toxicants and exposures (33, 34). Concern regarding potential health effects of U.S. 
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military service is demonstrated by the fact that typing “military OR veterans OR soldiers” into the search 
engine on the Institute of Medicine (IOM) website returns 103 reports published after 1998 (35). 
Unfortunately, one of the health consequences suspected to be associated with U.S. military service is 
ALS (34). 
An association between military-related factors and ALS was first proposed in connection with 
the 1990-1991 Persian Gulf War (Gulf War). Six cohort studies on this topic were published between 
2000 and 2005 (36-41). Four reported an increased rate of ALS incidence, hospitalization, or mortality 
among U.S. military veterans deployed to the Gulf War compared to veterans deployed to other areas (36-
38, 40), but one did not (39). Another study reported the ALS mortality rate was higher among U.S. men 
who reported military service compared to men who did not (41). In response to these studies, the U.S. 
Department of Veterans Affairs (VA) requested that the IOM establish a committee to “…review, 
evaluate, and summarize the scientific literature on ALS in veterans. If an association exists between 
military service and the development of ALS, then the committee might make recommendations that will 
help to identify risk factors” (34, p. 9). 
The IOM report, published in 2006, concluded that there was “limited and suggestive evidence of 
an association between military service and later development of ALS” (34, p. 3). The IOM report also 
recommended that further studies be conducted to “elucidate ALS risk factors relevant to military 
service” (34, p. 4). Several studies of the association between military-related factors and ALS incidence, 
prevalence, mortality, or survival were not included in the IOM report, and several new studies on this 
topic have been published since its publication. Therefore, we conducted a review of the literature with 
the goal of examining the weight of evidence for associations between military service, deployments, and 
exposures and ALS/MND etiology and survival (we combined ALS and MND together because studies 
often have not distinguished them). We also aimed to provide recommendations for future studies of these 
relationships. 
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MATERIALS AND METHODS 
 We conducted a search of journal articles that used human subjects and were published in English 
through the end of 2013 using the PubMed and Web of Science databases. Specifically, we used the 
following search terms in both databases: (“amyotrophic lateral sclerosis” OR “motor neuron disease” OR 
“motor neurone disease” OR “motor neuron diseases” OR “motor neurone diseases” OR motorneuron OR 
motorneurone OR ALS OR MND) AND (militar* OR “armed forces” OR soldier OR soldiers OR veteran 
OR veterans OR occupation OR occupat* OR professional OR profess* OR “world war” OR “korean 
war” OR “vietnam war” OR “gulf war” OR deploy*) (Figure 1.1). After removing duplicates, we 
excluded articles that did not study ALS/MND etiology or survival as the outcome or military service, 
deployments, or exposures as the exposure. We also excluded articles for other reasons (reviews, 
commentaries, case reports [no comparison group], animal studies, cell cultures, ALS clusters or possible 
clusters, familial ALS, etc.) (Figure 1.1). Finally, we identified relevant articles and abstracts from 
reference lists of articles found by our searches of the aforementioned databases or from other sources. 
After identifying articles that met our selection and inclusion criteria, we extracted the following 
information: study design, study population, sample size, outcome, exposure, matching or adjustment 
factors, statistical analysis, and result. We then categorized articles into (1) cohort studies of ALS/MND 
etiology, (2) case-control studies of ALS/MND etiology, (3) cross-sectional studies of ALS/MND 
etiology, and (4) cohort studies of ALS/MND survival. 
RESULTS 
We identified 567 and 405 articles by searching PubMed and Web of Science, respectively, for a 
total of 972 (Figure 1.1). After removing 237 duplicates, we excluded 712 additional articles for reasons 
shown in Figure 1.1. After adding seven articles and abstracts from other sources, we included a total of 
30 articles and abstracts in our review (Figure 1.1). Two cohort studies (42, 43), four case-control studies 
(44-47), and one cross-sectional study (48) did not have at least five exposed cases or controls or did not 
report an effect measure estimate or p-value for the association(s) of interest. We did not consider these 
studies informative, so we focused the remainder of our review on the other 23 articles and abstracts. For 
4 
completeness, however, we present extracted information from these seven studies in Appendix A, Table 
A.1. 
Cohort studies of ALS/MND etiology 
There have been 11 cohort studies of ALS/MND etiology and military-related factors (Table 1.1). 
The association between military service overall and ALS/MND etiology has been evaluated by two 
cohort studies (41, 49). The first was a prospective study of men conducted in the American Cancer 
Society’s Cancer Prevention Study II cohort (41). Using information on 217 cases among 281,874 U.S. 
military veterans and 63 cases among 126,414 non-veterans followed up to 10 years, this study reported 
that the ALS mortality rate among men who reported military service was 1.53 (95% confidence interval 
[CI] = 1.12, 2.09) times that of men who did not (41). This study also found that, compared to men who 
did not serve in the military, the ALS mortality rate was elevated for individuals who served in every 
branch except the Marine Corps (41). The lower rate among Marines, however, was based on only four 
ALS deaths (41). The ALS mortality rate was increased in every quintile of years of service, but the 
increase was not monotonic and the linear trend test was not significant (p = 0.26) (41). In addition, the 
ALS mortality rate was elevated for men who served during every time period of service evaluated, 
although service during the time of World War II was the only time period in which the elevated rate was 
statistically significant (41). Finally, the ALS mortality rate increased with increasing numbers of wars 
during the time of military service (ptrend = 0.004 when the reference group, men who did not report 
military service, was included in the test, but ptrend = 0.29 when it was not) (41). These results should be 
interpreted cautiously, however, because researchers did not have information on whether or not men who 
reported military service were actually deployed to the wars of interest (World War I, World War II, the 
Korean War, the Vietnam War), so they inferred it based on time periods of service (41).  
The second study that considered military service overall in relation to ALS/MND etiology was a 
retrospective cohort study of French military personnel, including 69 male and four female ALS cases, 
identified from the French National Military Health Care Fund, 1991-2007 (49). The overall ALS 
incidence rate among male active duty military personnel, 1.7 in 100,000 per year in 2007, was lower 
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than that in the general population, but age-specific rates were higher among the 40-44 and 50-54 age 
groups (1.9 and 5.1 in 100,000 per year in 2007, respectively) (49). 
Military deployment to the Gulf War has been evaluated in relation to ALS/MND etiology by 
seven cohort studies (36-40, 50, 51) (Table 1.1). The first of these used U.S. Department of Defense 
Defense Manpower Data Center (DMDC) deployment information for U.S. active-duty service personnel 
and found that 551,841 personnel deployed to the Gulf War were 1.66 (95% CI: 0.62, 4.44) times as 
likely to experience an ALS hospitalization during nine years of follow-up as 1,478,704 non-deployed 
personnel in the military during the same era (40). This result, however, was based on only six ALS 
hospitalizations among deployed personnel and 12 ALS hospitalizations among non-deployed personnel 
(40). The second study, which also used DMDC deployment information, reported that, during seven 
years of follow-up, 621,902 U.S. military veterans deployed to the Gulf War had an ALS mortality rate 
0.59 (95% CI: 0.21, 1.66) times that of a stratified random sample of 746,248 veterans who were in the 
military at that time, but who were not deployed to the Gulf War (39). The analysis was repeated after an 
additional six years of follow-up, and the updated hazard ratio, based on 23 deployed cases and 38 non-
deployed cases, was 0.96 (95% CI: 0.56, 1.62) (50). Although information on military rank, branch of 
service, deployment date, and type of service unit was available, associations between these factors and 
ALS mortality rates were not reported in either analysis (39, 50). 
Observed and expected incidence rates of ALS by age 45 were compared in another study of 
695,000 U.S. military veterans of the Gulf War followed for eight years (37). Military service and 
deployment to the Gulf War was confirmed via a non-military online database (37). Age-adjusted 
standardized morbidity ratios, using the entire U.S. male population as the standard, were calculated for 
two separate time intervals to allow a lag from exposure to onset of ALS symptoms. For 1991-1994, 
based on four confirmed cases, the age-adjusted standardized morbidity ratio was 0.94 (95% CI: 0.26, 
2.41) (37). The age-adjusted standardized morbidity ratio for 1995-1998, based on 13 confirmed cases, 
increased to 2.27 (95% CI: 1.27, 3.88) (37). A study of cumulative incidence rates of ALS over ten years, 
which used DMDC deployment information, found that 696,118 veterans deployed to the Gulf War were 
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1.92 (95% CI: 1.29, 2.84) times as likely to be diagnosed with ALS as 1,786,215 veterans not deployed 
but in the military during the same era (38). Although information was available, associations between 
ALS rates and branch of service or type of service unit were not reported in this study (38). A follow-up 
study of the same cohort aimed to evaluate the effect on the estimated risk ratio (RR) of probable 
underascertainment of ALS cases among veterans who were not deployed to the Gulf War (36). The 
underascertainment-corrected RR decreased slightly to 1.77 (lower 95% confidence limit: 1.21) (36). A 
second follow-up study of the same cohort reported that deployment to the Gulf War was associated with 
increased ALS incidence only during the first 10 years after the war and the highest incidence rate 
occurred in 1996 (51). 
Associations between specific military exposures and ALS/MND etiology have been evaluated 
by three cohort studies (50, 52, 53) (Table 1.1), one of which studied past experience as a prisoner of war 
(52). This study used records from the United Kingdom War Pensions Agency to form a cohort of 11,314 
British men who were prisoners of war in Japan and then followed them for 46 years (52). Using the 
entire English and Welsh male populations as the standard, the standardized mortality ratio for MND 
death was 0.62 (95% CI: 0.31, 1.11) and the proportional mortality ratio was 0.73 (95% CI: 0.36, 1.30) 
(52). A spatial analysis of the deployment locations, obtained from the DMDC, of 41 ALS cases who 
were veterans of the Gulf War reported a location about 500 km southeast of Khamisiyah, Iraq, where 
U.S. military troops destroyed munitions warehouses, bunkers, and rockets that contained nerve agents, 
had the highest spatial risk of ALS (posterior probability = 0.91, incidence rate ratio = 2.01) of any 
location evaluated (53). This study also reported significantly lower ALS incidence for members of the 
Marine Corps compared to members of the Army (incidence rate ratio = 0.2; 95% credible interval: 0.03, 
0.9) (53), but no overall test of the association between branch of service and ALS incidence was 
reported. Veterans potentially exposed to nerve/chemical warfare agents in and around Khamisiyah, Iraq, 
determined via a U.S. Department of Defense dispersion model (54), were 1.7 (95% credible interval: 0.7, 
3.7) times as likely as unexposed veterans to later develop ALS in the same study (53). Another study of 
621,902 U.S. military veterans deployed to the Gulf War used the same U.S. Department of Defense 
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dispersion model (54) and reported that potential exposure to chemical warfare agents in and around 
Khamisiyah, Iraq, was not associated with ALS mortality after 13 years of follow-up (50). This second 
study also reported no association between potential exposure to oil well fire smoke during Gulf War 
deployment, determined via U.S. Department of Defense data (55), and ALS mortality (50). 
Case-control studies of ALS/MND etiology 
Relationships between military service and ALS/MND etiology have been evaluated in four case-
control studies (14, 26, 56, 57) (Table 1.2). One study based on death certificates of 4,745 cases and 
14,235 matched controls in Texas reported an odds ratio (OR) of 2.28 (95% CI: 1.34, 3.87) for the 
association between veteran status and ALS/MND death among men, but an OR of 1.13 (95% CI: 0.77, 
1.67) for the same association among women (57). A significant inverse association between being a self-
reported male veteran and ALS (OR = 0.22; 95% CI: 0.09, 0.54) was found in a study of 95 cases and 106 
controls in Boston, Massachusetts (26). This study also reported a significant inverse association between 
being a male veteran who had performed active duty and ALS (OR = 0.23; 95% CI: 0.08, 0.62) (26). No 
association was found between self-reported branch of service and ALS in a study of 77 cases and 185 
controls in Rome, Italy (56). A study of 109 cases and 253 frequency-matched controls conducted in New 
England did not find an association between self-reported military service and ALS (OR = 1.2; 95% CI: 
0.7, 2.4) (14). Sub-grouping study participants by branch or duration of service or wartime service did not 
reveal notable variation in the association between military service and ALS (14). 
Other military-related factors have been evaluated in relation to ALS/MND etiology in five case-
control studies (58-61) (Table 1.2). No associations (p > 0.05) were found between ALS deaths and 
branch of service, arm of service within the Army, decorations and awards, highest rank attained, duration 
of service, location of any service overseas, campaign credits, whether service extended to Korean 
conflict, immunizations during military service, military occupational specialties, or whether a prisoner of 
war, all of which were obtained from military records, in a study of 504 deceased U.S. World War II 
veteran cases and 504 matched living controls conducted from 1963-1967 (59). Two studies of Japanese 
veterans reported that being a self-reported war prisoner outside of Japan was not associated with MND 
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(males: RR = 0.96; p > 0.05) or MND death (males: RR = 0.94; p > 0.05; females: RR = 1.00; p > 0.05); 
one was conducted from 1965-1966 and included 712 MND deaths and 637 matched living controls; the 
other was conducted in 1973 and included 158 MND cases and 158 individually-matched controls (58). A 
study of 8 Gulf War veteran ALS cases, 28 civilian cases, and 70 matched civilian controls from the U.S., 
Great Britain, Australia, and the Netherlands reported that ALS cases (veterans and civilians together) 
were more likely to have evidence of systemic mycoplasmal infections (especially Mycoplasma 
fermentans) in blood than civilian controls (83% vs. 3%, p < 0.001) and that the occurrence of infections 
was higher in 8 ALS cases who were Gulf War veterans than in 28 civilian cases (100% vs. 79%) (61). 
Finally, 12 single nucleotide polymorphisms in the paraoxonase (PON) gene cluster did not modify the 
association between deployment to the Vietnam War (used as a surrogate for organophosphate exposure) 
and ALS in a study of 1,165 U.S. military veteran cases and 530 veteran controls (60). 
Cross-sectional studies of ALS/MND etiology 
The association between military service overall and ALS/MND etiology has been evaluated by 
one cross-sectional study (62) (Table 1.3). This study used information from death certificates for 1982-
1991 from 27 U.S. states and found a positive association (proportionate mortality ratio = 1.88, p < 0.05) 
between occupation as military personnel and MND death among individuals ages 15-55 (62). 
Cohort studies of ALS/MND survival 
Relationships between military service or deployments and ALS/MND survival or progression 
have been evaluated in four cohort studies (24, 26, 63, 64) (Table 1.4). A study of 961 veteran ALS cases 
and 2,571 non-veteran cases in the Clinical Assessment, Research and Education Program database, a 
non-military database of ALS patients from North America (65), reported no relationship between veteran 
status and ALS survival (63). A study of 95 cases in Boston, Massachusetts, reported that, after one year 
of follow-up, both being a male veteran and a male veteran who had performed active duty were 
associated with faster disease progression, measured by the ALS functional rating scale, and with 
declining respiratory function, measured by predicted % forced vital capacity (26). Another study found 
that ALS survival, defined as the time between onset of symptoms and death, beginning of ventilation, or 
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end of follow-up (October 2002), was significantly shorter (hazard ratio = 0.62; 95% CI: 0.40, 0.96) 
among 43 U.S. military veterans deployed to the Gulf War (median survival time: 40.2 months), defined 
using DMDC data, than among 66 veterans who were not deployed but who were in the military during 
the same era (median survival time: 57.0 months) (64). Finally, a study of 1,063 U.S. military veteran 
ALS cases, 603 of whom had died or begun ventilation by October 2006, reported that DMDC-defined 
deployment to the Vietnam War was associated with shorter survival after ALS diagnosis (hazard ratio = 
1.73, 95% CI: 1.36, 2.19), but ALS survival was not associated with cumulative years or branch of 
military service or deployment to the Korean or Gulf Wars (24). 
DISCUSSION 
The IOM report (34) concluded there were suggestive, although not conclusive, findings that 
ALS rates may be higher among U.S. veterans, currently numbering more than 21 million, compared to 
non-veterans (41), particularly among those deployed to the Gulf War (36-38, 40). We conducted a 
review of the relevant literature, incorporating new research published since the IOM report (34). Our 
review focused on studies of associations between military service, deployments, and exposures and 
ALS/MND etiology and survival. 
Associations between military service-related factors and ALS/MND etiology were evaluated by 
three cohort (41, 49, 53), five case-control (14, 26, 56, 57, 59), and one cross-sectional study (62). Six of 
these studies (two cohort, three case-control, one cross-sectional) evaluated military service overall and 
ALS/MND etiology; three reported positive (41, 57, 62), one reported a null (14), and two reported 
inverse associations (26, 49). These differences may be explained in part by limitations of study design, 
such as control selection, power, and sources of information on exposure and outcome. For example, one 
of the case-control studies that reported an inverse association, conducted from April 1998 to August 
2002 in Boston, Massachusetts, used non-blood related relatives of the cases (e.g., spouses), friends who 
accompanied the cases to the clinics, or unrelated persons at the clinics as controls (26). These controls 
were likely not representative of the exposure distribution in the source population giving rise to the 
cases, potentially biasing results. For example, the proportions of veterans among cases (mean age 54 
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years) and controls (mean age 53 years) were 8% and 24%, respectively (26). Only 6% of Boston 
residents ages 18 and older, however, were U.S. military veterans in 2000 (4% of residents ages 18-64 
and 20% of residents ages 65 and older were veterans) (66). The cohort study that reported an inverse 
association overall found positive associations with ALS incidence among the 40-44 and 50-54 age 
groups (49). This study identified military personnel from the French National Military Health Care Fund, 
so military personnel who retired, left the military for other reasons, or obtained health care elsewhere 
were not in the database (49). The study that reported a null association (OR = 1.2; 95% CI: 0.7, 2.4) was 
based on 109 ALS cases, only 24 of whom had served in the military (14), so perhaps the weak positive 
association was not statistically significant due to low power. For comparison, two of the three studies 
that reported positive associations had 217 (41) and 1,476 (57) exposed cases, respectively, although the 
third had only 27 exposed cases (62). Two of the studies with positive associations ascertained 
information on occupation from death certificates (57, 62), which likely resulted in non-differential 
misclassification and bias to the null (67, 68). Furthermore, one of these studies found a positive 
association with MND mortality only after restricting to individuals ages 15-55 years (62). The other of 
these two studies (57) was published only in abstract form, which makes it difficult to evaluate the 
robustness of the reported result.  
Use of ALS/MND mortality as a surrogate for incidence was a problem common to all three 
studies reporting positive associations with military service (41, 57, 62). This could result in non-
differential misclassification and bias toward the null if military service was not related to survival, or 
differential misclassification and bias either toward or away from the null if it was. A recent review of 
ALS mortality studies (69) stated that ALS/MND mortality can accurately reflect trends in incidence. 
This statement was based on two high-quality studies (70, 71), but neither study investigated the possible 
occurrence of bias when ALS/MND mortality is used to estimate measures of association between 
exposures and incidence, such as rate differences or ratios. Therefore, while suggestive of a positive 
association, the current literature is too limited to draw conclusions regarding a possible association 
between military service and ALS/MND etiology. If such an association exists, however, then it may be 
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age-specific (49, 62), but it does not appear to vary by branch, duration, or time period of service (14, 41, 
53, 56, 59). 
Relationships between military deployment-related factors and ALS/MND etiology were 
evaluated in eight cohort (36-41, 50, 51) and two case-control (14, 59) studies. Deployment to the Gulf 
War and ALS/MND etiology was evaluated in seven of the cohort studies. Five of these reported positive 
associations (36-38, 40, 51) and two did not (39, 50). Two studies (37, 40) that reported positive 
associations, however, were based on small numbers of exposed cases and controls. One of these (37) had 
additional limitations (e.g., military service was confirmed via a non-military online database, expected 
incidence rates were calculated in an unorthodox manner). The remaining five studies arose from two 
different VA research groups. The first of these groups published three studies (36, 38, 51) reporting a 
positive association between Gulf War deployment and ALS incidence. The other group published two 
studies which used ALS mortality data (39, 50) and found no association. Other features of the studies 
conducted by the two groups, such as design, population, and exposure assessment, were similar (36, 38, 
39, 50, 51). A limitation of the first study by the group using incidence data (38) was potential 
underascertainment of cases among veterans not deployed to the Gulf War (36). The second study by this 
group used capture-recapture methods to estimate the number of missing cases among the non-deployed 
and to correct the original analysis for this potential underascertainment (36). The new results were 
slightly attenuated relative to the first, but the positive association remained (36). Studies by the group 
using mortality data (39, 50) were limited by low power; these studies had 43% fewer cases than the 
incidence studies. In addition, using mortality instead of incidence data could have resulted in differential 
or non-differential misclassification and bias toward or away from the null (see above). Therefore, the 
truth probably lies somewhere in between the results of the two VA research groups: there may be a 
moderate association between Gulf War deployment and ALS/MND etiology, but it is likely not as strong 
as that reported by the three positive studies (36, 38, 51). No association with any other military 
deployment or deployment-related factor is apparent from published literature (14, 41, 59). 
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Associations between several military exposures and ALS/MND etiology were considered in 
three cohort (50, 52, 53) and five case-control (58-61). Nevertheless, there is currently not strong 
evidence that any particular military exposure is associated with ALS/MND etiology. The higher 
prevalence of systemic mycoplasmal infections among ALS cases (veterans and civilians together) 
relative to civilian controls and the higher prevalence of these infections among Gulf War veteran ALS 
cases compared to civilian cases (61) needs to be confirmed in other non-military populations with larger 
sample sizes. 
Two cohort studies of associations between military service and ALS/MND survival or 
progression found disparate results: one reported no association with survival (63) and the other reported 
a significant association with faster progression (26). The first of these studies (63), however, was 
published in abstract form only, which makes it difficult to evaluate the robustness of the reported result. 
The study that used progression as the outcome was not adjusted for age at diagnosis (26), which is one of 
the most consistently reported prognostic factors for ALS survival (16-24). Two other cohort studies of 
the association between Gulf War deployment and ALS survival found conflicting results: one found an 
elevated hazard ratio (64) and the other found no association (24). Both of these studies were plagued by 
immortal person-time bias, which occurs when follow-up time is counted as person-time at risk for an 
outcome even though that time occurs before the last event required to enter the risk set (72, 73). A likely 
explanation for the discrepancy in the results of the two studies is that the first—which found a positive 
association—was restricted to Gulf War-era veterans (64) whereas the other—with no association—
included non-Gulf War-era veterans in the comparison group (24). The latter also reported a positive 
association between Vietnam War deployment and ALS survival (24). Clearly, associations between 
military service or deployment and ALS survival need to be evaluated in other populations before 
conclusions can be drawn. 
Some overall conclusions can be made regarding limitations of previous studies of military 
service, deployments, and exposures and ALS etiology and survival. First, ALS mortality was used as the 
outcome in 8 of 21 (38%) etiology studies (39, 41, 50, 52, 57-59, 62), which makes it difficult to 
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determine if reported associations were with ALS incidence, survival after ALS diagnosis, or a mixture of 
the two (see above). Second, only 4 of 25 (16%) studies were formal survival analyses (24, 26, 63, 64), 
but immortal person-time bias was likely present in at least two of them (24, 64) and one other study (63) 
did not provide enough information to make this determination. Third, important clinical information, 
such as date of diagnosis, site of onset, respiratory function, etc., was used to sub-group ALS cases in 
only 2 of 21 (10%) etiology studies (26, 56). Fourth, 18 of 25 (72%) studies had 124 or fewer ALS cases 
(14, 26, 36-40, 49-53, 56, 58, 61, 64) and the number of exposed cases was 48 or fewer in all but one of 
these studies (it had 73) (49), so power to detect associations between military-related factors and ALS 
etiology or survival was often limited. Fifth, associations between ALS etiology or survival and specific 
aspects of military service or specific deployments or exposures were usually not evaluated (because the 
relevant information was not collected) or were evaluated in a limited way. For example, only 9 of 25 
(36%) studies evaluated associations between more than one military-related factor and ALS etiology or 
survival (14, 24, 26, 41, 49, 50, 53, 59) and only one of these studies examined more than five military-
related factors (it examined 11) (59). Exposure metrics were also often vague or defined differently 
among studies. Furthermore, information on exposure gradient was used to evaluate exposure-response 
relationships for at least one exposure in only 5 of 25 (25%) studies (14, 24, 41, 49, 59). Clearly, studies 
that address limitations of previous studies of military service, deployments, and exposures and ALS 
etiology and survival are needed. Studies that evaluate associations between extensive, hypothesis-driven 
lists of factors related to military service, deployments, and exposures and ALS etiology or survival 
would be particularly valuable. 
Specific exposures and ALS in non-military populations 
As pointed out in the IOM report (34), studies conducted in non-military populations may provide 
clues regarding factors that may be more generally associated with ALS etiology or survival and are also 
likely to be related to military service. For example, the IOM report lists intensive physical activity, 
lifestyle factors, trauma, transmissible agents, occupational toxicants, and environmental toxicants as 
potential risk factors for ALS etiology that are likely experienced by military populations (34). Only 
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previous studies of specific exposures which will be evaluated in relation to ALS etiology and survival in 
the current study (see Chapter 3 for more details) will be reviewed here. 
Chemicals. Chemicals in general were evaluated in relation to ALS in four non-military 
populations, although none of these studies specified the type of chemicals to which study participants 
were exposed. Case-control studies in Rome, Italy, Sweden, and Japan all reported no association 
between exposure to chemicals and ALS/MND (56, 58, 74). ALS cases did crafts using chemicals 
significantly more than controls in a twin study in Great Britain (75). 
 Pesticides. The relationship between ALS or ALS mortality and exposure to any pesticide or to 
certain pesticide classes (e.g., fungicides, herbicides, organochlorine insecticides [OC]) has been assessed 
among non-military populations frequently. A study of occupational groups and ALS mortality from 
1992-1998 in 22 U.S. states reported that while working in pest control was not associated with ALS 
mortality, working in farming occupations, particularly those involving exposure to pesticides, was 
associated with ALS mortality (76). Three case-control studies from three different decades evaluated the 
relationship between exposure to any pesticide and ALS with one reporting a statistically significant 
relationship (26) and the other two reporting non-significant, but elevated ORs (77, 78). Two recent meta-
analyses, one restricted to men (79), reported overall associations between any pesticide and ALS with 
summary ratio effect measure estimates close to two (79, 80). 
Pesticides/herbicides were not associated with ALS mortality in a prospective cohort study of 
approximately 1.2 million Americans (81), but two case-control studies in Australia reported significant 
relationships between pesticides/herbicides and ALS in both men and women (relationships were stronger 
among men) (82, 83). One of the Australian studies also observed an exposure-response relationship and 
reported stronger associations when considering industrial pesticide/herbicide exposure alone (82). 
Furthermore, extending the study to gene-environment interactions between the PON1 gene, which 
detoxifies organophosphate insecticides, and pesticides/herbicides identified interactions at the allele level 
for some promoter single nucleotide polymorphisms, but not at the genotype or haplotype level (84). 
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Pesticides/insecticides were not associated with ALS in a case-control study in Sweden, based on 
three exposed cases (74), but a case-control study in India found an association and it was stronger among 
women (85). Fertilizers, herbicides, and insecticides were all related to ALS in a case-control study in 
western Washington State, but only when exposure was assigned by a panel of industrial hygienists (as 
opposed to self-reported) (15). In contrast, a case-control study in New England did not find associations 
between ALS and fumigants, fungicides, herbicides, or insecticides, although fewer than five cases were 
exposed to fungicides or herbicides (14). An analysis conducted in the Agricultural Health Study, a 
prospective cohort study of approximately 90,000 pesticide applicators and spouses in Iowa and North 
Carolina, reported that pesticides as a group were not associated with ALS mortality (80). However, ORs 
for ALS mortality were elevated (i.e., ≥ 1.4) for use of fumigants, herbicides, OCs, and pyrethroid 
insecticides as well as the individual OCs aldrin, dieldrin, 1,1’-(2,2,2-Trichloroethylidene)bis[4-
chlorobenzene] (DDT), and toxaphene (80). The main limitation of this study, however, was that it 
involved only 41 cases (80). Finally, a positive association was found between manufacturing 2-(2,4-
dichlorophenoxy)acetic acid (2,4-D), a component of Agent Orange (43), and ALS mortality in a cohort 
of chemical workers, but this result was based on only three ALS deaths (86). 
Paint. The association between paint and ALS or ALS mortality has been examined in several 
studies. A mortality study in England and Wales observed a MND mortality rate among painters and 
decorators that was 25% higher than expected (87). Similarly, a mortality study conducted in 22 U.S. 
states from 1992-1998 reported that painters and sculptors had an ALS mortality rate that was (non-
significantly) 18% higher than expected (76). House painters were significantly more likely to have 
increased odds of MND in a case-control study in Italy (44), but not in a case-control study of ALS 
mortality conducted among Swedish men (88). Neither self-reported nor industrial hygienist assigned 
exposure to paint, varnish, or stain were associated with ALS in a case-control study in western 
Washington State (15). Similarly, a case-control study in New England reported no association between 
oil-based paints and ALS (14). A twin study in Great Britain reported a significantly higher occurrence of 
occupational paint exposure in ALS cases than controls (75). In a small (25 ALS cases, 25 neuromuscular 
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disease clinic controls, 25 community controls) pilot case-control study in Minnesota, the odds of ALS 
were 1.9 (95% CI = 0.5, 7.4) times higher among individuals involved in paint/pigment manufacture than 
among those not involved in paint/pigment manufacture (89). 
 Gas, diesel, etc. Associations between gas, diesel, and related exposures and ALS or ALS 
mortality have been assessed by several studies. A case-control study of ALS mortality conducted among 
Swedish men reported a positive association between working as petrol station assistants and ALS 
mortality, but this result was based on only two exposed cases (88). Gas, diesel fuel, or motor or fuel oil 
were not associated with ALS in a case-control study in New England (14), but petrol was (non-
significantly) positively associated with ALS in another case-control study in Sweden (74). Length/time 
of petrochemical exposure was (non-significantly) positively associated with ALS in a twin study in Great 
Britain (75). Neither diesel engine exhaust nor gasoline exhaust were associated with ALS mortality in a 
prospective cohort study of approximately 1.2 million Americans (81). 
Solvents, gases. Several studies have evaluated associations between solvents and ALS or ALS 
mortality, although the specific type of solvent to which study participants were exposed was usually not 
specified. Occupational groups exposed to solvents had a significantly higher ALS mortality rate in a U.S. 
mortality study conducted in 22 states from 1992-1998 (76). Chemicals/solvents were positively 
associated with ALS in case-control studies in Scotland (77) and Australia (82). Additionally, another 
case-control study in Australia reported that the positive association between chemicals/solvents and ALS 
was present among both men and women separately (83). Solvents were not associated with ALS or ALS 
mortality in case-control studies in the United Kingdom (90) or the U.S. (26). Chemicals/acids/solvents 
were not associated with ALS mortality in a prospective cohort study of approximately 1.2 million 
Americans (81). A small pilot case-control study in Minnesota reported an OR for ALS in association 
with organic solvents was 1.2 (95% CI = 0.4, 3.7) (89). Solvents were positively associated with ALS in a 
case-control study in western Washington State, but only when exposure was self-reported (as opposed to 
being assigned by a panel of industrial hygienists) (15). Case-control studies in New England and Sweden 
reported no association between solvents and ALS (14, 74). A case-control study of gene-environment 
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interactions in Australia reported that only one glutathione synthetase haplotype interacted with 
chemicals/solvents to increase the risk of ALS (91). ALS was significantly positively associated with 
occupational exposures to gases in a case-control study in Japan (58). 
Ionizing radiation. Exposure to ionizing radiation has been evaluated in relation to ALS or ALS 
mortality in non-military populations. A study found that MND mortality rates increased steadily from 
1950-1990 in most industrialized countries (92, 93). In Japan, however, MND rates increased sharply 
from 1950-1963, decreased sharply from 1963-1975, and then increased steadily from 1975-1990 (92, 
93). A follow-up study found that the unusual pattern of MND mortality rates in Japan from 1950-1990 
correlated strongly with the pattern of radioactive fallout released by atmospheric weapons testing in the 
Pacific during the same time period (93). A prospective cohort study of approximately 1.2 million 
Americans reported that the radio/dental/MD/x-ray/laboratory technician occupation was significantly 
positively associated with ALS mortality among men, but not among women (94). A different analysis 
conducted in the same cohort reported that exposure to x-rays/radiation was not associated with ALS 
mortality (81). 
Electromagnetic radiation. A mortality analysis conducted among commercial pilots and 
navigators from 1984-1991 using data from 24 U.S. states found a significantly higher MND mortality 
rate among this group than expected (95). The authors suggest this result could be due to exposure to 
cosmic radiation and/or magnetic fields generated by the aircraft’s electrical system (95). A recent meta-
analysis reported a weak overall association between occupational exposure to extremely low-frequency 
magnetic fields and ALS among studies that assessed exposure via occupational titles, but not among 
studies that used actual magnetic field measurements (96). 
Vaccinations. A case-control study in the U.S. did not find an association between swine flu 
vaccination and ALS overall or among men and women separately (97). Similarly, another case-control 
study in the U.S. reported no association between polio vaccination and ALS (26). In addition, polio 
vaccination was not associated with changes in disease progression or respiratory function after one year 
of follow-up in a cohort study of 95 ALS cases in the U.S. (26).  
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Mixed exposures. A case-control study in Rome, Italy, reported no association between toxic 
agents and ALS (56). A positive association between toxicant exposure (including pesticides, lead, 
solvents, and miscellaneous toxicant, evaluated as a group) and ALS was found in a case-control study in 
the U.S. (26). A cohort study of 95 ALS cases in the U.S. reported that toxicant exposure was not 
associated with changes in disease progression or respiratory function after one year of follow-up (26). 
The Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis 
(GENEVA) Study.  
The request for the IOM to review the six cohort studies published between 2000 and 2005 (36-
41) was initiated by the VA (34). In addition, the VA established a National Registry of Veterans with 
ALS (Registry) (98, 99), which enrolled approximately 2,000 living veteran cases from April 2003 to 
September 2007. The Registry (98, 99) was established with the goal to identify and enroll all living U.S. 
military veterans with ALS, follow their health and disease progression over time, collect information that 
could be used for epidemiological studies of ALS, and provide a way to inform veterans with ALS about 
clinical trials for which they may be eligible (98, 100).  
Soon after veterans with ALS began to enroll in the Registry, researchers at Duke University 
(Durham, North Carolina), in collaboration with the VA, began enrolling cases from the Registry into the 
Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis (GENEVA) study, 
a case-control study of 630 cases from the Registry and 975 controls identified via VA databases and 
frequency-matched to cases on age and use of the VA health care system (100). The goal of the GENEVA 
study is to evaluate associations between ALS and environmental factors, genetic susceptibility, and their 
interactions (100).  
Several of the limitations of previous studies of military service, deployments, and exposures and 
ALS etiology and survival outlined above can be addressed using data from the GENEVA study. 
Specifically, the GENEVA study can be used for both etiological and survival research because of the 
following features. Living cases were identified via the Registry and ALS diagnoses were confirmed via 
medical record review (100). Important and high quality clinical information, such as date of diagnosis, 
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site of onset, respiratory function, etc., is also available. In addition, controls were identified via VA 
databases and frequency-matched to cases on age and use of the VA health care system (100). 
Information on the vital status of ALS cases is current through July 2013. Formal survival analyses, with 
the appropriate mitigation of immortal person-time bias, can be conducted. Thus, associations between 
military-related factors and ALS etiology or survival can be evaluated more carefully than in previous 
studies. In addition, having 630 ALS cases makes the GENEVA study one of the largest studies of 
military-related factors and ALS etiology or survival and will provide better power for evaluating 
associations of interest. Finally, the GENEVA study collected extensive information on various aspects of 
military service and deployments as well as on 40 specific exposures related to military service (100), 
including pesticides, chemicals, paint, gas, diesel, solvents, ionizing and non-ionizing radiation, vaccines, 
and riot control substances, which was not available in any previous study of military exposures and ALS 
etiology or survival. Other studies that address the limitations of previous studies of military service, 
deployments, and exposures and ALS etiology and survival are also needed. 
The GENEVA study may also have some limitations. Recall bias may be possible, and 
differential by war of service, because the GENEVA study interview occurred up to 65 years after 
participants served in the military (98, 100). There seems to be little evidence, however, that cases of 
various diseases and controls recall past exposures differentially (101). Another possible limitation of the 
GENEVA study, and possibly other case-control studies of ALS, especially register- or population-based 
ones, is potential selection bias arising from non-participation of potential controls and the fact that the 
fastest progressing cases likely died before they could enroll. Therefore, analyses of the GENEVA study 
data will need to evaluate and address these and other potential sources of bias. 
In conclusion, although the current literature suggests a positive association between military 
service and ALS/MND etiology, it is too limited to make definitive statements regarding possible 
associations between military service and ALS/MND etiology or survival. An association between Gulf 
War deployment and ALS/MND etiology is possible. There is not currently strong evidence that any 
particular military exposure is a risk factor for ALS/MND etiology. Future studies of military service, 
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deployments, and exposures and ALS etiology and should address limitations of previous ones, such as 
reliance on mortality as a surrogate for incidence, a dearth of survival analyses, lack of clinical data, low 
statistical power, and limited exposure assessment. The GENEVA study provides one such attempt, but 
other, additional studies are clearly needed to determine if military-related factors are associated with 
ALS and to assess potential prevention strategies. 
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Figure 1.1. Flow diagram of the article search and selection strategy employed in the present review. 
Solid lines represent articles which remained in the review after each step shown whereas small dashed 
lines represent articles which were excluded after each step shown. Only articles published through the 
end of 2013 were considered. Abbreviations: ALS, amyotrophic lateral sclerosis; MND, motor neuron 
disease. 
Articles and Abstracts 
From Reference Lists and 
Other Sources, 
n = 7 
Articles and Abstracts Included in Review, 
n = 30 
Articles, 
n = 972 
Duplicate Articles 
Excluded, 
n = 237 
Unique Articles, 
n = 735 
Articles Excluded 
Because They Were Not 
Related to ALS/MND or 
Military or Were Reviews, 
Commentaries, Case 
Reports, Animal Studies, 
Cell Cultures, Clusters, 
Familial ALS or for Other 
Reasons, 
n = 712 
Articles, 
n = 23 
PubMed Articles 
n = 567 
 
Search Terms Used Were (“amyotrophic lateral sclerosis” 
OR “motor neuron disease” OR “motor neurone disease” 
OR “motor neuron diseases” OR “motor neurone diseases” 
OR motorneuron OR motorneurone OR ALS OR MND) 
AND (militar* OR “armed forces” OR soldier OR soldiers 
OR veteran OR veterans OR occupation OR occupat* OR 
professional OR profess* OR “world war” OR “korean war” 
OR “vietnam war” OR “gulf war” OR deploy*) 
  
Filters Applied Were Article Type (Journal Article), 
Language (English), Publication Dates (by December 31, 
2013), Species (Humans) 
Web of Science Articles 
n = 405 
 
Search Terms Used Were (“amyotrophic lateral sclerosis” 
OR “motor neuron disease” OR “motor neurone disease” 
OR “motor neuron diseases” OR “motor neurone 
diseases” OR motorneuron OR motorneurone OR ALS OR 
MND) AND (militar* OR “armed forces” OR soldier OR 
soldiers OR veteran OR veterans OR occupation OR 
occupat* OR professional OR profess* OR “world war” OR 
“korean war” OR “vietnam war” OR “gulf war” OR deploy*) 
  
Filters Applied Were Document Type (Article), Language 
(English), Timespan (Before 2014) 
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 Table 1.1. Cohort Studies of the Association Between Military Service, Deployments, or Exposures and ALS/MND Etiology Published Through 
the end of 2013. 
First Author, Year 
(Reference No.) 
Study Population Sample Size Outcome Exposure Matching or Adjustment 
Factors 
Statistical Analysis Result 
Gale, 1999 (52) Male British 
former prisoners 
of war in Japan 
followed from 
1952 to death or 
1997 
11,314 former 
prisoners of war, 11 
deceased MND 
cases 
MND death rate NA Age SMR, PMR (using the 
entire English and 
Welsh male 
populations as the 
standard for both 
statistics) 
1952-1965: n = 2 deceased cases, 
SMR = 1.33; 95% CI: 0.16, 4.82; 
1966-1980: n = 5 deceased cases, 
SMR = 0.91; 95% CI: 0.30, 2.12; 
1980-1997: n = 4 deceased cases, 
SMR = 0.38; 95% CI: 0.10, 1.00; 
1952-1997: SMR = 0.62; 95% CI: 
0.31, 1.11; PMR = 0.73; 95% CI: 
0.36, 1.30 
Smith, 2000 (40) Active-duty Gulf 
War era U.S. 
military service 
personnel 
followed from 
October 1988 to 
July 1997 
551,841 active-duty 
service personnel (6 
ALS hospitalizations) 
deployed to the Gulf 
War; 1,478,704 
active-duty service 
personnel (12 ALS 
hospitalizations) not 
deployed to the Gulf 
War 
ALS 
hospitalization 
rate 
DMDC provided 
deployment to 
the Gulf War 
Age Cox proportional 
hazards regression 
Deployment: HR = 1.66; 95% CI: 
0.62, 4.44 
Kang, 2001 (39) Gulf War era U.S. 
military veterans 
followed from 
May 1991 to 
death or 
December 1997 
621,902 veterans 
(number of cases not 
reported) deployed to 
the Gulf War; 
746,248 veterans 
(number of cases not 
reported) from a 
stratified random 
sample of all U.S. 
troops not deployed 
to the Gulf War 
ALS mortality 
rate 
DMDC provided 
deployment to 
the Gulf War 
Age, race, marital 
status, branch of 
service, type of service 
unit 
Cox proportional 
hazards regression 
Deployment: HR = 0.59; 95% CI: 
0.21, 1.66 
Haley, 2003 (37) Gulf War era U.S. 
military veterans 
followed from 
1991 to 1998 
Approximately 
695,000 veterans (17 
cases) deployed to 
the Gulf War 
ALS incidence 
rate 
NA Age SMR (using the entire 
U.S. male population 
as the standard) 
1991-1994: n = 4 cases, SMR = 0.94; 
95% CI: 0.26, 2.41; 1995-1998: n = 
13 cases, SMR = 2.27; 95% CI: 
1.27, 3.88 
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 First Author, Year 
(Reference No.) 
Study Population Sample Size Outcome Exposure Matching or Adjustment 
Factors 
Statistical Analysis Result 
Horner, 2003 (38) Gulf War era U.S. 
military veterans 
(active-duty or 
activated 
reserves and 
National Guard) 
followed for 10 
years beginning 
August 1990 
696,118 veterans (40 
cases) deployed to 
the Gulf War; 
1,786,215 veterans 
(67 cases) not 
deployed to the Gulf 
War 
ALS incidence 
rate 
DMDC provided 
deployment to 
the Gulf War 
Age Risk ratio, 95% 
confidence interval 
Deployment: RR = 1.92; 95% CI: 
1.29, 2.84 
Coffman, 2005 
(36) 
Gulf War era U.S. 
military veterans 
(active-duty or 
activated 
reserves and 
National Guard) 
followed for 10 
years beginning 
August 1990 
696,118 veterans (40 
cases) deployed to 
the Gulf War; 
1,786,215 veterans 
(67 cases) not 
deployed to the Gulf 
War 
ALS incidence 
rate 
DMDC provided 
deployment to 
the Gulf War 
Case 
underascertainment; 
age 
Capture-recapture 
methods: log-linear 
models, sample 
coverage approach, 
ecological models; 
risk ratio, 95% 
confidence interval 
n = 42 deployed cases, 76 non-
deployed cases; deployment: RR = 
1.77; 95% CI: 1.21, 2.59 
Weisskopf, 2005 
(41) 
ACS CPS II 
males followed 
from 1989 to 
1998 
281,874 U.S. military 
veterans (217 cases); 
126,414 non-
veterans (63 cases) 
ALS mortality 
rate 
Military service 
(veteran 
status); branch, 
number of 
years, and time 
period of 
service; 
number of wars 
during period of 
service 
(inferred) 
Age, smoking, 
education, alcohol 
intake, self-reported 
exposure to pesticides 
and herbicides, and 
main lifetime 
occupation as a 
farmer, in a job 
involving electrical 
work or welding, or 
food preparation 
Cox proportional 
hazards regression 
Military service: HR = 1.53; 95% CI: 
1.12, 2.09; result largely 
independent of branch, number of 
years, and time period of service; 
increasing ALS mortality rates with 
increasing numbers of wars during 
period of service (inferred) 
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 First Author, Year 
(Reference No.) 
Study Population Sample Size Outcome Exposure Matching or Adjustment 
Factors 
Statistical Analysis Result 
Horner, 2008 (51) Gulf War era U.S. 
military veterans 
followed from 
1991 to death or 
2001 
696,118 veterans (48 
cases) deployed to 
the Gulf War; 
1,786,215 veterans 
(76 cases) not 
deployed to the Gulf 
War 
ALS incidence 
rate 
Deployment to 
the Gulf War 
(DMDC 
provided, self-
reported) 
Age SIR (using the non-
deployed group as 
the standard for the 
deployed group and a 
group of men in 
western Washington 
state (102) as the 
standard for the non-
deployed group), χ2 
for homogeneity, χ2 
for trend 
Deployed: SIR peaks in 1996 at ~1.5 
then drops to near zero in 2001, p 
for homogeneity = 0.0003, p for 
trend = 0.74; non-deployed: SIR 
fairly constant between 0.25 and 0.5 
from 1991-2001, p for homogeneity 
= 0.0002, p for trend = 0.48 
Miranda, 2008 
(53) 
U.S. military 
veterans 
deployed to the 
Gulf War 
followed from 
1991 to death or 
2001 
41 cases ALS incidence 
rate 
Spatial risk, 
branch of 
service, 
potential 
exposure to 
chemical 
warfare agents 
in and around 
Khamisiyah, 
Iraq 
Spatial risk, branch of 
service, potential 
exposure to chemical 
warfare agents in and 
around Khamisiyah, 
Iraq 
Bayesian Poisson 
regression 
Spatial risk highest for a location 
about 500 km southeast of 
Khamisiyah (posterior probability of 
ALS = 0.91, IRR = 2.01); branch of 
service: Army: IRR = 1.00 
(reference), Air Force: IRR = 1.7; 
95% CrI: 0.6, 4.1, Marine Corps: IRR 
= 0.2; 95% CrI: 0.03, 0.9, Navy: IRR 
= 0.3; 95% CrI: 0.06, 1.1; 
Khamisiyah: IRR = 1.7; 95% CrI: 0.7, 
3.7 
Barth, 2009 (50) Gulf War era U.S. 
military veterans 
followed from 
May 1991 to 
death or 2004 
621,902 veterans (23 
cases) deployed to 
the Gulf War; 
746,248 veterans (38 
cases) from a 
stratified random 
sample of all U.S. 
troops not deployed 
to the Gulf War 
ALS mortality 
rate 
DMDC provided 
deployment to 
Gulf War; 
potential 
exposure to 
nerve agents at 
Khamisiyah, 
Iraq; potential 
exposure to oil 
well fire smoke 
Age, sex, race, marital 
status, branch of 
service, type of service 
unit; stratified by sex 
Cox proportional 
hazards regression 
Deployment: all veterans: HR = 0.96; 
95% CI: 0.56, 1.62; males: HR = 
0.91; 95% CI: 0.53, 1.56; females: 
NA (n = 1 deceased case); 
Khamisiyah: no association (data not 
shown); oil well fire smoke: no 
association (data not shown) 
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 First Author, Year 
(Reference No.) 
Study Population Sample Size Outcome Exposure Matching or Adjustment 
Factors 
Statistical Analysis Result 
Drouet, 2010 (49) French military 
personnel 
identified from 
the French 
National Military 
Health Care 
Fund, 1991-2007 
69 male ALS cases, 4 
female ALS cases 
ALS incidence 
rate 
Branch of 
service, 
duration of 
active duty 
Stratified by age, sex Incidence rate Incidence rate among male active 
duty military personnel (1.7 in 
100,000 per year in 2007) lower than 
general population, but higher in 40-
44 and 50-54 age groups (1.9 and 
5.1 in 100,000 per year in 2007, 
respectively) 
Abbreviations: ACS, American Cancer Society; ALS, amyotrophic lateral sclerosis; CI, confidence interval; CPS II, Cancer Prevention Study II; CrI, credible interval; DMDC, 
Defense Manpower Data Center; Gulf War, 1990-1991 Persian Gulf War; HR, hazard ratio; IRR, incidence rate ratio; MND, motor neuron disease; NA, not available; PMR, 
proportional mortality ratio; RR, risk ratio; SIR, standardized incidence ratio; SMR, standardized morbidity/mortality ratio; U.S., United States. 
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 Table 1.2. Case-Control Studies of the Association Between Military Service, Deployments, or Exposures and ALS/MND Etiology Published 
Through the end of 2013. 
First Author, Year 
(Reference No.) Study Population Sample Size Outcome Exposure 
Matching or Adjustment 
Factors 
Statistical 
Analysis Result 
Kurtzke, 1980 (59) Male U.S. WWII 
veterans, 1963-1967 
504 deceased 
cases; 504 
randomly-selected, 
living controls 
ALS death Branch of service, arm of 
service within the Army, 
decorations and awards, 
highest rank attained, 
duration of service, 
location of any service 
overseas, campaign 
credits, whether service 
extended to Korean 
conflict, immunizations 
during military service, 
military occupational 
specialties, whether a 
prisoner of war 
Year of birth, date of entry 
into military service, 
branch of service 
Direct 
comparison 
of counts; 
continuity-
corrected chi-
square, 
matched-pair 
analysis, 2 × r 
chi-square 
All p > 0.05 
Kondo, 1981: Study 
A (58) 
Japan, 1965-1966 458 deceased male 
cases, 254 
deceased female 
cases; 216 living 
male controls 
(husbands of 
female cases), 421 
living female 
controls (wives of 
male cases) 
MND 
death 
War prisoner outside of 
Japan 
Sex Risk ratio Males: RR = 0.94, p > 0.05; 
females: RR = 1.00, p > 0.05 
Kondo, 1981: Study 
B (58) 
Japan, 1973 104 male cases, 54 
female cases; 104 
male controls 
(unrelated healthy 
persons or patients 
at the hospital), 54 
female controls 
(unrelated healthy 
persons or patients 
at the hospital) 
MND War prisoner outside of 
Japan 
Individually-matched on 
age, sex, residence 
Risk ratio Males: RR = 0.96, p > 0.05; 
females: NA 
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 First Author, Year 
(Reference No.) Study Population Sample Size Outcome Exposure 
Matching or Adjustment 
Factors 
Statistical 
Analysis Result 
Nicolson, 2002 (61) U.S., Great Britain, 
Australia, Netherlands 
8 Gulf War veteran 
cases; 28 civilian 
cases, 70 civilian 
controls 
ALS Systemic mycoplasmal 
infections in blood (M. 
penetrans, M. 
fermentans, M.hominis, 
M. pneumoniae) 
Age, sex Percentages, 
p-values (test 
not specified) 
Any infection: Gulf War veteran 
cases: 100%, civilian cases: 
79%, civilian controls: 9% (p < 
0.001 for all cases vs. 
controls); M. fermentans: Gulf 
War veteran cases: 88%, 
civilian cases: 46%, civilian 
controls: 3% (p < 0.001 for all 
cases vs. controls) 
White, 2002 
[abstract] (57) 
Texas deaths, 1979-
2000 
4,745 deceased 
cases; 14,235 
deceased controls 
ALS/MND 
death 
Veteran status Age group, year of death, 
gender 
Conditional 
logistic 
regression 
Males: OR = 2.28; 95% CI: 
1.34, 3.87; females: OR = 
1.13; 95% CI: 0.77, 1.67 
Qureshi, 2006 (26) Neuromuscular clinic at 
Massachusetts 
General Hospital in 
Boston, 
Massachusetts, April 
1998-August 2002 
95 cases; 106 
controls (51 non-
blood related 
relatives of cases, 
55 friends or 
unrelated persons) 
ALS Male veteran, male 
veteran performing active 
duty 
Unrelated controls 
matched on age; adjusted 
for age, gender 
Multiple 
logistic 
regression 
Male veteran: OR = 0.22; 95% 
CI: 0.09, 0.54; male veteran 
performing active duty: OR = 
0.23; 95% CI: 0.08, 0.62 
Binazzi, 2009 (56) Neurology clinics in 
Rome, Italy, January 
2005-July 2006 
77 cases; 185 
controls (healthy 
relatives or 
accompanying 
persons of non-ALS 
outpatients at the 
clinics) 
ALS Military service (Army, 
Aviation, Navy) 
Age, gender Mantel-
Haenszel 
odds ratios 
No association (data not 
shown) 
Fang, 2009 (14) Cases from two referral 
centers (Tufts-New 
England Medical 
Center, Brigham and 
Women’s Hospital) in 
Boston, 
Massachusetts; 
controls from random 
telephone screening, 
1993-1996 
109 ALS cases, 253 
controls 
ALS Ever military service, 
branch of service, 
duration of service, 
wartime service 
Frequency-matched on 
age, sex, region of 
residence within New 
England; adjusted for age, 
sex, region of residence 
within New England, 
smoking history, 
education level; stratified 
by smoking history 
Multiple 
logistic 
regression 
Ever military service: OR = 1.2; 
95% CI: 0.7, 2.4; no clear 
variation of ORs when ever 
military service sub-grouped 
by branch or duration of 
service or wartime service 
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 First Author, Year 
(Reference No.) Study Population Sample Size Outcome Exposure 
Matching or Adjustment 
Factors 
Statistical 
Analysis Result 
Kwee, 2009 
[abstract] (60) 
U.S. military veterans; 
cases enrolled 
beginning in May 
2005, controls 
enrolled beginning in 
January 2006 
1,165 veteran cases; 
530 randomly-
selected veteran 
controls 
ALS Interactions between 
Vietnam deployment (as a 
crude surrogate for 
organophosphate 
exposure) and 12 SNPs 
in the PON gene cluster 
Controls frequency-
matched to some cases 
on age and use of the VA 
system for health care; no 
adjustment factors 
mentioned 
Logistic 
regression 
Interaction terms not significant 
(data not shown) 
Abbreviations: ALS, amyotrophic lateral sclerosis; CI, confidence interval; Gulf War, 1990-1991 Persian Gulf War; M., Mycoplasma; MND, motor neuron disease; NA, not 
available; OR, odds ratio; PON, paraoxonase; RR, risk ratio; SNP, single nucleotide polymorphism; U.S., United States; VA, Department of Veterans Affairs; WWII, World War II. 
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 Table 1.3. Cross-Sectional Study of the Association Between Military Service and ALS/MND Etiology Published Through the end of 2013. 
First Author, Year 
(Reference No.) Study Population Sample Size Outcome Exposure 
Matching or Adjustment 
Factors Statistical Analysis Result 
Schulte, 1996 (62) 27 U.S. states, 
1982-1991 
9,435 deceased MND 
cases; 130,420 total 
neurodegenerative 
disease deaths 
MND death Occupation as military 
personnel 
Age-standardized, 
stratified by gender, 
race 
PMR Ages 15-55: n = 27 
deceased cases, PMR = 
188, p < 0.05 
Abbreviations: ALS, amyotrophic lateral sclerosis; MND, motor neuron disease; PMR, proportionate mortality ratio; U.S., United States. 
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 Table 1.4. Cohort Studies of the Association Between Military Service or Deployments and ALS/MND Survival Published Through the end of 
2013. 
First Author, Year 
(Reference No.) 
Study 
Population Sample Size Outcome Exposure 
Matching or Adjustment 
Factors 
Statistical 
Analysis Result 
Brooks, 2003 
[abstract] (63) 
ALS CARE 
Database, 
beginning in 
1996 
946 male 
veteran 
cases, 15 
female 
veteran 
cases; 1,154 
male non-
veteran 
cases, 1,417 
female non-
veteran cases 
(number of 
deaths not 
specified) 
ALS survival Veteran status Not specified, but 
investigated age, gender, 
region affected and 
disease course, co-
morbidities, modes of 
treatment, site of 
treatment, caregiver status 
Stepwise 
multiple 
logistic 
regression 
Decreased survival among veterans, but 
decrease disappeared after adjustment 
for age (data not shown) 
Qureshi, 2006 (26) Neuromuscular 
clinic at 
Massachusetts 
General 
Hospital 
followed for 
one year from 
enrollment 
(April 1998-
August 2002) 
95 cases ALS 
Functional 
Rating 
Scale, 
predicted % 
forced vital 
capacity 
Male veteran, 
male veteran 
performing 
active duty 
Gender Random slope 
regression 
Male veteran: change in ALSFRS: β (SE) 
= -0.02 (0.01), p = 0.13; change in 
predicted %FVC: β (SE) = -0.07 (0.03), p 
= 0.04; male veteran performing active 
duty: change in ALSFRS: β (SE) = -0.02 
(0.01), p = 0.03; change in predicted 
%FVC: β (SE) = -0.08 (0.04), p = 0.04 
Kasarskis, 2009 
(64) 
Gulf War era 
U.S. military 
veterans with 
ALS followed 
from 1991 to 
death or 
October 2002 
43 cases 
deployed to 
the Gulf War; 
66 cases not 
deployed to 
the Gulf War 
(number of 
deaths not 
specified) 
ALS survival 
(onset of 
symptoms to 
death or 
ventilation) 
Deployment to 
the Gulf War 
(DMDC 
provided, self-
reported) 
Age, site of onset Cox 
proportional 
hazards 
regression 
Median survival time: deployed: 40.2 
months; non-deployed: 57.0 months; HR 
= 0.62; 95% CI: 0.40, 0.96 
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 First Author, Year 
(Reference No.) 
Study 
Population Sample Size Outcome Exposure 
Matching or Adjustment 
Factors 
Statistical 
Analysis Result 
Pastula, 2009 (24) U.S. military 
veterans with 
ALS followed 
from April 2003 
to death or 
October 2006 
1,063 veteran 
cases (603 
dead or on 
ventilation) 
ALS survival 
(diagnosis to 
death or 
ventilation) 
Cumulative 
military service 
(years), branch 
of service; 
deployment to: 
Korean War, 
Vietnam War, 
Gulf War 
Age, race, site of onset, 
ALS type, time from onset 
of symptoms to diagnosis; 
history of: MI, CVD, 
diabetes, cancer, traumatic 
injury; cigarette smoking, 
cumulative military service, 
branch of service; 
deployment to: Korean 
War, Vietnam War, Gulf 
War 
Cox 
proportional 
hazards 
regression 
Cumulative military service (per 10 year 
increase): HR = 1.03; 95% CI: 0.91, 1.17; 
branch of service: Air Force: HR = 1.00 
(reference), Army: HR = 1.08; 95% CI: 
0.84, 1.41, Coast Guard: HR = 2.14; 95% 
CI: 0.92, 4.98, Marines: HR = 1.26; 95% 
CI: 0.91, 2.03, Navy: HR = 1.24; 95% CI 
= 0.93, 1.66; deployment to: Korean War: 
HR = 0.98; 95% CI: 0.74, 1.30, Vietnam 
War: HR = 1.73; 95% CI: 1.36, 2.19, Gulf 
War: HR = 0.92; 95% CI: 0.57, 1.50 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS, ALS Functional Rating Scale; CARE, Clinical Assessment, Research and Education Program; CI, confidence interval; 
CVD, stroke/cerebrovascular disease; DMDC, Defense Manpower Data Center; FVC, forced vital capacity; Gulf War, 1990-1991 Persian Gulf War; HR, hazard ratio; MI, 
myocardial infarction; MND, motor neuron disease; SE, standard error; U.S., United States.
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 CHAPTER TWO: SPECIFIC AIMS 
 
SPECIFIC AIM 1 
Evaluate associations between aspects of military service, deployments, and 40 exposures and 
ALS etiology. 
Hypothesis 
Some aspects of military service and some deployments and exposures will be positively 
associated with ALS etiology. 
Rationale  
Among two studies that examined branch of service, one (56) reported no association with ALS 
and the other (53) reported a significantly lower risk of ALS incidence for members of the Marines and 
Navy who were deployed to the Gulf War compared to members of the Army who were also deployed. 
The increased rate of ALS mortality among all U.S. military veterans compared to the general population 
mentioned above was largely independent of branch, number of years, and time period of military service 
(41). A case-control study in New England that found no association between military service and ALS 
reported no notable variation in results when sub-grouping study participants by branch or duration of 
service or wartime service (14). Two studies among veterans who were deployed to the Gulf War found 
no association between potential exposure to nerve/chemical warfare agents at Khamisiyah, Iraq (where 
U.S. military troops destroyed munitions warehouses, bunkers, and rockets that contained nerve agents), 
and ALS incidence (53) or ALS mortality (50). The study of ALS mortality (50) also reported no 
association with deployment to the Gulf War or potential exposure to oil well fire smoke. A case-control 
study of U.S. military veterans evaluated associations between approximately 10 military-related factors 
(e.g., immunizations, branch of service, whether a prisoner of war, duration of service, etc.) and ALS, but 
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 none of the factors were significantly associated with ALS (59). In non-military settings, however, higher 
ALS incidence or mortality has been associated with exposure to toxicants, including several that occur in 
the military, such as pesticides (79, 80), lead (103, 104), paint (44), solvents (83), ionizing radiation (94), 
magnetic fields (96), etc. 
Sub-aim 
Evaluate and adjust for (using inverse-probability weighting [IPW] (105)) potential selection bias 
resulting from using the GENEVA study cases and controls for ALS etiological research. 
SPECIFIC AIM 2 
Evaluate associations between aspects of military service, deployments, and 40 exposures and 
ALS survival. 
Hypothesis 
Some aspects of military service and some deployments and exposures will be positively 
associated with shorter ALS survival. 
Rationale 
A study of U.S. military veterans who had ALS found a positive association between deployment 
to the Gulf War and shorter ALS survival (64), whereas a study of ALS cases from the ALS Clinical 
Assessment, Research and Education database, which includes both veteran and non-veteran cases 
enrolled at clinical sites across North America (65), found no association between U.S. military veteran 
status and ALS survival (63). A prior study in the National Registry of Veterans with ALS found an 
association between past deployment to Vietnam and shorter ALS survival (24). In the same study, ALS 
survival was not associated with cumulative military service, branch of service, or deployment to the 
Korean War or to the Gulf War (24). A study of ALS cases in the U.S. reported that both being a male 
veteran and being a male veteran who had performed active duty were associated with decreases in the 
ALS functional rating scale (ALSFRS) score and predicted % forced vital capacity (FVC; indicating a 
faster disease progression and poorer survival) after one year of follow-up (26). The same study did not 
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 find an association between toxicant exposure (e.g., pesticides, lead, solvents, etc. evaluated as a group) 
and changes in the ALSFRS score or FVC (26). 
Sub-aim 
Evaluate and adjust for (using IPW (105)) potential selection bias resulting from using the 
GENEVA study cases for ALS survival research. 
INNOVATION 
Previous studies of military service, deployments, and exposures and ALS etiology or survival 
were limited by one or more of the following: 1) the outcome was ALS mortality (in etiologic studies), 2) 
a dearth of survival analyses (and at least half of the few existing survival analyses are likely plagued by 
immortal person-time bias), 3) important clinical information, such as date of diagnosis, site of onset, 
respiratory function, etc., was unavailable, 4) limited statistical power resulting from having fewer than 
124 ALS cases (and fewer than 48 exposed cases), and 5) a dearth of information on specific aspects of 
military service, deployments, or exposures, including exposure gradients, that may be associated with 
ALS etiology or survival. 
Several of these limitations can and will be addressed in the current study by using data from the 
GENEVA case-control study. Specifically, the GENEVA study can and will be used for both etiological 
and survival research because living ALS cases were identified via the Registry and ALS diagnoses were 
confirmed via medical record review (100). Important and high quality clinical information is also 
available. In addition, controls were identified via VA databases and matched to cases on age and use of 
the VA system for health care (100). Information on the vital status of ALS cases is current through July 
25, 2013. Formal survival analyses, with the appropriate mitigation of immortal person-time bias, can be 
conducted. Thus, we will be able to more carefully evaluate associations between military-related factors 
and ALS etiology and survival. 
The GENEVA study’s large number of ALS cases (n = 630) makes it one of the largest studies of 
military-related factors and ALS etiology or survival, including all six (36-41) of the studies reviewed in 
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 the IOM report (34). Therefore, we will have better statistical power to evaluate associations of interest 
than the large majority of previous studies. 
Finally, the current study will incorporate the following innovative approaches and methods that 
have not been used in any previous studies of military-related factors and ALS etiology or survival: 
Extensive information on: 
 Several aspects of military service and deployments as well as on 40 military exposures, 
 Exposure gradients for many of these aspects, deployments, and exposures, 
 Whether or not veterans felt ill after experiencing these exposures. 
IPW to evaluate and adjust for potential selection bias resulting from: 
 Long-surviving ALS cases, 
 Non-participation of potential controls. 
If results of our study are as hypothesized, then our study has the potential to “elucidate ALS risk 
factors relevant to military service”, as the IOM recommended (34, p. 4), identify factors affecting ALS 
survival, and demonstrate an approach to mitigating selection bias in ALS studies based on registries.
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 CHAPTER THREE: METHODS 
 
STUDY DESIGN 
The GENEVA study is a case-control study of 630 veterans with ALS and 975 veteran controls, 
identified via VA databases, frequency-matched to ALS cases on age and use of the VA health care 
system (100). The goal of the GENEVA study is to evaluate associations between ALS and 
environmental factors, genetic susceptibility, and their interactions (100). We used data from the 
GENEVA study to evaluate associations between military-related factors and ALS etiology and survival. 
We also evaluated and adjusted for potential selection bias arising from non-participation of potential 
controls and the fact that the fastest progressing cases likely died before they could enroll (see Analyses 
to Address Specific Aims for more details). 
STUDY POPULATION 
The methods used to enroll ALS cases first in the Registry and later in the GENEVA study have 
been published previously (98, 100).  
Cases 
 In total, 7,116 veterans were identified as possible ALS cases, 4,626 completed the screening 
interview, and 2,600 were eligible to join the Registry (98). Of those eligible, 2,400 veterans consented to 
join the Registry, 2,265 provided medical records for review, and 2,122 enrolled in the Registry of which 
2,100 had a diagnosis of ALS or a related MND confirmed (98, 100). 
The ascertainment of the GENEVA study cases from the Registry is shown in Figure 3.1. Of the 
248 veterans enrolled in the Registry who did not have a diagnosis of sporadic ALS, diagnoses were 
primary lateral sclerosis (PLS; n = 129), clinically definite and lab supported familial ALS (n = 3), no 
ALS (n = 20), indeterminate (n = 94), and other (n = 2). Of the 25 ALS cases who were ineligible for the 
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 GENEVA study, reasons included a diagnosis of dementia (n = 9), a change in diagnosis (e.g., to no 
ALS/MND; n = 2), withdrawal from the DNA bank (n = 3), or infeasibility of a telephone interview for 
other reasons (n = 11). In total, 630 cases enrolled in the GENEVA study with 604 providing a complete 
telephone interview and 26 providing partial interviews. 
Controls 
To identify controls, the GENEVA study team obtained a random sample of 10,000 records from 
the Veterans Benefits Administration’s Beneficiary Identification and Records Locator System (BIRLS) 
database in June 2005 (100). The BIRLS database contains a record for all veterans with a release of 
activity date (RAD) of 1973 or later and a subset of veterans with a RAD before 1973 (100). The subset 
of records with a RAD before 1973 primarily included veterans who applied for any type of VA 
benefit(s), veterans whose surviving relatives applied for death benefits, and all recipients of the Medal of 
Honor (100). In 2005, the BIRLS database contained records for approximately 21.2 million living 
veterans born between 1900 and 1980 (100). For comparison, the total U.S. military veteran population 
was estimated to be 25.5 million in 2000 (31) and 21 million in 2010 (30). Of the 10,000 obtained 
records, 2,000 records came from each of the following five birth cohorts: 1900-1930, 1931-1940, 1941-
1950, 1951-1960, and 1961-1980 (100). 
Information obtained from the BIRLS database included sex (available for 69% of the 10,000 
obtained records), the most recent RAD (80%) and military service branch (78%) (100). Unfortunately, 
current contact information is not reliably maintained in the BIRLS database (100). Thus, the VA 
established an interagency agreement with the National Institute of Occupational Safety and Health to 
access Internal Revenue Service mailing address databases for the 10,000 records obtained from the 
BIRLS database (100). Addresses reported at the most recent tax filing date were merged to the 10,000 
BIRLS records in 2005 and again in 2006 (100). Addresses were found for 89% of the 10,000 records 
(100). The 10,000 BIRLS records were also cross-checked against the VA National Enrollment Database 
in December 2005 to obtain information on past use of the VA health care system (100). 
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 The GENEVA study controls were frequency matched to cases on age (using five-year age 
groups with the ALS cases’ ages at diagnosis as the target) and on use of the VA health care system prior 
to date of ALS diagnosis for cases and prior to date of interview for controls (100). These factors were 
chosen as matching factors because increasing age is a risk factor for ALS (1-3) and there are 
socioeconomic differences between veterans who use the VA system for health care and individuals 
(veterans and non-veterans) who exclusively use other systems for health care (106). Furthermore, cases 
may have stronger motivation to use the VA system for health care after diagnosis because of the 
publicity given to studies on the relationship between military service and ALS. In addition, the 
GENEVA study team wished to match on sex and race/ethnicity, but the BIRLS database does not have 
information on race/ethnicity and, as mentioned previously, had information on sex for only 69% of the 
10,000 obtained records (100). While the additional information obtained from the BIRLS database was 
not used to match controls to cases, it was useful for evaluating and adjusting for the selection bias 
resulting from using the GENEVA study controls for ALS etiological research (see Analyses to Address 
Specific Aims for more details). 
Figure 3.2 shows the ascertainment of the GENEVA study controls. Nine potential controls who 
were not part of the original BIRLS sample contacted the GENEVA study team regarding joining and the 
team was able to determine their eligibility for inclusion in the GENEVA study. Among the 91 potential 
controls who were ineligible for the GENEVA study, reasons included not being a U.S. military veteran 
(n = 13); a diagnosis of ALS (n = 1), Alzheimer’s disease or another form of dementia (n = 7), 
Parkinson’s disease (n = 8), multiple sclerosis (n = 1), post-polio syndrome (n = 1), Gulf War Illness (n = 
2), neuropathy (n = 11), or muscle weakness (n = 1); or other reasons (n = 46). In total, 975 controls 
enrolled in the GENEVA study with 959 providing a complete telephone interview and 16 providing 
partial interviews. 
Descriptive Statistics 
Among the 630 ALS cases enrolled in the GENEVA study and shown in Table 3.1, 74% received 
a diagnosis of clinically definite, probable, or probable and lab supported ALS and 4% had a family 
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 history of ALS. Fourteen percent of cases experienced bulbar onset, whereas 81% experienced extremity 
onset. The median number of months between symptom onset and diagnosis, diagnosis and enrollment in 
the Registry, and enrollment in the Registry and enrollment in the GENEVA study was 13, 18, and nine, 
respectively. The median baseline (i.e., measured closest to the time of enrollment in the GENEVA study) 
ALS Functional Rating Scale-Revised (ALSFRS-R) score, a measure of disease progression, was 27 
(possible range: 0-48), which is much lower than the 38 reported in an ALS clinic population in New 
York (27). At baseline in the GENEVA study, 50% of cases were currently using riluzole and 20% were 
currently using a feeding tube. Relatively few cases required assistance with breathing at baseline (Table 
3.1). 
Controls were closely matched to cases on age (at date of diagnosis for cases and at date of 
interview for controls) and use of the VA health care system (Table 3.1). After adjustment for the 
matching factors, veterans who had a family history of ALS were significantly more likely to have ALS 
than veterans who did not. Women and Blacks or African Americans were significantly less likely to have 
ALS than men and Whites, respectively. The odds of ALS decreased as the highest educational degree 
attained increased. This inverse trend was also apparent when evaluating years of schooling completed 
(linear trend OR = 0.70; 95% CI = 0.61, 0.81 for a four year increase). 
Distinct time trends were evident in the odds of ALS associated with end of most recent period of 
military service and war/operation of longest deployment (Table 3.1). Specifically, the odds of ALS were 
highest for periods of service and war/operations furthest in the past and decreased steadily as periods of 
service and wars/operations became more recent. While there was no difference in the odds of ALS 
among veterans of the Air Force, Army, Marines, and Navy, officers and veterans who had served in a 
branch of military service other than the four major ones (e.g., Coast Guard, National Guard, Reserves) 
had significantly lower odds of ALS compared to non-officers and veterans who had served in the Army, 
respectively. Veterans who had served in the military for more than five years were less likely to have 
ALS than those who served for more than one, but less than five years. It is possible that this last result 
reflects uncontrolled confounding or the selection biases among ALS cases and controls mentioned 
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 above. This may also be true for time the observed trends in end of most recent period of military service 
and war/operation of longest deployment. 
Compared to all U.S. military veterans, the GENEVA study participants (i.e., cases and controls 
together) had few veterans of young (e.g., < 50) or old (> 79) ages (Table 3.1) (31). GENEVA 
participants were also more likely to have used the VA health care system or have at least a college 
diploma compared to all U.S. military veterans and were less likely to be women, non-White, 
Hispanic/Latino, or current cigarette smokers (31). GENEVA participants were less likely to have served 
in the Army or to have been deployed to any of the four wars evaluated than all U.S. military veterans 
(31), although these last two differences may at least in part reflect differences in the questions used by 
the GENEVA study and the National Center for Veterans Analysis and Statistics (NCVAS) as well as the 
way the results were presented. For example, the GENEVA study asked veterans the branches in which 
they had served (Appendix B) and results were presented as the veterans’ branch of longest service 
whereas the NCVAS asked veterans the branches in which they had served during active duty and results 
were presented as every branch in which veterans served, so that percentages total more than 100 (31). 
Similarly, the GENEVA study asked veterans the wars/operations to which they had deployed (Appendix 
B) and results were presented as the veterans’ war/operation of longest deployment whereas the NCVAS 
asked veterans the periods in which they had served, organized by war, and results were presented for 
every war to which veterans deployed, so that percentages total more than 100. (31). 
For survival analyses (Specific Aim 2), we restricted the GENEVA study sample to the 616 ALS 
cases who had information on date of diagnosis and who had not died before enrollment in the GENEVA 
study. As of July 25, 2013, a total of 24,267 person-months (PM) had been observed since enrollment in 
the GENEVA study (Table 3.2). The median follow-up time was 28 months (interquartile range [IQR] = 
59). There had also been 446 deaths (median follow-up time = 17 months [IQR = 27]) for a crude overall 
mortality rate of 18.38 per 1,000 PM. 
After adjustment for age, cases with clinically probable and lab supported ALS were significantly 
less likely to die than cases with clinically probable ALS (Table 3.2). Hazard ratios (HRs) for death 
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 decreased with increases in time from symptom onset to diagnosis, time from diagnosis to enrollment in 
the Registry, and baseline ALSFRS-R score. As time from enrollment in the Registry to enrollment in the 
GENEVA study increased, however, HRs increased. HRs were higher among cases currently using a 
feeding tube at baseline and among cases currently using Bi-level Positive Airway Pressure (BiPAP), a 
ventilator, or tracheostomy to assist with breathing at baseline. HRs increased with increasing age and 
appeared to be higher among cases who served less than or equal to one year or more than 15, but less 
than 20, years in the military compared to cases who served more than 1, but less than 5, years in the 
military. No other clinical, demographic or military-related characteristic was associated with ALS 
survival. 
OUTCOME ASSESSMENT 
The methods used to confirm the ALS diagnoses of the Registry participants and the GENEVA 
study cases have been described in detail previously (98, 100). Briefly, potential cases had to first pass a 
telephone screening interview (Appendix C) by indicating that they were U.S. military veterans and had 
been diagnosed by a physician with ALS or a related motor neuron disorder or that they had not been 
diagnosed with ALS by a physician, but that they had unexplained progressive muscle weakness (98, 
100). After passing the telephone screening interview and after providing informed consent, the medical 
records (e.g., neurologist consultations and notes, electromyography reports, nerve conduction velocity 
tests, imaging studies, and other laboratory tests used to establish an ALS diagnosis) (Appendix D) of 
each potential U.S. veteran ALS case were reviewed by a neurologist specializing in ALS (98, 100). 
Potential cases were then classified in accordance with the gold standard World Federation of Neurology 
Revised El Escorial ALS Diagnostic Criteria (107, 108) into one of the following categories (the number 
of GENEVA. cases in each category is given in parentheses): clinically definite (n = 151), clinically 
probable (n = 215), clinically probable and lab supported (n = 102), clinically possible (n = 48), or 
suspected (including progressive muscular atropy [PMA; n = 112] and progressive bulbar palsy [PBP; n = 
2]) (Table 3.1) (98, 100). Individuals receiving a diagnosis of clinically definite and lab supported familial 
ALS or PLS, a form of MND with only upper motor neuron involvement diagnosed with the criteria set 
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 forth by Pringle et al. (109), were included in the Registry and the GENEVA study initially, but we 
excluded them from all of our analyses because familial and sporadic ALS may differ and PLS may not 
progress to ALS (98). In contrast, we included cases with PMA, in which individuals present with only 
lower motor neuron involvement (1-3), and PBP, which involves only bulbar-innervated muscles and 
could result from loss of either upper or lower motor neurons or both (1-3), in our analyses because PMA 
and PBP usually progress to ALS (98). 
ALS diagnoses used in the GENEVA study are likely accurate with minimal misclassification 
because neurologists specialized in ALS confirmed diagnoses via medical record review. In fact, eight of 
nine studies that have evaluated the validity of ALS mortality data and four studies that evaluated the 
validity of hospital discharge diagnosis codes for ALS used medical record review as the gold-standard 
(87, 110-121). 
For Specific Aim 2, the primary outcome measure was time (days) from the date of ALS 
diagnosis to the date of death (survival) or the end of the follow-up period (July 25, 2013) with late entry 
at the date of enrollment in the GENEVA study. Time since ALS diagnosis was the most clinically 
meaningful time scale and accounting for late entry at the date of enrollment in the GENEVA study 
addressed concerns of immortal person-time bias (72). Time to death has been recommended over other 
ALS survival outcomes, which incorporate time to tracheostomy, prolonged noninvasive ventilation, or 
permanent assisted ventilation, because these respiratory interventions are not uniformly defined or used 
across centers (122). Thus, death is the least variable and most easily identifiable measure of survival 
among ALS cases (122). 
Date of ALS diagnosis was available from the medical record and date of enrollment in the 
GENEVA study was available from the GENEVA study telephone interview (Appendix B). Information 
on death was available through July 25, 2013, and was obtained from the Austin Vital Status File (AVSF) 
housed at the Austin (Texas) Automation Center. The AVSF contains vital status information from 
several sources within the VA, including the Medicare Vital Status Files, Social Security Administration 
Death Master File, BIRLS Death File, and Veterans Health Administration Medical SAS Inpatient 
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 Datasets (123). Using the National Death Index (NDI) (124) as the gold standard, a VA Information 
Resource Center validation study found that the AVSF was 98.3% sensitive and 99.8% specific (κ = 
0.981) for identifying deaths among veterans (123). No study has assessed the ability of the AVSF to 
accurately identify ALS deaths among veterans, but a non-military study of lead exposure and ALS 
survival that ascertained deaths from NDI Plus reported that 71% and 17% of neurologist-confirmed ALS 
cases had perfect and partial matches, respectively (125). In addition, a validation study in the CPS II 
cohort found that the NDI identified 93% of known deaths overall (not from ALS specifically) and 97% 
of known deaths when a social security number was available for the search (126). The NDI’s sensitivity 
varied by race and sex, but was highest among white males (95%) (126). Thus, it is likely that only a 
small proportion of deaths among the GENEVA study cases will be misclassified because the majority of 
cases (n = 571; 92%) are white males. 
EXPOSURE ASSESSMENT 
Extensive information on military service, deployments, and exposures was collected for the 
GENEVA study via telephone interviews (Appendix B) (100). ALS cases and controls were asked to use 
the date of ALS diagnosis and the date of interview, respectively, as the reference date for all information 
they provided (100). While controls may have more time than ALS cases for which they could have been 
exposed (because median time from diagnosis to enrollment in the GENEVA study was approximately 32 
months), this difference should not affect analyses of the 40 military exposures potentially incurred 
during deployment to World War II (WWII), the Korean War, the Vietnam War, and/or the Gulf War 
because these exposures would have been incurred 12-66 years before ALS cases enrolled in the 
GENEVA study (see below). 
Information on military service included branch(es) of service, officer or warrant officer, and 
time period(s) of service. Information on military deployments included deployment to and time period(s) 
deployed to WWII, the Korean War, the Vietnam War, and/or the Gulf War. Information was also 
collected on deployment, year of first deployment, and months deployed to operations in Lebanon, 
Panama, Somalia, Bosnia, Kosovo, Rwanda, Afghanistan, and/or Iraq/Persian Gulf region (Gulf War II). 
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 Information was also collected on ever deployment to any other country (besides the four wars and nine 
operations listed above), ever receiving imminent danger pay, hardship duty, or combat zone tax 
exclusion benefits for deployment (i.e., deployment benefits), and time period(s) for which deployment 
benefits were received. 
Information on military exposures was collected via questions regarding herbicides, 
pyridostigmine bromide pills (taken to protect against exposure to nerve agents), the anthrax and 
smallpox vaccines, and nasopharyngeal radium (used to treat submariners and aviators for aerotitis media 
(127)). Additionally, information was collected on 40 military exposures potentially incurred during 
deployment to WWII, the Korean War, the Vietnam War, and/or the Gulf War (Table 3.3). Specifically, 
the GENEVA study participants were asked whether they had ever had direct contact with the war 
deployment-related exposure, the number of days they were exposed (5 days or less, 6-30 days, > 30 
days), and whether they felt ill after exposure. Only number, as opposed to ever receipt, of vaccines was 
reported for vaccines received orally or by injection within or outside of the U.S. during each war. The 
GENEVA study participants were also asked if they had ever had any exposure or experience, other than 
those queried, during the conflicts to which they had been deployed which they considered harmful or 
extremely stressful. It should be noted that information on war deployment-related exposures is only 
available for the GENEVA study participants who were deployed to at least one of the four wars listed 
(i.e., 234 cases and 347 controls). Finally, the GENEVA study participants were asked questions 
regarding time spent in the island of Guam, the islands of New Guinea, or the Kii Peninsula of Japan 
(including any time spent there in the military), where clusters of a form of ALS have been identified 
among individuals living in those areas (1-3). 
For the GENEVA study, collecting information on military exposures via self-report was the best 
option. Two alternative approaches would have been to 1) use biomarkers to estimate compounds’ half-
lives and provide information about study participants’ historical exposures (101), or  2) use of relevant 
information from military databases to model past exposures (for an example, see (50, 54)). In the 
GENEVA study, however, many military exposures of interest lack biomarkers or biomarkers that have 
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 long enough half-lives for exposures incurred during the deployments in question and it is doubtful that 
military databases contain relevant information for an extensive list of military exposures incurred during 
multiple deployments over several decades. In addition, use of military databases would likely result in 
non-differential exposure misclassification because exposures would likely be assigned in an ecological 
manner (e.g., using geographic information systems to assign exposures to platoon/squadron locations 
during certain time periods). 
The validity and reliability of self-reported military deployments or military-related exposures 
has been evaluated previously (38, 128-136). An analysis of 51,741 participants in the Millennium Cohort 
Study (MCS) compared self-reported deployment status for U.S. operations in Afghanistan and Iraq to 
deployment data from the DoD Defense Manpower Data Center (DMDC) (134). Self-reported and 
DMDC deployment status agreed 92% of the time (κ = 0.81). In addition, the agreement between self-
reported and DMDC deployment frequency was substantial (weighted κ = 0.72), although agreement for 
number of deployments was only moderate (weighted κ = 0.57). Self-reported and DMDC deployment 
start dates were within one month of each other 82% of the time for individuals who had been deployed 
once, whereas 50% of individuals who had been deployed more than once reported start dates that were 
within one month of the DMDC start dates for every time they had been deployed.  
The VA’s previous study of ALS in veterans of the Gulf War (38), although not a reliability 
study,  classified the deployment status of veterans with ALS based on self-report and on data from the 
DMDC. The DMDC deployment status data are known to have a five percent error rate during the Gulf 
War era (38), so treating the DMDC deployment status as a gold standard may not be appropriate. Using 
the information provided (38), the calculated percent agreement between the self-reported and DMDC 
deployment status of the 107 Gulf War era ALS cases was 86% (κ = 0.71; 95% CI = 0.58-0.85). 
Another study conducted in the MCS found that self-reported and electronic records of military 
occupation showed substantial agreement overall (κ = 0.68; 95% CI = 0.67-0.68), but a range of 
agreement across occupations (κ = 0.12-0.84, although eight of ten occupations evaluated had κ > 0.5) 
(135). Occupations that were likely to self-report certain military exposures (e.g., witnessing death, 
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 witnessing trauma, chemical or biological warfare, depleted uranium, pesticides) were also reported in the 
same study (135). 
Two more studies conducted in the MCS found that agreement between self-reported and DMDC 
anthrax and smallpox vaccination was 92% (κ = 0.80) and 84% (κ = 0.62), respectively (130, 133). 
Another study of veterans deployed to the Gulf War found that 260 out of 294 (88%) veterans who 
appeared on various DoD lists as recipients of anthrax vaccination also self-reported receiving anthrax 
vaccination (131). 
A study of veterans of Operation Ranch Hand, the U.S. Air Force herbicide spraying mission in 
Vietnam, used questionnaire data to construct various exposure indices for 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), a contaminant of herbicides sprayed during Operation Ranch Hand, which were then 
compared to the TCDD body burden in these veterans (137). Job classification was a good predictor of 
TCDD levels (R2 = 0.60) and number of days of skin exposure was the most significant predictor of 
TCDD levels among flight engineers and ground crew (137). 
Four studies compared the reliability of between seven and 19 combat-related experiences, 
exposures, and/or traumatic events (e.g., flew in aircraft, contact with sick/hungry locals, retrieved dead 
bodies from field, received incoming fire, encountered mines and traps, received sniper or sapper fire, 
unit ambushed, saw soldiers/locals killed/dying or wounded, was wounded, rejection by local population, 
etc.) reported by military personnel between nine months and three years apart and observed 64-100% 
agreement (κ = -0.03 to 1.00) for specific items queried (128, 129, 132, 136). Exposure indices created by 
summing or averaging individuals’ responses for the individual items showed a range of agreement (95% 
agreement; weighted κ = 0.84; r = 0.66-0.72) (128, 129, 132, 136). Two of the studies found scores on the 
exposure indices increased from the first assessment to the second (132, 136), whereas the other two 
studies found no change (128, 129). 
Taken together, the above studies suggest that self-reports of military deployments or military-
related exposures are generally valid and reliably ascertained over time. None of these studies, however, 
was able to assess the validity or reliability of self-reported military deployments or military-related 
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 exposures experienced up to 66 years in the past (the longest time between exposure and exposure 
assessment in these studies was about 10 years (38)). Thus, the validity and reliability of self-reported 
military deployments and military-related exposures for which information was collected in the GENEVA 
study are unknown, but could be differential by war and substantially less than those reported by the 
studies reviewed here. 
A review of exposure assessment methods used in epidemiological studies reported the validity 
and reliability of self-reported occupational history information is reasonable with 70-90% agreement 
between self-report and company, pension, or union records, although agreement is reduced by factors 
such as length of recall, duration of job, and complexity of the individual’s occupational history (101). 
Self-report of exposure to specific agents, chemicals, or compounds has been found to be less valid and 
reliable than self-reported occupational history data (R2 = 0.03-0.71 when compared to industrial hygiene 
measurements), although this may be partly explained by the metrics used as the gold standards (e.g., 
industrial hygiene measurements are known to be extremely variable over time and place) (101). The 
validity and reliability of self-reported exposures also varies widely between studies and between agents 
investigated in the same studies (101). There seems to be little evidence, however, that cases of various 
diseases recall past exposures differently than controls (101). 
We expect the validity and reliability of self-reported exposures in the GENEVA study to vary by 
exposure and time period (e.g., wars, length of recall). While some exposures may have good validity and 
reliability, others may be low. However, many strategies found to improve recall of occupational histories 
and/or past exposures (101) were utilized during the GENEVA study telephone interviews. Specifically, 
participants were interviewed regarding exposures that can be sensed (e.g., explosions in the air; bathing 
in or drinking of water contaminated with smoke, oil, dead animals or any chemicals; petrochemical 
fumes, etc.), using general terms (e.g., flea collar instead of the names of specific pesticides or products), 
querying a list of specific exposures of interest instead of asking open-ended questions, and by providing 
benchmarks against which respondents could compare their levels of exposure (e.g., feeling ill after 
exposure) (100). 
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 Many ALS cases suffer from impairments in communication and some suffer from impairments 
in cognition (1-3, 107). Interviewing a proxy instead of the actual case is appropriate in these situations or 
when the case is deceased (138, 139). Therefore, telephone interviews for the GENEVA study were 
conducted with proxies for 34 (5%) cases and with a person communicating with the study participant for 
138 (22%) cases and one (< 1%) control. In these instances, the proxy or person communicating with the 
study participant was their spouse 144 (83%) times, a son or daughter eight (5%) times, a sibling three 
(2%) times, and a parent seven (4%) times. Overall, 450 (73%) case interviews were rated by telephone 
interviewers as “very reliable”, 139 (22%) as “somewhat reliable”, and 28 (5%) as less than “somewhat 
reliable” (13 case interviews were not rated). The corresponding numbers for control interviews are 892 
(92%) “very reliable”, 71 (7%) “somewhat reliable”, and 11 (1%) interviews less than “somewhat 
reliable” (one control interview was not rated). 
The validity and reliability of obtaining occupational history information from proxy respondents 
has been reported and discussed in previous studies (138-155). In general, overall agreement of case and 
surrogate responses has ranged from poor to good (e.g. κ < 0-0.80) for most items relevant to 
occupational histories (e.g., number of jobs, job titles or tasks, years worked, etc.) (140-142, 145, 146, 
149, 150, 152, 154, 155), although main occupation, last job, and a few other aspects were reported 
excellently (e.g., κ > 0.80) in some studies (138, 144, 146, 147, 152). The industries in which the cases 
worked have been reported with higher agreement than the corresponding occupations (142, 150). 
Surrogates recalled fewer jobs and years worked than cases recalled (138, 143, 148, 149, 151), but most 
of the jobs the surrogates failed to report occurred earlier in cases’ lives (e.g., before marriage if a 
surrogate was a spouse) (142, 147, 148). In general, the agreement between occupational history 
information provided by cases and proxies decreased with an increase in the level of detail requested 
(e.g., names of specific industries or occupations, number of jobs, etc.) (148). 
The validity and reliability of proxy-reported information on military service or occupational 
exposures queried in the GENEVA study has also been evaluated (138-141, 143, 144, 148-150, 156-163). 
Military service was reported with perfect overall agreement (κ = 1.00) between cases and surrogate 
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 respondents in a case-control study of Alzheimer’s disease (141). Overall agreement between proxy and 
case reports of past occupational exposures (e.g., fertilizer/pesticides/herbicides, solvents, radiation, 
metals/fumes, paints, gas/fuel oil, dust) generally ranged from poor to good (141, 143, 150, 157, 162), but 
was excellent in some studies of proxy reports of pesticides (158, 160) or radiation (149). Agreement 
between proxy and case reports of exposures was better if the proxy was the case’s spouse (140, 148, 157, 
158). 
Use of any pesticide has been reported with higher agreement than use of pesticide classes (e.g., 
herbicides, insecticides, etc.) and use of pesticide classes has been reported with higher agreement than 
use of specific pesticides (160). In addition, the agreement between information on overall pesticide use 
provided by cases and proxies decreased as the level of detail requested (e.g., names of specific 
pesticides, number of days of use per year) increased (138). 
COVARIATE ASSESSMENT 
Information on demographic characteristics, potential confounders, and family history of ALS 
was collected from all study participants via telephone interviews (Appendix B) (100). For cases only, 
information on other clinical characteristics were abstracted and/or calculated from medical records 
(Appendix D) (98), the Registry follow-up telephone interviews (Appendix E), or the GENEVA study 
telephone interview (Appendix B). 
Covariates that were used to describe the GENEVA study sample included age, use of the VA 
health care system, sex, race/ethnicity, ever applied for VA benefits of any type, highest degree attained, 
years of schooling completed, and cigarette smoking status. For cases only, most recent diagnosis, family 
history of ALS, site of symptom onset, time from symptom onset to ALS diagnosis, time from ALS 
diagnosis to enrollment in the Registry, time from enrollment in the Registry to enrollment in the 
GENEVA study, baseline (i.e., measured closest to the time of enrollment in the GENEVA study) 
ALSFRS-R score, and baseline use of riluzole, a feeding tube, or BiPAP, Continuous Positive Airway 
Pressure, a ventilator, or tracheostomy to assist with breathing were also used to describe the study 
sample. ALSFRS-R scores obtained via telephone have been shown to correlate very highly (r = 0.966; 
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 intraclass correlation coefficient = 0.97, 95% CI = 0.93–0.98; r2 = 0.941) with those obtained in person in 
the clinic (164-167). 
Covariates that were used to match controls to ALS cases in the GENEVA study or that are likely 
to be associated with both military-related factors and ALS etiology and, as such, were of particular 
interest as potential confounders for Specific Aim 1 of the current study include age, use of the VA health 
care system, sex, and race/ethnicity. For associations involving military deployments and exposures, we 
also considered military branch of longest service as a potential confounder. 
Age and sex are the only covariates that are likely to be associated with both military-related 
factors and ALS survival and, as such, were of particular interest as potential confounders for Specific 
Aim 2 of the current study. We did not adjust for sex in our main models, however, due to the small 
number of female cases (n = 13) and deaths (n = 10). For associations between military exposures and 
ALS survival, we also considered war/operation of longest deployment as a potential confounder. 
For Specific Aim 1 (ALS etiology), we included the following covariates in the models used to 
calculate the IPWs for the cases because they are likely related to ALS survival: site of symptom onset 
(17-22, 24-26), clinical features (e.g., baseline disease progression) (17-19, 21, 23, 27, 28), time between 
symptom onset and diagnosis (17-19, 24-26, 29), and diagnosis category (17). We also included age at 
diagnosis, use of the VA health care system, time from diagnosis to enrollment in the Registry, sex, 
race/ethnicity, and—for associations involving military deployments and exposures—military branch of 
longest service. For the models used to calculate the IPWs for controls, we included age, use of the VA 
health care system, sex, race/ethnicity, the pairwise interaction between age and use of the VA health care 
system, and—for associations involving military deployments and exposures—military branch of longest 
service. The models used to calculate the IPWs for the ALS survival analysis (Specific Aim 2) were 
similar to those used for the cases for the ALS etiology analysis. 
Given the high validity and reliability of self-report of the potential confounders that we 
considered in the current study and the fact that the proxy or person communicating with the study 
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 participant was their spouse 144 (83%) times, we expect residual confounding that may have resulted 
from inadequate measurement of these covariates to be minimal. 
STATISTICAL ANALYSES 
The GENEVA study was approved by the Institutional Review Boards of the Durham VAMC, 
Duke University Medical Center (Durham, NC), and the National Institute of Environmental Health 
Sciences (Research Triangle Park, NC); the Institutional Review Board of the University of North 
Carolina at Chapel Hill approved this analsysis. All participants gave either written or oral informed 
consent before participating in the telephone interview. I previously completed ethics training 
administered by the University of North Carolina at Chapel Hill and the National Institute of 
Environmental Health Sciences. 
Data management/quality control 
The data management and quality control methods used to establish and maintain the Registry 
and later the GENEVA study have been described previously (98, 100).  
Cases: Enrollment of ALS cases into the Registry and post-enrollment follow-up of cases was 
complex, so Microsoft Access databases, some of which accommodated real-time data entry, were created 
to help investigators keep track of recruitment; screening; patient consent; requesting, receiving, and 
reviewing medical records; and semi-annual follow-up interviews (98). 
In some instances, neurologists could not determine whether a veteran qualified for a diagnosis of 
ALS until further medical records were received and reviewed at a later time (98). In these instances, 
medical records were reviewed by the clinical director of the Registry (98). In addition, a random sample 
of all other medical records was reviewed by the clinical director of the Registry to ensure accurate and 
consistent abstraction and diagnosing (98). All baseline (between April 1, 2003, and September 30, 2007) 
and semi-annual follow-up interviews used the same questionnaire (Appendix E) and were conducted via 
telephone (98). No follow-up interviews were conducted after September 30, 2009. 
Controls: The protocol for recruiting controls incorporated parts of the Dillman method (168), 
which was originally designed for use with mailed questionnaires (100). Specifically, invitation letters 
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 and study brochures were mailed to potential controls followed by up to three reminder letters within the 
next two months (100). The reminder letters also included a stamped return envelope and a response form 
by which potential controls could 1) opt out of or into the GENEVA study and 2) provide a current 
telephone number and preferred contact time (100). The GENEVA study team then attempted telephone 
contact with potential controls who opted into the study or who did not return the response form (100). 
Telephone numbers for potential controls who did not return the response form were obtained from freely 
available internet search engines and a commercial locator (100). Telephone calls were made at various 
times of day with the highest priority assigned to potential controls who opted into the study (100). 
The GENEVA Study Interview: The majority of the GENEVA study questionnaire (Appendix B) 
was comprised of modules developed by the ALS Consortium of Epidemiologic Studies (100), which is 
an international group of scientists (e.g., neurologists, epidemiologists, geneticists, toxicologists, and 
other researchers) with the common goal of identifying environmental, lifestyle, and genetic risk factors 
for ALS (169). Parts of the questionnaires used in the Iowa Gulf War study (170) and the MCS (171, 172) 
that were related to military service, deployments, and exposures were also adapted for use in the 
GENEVA study (100). 
Veterans enrolled in the GENEVA study were interviewed via telephone by staff at the Durham 
VAMC or by interviewers at Social and Scientific Systems, Inc. (Durham, NC), who were trained by the 
Durham VAMC staff (100). Many interviews were conducted over multiple phone calls to ease the 
burden on the patient and/or proxy/caregiver (100). Quality control checks were performed periodically 
for up to 25% of completed interviews by comparing information written down on paper copies of the 
questionnaire to that contained in an Oracle database (100). 
ALS cases and controls were asked to use the date of ALS diagnosis and the date of interview, 
respectively, as the reference date for all information they provided during the interview (100). While 
using the date of symptom onset as the reference date for ALS cases may have been theoretically 
preferable (173), the date of ALS diagnosis is likely more concrete (100) due to the insidious onset of 
ALS (3). Furthermore, the median number of months between symptom onset and ALS diagnosis among 
53 
 ALS cases in the GENEVA study was 13 months (Table 3.1), which is a relatively short amount of time 
compared to a military exposure history that usually extended years and even decades into the past (100). 
Descriptive analyses 
We conducted all analyses in the current study with SAS version 9.3 or above (SAS Institute Inc., 
Cary, NC, 2011). We used frequencies and percentages to describe distributions of clinical and 
demographic characteristics and potential confounders, such as most recent ALS diagnosis, age, etc. We 
used histograms and summary statistics such as median and interquartile range to describe variables such 
as time from symptom onset, etc., because these covariates might have been better represented in 
subsequent analyses as continuous, rather than categorical (indicator), variables. We also used histograms, 
summary statistics, frequencies, and percentages to describe distributions of outcome variables and of 
exposure variables. 
Exposure variable construction 
We constructed exposure variables the same way for analyses addressing both Specific Aims 1 
and 2 whenever possible. Differences in the natures of the outcome variables used for Specific Aims 1 
and 2 as well as the smaller sample size available for Specific Aim 2 (i.e., only ALS cases who had 
information on date of diagnosis and who had not died before enrollment in the GENEVA study), 
however, necessitated some differences in the way we constructed exposure variables for each specific 
aim. 
For analyses of military service variables, we used information on branch(es) of service and time 
period(s) of service to create variables representing number of branches of service and branch of longest 
service. We evaluated officer or warrant officer as a dichotomous variable. We used information on time 
period(s) of service to calculate years of service and to create a variable representing end (month/year) of 
most recent period of service. We evaluated number of branches of service, years of service, and end of 
most recent period of service as categorical (indicator) variables with categories formed on the basis of 
subject matter knowledge, the distributions of the variables, and/or relationships between the variables 
and the relevant outcome variable. 
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 For analyses of military deployment variables, we used information on deployment to and time 
period(s) deployed to WWII, the Korean War, the Vietnam War, and/or the Gulf War as well as 
deployment, year of first deployment, and months deployed to operations in Lebanon, Panama, Somalia, 
Bosnia, Kosovo, Rwanda, Afghanistan, and/or Iraq/Persian Gulf region (Gulf War II) to create variables 
representing ever deployed to any war/operation and war/operation of longest deployment. We evaluated 
ever deployment to any other country (besides the four wars and nine operations listed above) as well as 
ever receiving imminent danger pay, hardship duty, or combat zone tax exclusion benefits for deployment 
(i.e., deployment benefits) as two separate dichotomous variables. We used information on time period(s) 
deployed to WWII, the Korean War, the Vietnam War, and/or the Gulf War as well as year of first 
deployment and months deployed to operations in Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, 
Afghanistan, and/or Gulf War II to calculate years of deployment and to create a variable representing 
end (month/year) of most recent deployment. We used information on time period(s) for which 
deployment benefits were received to calculate total time of all periods for which deployment benefits 
were received. We evaluated years of deployment, end of most recent deployment, and total time of all 
periods for which deployment benefits were received as categorical (indicator) variables with categories 
formed on the basis of subject matter knowledge, the distributions of the variables, and/or relationships 
between the variables and the relevant outcome variable. 
For analyses of military exposure variables, we evaluated ever exposure to herbicides; 
pyridostigmine bromide pills; the anthrax and smallpox vaccines; nasopharyngeal radium; 39 (not 
counting total number of vaccines) military exposures incurred during deployment to WWII, the Korean 
War, the Vietnam War, and/or the Gulf War (these 39 exposures were evaluated separately, but combined 
over the four wars); and any exposure or experience, other than those queried, during the conflicts to 
which they had been deployed which they considered harmful or extremely stressful as well as ever 
having visited or resided in the island of Guam, the islands of New Guinea, and the Kii Peninsula of 
Japan as separate dichotomous variables. We used information on total days took pyridostigmine bromide 
pills and number of pills taken per day to calculate total number of pills taken. We evaluated exposure 
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 gradient versions of several of the exposures just listed (e.g., number of anthrax vaccine shots received) as 
well as of total number of vaccines received during deployment to WWII, the Korean War, the Vietnam 
War, and/or the Gulf War as categorical (indicator) variables with categories formed on the basis of 
subject matter knowledge, the distributions of the variables, and/or relationships between the variables 
and the relevant outcome variable. We evaluated number of days exposed to 39 military exposures 
incurred during deployment to WWII, the Korean War, the Vietnam War, and/or the Gulf War as separate 
categorical (indicator) variables (but summed over the four wars) collapsing categories when necessary. 
We evaluated felt ill after exposure to 39 military exposures incurred during deployment to WWII, the 
Korean War, the Vietnam War, and/or the Gulf War as separate categorical (indicator) variables. 
Analyses to address specific aims 
For Specific Aim 1 (ALS etiology), we used unconditional logistic regression models to estimate 
ORs and 95% CIs for associations between each military-related factor and ALS (174, 175). 
Unconditional logistic regression models were appropriate because ALS was modeled as a dichotomous 
categorical (indicator) variable (case, control) (174, 175). For exposures that had fewer than five exposed 
or unexposed cases or controls, we used exact logistic regression models. For continuous explanatory 
variables, estimated ORs represented changes in the odds of ALS resulting from one unit changes in the 
explanatory variables (174, 175). For categorical explanatory variables, estimated ORs represented 
changes in the odds of ALS resulting from changing from the reference category to an index category of 
the explanatory variables (174, 175). 
For Specific Aim 2 (ALS survival), we restricted analyses to the 616 ALS cases who had 
information on date of diagnosis and who had not died before enrollment in the GENEVA study. We used 
Cox proportional hazards regression models to estimate HRs and 95% CIs for associations between each 
military-related factor and ALS survival (176). Cox proportional hazards regression models were 
appropriate because time from the date of ALS diagnosis was modeled as a continuous variable (176). For 
continuous explanatory variables, estimated HRs represented changes in the hazard (i.e., instantaneous 
rate) of death resulting from one unit changes in the explanatory variables (176). For categorical 
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 explanatory variables, estimated HRs represented changes in the hazard of death resulting from changing 
from the reference category to an index category of the explanatory variables (176). 
For both Specific Aims 1 and 2, we adjusted for potential confounders identified from previous 
literature and evaluated using Directed Acyclic Graphs (DAGs) (177, 178). DAGs are a type of graphical 
causal diagram that facilitate the planning of research, communication of results, selection of 
covariates/potential confounders for inclusion in adjusted analyses, and conduct of sensitivity analyses 
(177, 178). DAGs can also be used to help analyze the type, direction, magnitude, and structure of 
unmeasured confounding bias, selection bias, missing data bias, or other biases on analytic results (177, 
178). To construct a DAG to analyze confounding and identify covariates that need to be controlled to 
mitigate it, the exposure, outcome, and relevant covariates/potential confounders of the exposure-outcome 
relationship are plotted (177, 178). Causal (or potentially causal) relationships between the exposure, 
outcome, and/or covariates are depicted on the DAG as arrows (177, 178). The location and direction of 
the arrows are determined using information from previous literature and subject-matter knowledge (177, 
178). A set of rules is then followed to arrive at the set of covariates/potential confounders, called the 
“minimally sufficient adjustment set” (MSAS), that need to be controlled in order to mitigate the 
confounding bias depicted by the DAG (177, 178). 
For Specific Aim 1, we identified the following risk factors for ALS from previous literature to 
consider as potential confounders: age, gender, cigarette smoking, race/ethnicity, family history of ALS 
or other neurodegenerative diseases, trauma, head injury, physical activity/professional sports, rural 
residence, occupation, pesticides, electrical injury/shock or magnetic fields (non-ionizing radiation), lead 
or other heavy metals, and solvents. Note that occupation, pesticides, non-ionizing radiation, and solvents 
are also exposures of interest in the current study. 
The DAG shown in panel (a) of Figure 3.3 corresponds to all analyses involving military service 
variables. The arrows from age, sex, and race/ethnicity to military service variables and ALS etiology 
depict relationships between each covariate and military service variables and ALS etiology, respectively. 
We did not include family history of ALS or other neurodegenerative diseases and geographic residence 
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 in the DAG because they have not been associated with military service, deployments, and/or exposures 
in previous studies. Similarly, we thought that the following covariates were potentially affected by 
and/or more likely to occur temporally after military service, deployments, and/or exposures, so we did 
not include them in our DAG: cigarette smoking, electrical injury, magnetic fields, lead, occupation, 
pesticides, physical activity/professional sports, solvents, and trauma/head injury. 
Age, sex, and race/ethnicity all have relationships with both military service variables and ALS 
etiology. Therefore, all three variables are confounders, are part of the MSAS, and were controlled in all 
of our analyses. In addition, we adjusted for factors used to match the GENEVA study controls to cases 
(age and use of VA health care system) (100). 
The DAG shown in panel (b) of Figure 3.3 corresponds to all analyses involving military 
deployments and exposures. The addition of branch of service is the only difference between the DAGs 
shown in panels (a) and (b) of Figure 3.3. Branch of service is related to both military deployments and 
exposures and ALS etiology. Therefore, branch of service is a confounder, part of the MSAS, and was 
controlled in all of our analyses involving military deployments and exposures. 
For Specific Aim 2, we identified the following prognostic factors for ALS survival from 
previous literature to consider as potential confounders: age at diagnosis, bulbar onset, clinical features 
(e.g., lower baseline ALSFRS-R score), time between symptom onset and diagnosis, diagnosis category, 
gender, psychosocial factors, therapeutic interventions (e.g., riluzole treatment, non-invasive positive 
pressure ventilation), agricultural occupation, and lead exposure. 
The DAG shown in panel (a) of Figure 3.4 corresponds to all analyses involving military service 
variables and deployments. The arrows from age and sex to military service variables and deployments 
and ALS survival depict relationships between each covariate and military service variables and 
deployments and ALS survival, respectively. We did not include the following covariates in the DAG 
because they have not been associated with military service, deployments, and/or exposures in previous 
studies: agricultural occupation, baseline ALSFRS-R score, bulbar onset, diagnosis category, therapeutic 
interventions, and time between symptom onset and diagnosis. Similarly, we thought that lead exposure 
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 and psychosocial factors were potentially affected by and/or more likely to occur temporally after military 
service, deployments, and/or exposures, so we did not include them in our DAG. 
Only age and sex have relationships with military service variables and deployments and ALS 
survival. Therefore, age and sex are confounders and are part of the MSAS. We did not adjust for sex in 
our main models, however, due to the small number of female cases (n = 13) and deaths (n = 10) in our 
study. 
The DAG shown in panel (b) of Figure 3.4 corresponds to all analyses involving military 
exposures. The only difference between the DAGs shown in panels (a) and (b) of Figure 3.4 is the 
addition of wars/operations of deployment. Wars/operations of deployment is related to both military 
exposures and ALS survival. Therefore, wars/operations of deployment is a confounder, part of the 
MSAS, and was controlled in all of our analyses involving military exposures. 
For our main analyses and to address the sub-aims for Specific Aims 1 and 2 (selection bias), we 
used stabilized inverse probability weights (IPW) (105, 179), a type of propensity score, to adjust 1) for 
the confounders identified by the four DAGs described above, 2) for potential bias resulting from missing 
data in ALSFRS-R scores for 8% of cases enrolled in the Registry, and 3) for potential selection bias 
resulting from studying ALS cases who likely represent long survivors and controls who may be different 
from U.S. military veterans at large (100, 180). Specifically, we used linear, logistic, or polytomous 
logistic regression models, depending on the nature of the exposure variable, to calculate stabilized 
confounding weights for each exposure separately (179, 181). We also used logistic regression models to 
calculate stabilized missing covariate data and selection weights, which were informed by our analysis of 
relationships between clinical, demographic, and/or military characteristics and participation in the 
GENEVA study among the Registry cases (Appendix F, Tables F.1; Appendix G, Tables G.1) and among 
the BIRLS potential controls (Appendix F, Tables F.2), and then multiplied the three weights to obtain an 
overall stabilized weight (179, 181). 
IPW for confounding creates a pseudo-population in which confounding by measured covariates 
does not exist (179, 181-183). In terms of the DAG in panel (a) of Figure 3.3, this would be akin to 
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 removing the arrows between military service variables and the three potential confounders in the MSAS 
(i.e., age, sex, and race/ethnicity) (181). The idea is also similar to using sampling weights (which are 
usually defined as the inverse of the probability of selection (184)) to generalize the results of a sample to 
a target population or to standardizing disease rates of one population to the distribution of a particular 
covariate (e.g., age) in another population. In fact, IPW have been shown to be a tool for standardization 
(185). In standard regression model analyses, each person in the model has a weight of one (i.e., he or she 
represents himself or herself only). IPWs for confounding create the pseudo-population by re-weighting 
each person in the model in such a way that the resulting distributions of the potential confounders are not 
associated with the exposure (i.e., no confounding) (179, 181-183). Unstabilized IPWs for confounding 
are calculated as one over the probability of exposure conditional on the potential confounders (181-183, 
185). Standard regression models (e.g., linear, logistic, polytomous logistic) are used to calculate the 
conditional probability of exposure (181, 182). 
IPWs for missing covariate data bias and selection bias are calculated in similar ways and 
selection bias can be conceptualized as missing data bias (105). Thus, only IPWs for selection bias will be 
described here, but the concepts and procedures apply equally well to missing covariate data bias (105). 
IPWs for selection bias create a pseudo-population in which the selection bias does not exist 
(105). As stated above, in standard regression model analyses, each person in the model has a weight of 
one, which means potential selection bias is ignored. IPWs for selection bias create the pseudo-population 
by re-weighting each person who joined the study to represent those with identical covariate patterns who 
died or chose not to participate (105). For example, consider two 65 year-old male ALS cases who had 
enrolled in the Registry and who had definite ALS, bulbar onset of symptoms, and a baseline (i.e., at 
enrollment in the Registry) ALSFRS-R score of 30 (for simplicity, the other covariates that were used to 
construct IPWs are ignored here). If one ALS case decided not to participate in the GENEVA study, then 
the other ALS case would be re-weighted to represent himself or herself and the non-participating ALS 
case (i.e., the ALS case who participated in the study would be assigned a weight of two). Unstabilized 
IPWs for selection bias are calculated as one over the probability of participation conditional on variables 
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 that are related to selection/participation, the exposure, and the outcome under study (182). Standard 
logistic regression models are used to calculate the conditional probability of participation, which is 
generally represented as a dichotomous variable (182). 
The precision of effect measure estimates calculated via IPWs can be improved (i.e., narrower 
CIs) by stabilizing the weights (179, 181-183, 186). IPWs for confounding are stabilized by replacing the 
numerator of the weight, one in unstabilized weights, with the overall probability of exposure, which is 
calculated using an intercept-only regression model (181-183, 185). Similarly, IPWs for missing covariate 
data or selection bias are stabilized by replacing the numerators of the weights, one in unstabilized 
weights, with the overall probability of complete data or participation, respectively, which is calculated 
using an intercept-only regression model (181, 182). The overall stabilized weight is simply the product 
of the stabilized confounding, missing covariate data, and selection weights (179, 181). The sum of the 
stabilized missing covariate data weights equals the size of the sample after missing covariate data has 
occurred, whereas the sum of the stabilized selection weights equals the size of the sample after censoring 
(i.e., non-participation) has occurred (183). The mean of the overall stabilized IPWs equals one, which is 
also true for the separate sums of the stabilized IPWs for confounding, missing covariate data, and 
selection (179, 183). 
The four assumptions that must be met in order for IPWs to yield valid causal inferences are 
consistency, exchangeability, positivity, and no misspecification of the model(s) used to estimate the 
weights (179, 181, 182). Consistency, which is often assumed to be met, “means that a subject’s 
counterfactual outcome under her observed exposure history is precisely her observed outcome” (179). 
Exchangeability means there is no unmeasured confounding/missing covariate data/selection bias (105, 
179, 181-183, 185, 186). Positivity refers to the requirement that “there are both exposed and unexposed 
individuals at every level of the confounders” or at every level of variables related to missing covariate 
data or selection/participation and the outcome of interest (179, 183). Often, this assumption can be 
ignored if non-positivity (i.e., zero cells at one or more levels of the confounders) is random, but not if it 
is non-random (179). An example of non-random non-positivity is an occupational epidemiological study 
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 of the health effects of a certain chemical. In such studies, being at work is often used as a proxy for 
health status, which is a potential confounder (179). If a worker cannot be exposed to the chemical of 
interest outside of work, then non-random non-positivity occurs because the probability of exposure 
among those who no longer work is zero (105, 179, 181). Examples of methods that can be used to check 
the assumptions are provided elsewhere, although consistency is not empirically verifiable (179). More 
detailed information on descriptions of, the rationale behind, and assumptions for IPWs are also provided 
elsewhere (105, 179, 181-183, 185, 186). 
For Specific Aim 1, we calculated the numerators of the stabilized confounding weights as 
described above and the denominators of these weights as predicted probabilities of exposure from a 
model including the matching factors (age, use of VA health care system) and the covariates in the 
pertinent MSAS as independent variables. For the denominator models, we centered age at 60—the 
median age among controls—and modeled it with linear and quadratic terms because this form gave the 
lowest value of the Akaike Information Criterion (AIC) (187, 188). Race and ethnicity were combined 
into one variable and modeled with two categories: non-Hispanic White and other. Use of VA health care 
system, sex, and branch of longest service (for military deployment and exposure variables only) were 
modeled as shown in Table 3.1. 
We calculated stabilized selection weights for ALS cases and controls separately because cases 
were enrolled from the Registry whereas controls were enrolled from the BIRLS database and these two 
sampling frames contained different types and breadths of data (100). Furthermore, the causes of 
participation in the GENEVA study and factors related to it likely differed among cases and controls. For 
example, the main causes of participation among cases were likely vital status and the progression of the 
disease and, therefore, factors related to ALS progression and survival were also likely related to 
participation. For controls, the main causes of participation were likely the matching strategy employed 
by the study design and other causes present in typical epidemioligcal studies (e.g., altruism). Therefore, 
the matching factors and other demographic factors were likely related to participation among controls 
(100, 180). 
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 For the numerators of the ALS case selection weights, we calculated the predicted probabilities of 
participation as described above; and, for the denominators of the weights, we calculated the predicted 
probabilities conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent 
ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis, time from diagnosis to 
enrollment in the Registry, and baseline (i.e., at enrollment in the Registry) ALSFRS-R score. We did not 
include the exposures of interest in the numerator or denominator models for the case selection weights 
because data on the exposures of interest were available for only the 630 ALS cases who enrolled in the 
GENEVA study. For the denominator model, we modeled race/ethnicity the same way as for the 
confounding weights and being a current patient of a VA Medical Center, most recent ALS diagnosis, and 
site of symptom onset as shown in Table 3.1 and Appendix F, Table F.1. We modeled time from 
symptom onset to diagnosis with linear, quadratic, and cubic terms; time from diagnosis to enrollment in 
the Registry with a linear term; and baseline ALSFRS-R score with a restricted, quadratic spline with 
knots at 12, 34, and 44 based on percentiles of the distribution in the GENEVA study cases (we used SAS 
code from (188) to create the splines) because these forms gave the lowest values of the AIC (187, 188). 
For controls, we calculated the numerators of the stabilized selection weights as described above 
and the denominators of these weights as predicted probabilities of participation from a model including 
year of birth, use of VA health care system, and their interaction as independent variable. We did not 
include the exposures of interest in the numerator or denominator models for the control selection weights 
because data on the exposures of interest were available only for the 975 controls who enrolled in the 
GENEVA study. For the denominator model, we modeled use of VA health care system the same way as 
for the confounding weights and year of birth with a restricted, quadratic spline with knots at 1920, 1947, 
and 1974 based on percentiles of the distribution in the BIRLS potential controls (we used SAS code from 
(188) to create the splines) because this form gave the lowest value of the AIC (187, 188). 
Eight percent of ALS cases enrolled in the Registry were missing data in baseline (i.e., at 
enrollment in the Registry) ALSFRS-R scores, which was included as a covariate in the denominator 
models of the ALS case stabilized selection weights. Therefore, for cases only, we also calculated 
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 stabilized missing covariate data weights to account for this potential bias. For the numerators of these 
weights, we calculated the predicted probabilities of not missing data in baseline ALSFRS-R score as 
described above; and, for the denominators of the weights, we calculated the predicted probabilities 
conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis, 
and time from diagnosis to enrollment in the Registry. We did not include the exposures of interest in the 
numerator or denominator models for the missing covariate data weights because data on the exposures of 
interest were available for only the 630 ALS cases who enrolled in the GENEVA study. For the 
denominator model, we modeled most recent ALS diagnosis and site of symptom onset as shown in Table 
3.1. We modeled time from symptom onset to diagnosis with the natural logarithm of a linear term and 
time from diagnosis to enrollment in the Registry with a restricted, quadratic spline with knots at 7.72, 
13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing 
covariate data (we used SAS code from (188) to create the splines) because these forms gave the lowest 
values of the AIC (187, 188). 
For Specific Aim 2, the procedures used to calculate the stabilized confounding, selection, and 
missing covariate data weights were identical to those used for the cases for Specific Aim 1 with the only 
difference being the covariates from the relevant MSASs included in the denominator models for the 
confounding weight. Specifically, we calculated the denominators of the confounding weights as 
predicted probabilities of exposure from a model including age as the only independent variable. We 
modeled age with indicator variables corresponding to five-year groups. There were no other differences 
between the procedures used to calculate the stabilized confounding, selection, and missing covariate data 
weights for Specific Aims 1 and 2. 
To informally assess the bias-variance (validity-precision) tradeoff (189, 190), we progressively 
truncated the overall stabilized weights by symmetrically resetting weights less or greater than a certain 
percentile (e.g., 1st and 99th, 5th and 95th, 10th and 90th, etc.) to the value of that percentile (179). 
Regarding the ORs or HRs derived from the untruncated weights as the “true” values, we informally 
evaluated bias-variance tradeoff by looking at how features of both the weights and the corresponding 
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 ORs or HRs changed with increasing truncation. Truncating the overall stabilized weights at the 0.5 and 
99.5 percentiles appeared to be the best balance of validity and precision for Specific Aim 1, whereas not 
truncating the overall stabilized weights appeared to be the best balance of validity and precision for 
Specific Aim 2. 
After the overall stabilized weights were calculated (and truncated if applicable), we applied the 
overall stabilized weights to logistic (Specific Aim 1) or Cox proportional hazards (Specific Aim 2) 
regression models for ALS etiology or survival, respectively, that contained the exposure of interest as the 
only explanatory variable in the same way sampling weights are applied when analyzing data from 
complex survey sampling designs (179, 181). We calculated 95% CIs using robust variance estimates 
because using weights for analysis induces within-subject correlation (182). The weighted ORs and 95% 
CIs apply to the population of 1,785 Registry cases who had diagnoses of clinically definite, probable, 
probable and lab supported, possible, or suspected ALS and no missing data on any covariates used to 
calculate the various IPWs as well as the population of 9,992 potential controls obtained from the BIRLS 
database who had no missing data on any covariates used to calculate the various IPWs. Similarly, the 
weighted HRs and 95% CIs apply to the population of 1,783 Registry cases who had diagnoses of 
clinically definite, probable, probable and lab supported, possible, or suspected ALS; had not died before 
enrolling in the Registry (some cases were enrolled by proxy after they died); had a date of diagnosis 
available; and had no missing data on any covariates used to calculate the various IPWs. 
We modeled the exposure variables as categorical (i.e., indicator) variables to determine and 
describe the shapes of exposure-response relationships between the variables and the relevant outcome 
variable. In addition, we used within-category medians, calculated using all controls for Specific Aim 1 
and using all cases for Specific Aim 2, to assess linear exposure-response trends for eight exposures (191) 
and scaled many linear trend ORs or HRs to interquartile range increases in the original continuous 
exposure variables, calculated using all controls for Specific Aim 1 and using all cases for Specific Aim 
2. We used the midpoints of each category, and 50% above the lower bound of the top category, to 
separately assess linear exposure-response trends for number of days exposed to 32 military exposures 
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 incurred during deployment to WWII or the Korean, Vietnam, or Gulf Wars (summed over the four 
wars). We used ordinal scores to separately assess linear exposure-response trends for feeling ill after 
exposure to the same 32 exposures. 
We tested regression model and IPW assumptions throughout the analyses. Specifically, we 
checked regression model convergence, coefficient estimation, residual diagnostics, etc. (174-176). For 
Specific Aim 2, we checked the proportional hazards assumption for Cox proportional hazards regression 
models by evaluating the statistical significance of interactions between the covariate of interest and three 
versions (linear, natural logarithm of linear, and dichotomized at the median in separate models) of time 
since diagnosis (176). For IPW, we checked nearness of the mean weights to one, number of extreme 
weights, positivity, no misspecification of the model(s) used to estimate the weights, etc. (179, 181, 182). 
We also conducted several secondary analyses. We used standard regression adjustment methods 
to adjust for potential confounding but without adjustment for potential selection or missing covariate 
data bias. We separately analyzed deployment-specific exposures for veterans who were deployed to the 
Vietnam War (cases: n = 149 of 234, 64%; controls: n = 278 of 347, 80%); there were too few veterans 
who were deployed to WWII (cases: n = 37 of 234, 16%; controls: n = 12 of 347, 3%), the Korean War 
(cases: n = 38 of 234, 16%; controls: n = 38 of 347, 11%), or the Gulf War (cases: n = 16 of 234, 7%; 
controls: n = 31 of 347, 9%) to analyze deployment-specific exposures for these wars separately. To 
reduce heterogeneity in the outcome used for Specific Aim 1, we restricted separate analyses to cases who 
enrolled in the GENEVA study within two years of diagnosis (n = 248 of 623, 40%); cases who received 
a diagnosis of clinically definite, clinically probable, or clinically probable and lab supported ALS (n = 
468 of 630, 74%); participants who did not report a family history of ALS (cases: n = 585 of 602, 97%; 
controls: n = 951 of 957, 99%); or participants who did not ever visit or reside in the island of Guam, the 
islands of New Guinea, or the Kii Peninsula of Japan (cases: n = 498 of 594, 84%; controls: n = 764 of 
956, 80%). For better control of confounding by sex and/or race/ethnicity, we restricted analyses to 
participants who were men (cases: n = 617 of 630, 98%; controls: n = 907 of 975, 93%) or non-Hispanic 
White men (cases: n = 560 of 622, 90%; controls: n = 787 of 960, 82%). To mitigate potential bias from 
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 exposure misclassification, we restricted analyses to participants who did not require a proxy to complete 
the telephone interview (cases: n = 596 of 630, 95%; controls: n = 974 of 975, 100%). Because ALS cases 
and controls were asked to use the date of ALS diagnosis and the date of interview, respectively, as the 
reference date for all information they provided (100), controls may have had more time than ALS cases 
during which they could have been exposed. To address potential bias from this source, we excluded 
exposure time from a control’s time-related variables (e.g., years of service) if the end of the control’s 
period of service or deployment was within 30 months, the median time between diagnosis and interview 
for cases), of the control’s interview date. For analyses involving military exposures, we calculated 
Spearman correlation coefficients to identify moderate to high correlations between exposures and then 
attempted to account for these correlations by adjusting for the exposure that was most strongly correlated 
with the exposure of interest. 
Data interpretation issues 
There are likely inherent selection biases in the GENEVA study. These biases and our approach 
to mitigating their effect on our results have been discussed in detail in Chapter 1 and in Analyses to 
Address Specific Aims. 
There were likely multiple sources of bias from exposure measurement error (i.e., 
misclassification) in the current study as well (e.g., recall bias, use of proxy respondents for 34 cases, 
5%). A detailed discussion of several of these biases was provided in Exposure Assessment. 
The exposure status of participants in the GENEVA study may have been misclassified in the 
current study because individuals may have experienced specific exposures in non-military settings. The 
GENEVA study collected the entire occupational histories of study participants, but these data are 
currently undergoing industrial hygiene review and/or data cleaning and were not available for the current 
analysis. Therefore, we were not able to address this potential source of exposure misclassification in the 
current analysis. 
Missing covariate data bias was also possible in the current study and could have affected the 
variables that were included in the IPWs described in Analyses to Address Specific Aims. In fact, we 
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 created another IPW to address missing covariate data bias in baseline (i.e., at enrollment in the Registry) 
ALSFRS-R scores for 8% of cases enrolled in the Registry. 
Heterogeneity in the outcome used for Specific Aim 1 (ALS etiology) may have affected results. 
Our approach to exploring its effect on our results was described in Analyses to Address Specific Aim. 
Similarly, our approach to mitigating immortal person-time bias was described in Outcome Assessment. 
For both Specific Aims 1 and 2, there may have been unmeasured confounders of the 
relationships under study. The Registry and the GENEVA study, however, collected information on a 
number of potential confounders. Furthermore, we used previous literature and DAGs to investigate the 
structure of confounding that may have been expected in our study and to identify covariates to control to 
mitigate it. We also conducted analyses in which we restricted analyses to participants who were men or 
non-Hispanic White men. 
The assumptions needed to correctly use regression models and/or IPW could have been violated 
in the current study. Our approach to testing/checking regression model and IPW assumptions was 
described in Analyses to Address Specific Aims. 
One of the strengths of the current study is that we evaluated associations between aspects of 
military service, deployments, and 40 exposures and ALS etiology and survival. This strength will 
undoubtedly be viewed by some as a “multiple comparisons problem”. This view, however, relies on the 
“universal null hypothesis” that all associations observed within a given body of data reflect only random 
variation (192, 193). In other words, nature is not governed by natural laws or causal relations, but 
random variation instead (192, 193). Such a notion is absurd (192, 193). Furthermore, the implicit 
assumption that high (or low) p-values indicate the absence (or presence) of causal relationships ignores 
the facts that variability from sources other than random variability, such as measurement, confounding, 
or selection, also determine the final effect measure estimates and p-values (192, 193). It is entirely 
possible that the current study identified an association between a certain exposure and ALS which 
disappeared after controlling for confounders or after adjusting for selection bias. Correcting for multiple 
comparisons diminishes the effective power of studies and increases the probability of a type II error (i.e., 
68 
 the probability of failing to reject the null hypothesis when, in fact, it is false) (192, 193). Another 
absurdity that is ignored in practice is that correcting for multiple comparisons would need to be 
completed across different papers arising from the same study (192, 193). For example, instead of just 
correcting for the number of hypothesis tests that were completed in the current study, we would also 
need to correct for all of the other published and unpublished (and not yet planned) hypotheses tests that 
have been and will be completed using data from the GENEVA study (192, 193). Thus, for these and 
other reasons discussed elsewhere (192, 193), it is incorrect and inappropriate to correct for multiple 
comparisons and, therefore, we did not do so in the current study. 
Exposures encountered during military service may have been correlated. Therefore, for analyses 
involving military exposures, we calculated Spearman correlation coefficients to identify moderate to 
high correlations between exposures and then attempted to account for these correlations by adjusting for 
the exposure that was most strongly correlated with the exposure of interest. More sophisticated methods, 
such as latent class analysis (194) (which could have been used to derive exposure patterns (195)), were 
likely not possible because of missing data in the exposure variables. For example, for the 17 military 
exposures for which information was collected for all four major wars (WWII and the Korean, Vietnam, 
and Gulf Wars; Table 3.1), the effective sample size would have been reduced by missing data from 581 
participants (234 cases, 347 controls) to 347 participants (136 cases, 211 controls) (i.e., a 40% reduction). 
STATISTICAL POWER 
For Specific Aim 1, all statistical power calculations were completed via Monte Carlo simulation 
using 1,000 random iterations and SAS, version 9.3 (SAS Institute Inc., Cary, NC). For simplicity, we 
only performed statistical power calculations for unadjusted associations between dichotomous military 
service, deployment, and exposure variables and ALS. Specifically, we performed calculations for the 
approximate minimum, median, and maximum levels of three criteria observed among exposure variables 
in our data. These three criteria were 
1) the proportion of missing data in exposure variables (for military service, deployment, and 
exposure variables: minimum = 0.01, median = 0.05, maximum = 0.1; for military exposure 
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 variables incurred during deployment to WWII or the Korean, Vietnam, or Gulf Wars: minimum 
= 0.01, median = 0.05, maximum = 0.1) 
2) the exposure prevalence (for military service, deployment, and exposure variables: minimum = 
0.01, median = 0.2, maximum = 0.85; for military exposure variables incurred during deployment 
to WWII or the Korean, Vietnam, or Gulf Wars: minimum = 0.02, median = 0.25, maximum = 
0.65) 
3) the baseline risk of ALS in the unexposed (for military service variable, deployment, and 
exposure variables: minimum = 0.35, median = 0.4, maximum = 0.45; for military exposure 
variables incurred during deployment to WWII or the Korean, Vietnam, or Gulf Wars: minimum 
= 0.35, median = 0.4, maximum = 0.45) 
We simulated the values of the OR that will be detectable with 0.8 power for two-sided hypothesis tests at 
a conventional significance level of α = 0.05. 
Statistical power calculations for associations between military service, deployment, and 
exposure variables and ALS, based on 1,605 participants, are shown in Table 3.4. If the proportion of 
missing data is 0.05, the exposure prevalence is 0.2, and the baseline risk of ALS in the unexposed is 0.4 
(i.e., the approximate median values of all three criteria), then for Specific Aim 1 we will have 0.8 power 
to detect an OR of 1.43 or greater for a two-sided test at α = 0.05 (Table 3.4). Other scenarios are shown 
in Table 3.4. 
Table 3.5 shows statistical power calculations for associations between ALS and military 
exposure variables incurred during deployment to WWII or the Korean, Vietnam, or Gulf Wars. These 
calculations are based on the 581 participants who were deployed to one of the four wars just listed. If the 
proportion of missing data is 0.05, the exposure prevalence is 0.25, and the baseline risk of ALS in the 
unexposed is 0.4 (i.e., the approximate median values of all three criteria), then for Specific Aim 1 we 
will have 0.8 power to detect an OR of 1.74 or greater for a two-sided test at α = 0.05 (Table 3.5). Other 
scenarios are shown in Table 3.5. 
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 For Specific Aim 2, all statistical power calculations were completed via the POWER procedure 
in SAS, version 9.3 (SAS Institute Inc., Cary, NC). For simplicity, we only performed statistical power 
calculations for unadjusted associations between dichotomous military service, deployment, and exposure 
variables and ALS survival. Specifically, we performed calculations for the approximate minimum, 
median, and maximum levels of the same three criteria listed for Specific Aim 1 above. These three 
criteria were 
1) the proportion of missing data in exposure variables (for military service, deployment, and 
exposure variables: minimum = 0.01, median = 0.1, maximum = 0.25; for military exposure 
variables incurred during deployment to WWII or the Korean, Vietnam, or Gulf Wars: minimum 
= 0.02, median = 0.05, maximum = 0.15) 
2) the exposure prevalence (for military service, deployment, and exposure variables: minimum = 
0.01, median = 0.15, maximum = 0.85; for military exposure variables incurred during 
deployment to WWII or the Korean, Vietnam, or Gulf Wars: minimum = 0.02, median = 0.25, 
maximum = 0.7) 
3) the baseline risk of death in the unexposed (for military service variable, deployment, and 
exposure variables: minimum = 0.7, median = 0.72, maximum = 0.75; for military exposure 
variables incurred during deployment to WWII or the Korean, Vietnam, or Gulf Wars: minimum 
= 0.7, median = 0.75, maximum = 0.8) 
We calculated the values of the HR that will be detectable with 0.8 power for two-sided hypothesis tests 
at a conventional significance level of α = 0.05. 
Statistical power calculations for associations between military service, deployment, and 
exposure variables and ALS survival, based on 616 ALS cases, are shown in Table 3.6. If the proportion 
of missing data is 0.1, the exposure prevalence is 0.15, and the baseline risk of death in the unexposed is 
0.72 (i.e., the approximate median values of all three criteria), then for Specific Aim 2 we will have 0.8 
power to detect an HR of 1.47 or greater for a two-sided test at α = 0.05 (Table 3.6). Other scenarios are 
shown in Table 3.6. 
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 Table 3.7 shows statistical power calculations for associations between ALS survival and military 
exposure variables incurred during deployment to WWII or the Korean, Vietnam, or Gulf Wars. These 
calculations are based on the 228 ALS cases who were deployed to at least one of the four wars just 
listed. If the proportion of missing data is 0.05, the exposure prevalence is 0.25, and the baseline risk of 
death in the unexposed is 0.75 (i.e., the approximate median values of all three criteria), then for Specific 
Aim 2 we will have 0.8 power to detect an HR of 1.63 or greater for a two-sided test at α = 0.05 (Table 
3.7). Other scenarios are shown in Table 3.7.
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 Figure 3.1. Flow diagram depicting the ascertainment of the GENEVA study cases. Solid boxes or lines 
represent cases who advanced past each step shown. Small-dashed boxes or lines represent cases who 
were excluded after each step shown. Abbreviations: ALS, amyotrophic lateral sclerosis; GENEVA, 
Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis. 
 
Final sample: n = 630 
Complete interview: n = 604 Partial interview: n = 26 
Withdrawal: n = 31 Deceased: n = 33 Passive refusal: n = 30 
Consented: n = 724 
Able to contact for GENEVA enrollment: n = 843 
Did not attempt to contact: n = 266 Unable to contact: n = 37 
Consented for DNA Bank: n = 1,346 
Missing: n = 75 Deceased: n = 214 
 
Permission to re-contact for further studies: n = 1,830 
No permission to re-contact for further studies: n = 26 
Enrolled in the National Registry of Veterans with ALS: n = 2,122 
Sporadic ALS: n = 1,856 
Not sporadic ALS: n = 248 Withdrawal: n = 18 
Refused: n = 195 
Deceased: n = 200 
 
Ineligible: n = 25 Passive refusal: n = 10 Active refusal: n = 84 
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 Figure 3.2. Flow diagram depicting the ascertainment of the GENEVA study controls. Solid boxes or 
lines represent potential controls who advanced past each step shown. Small-dashed boxes or lines 
represent potential controls who were excluded after each step shown. Abbreviations: GENEVA, Genes 
and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis.  
 
Beneficiary Identification and Records Locator System sample: n = 10,000 
Address available: n = 8,929 
No address available: n = 1,071 
Invitation mailed: n = 4,420 
No invitation mailed: n = 4,509 
Able to contact by telephone: n = 2,728 
Deceased: n = 106 Unable to contact by telephone: n = 1,586 
Eligibility status determined: n = 1,618 + 9 = 1,627 
Passive refusal: n = 36 Active refusal: n = 1,074 
Contacted GENEVA: n = 9 
Eligible: n = 1,536 
Ineligible: n = 91 
Consented: n = 1,055 
Deceased: n = 1 Passive refusal: n = 232 Active refusal: n = 248 
Complete interview: n = 959 Partial interview: n = 16 
Withdrawal: n = 38 Deceased: n = 2 Passive refusal: n = 40 
Final sample: n = 975 
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 Table 3.1. Distributions of ALS cases and controls in the GENEVA study (100) compared to all U.S. veterans (31) for certain demographic and 
military characteristics. 
  Cases (n = 630) Controls (n = 975) Adjusteda U.S. Veterans [n ≈ 21,000,000 (30)] 
Characteristic No. % No. % OR 95% CI % 
Most recent ALS diagnosis        
Clinically definite 151 24      
Clinically probable 215 34      
Clinically probable and lab supported 102 16      
Clinically possible 48 8      
Suspected (progressive bulbar palsy or progressive muscular atrophy) 114 18      
Family history of ALS        
No 585 97 951 99 1.00 Referent  
Yes 17 3 6 1 4.73 1.85, 12.09  
Missing 28  18     
Site of symptom onset        
Bulbar 89 14      
Extremities 509 81      
Otherb 31 5      
Missing 1       
Time from symptom onset to diagnosis (months)        
≤ 6 118 19      
> 6-12 168 27      
> 12-18 105 17      
> 18-24 47 8      
> 24 173 28      
Missing 19       
Median ± IQR 13 ± 18       
Time from diagnosis to enrollment in the Registry (months)        
≤ 12 220 35      
> 12-24 144 23      
> 24-36 75 12      
> 36-48 44 7      
> 48 140 22      
Missing 7       
Median ± IQR 18 ± 32       
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   Cases (n = 630) Controls (n = 975) Adjusteda U.S. Veterans [n ≈ 21,000,000 (30)] 
Characteristic No. % No. % OR 95% CI % 
Time from enrollment in the Registry to enrollment in the GENEVA study (months)        
≤ 6 181 29      
> 6-12 208 33      
> 12-18 97 15      
> 18-24 74 12      
> 24 70 11      
Median ± IQR 9 ± 11       
Baselinec ALSFRS-R score (possible range: 0-48)d        
≤ 16 135 21      
> 16-23 120 19      
> 23-30 139 22      
> 30-35 114 18      
> 35 122 19      
Median ± IQR 27 ± 16       
Currently using riluzole (baselinec)        
No 306 50      
Yes 308 50      
Missing 16       
Currently using BiPAP to assist with breathing (baselinec)        
No 493 79      
Yes 131 21      
Missing 6       
Currently using CPAP to assist with breathing (baselinec)        
No 605 96      
Yes 24 4      
Missing 1       
Currently using a ventilator (≥ two weeks, 15 hours/day) to assist with breathing 
(baselinec)        
No 586 93      
Yes 44 7      
Currently using tracheostomy to assist with breathing (baselinec)        
No 583 93      
Yes 44 7      
Missing 3       
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   Cases (n = 630) Controls (n = 975) Adjusteda U.S. Veterans [n ≈ 21,000,000 (30)] 
Characteristic No. % No. % OR 95% CI % 
Currently using a feeding tube (baselinec)        
No 440 80      
Yes 111 20      
Missing 79       
Age (years)        ≤ 29 9 1 6 1   5 
30-39 33 5 48 5   6 
40-49 69 11 117 12   15 
50-59 174 28 287 29   18 
60-69 210 33 332 34   26 
70-79 121 19 172 18   19 
> 79 14 2 13 1   11 
Median ± IQR 60 ± 14  60 ± 15    NA Use of VA health care system        
No 368 59 571 59   72 
Yes 261 41 402 41   28 
Missing 1  2     
Sex        Male 617 98 907 93 1.00 Referent 92 
Female 13 2 68 7 0.27 0.15, 0.49 8 
Racial category        White 583 93 866 90 1.00 Referent 87 
Black or African-American 24 4 61 6 0.59 0.36, 0.95 11 
Other/Multiple 17 3 36 4 0.70 0.39, 1.25 3 
Missing 6  12     Ethnic group        Not Hispanic/Latino 612 98 937 97 1.00 Referent 95 
Hispanic/Latino 15 2 32 3 0.73 0.39, 1.36 5 
Missing 3  6     Ever applied for VA benefits of any type        No 100 18 154 16 1.00 Referent NA 
Yes 468 82 820 84 0.79 0.59, 1.05 NA 
Missing 62  1     
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   Cases (n = 630) Controls (n = 975) Adjusteda U.S. Veterans [n ≈ 21,000,000 (30)] 
Characteristic No. % No. % OR 95% CI % 
Highest degree attained        Grade school (grades 1-8) 21 3 17 2 1.47 0.76, 2.84 5 
High school diploma 265 42 315 32 1.00 Referent 56e 
Technical or vocation school diploma or Associate degree 118 19 231 24 0.61 0.46, 0.80 9 
College or graduate school or doctorate 221 35 348 36 0.75 0.59, 0.95 29 
Other 5 1 64 7 0.09 0.04, 0.24 NA 
Cigarette smoking status        
Never 214 35 358 37 1.00 Referent 36 
Past 311 51 471 49 1.12 0.89, 1.41 45 
Current 86 14 134 14 1.11 0.80, 1.53 19 
Missing 19  12     
Military branch of longest servicef, g        Air Force (including Army Air Force) 130 21 204 21 0.80 0.60, 1.05 20 
Army 255 41 321 33 1.00 Referent 47 
Marines (including Merchant Marines) 58 9 76 8 0.93 0.64, 1.37 10 
Navy 140 22 186 19 0.94 0.71, 1.24 23 
Otherh 45 7 186 19 0.30 0.21, 0.43 2 
Missing 2  2     Officer or Warrant Officer        No 526 84 756 78 1.00 Referent NA 
Yes 102 16 217 22 0.67 0.52, 0.87 NA 
Missing 2  2     Years of military service        ≤ 1 15 2 23 2 0.65 0.33, 1.26 NA 
> 1-5 425 68 434 45 1.00 Referent NA 
> 5-10 60 10 184 19 0.31 0.22, 0.43 NA 
> 10-20 48 8 104 11 0.44 0.30, 0.64 NA 
> 20 80 13 230 24 0.36 0.27, 0.48 NA 
Missing 2  0     Median ± IQR 4 ± 6  6 ± 17  0.48
i 0.39, 0.59i NA 
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   Cases (n = 630) Controls (n = 975) Adjusteda U.S. Veterans [n ≈ 21,000,000 (30)] 
Characteristic No. % No. % OR 95% CI % 
End of most recent period of military service (year)j        ≤ 1949 48 8 12 1 83.97 32.07, 219.84 8 
1950-1954 51 8 27 3 23.16 11.46, 46.81 5 
1955-1959 80 13 53 5 8.76 5.24, 14.63 9 
1960-1964 75 12 55 6 4.54 2.88, 7.15 9 
1965-1974 188 30 267 27 1.00 Referent 25 
1975-1979 37 6 117 12 0.32 0.20, 0.49 7 
1980-1989 55 9 185 19 0.27 0.18, 0.41 12 
1990-1999 68 11 156 16 0.26 0.18, 0.40 13 
> 1999 26 4 103 11 0.11 0.06, 0.20 13 
Missing 2   0         
Median ± IQR 1968 ± 21  1978 ± 22  0.13
i 0.10, 0.17i NA 
Ever deployed to any war/operationk        No 356 58 562 58 1.00 Referent NA 
Yes 253 42 401 42 1.00 0.81, 1.23 NA 
Missing 21  12     War/operation of longest deploymentf, k, l        Not deployed 356 60 562 59 1.00 Referent NA 
World War II 32 5 12 1 5.51 2.63, 11.52 9 
Korean War 31 5 33 3 1.83 1.06, 3.17 11 
Vietnam War 144 24 265 28 0.89 0.69, 1.14 34 
Gulf War 9 2 22 2 0.56 0.25, 1.25 19 
Otherm 24 4 62 6 0.55 0.33, 0.91 59 
Missing 34  19     Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R; ALS Functional Rating Scale-Revised; BiPAP; Bi-level Positive Airway Pressure; CI, confidence interval; CPAP, 
Continuous Positive Airway Pressure; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf War, 1990-1991 Persian Gulf War; 
IQR, interquartile range; NA, not available; OR, odds ratio; VA, Department of Veterans Affairs. 
aAdjusted for the matching factors: age (modeled with linear and quadratic terms) and use of the VA health care system. 
bIncludes “all over” (n = 4), “cramps/fasciculations” (n = 26), and “loss of appetite” (n = 1). 
cThe ALSFRS-R score or use status of riluzole, BiPAP, CPAP, ventilator, tracheostomy, or feeding tube that was measured closest to the time of enrollment (i.e., interview) in the 
GENEVA study. 
dCategory boundaries were set at quintiles of the ALSFRS-R score among all cases. 
eIncludes "High school diploma/GED" (26%), "Some college credit, but less than 1 year of college credit" (12%), and "1 or more years of college credit, no degree" (18%). 
f ercentages may total more than 100% because veterans may have served in the military during more than one branch and/or in more than one war/period. 
gReference (31) asked all U.S. veterans the military branches in which they served during active duty. 
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 hIncludes Coast Guard (cases: n = 8; controls: n = 11), Activated National Guard (cases: n = 6; controls = 28), Activated Reserves (cases: n = 17; controls = 38), Inactivated 
National Guard (cases: n = 4; controls = 30), Inactivated Reserves (cases: n = 9; controls = 76), Department of Defense (cases: n = 0; controls: n = 0), National Oceanic and 
Atmospheric Administration (cases: n = 1; controls = 0), and Public Health Service (cases: n = 0; controls = 3). 
iScaled the OR to an IQR-unit increase in years of military service or end of most recent period of military service among all controls. 
jCategory boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and May 1975) and followed (98, 100). 
kThe GENEVA study questionnaire (Appendix B) asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II 
(defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War 
(defined as the period from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The GENEVA study 
questionnaire also asked "Ever deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, 
Bosnia, Kosovo, Rwanda, Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
lReference (31) asked all U.S. veterans the periods in which they served where World War II was defined as the period from December 1941 to December 1946, the Korean War 
was defined as the period from July 1950 to January 1955, the Vietnam War was defined as the period from August 1964 to April 1975, and the Gulf War was defined as the 
period from August 1990 to August 2001. 
mIncludes Grenada (cases: n = 0; controls: n = 1), Lebanon (cases: n = 5; controls: n = 9), Panama (cases: n = 8; controls: n = 29), Somalia (cases: n = 2; controls: n = 0), Bosnia 
(cases: n = 2; controls: n = 1), Kosovo (cases: n = 0; controls: n = 0), Rwanda (cases: n = 0; controls: n = 0), Afghanistan (cases: n = 1; controls: n = 2), and Iraq/Persian Gulf 
region (Gulf War II) (cases: n = 6; controls: n = 20).
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 Table 3.2. Distributions of ALS deaths and total ALS casesa in the GENEVA study (100) for certain demographic and military characteristics. 
  Deaths Total Crude Adjustedb 
Characteristic No. PMc No. PMc HRd 95% CId HRd 95% CId 
Total 446 10,558 616 24,267     Most recent ALS diagnosis         
Clinically definite 99 2,671 148 6,778 0.86 0.67, 1.12 0.90 0.69, 1.18 
Clinically probable 166 3,672 209 7,145 1.00 Referent 1.00 Referent 
Clinically probable and lab supported 66 1,467 102 4,377 0.68 0.51, 0.90 0.67 0.50, 0.89 
Clinically possible 37 854 47 1,681 1.04 0.73, 1.49 1.07 0.75, 1.54 
Suspected (progressive bulbar palsy or progressive muscular atrophy) 78 1,894 110 4,286 0.91 0.70, 1.20 0.86 0.65, 1.13 
Family history of ALS         
No 412 9,885 571 22,748 1.00 Referent 1.00 Referent 
Yes 15 365 17 532 1.36 0.81, 2.29 1.65 0.97, 2.80 
Missing 19  28      
Site of symptom onset         
Bulbar 70 1,362 85 2,551 1.35 1.04, 1.75 1.23 0.94, 1.61 
Extremities 352 8,586 499 20,512 1.00 Referent 1.00 Referent 
Othere 23 579 31 1,171 0.84 0.55, 1.29 0.96 0.63, 1.48 
Missing 1  1      
Time from symptom onset to diagnosis (months)         
≤ 6 90 2,299 116 4,483 0.85 0.65, 1.11 0.88 0.67, 1.15 
> 6-12 138 2,868 166 5,041 1.00 Referent 1.00 Referent 
> 12-18 73 1,434 104 3,869 0.74 0.56, 0.98 0.77 0.58, 1.03 
> 18-24 36 799 46 1,617 0.88 0.61, 1.28 0.85 0.59, 1.24 
> 24 104 2,940 172 8,426 0.56 0.43, 0.72 0.49 0.38, 0.64 
Missing 5  12      
Median ± IQR 11 ± 15  13 ± 18  0.82f 0.75, 0.91f 0.77f 0.70, 0.86f 
Time from diagnosis to enrollment in the Registry (months)         
≤ 12 185 3,372 216 5,699 1.00 Referent 1.00 Referent 
> 12-24 116 2,838 142 4,865 0.95 0.74, 1.21 0.86 0.67, 1.11 
> 24-36 47 1,091 75 3,347 0.76 0.53, 1.09 0.73 0.50, 1.05 
> 36-48 26 643 44 2,071 0.83 0.51, 1.32 0.76 0.47, 1.23 
> 48 72 2,614 139 8,284 0.73 0.44, 1.21 0.70 0.42, 1.17 
Missing 15 ± 25  19 ± 32  0.82f 0.66, 1.03f 0.82f 0.65, 1.02f 
Median ± IQR         
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   Deaths Total Crude Adjustedb 
Characteristic No. PMc No. PMc HRd 95% CId HRd 95% CId 
Time from enrollment in the Registry to enrollment in the GENEVA study (months)         
≤ 6 140 2,795 178 5,634 0.99 0.78, 1.26 1.01 0.79, 1.30 
> 6-12 142 3,101 204 8,157 1.00 Referent 1.00 Referent 
> 12-18 72 1,951 95 3,896 1.36 1.02, 1.81 1.30 0.97, 1.74 
> 18-24 51 1,526 71 3,286 1.34 0.96, 1.86 1.36 0.97, 1.90 
> 24 41 1,186 68 3,294 1.31 0.90, 1.90 1.34 0.92, 1.95 
Median ± IQR 9 ± 11  9 ± 11  1.16f 1.01, 1.34f 1.18f 1.02, 1.37f 
Baselineg ALSFRS-R score (possible range: 0-48)h         
≤ 16 108 2,071 133 4,167 1.87 1.41, 2.47 2.09 1.57, 2.77 
> 16-23 94 1,815 116 3,674 1.50 1.13, 1.99 1.69 1.27, 2.25 
> 23-30 99 2,730 137 5,787 1.00 Referent 1.00 Referent 
> 30-35 77 1,792 111 4,466 0.88 0.65, 1.19 0.89 0.66, 1.21 
> 35 68 2,151 119 6,172 0.53 0.39, 0.73 0.56 0.41, 0.76 
Median ± IQR 26 ± 16  27 ± 16  0.54f 0.47, 0.62f 0.51f 0.44, 0.59f 
Currently using riluzole (baselineg)         
No 207 5,107 298 12,448 1.00 Referent 1.00 Referent 
Yes 229 5,200 302 11,166 1.08 0.90, 1.31 1.14 0.94, 1.39 
Missing 10  16      
Currently using BiPAP to assist with breathing (baselineg)         
No 332 8,593 482 20,656 1.00 Referent 1.00 Referent 
Yes 109 1,849 128 3,402 1.78 1.43, 2.22 1.83 1.46, 2.28 
Missing 5  6      
Currently using CPAP to assist with breathing (baselineg)         
No 431 10,174 591 23,087 1.00 Referent 1.00 Referent 
Yes 14 382 24 1,177 0.82 0.48, 1.40 0.74 0.43, 1.26 
Missing 1  1      
Currently using a ventilator (≥ two weeks, 15 hours/day) to assist with breathing 
(baselineg)         
No 415 9,699 573 22,353 1.00 Referent 1.00 Referent 
Yes 31 859 43 1,914 1.31 0.89, 1.91 1.55 1.06, 2.28 
Currently using tracheostomy to assist with breathing (baselineg)         
No 412 9,611 570 22,264 1.00 Referent 1.00 Referent 
Yes 31 872 43 1,928 1.33 0.91, 1.95 1.58 1.07, 2.33 
Missing 3  3      
Currently using a feeding tube (baselineg)         
No 295 7,261 430 18,106 1.00 Referent 1.00 Referent 
Yes 89 1,815 108 3,390 1.74 1.37, 2.21 1.86 1.46, 2.38 
Missing 62  78      
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   Deaths Total Crude Adjustedb 
Characteristic No. PMc No. PMc HRd 95% CId HRd 95% CId 
Age (years)         ≤ 39 17 409 42 2,470 0.60 0.36, 1.02   40-49 35 1,150 68 3,853 0.74 0.50, 1.09   50-59 117 2,893 171 7,186 1.00 Referent   60-69 165 3,624 203 6,708 1.45 1.14, 1.84   70-79 100 2,264 119 3,767 1.45 1.11, 1.90   > 79 12 219 13 283 1.98 1.09, 3.59   Median ± IQR 62 ± 14  60 ± 14  1.43
f 1.26, 1.63f   Sex         Male 436 10,240 603 23,698 1.00 Referent 1.00 Referent 
Female 10 318 13 569 1.00 0.53, 1.87 1.26 0.66, 2.39 
Race/Ethnicity         Non-Hispanic White 413 9,491 561 21,419 1.00 Referent 1.00 Referent 
Other 29 1,009 48 2,569 0.68 0.47, 1.00 0.74 0.51, 1.09 
Missing 4  7      Use of VA health care system         No 254 5,920 361 14,502 1.00 Referent 1.00 Referent 
Yes 192 4,639 254 9,686 1.04 0.86, 1.25 1.00 0.82, 1.21 
Missing 0  1      Ever applied for VA benefits of any type         No 73 1,536 100 3,741 1.00 Referent 1.00 Referent 
Yes 335 7,918 455 17,264 0.90 0.70, 1.16 0.92 0.71, 1.19 
Missing 38  61      Highest degree attained         Grade school (grades 1-8) 17 496 20 753 1.22 0.74, 2.00 1.00 0.61, 1.66 
High school diploma or other 191 4,455 266 10,474 1.00 Referent 1.00 Referent 
Technical or vocation school diploma or Associated degree 81 1,604 114 4,207 0.95 0.73, 1.24 0.96 0.73, 1.25 
College or graduate school diploma 145 3,692 199 8,152 0.98 0.79, 1.22 0.99 0.80, 1.24 
Doctorate 12 310 17 681 0.88 0.49, 1.59 0.84 0.47, 1.52 
Cigarette smoking status         Never 141 3,261 207 8,558 1.00 Referent 1.00 Referent 
Past 232 5,531 305 11,380 1.13 0.92, 1.40 1.04 0.84, 1.29 
Current 58 1,547 85 3,808 0.96 0.71, 1.31 1.02 0.75, 1.39 
Missing 15  19      
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   Deaths Total Crude Adjustedb 
Characteristic No. PMc No. PMc HRd 95% CId HRd 95% CId 
Military branch of longest service         Air Force (including Army Air Force) 97 2,124 129 4,784 1.04 0.81, 1.33 1.11 0.86, 1.42 
Army 182 4,403 249 9,775 1.00 Referent 1.00 Referent 
Marines (including Merchant Marines) 36 638 55 2,175 0.92 0.64, 1.31 1.00 0.69, 1.43 
Navy 98 2,570 136 5,616 0.90 0.70, 1.15 0.93 0.72, 1.19 
Otheri 32 816 45 1,815 0.86 0.59, 1.26 0.94 0.64, 1.37 
Missing 1  2      Officer or Warrant Officer         No 373 8,685 514 20,110 1.00 Referent 1.00 Referent 
Yes 72 1,858 100 4,060 0.98 0.76, 1.26 0.97 0.68, 1.38 
Missing 1  2      Years of military service         ≤ 1 13 241 15 400 1.45 0.83, 2.53 1.74 0.98, 3.07 
> 1-5 305 7,022 414 15,896 1.00 Referent 1.00 Referent 
> 5-10 42 1,202 59 2,497 0.81 0.58, 1.12 0.92 0.65, 1.28 
> 10-15 14 436 26 1,398 0.60 0.35, 1.04 0.92 0.52, 1.64 
> 15-20 19 502 21 684 1.34 0.84, 2.13 1.56 0.97, 2.52 
> 20 52 1,147 79 3,290 0.77 0.57, 1.03 0.83 0.62, 1.13 
Missing 1  2      Median ± IQR 4 ± 5  4 ± 6  0.94
f 0.88, 1.01f 0.97f 0.91, 1.05f 
End of most recent period of military service (month/year)j         ≤ 12/1946 26 593 32 1,073 1.93 1.27, 2.95 1.41 0.77, 2.58 
01/1947-06/1950 9 185 11 341 1.57 0.80, 3.09 1.25 0.56, 2.78 
07/1950-01/1955 48 1,332 56 2,003 1.34 0.96, 1.86 1.04 0.64, 1.67 
02/1955-02/1961 78 1,648 97 3,266 1.42 1.07, 1.87 1.03 0.71, 1.48 
03/1961-07/1964 34 849 43 1,603 1.20 0.82, 1.75 0.87 0.57, 1.33 
08/1964-04/1975 134 3,160 192 7,732 1.00 Referent 1.00 Referent 
05/1975-08/1980 26 606 42 1,903 0.97 0.63, 1.48 1.12 0.72, 1.74 
09/1980-07/1990 36 818 53 2,156 0.95 0.65, 1.37 0.98 0.66, 1.45 
08/1990-08/2001 44 1,177 71 3,299 0.78 0.55, 1.10 0.97 0.67, 1.40 
> 08/2001 10 182 17 789 0.68 0.36, 1.29 0.89 0.45, 1.76 
Missing 1   2           
Median ± IQR 07/1967 ± 20 yr.  07/1968 ± 21 yr.  0.72
f 0.63, 0.83f 0.96f 0.77, 1.19f 
Ever deployed to any war/operationk         No 250 5,790 348 13,683 1.00 Referent 1.00 Referent 
Yes 179 4,472 247 9,986 1.00 0.82, 1.21 0.99 0.81, 1.21 
Missing 17  21      
         
         
 
84 
   Deaths Total Crude Adjustedb 
Characteristic No. PMc No. PMc HRd 95% CId HRd 95% CId 
War/operation of longest deploymentk         Not deployed 250 5,790 348 13,683 1.00 Referent 1.00 Referent 
World War II 24 671 29 1,076 1.27 0.83, 1.94 0.81 0.47, 1.42 
Korean War 29 686 32 931 1.61 1.09, 2.37 1.32 0.87, 2.00 
Vietnam War 98 2,318 138 5,474 0.94 0.75, 1.19 0.98 0.76, 1.27 
Otherl 19 584 35 1,926 0.60 0.38, 0.96 0.87 0.53, 1.43 
Missing 26  34      Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R; ALS Functional Rating Scale-Revised; BiPAP; Bi-level Positive Airway Pressure; CI, confidence interval; CPAP, 
Continuous Positive Airway Pressure; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; HR, hazard ratio; IQR, interquartile range; 
PM, person-months; VA, Department of Veterans Affairs. 
aFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) they died before the interview (i.e., the interview was 
completed by a proxy after the case died; n = 7). 
bAdjusted for age (modeled with indicator variables corresponding to 5-year groups). 
cPerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 2013). 
dHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
eIncludes “all over” (deaths: n = 4; total: n = 4), “cramps/fasciculations” (deaths: n = 18; total: n = 26), and “loss of appetite” (deaths: n = 1; total: n = 1). 
fScaled the HR to an IQR-unit increase in time from onset to diagnosis, time from diagnosis to enrollment in the Registry, time from enrollment in the Registry to enrollment in the 
GENEVA study, baseline ALSFRS-R score, age, years of military service, or end of most recent period of military service among all cases. 
gThe ALSFRS-R score or use status of riluzole, BiPAP, CPAP, ventilator, tracheostomy, or feeding tube that was measured closest to the time of enrollment (i.e., interview) in the 
GENEVA study. 
hCategory boundaries were set at quintiles of the ALSFRS-R score among all cases. 
iIncludes Coast Guard (deaths: n = 6; total: n = 8), Activated National Guard (deaths: n = 5; total = 6), Activated Reserves (deaths: n = 11; total = 17), Inactivated National Guard 
(deaths: n = 2; total = 4), Inactivated Reserves (deaths: n = 8; total = 9), Department of Defense (deaths: n = 0; total: n = 0), National Oceanic and Atmospheric Administration 
(deaths: n = 0; total = 1), and Public Health Service (deaths: n = 0; total = 0). 
jCategory boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and May 1975) and followed (98, 100). 
kThe GENEVA study questionnaire (Appendix B) asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II 
(defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War 
(defined as the period from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The GENEVA study 
questionnaire also asked "Ever deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, 
Bosnia, Kosovo, Rwanda, Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
lIncludes Grenada (deaths: n = 0; total: n = 0), Lebanon (deaths: n = 3; total: n = 5), Panama (deaths: n = 4; total: n = 8), 1990-1991 Persian Gulf War (deaths: n = 4; total: n = 11), 
Somalia (deaths: n = 1; total: n = 2), Bosnia (deaths: n = 1; total: n = 2), Kosovo (deaths: n = 0; total: n = 0), Rwanda (deaths: n = 0; total: n = 0), Afghanistan (deaths: n = 1; total: 
n = 1), and Iraq/Persian Gulf region (Gulf War II) (deaths: n = 5; total: n = 6).
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 Table 3.3. War deployment-related exposures for which information was collected in the GENEVA study (100). 
  Collected for which war 
Exposure WWII Korean Vietnam Gulf 
Manufacture, testing, or use of chemical protective gear (for mustard gas, tear gas, etc.) Do not include training X X X X 
Ionizing radiation from nuclear weapon testing or occupation of Hiroshima/Nagasaki X X X X 
Use of personal pesticides, like creams, sprays or flea collars X X X X 
Use of pesticides on your clothing or bedding X X X X 
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters) X X X X 
Exposure to diesel and/or other petrochemical fumes X X X X 
Burning trash or burning feces/manure X X X X 
Exposure to paint, solvents, or petrochemical substances X X X X 
High-intensity radar waves (e.g., as radar operator, radio operator, aviation electrician's mate) X X X X 
Food contaminated with smoke, oil, or other chemicals X X X X 
Local food other than food provided by the Armed Forces X X X X 
Bathing in or drinking of water contaminated with smoke, oil, dead animals or any chemicals X X X X 
Heat cramps, heat exhaustion, heat stroke or other heat illness X X X X 
Heard chemical alarms sounding X X X X 
Explosion in the air or on the ground within one mile of you (e.g., artillery, rockets, mortars) X X X X 
Have you suffered a combat-related injury that required medical attention during your deployment? X X X X 
Vaccines received orally or by injection within or outside of the United States X X X X 
Mixing and application of burning agents X X X  Exposure to burning agents in the field X X X  Mixing and application of herbicides X X X  Exposure to herbicides in the field X X X  Mixing and application of riot control substances X X X  Exposure to riot control substances in the field X X X  Microwave radiation  X X X Mixing and application of Agent Orange   X  Exposure to Agent Orange in the field   X  CARC (Chemical Agent Resistant Compound) Paint    X Exposure to nerve gas (e.g., during munitions destruction)    X Ground level fumigation    X High levels of dust/sand    X Scud missile explosion in the air or on the ground within one mile of you    X Smoke from oil well fires    X Use of depleted uranium (DU) for munitions or armor    X Abbreviations: CARC, Chemical Agent Resistant Compound; DU, depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral 
Sclerosis; Gulf, 1990-1991 Persian Gulf; WWII, World War II.
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Figure 3.3. Directed acyclic graphs for Specific Aim 1: (a) military service variables and ALS etiology in 
the GENEVA study (100) and (b) military deployments and exposures and ALS etiology in the GENEVA 
study (100).  
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 Figure 3.4. Directed acyclic graphs for Specific Aim 2: (a) military service variables and deployments and 
ALS survival in the GENEVA study (100) and (b) military exposures and ALS survival in the GENEVA 
study (100).  
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 Table 3.4. Odds ratios (Specific Aim 1) for dichotomous military service, deployment, and exposure 
variables detectable with 0.8 power for a two-sided test at α = 0.05 in the GENEVA study (100). 
  
Baseline risk of ALS in the 
unexposed 
Proportion missing dataa Exposure prevalence 0.35 0.40 0.45 
0.01 0.01 4.12 4.45 4.70 
 0.20 1.43 1.42 1.43 
 0.85 1.50 1.49 1.48 0.05 0.01 4.48 4.58 4.83 
 0.20 1.44 1.43 1.43 
 0.85 1.51 1.50 1.49 0.10 0.01 4.36 5.07 5.76 
 0.20 1.45 1.45 1.45 
 0.85 1.54 1.51 1.52 Abbreviations: ALS, amyotrophic lateral sclerosis; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis. 
aStarting sample size was 1,605, so 1% missing data, for example, reduces the sample size to 1,589. 
 
 
 
Table 3.5. Odds ratios (Specific Aim 1) for dichotomous military exposure variables incurred during 
deployment to WWII or the Korean, Vietnam, or Gulf Wars detectable with 0.8 power for a two-sided test 
at α = 0.05 in the GENEVA study (100). 
  
Baseline risk of ALS in the 
unexposed 
Proportion missing dataa Exposure prevalence 0.35 0.40 0.45 
0.01 0.02 5.53 6.16 7.23 
 0.25 1.72 1.70 1.72 
 0.65 1.66 1.63 1.64 0.05 0.02 6.65 7.01 8.47 
 0.25 1.73 1.74 1.75 
 0.65 1.65 1.67 1.67 0.10 0.02 6.30 8.88 11.55 
 0.25 1.75 1.75 1.76 
 0.65 1.67 1.67 1.67 Abbreviations: ALS, amyotrophic lateral sclerosis; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; WWII, World War II. 
aStarting sample size was 581, so 1% missing data, for example, reduces the sample size to 575. 
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 Table 3.6. Hazard ratios (Specific Aim 2) for dichotomous military service, deployment, and exposure 
variables detectable with 0.8 power for a two-sided test at α = 0.05 in the GENEVA study (100). 
  
Baseline risk of death in 
the unexposed 
Proportion missing dataa Exposure prevalence 0.70 0.72 0.75 
0.01 0.01 5.39 5.19 4.90 
 0.15 1.45 1.44 1.43 
 0.85 1.42 1.41 1.40 0.10 0.01 6.12 5.89 5.54 
 0.15 1.47 1.47 1.45 
 0.85 1.44 1.43 1.43 0.25 0.01 7.22 6.92 6.50 
 0.15 1.52 1.51 1.50 
 0.85 1.48 1.48 1.47 Abbreviations: GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis. 
aStarting sample size was 616, so 1% missing data, for example, reduces the sample size to 610. 
 
 
 
 
Table 3.7. Hazard ratios (Specific Aim 2) for dichotomous military exposure variables incurred during 
deployment to WWII or the Korean, Vietnam, or Gulf Wars detectable with 0.8 power for a two-sided test 
at α = 0.05 in the GENEVA study (100). 
  
Baseline risk of death in 
the unexposed 
Proportion missing dataa Exposure prevalence 0.70 0.75 0.80 
0.02 0.02 7.22 6.50 5.84 
 0.25 1.64 1.62 1.61 
 0.70 1.56 1.55 1.54 0.05 0.02 7.22 6.50 5.84 
 0.25 1.65 1.63 1.61 
 0.70 1.58 1.57 1.56 0.15 0.02 9.03 8.08 7.21 
 0.25 1.70 1.68 1.67 
 0.70 1.62 1.60 1.59 Abbreviations: GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 
Persian Gulf; WWII, World War II. 
aStarting sample size was 228, so 2% missing data, for example, reduces the sample size to 223.
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 CHAPTER FOUR: MILITARY SERVICE, DEPLOYMENTS, AND EXPOSURES IN 
RELATION TO AMYOTROPHIC LATERAL SCLEROSIS ETIOLOGY 
 
INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease that involves 
motor neuron loss in the central nervous system (1-3). A possible association between military-related 
factors and ALS was first suggested in connection with the 1990-1991 Persian Gulf War (hereafter “Gulf 
War”). Four of five studies reported an increased rate of ALS incidence, hospitalization, or mortality 
among U.S. military veterans deployed to the Gulf War compared to veterans deployed elsewhere (36-
40). A subsequent study extended this finding to all veterans, finding that U.S. men who reported military 
service had a higher ALS mortality rate than men who did not (41). Most of these studies, and 24 others 
we recently reviewed on the same topic, were limited by reliance on mortality as a surrogate for 
incidence, low statistical power, and sparse information on military-related factors (196). Thus, the causal 
factors underlying the possibly increased rate of ALS among veterans remain unidentified. 
The Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis 
(GENEVA) study is a case-control study of 630 veteran ALS cases from the U.S. National Registry of 
Veterans with ALS (hereafter “Registry”) (98) and 975 frequency-matched veteran controls identified via 
U.S. Department of Veterans Affairs (VA) databases from 2005-2010 (100). The goal of GENEVA is to 
evaluate associations between ALS and environmental factors, genetic susceptibility, and their 
interactions (100). We used GENEVA data to evaluate associations between military-related factors and 
ALS etiology. 
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 MATERIALS AND METHODS 
Study Population and Case Definition 
The methods used to enroll cases first in the Registry and later in GENEVA were published 
previously (98, 100). The ascertainment of GENEVA cases from the 2,122 veterans enrolled in the 
Registry is shown in Figure 4.1. Of the 248 veterans enrolled in the Registry who did not have a diagnosis 
of sporadic ALS, diagnoses were primary lateral sclerosis (PLS; n = 129), clinically definite and lab 
supported familial ALS (n = 3), no ALS (n = 20), indeterminate (n = 94), and other (n = 2). Of the 25 
ALS cases who were ineligible for GENEVA, reasons included a diagnosis of dementia (n = 9), a change 
in diagnosis (e.g., to no ALS/MND; n = 2), withdrawal from the DNA bank (n = 3), or infeasibility of a 
telephone interview for other reasons (n = 11). In total, 630 cases enrolled in GENEVA with 604 
providing a complete telephone interview and 26 providing partial interviews. We excluded nine cases 
from all analyses because they were missing covariate data, leaving 621 cases available for analyses. 
ALS specialists neurologists reviewed potential cases’ medical records and confirmed diagnoses 
in accordance with the gold standard World Federation of Neurology Revised El Escorial ALS Diagnostic 
Criteria (107, 108). 
The methods used to enroll controls in GENEVA were published previously (100). The 
ascertainment of GENEVA controls from an age-stratified random sample of 10,000 records from the 
Veterans Benefits Administration’s Beneficiary Identification and Records Locator System (BIRLS) 
database, obtained in June 2005 (100), is shown in Figure 4.2. Nine potential controls who were not part 
of the original BIRLS sample contacted the GENEVA study team regarding joining and the team was 
able to determine their eligibility for inclusion in GENEVA. Among the 91 potential controls who were 
ineligible for GENEVA, reasons included not being a U.S. military veteran (n = 13); a diagnosis of ALS 
(n = 1), Alzheimer’s disease or another form of dementia (n = 7), Parkinson’s disease (n = 8), multiple 
sclerosis (n = 1), post-polio syndrome (n = 1), Gulf War Illness (n = 2), neuropathy (n = 11), or muscle 
weakness (n = 1); or other reasons (n = 46). In total, 975 controls enrolled in GENEVA with 959 
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 providing a complete telephone interview and 16 providing partial interviews. We excluded 17 controls 
from all analyses because they were missing covariate data leaving 958 controls available for analyses. 
Controls were frequency matched to cases on age (using five-year age groups with the ALS 
cases’ ages at diagnosis as the target) and on use of the VA health care system prior to date of ALS 
diagnosis (cases) or to date of interview (controls) (100). These factors were chosen as matching factors 
because increasing age is a risk factor for ALS (1-3) and there are socioeconomic differences between 
veterans who use the VA system for health care and individuals (veterans and non-veterans) who 
exclusively use other systems (106). Furthermore, cases may have stronger motivation to use the VA 
system for health care after diagnosis because of the publicity given to studies on the relationship between 
military service and ALS. 
GENEVA was approved by the Institutional Review Boards of the Durham VA Medical Center, 
Duke University Medical Center, and the National Institute of Environmental Health Sciences; the 
Institutional Review Board of the University of North Carolina at Chapel Hill approved this analysis. All 
participants gave written or oral informed consent before the telephone interview. 
Exposure Assessment 
Information on clinical characteristics (e.g., site of symptom onset, ALS functional rating scale-
revised [ALSFRS-R] score, etc.) was extracted from medical records or the Registry semi-annual 
telephone follow-up interviews. Extensive information on military service, deployments, and exposures, 
as well as on potential confounders, was collected for GENEVA via telephone interviews (Appendix B) 
(100). Cases and controls were asked to use the date of ALS diagnosis and the date of interview, 
respectively, as the reference date for all information they provided (100). 
Information on military service included branch and number of branches, officer, total time of 
service, and end of most recent service. Military deployment information was collected about World War 
II (WWII) and the Korean, Vietnam, and Gulf Wars as well as operations in Grenada, Lebanon, Panama, 
Somalia, Bosnia, Kosovo, Rwanda, Afghanistan, and the Iraq/Persian Gulf region (Gulf War II). 
Specifically, information included ever deployment to any war/operation, war/operation of longest 
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 deployment, total time of all deployments, and end of most recent deployment. Information was also 
collected on ever deployment to any other country, ever receiving imminent danger pay, hardship duty, or 
combat zone tax exclusion benefits for deployment to 17 foreign countries and/or five sea regions (plus 
fill-in options for locations not listed); and total time deployed to those countries/sea regions. 
Information was collected for 40 specific military exposures, 33 of which were queried in 
reference only to exposures incurred during deployment to WWII or the Korean, Vietnam, and/or Gulf 
Wars (231 cases and 338 controls were deployed to one of the four wars listed). For 32 of 33 war-specific 
exposures (the exception was number of vaccinations received), participants were asked if they had ever 
been exposed, number of days exposed (≤ 5 days, 6-30 days, > 30 days), and whether they felt ill after 
exposure. For the other seven exposures, information included ever exposure and, for some, exposure 
gradient (e.g., number of shots, pills, etc.). 
Statistical Analyses 
We identified the following risk factors for ALS from previous literature to consider as potential 
confounders: age, gender, cigarette smoking, race/ethnicity, family history of ALS or other 
neurodegenerative diseases, trauma, head injury, physical activity/professional sports, rural residence, 
occupation, pesticides, electrical injury/shock or magnetic fields (non-ionizing radiation), lead or other 
heavy metals, and solvents. Note that occupation, pesticides, non-ionizing radiation, and solvents are also 
exposures of interest in the current study. 
We used directed acyclic graphs (DAGs) (177, 178) to identify minimally sufficient adjustment 
sets (MSASs) among potential confounders (Appendix F, Figure F.1 and Explanation of Figure F.1). For 
analyses involving military service variables, the MSAS was age, sex, and race/ethnicity. For analyses 
involving military deployment and exposure variables, the MSAS was age, sex, race/ethnicity, and branch 
of service. We also adjusted for use of VA health care system before the reference date because it was a 
matching factor (100). 
For our main analyses, we used unconditional logistic regression models to calculate odds ratios 
(ORs) and 95% confidence intervals (CIs) for associations between military-related factors and ALS 
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 etiology. We calculated three types of stabilized inverse probability weights (IPW) (105, 179), a type of 
propensity score, to adjust 1) for the confounders in the MSASs, 2) for potential bias resulting from 
missing data in ALSFRS-R scores for 8% of cases enrolled in the Registry, and 3) for potential selection 
bias resulting from studying cases who likely represent long survivors and controls who may be different 
from U.S. military veterans at large (100, 180) (Appendix F, Statistical Analyses: Inverse Probability 
Weights). We used linear, logistic, or polytomous logistic regression models, depending on the nature of 
the exposure variable, to calculate stabilized confounding weights for each exposure separately (179, 
181). We used logistic regression models to calculate stabilized missing covariate data and selection 
weights (179, 181), which were informed by our analysis of relationships between clinical, demographic, 
and/or military characteristics and participation in GENEVA among the Registry cases (Appendix F, 
Tables F.1) and among BIRLS potential controls (Appendix F, Tables F.2). We multiplied the three types 
of weights to obtain the overall stabilized weights and applied them to unconditional logistic regression 
models containing the exposure of interest as the only explanatory variable in the same way sampling 
weights are applied when analyzing data from complex survey sampling designs (179, 181). We 
calculated 95% CIs using robust variance estimates because using weights for analysis induces within-
subject correlation (182). The weighted ORs and 95% CIs apply to the population of 1,785 Registry cases 
who had diagnoses of clinically definite, probable, probable and lab supported, possible, or suspected 
(progressive bulbar palsy or progressive muscular atrophy) ALS and no missing data on any covariates 
used to calculate the various IPWs, as well as the population of 9,992 potential controls obtained from the 
BIRLS database who had no missing data on any covariates used to calculate the various IPWs. 
We used four criteria to evaluate the appropriateness of the weights in our analyses: 1) nearness 
of the mean weight to one, 2) number of extreme weights (e.g., < 0.05 or > 20), 3) positivity, and 4) bias–
variance (validity–precision) tradeoff (179). To informally assess the bias-variance tradeoff (189, 190), 
we progressively truncated the overall stabilized weights by symmetrically resetting weights less (greater) 
than a certain percentile (e.g., 1st and 99th, 5th and 95th, 10th and 90th, etc.) to the value of that percentile 
(179). Regarding the ORs derived from the untruncated weights as the “true” values, we informally 
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 evaluated bias-variance tradeoff by looking at how features of both the weights and the corresponding 
ORs changed with increasing truncation. Truncating the overall stabilized weights at the 0.5 and 99.5 
percentiles appeared to be the best balance of validity and precision. 
For war-specific exposures, the structure of the GENEVA telephone interview guaranteed 
structural non-positivity—empty cells (179, 183)—in cross tabulations of age and the exposures because 
only veterans deployed to one of the four major wars were asked about exposures incurred during their 
deployment(s). In other words, our IPWs weighted GENEVA cases to represent all of the Registry cases 
and GENEVA controls to represent all of the BIRLS potential controls regardless of age, but only 
veterans of the Vietnam War were asked about direct contact with exposures specific to that war such as 
Agent Orange. To mitigate this problem, we restricted our sample for analyses of Vietnam War-specific 
exposures to the Registry and GENEVA cases, the BIRLS potential controls, and GENEVA controls who 
were between the ages of 18 and 25 years during the Vietnam War. 
We used category midpoints, and 50% above the lower bound of the top category, to separately 
assess linear exposure-response trends for number of days exposed to 32 military exposures incurred 
during deployment to WWII or the Korean, Vietnam, or Gulf Wars (summed over the four wars). We 
used ordinal scores to separately assess linear exposure-response trends for feeling ill after exposure to 
the same 32 exposures. 
We also conducted several secondary analyses. We used standard regression methods to adjust 
for potential confounding but without adjustment for potential selection or missing covariate data bias. 
We separately analyzed deployment-specific exposures for veterans who were deployed to the Vietnam 
War (cases: n = 148 of 231, 64%; controls: n = 270 of 338, 80%); there were too few veterans who were 
deployed to WWII (cases: n = 36 of 231, 16%; controls: n = 12 of 338, 4%), the Korean War (cases: n = 
37 of 231, 16%; controls: n = 38 of 338, 11%), or the Gulf War (cases: n = 16 of 231, 7%; controls: n = 
30 of 338, 9%) to analyze deployment-specific exposures for these wars separately. To reduce 
heterogeneity in the outcome, we restricted analyses to cases who enrolled in GENEVA within two years 
of diagnosis (n = 246 of 615, 40%); cases who received a diagnosis of clinically definite, probable, or 
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 probable and lab supported ALS (n = 462 of 621, 74%); participants who did not report a family history 
of ALS (cases: n = 579 of 594, 97%; controls: n = 935 of 941, 99%); or participants who did not ever visit 
or reside in the island of Guam, the islands of New Guinea, or the Kii Peninsula of Japan (cases: n = 492 
of 586, 84%; controls: n = 749 of 937, 80%; there have been clusters of a form of ALS among individuals 
living in those areas (1-3)). For better control of confounding by sex and/or race/ethnicity, we restricted 
analyses to participants who were men (cases: n = 608 of 621, 98%; controls: n = 890 of 958, 93%) or 
non-Hispanic White men (cases: n = 559 of 621, 90%; controls: n = 785 of 958, 82%). To mitigate 
potential bias from exposure misclassification, we restricted analyses to participants who did not require a 
proxy for the telephone interview (cases: n = 587 of 621, 95%; controls: n = 958 of 958, 100%). We 
excluded the median (30 months) time between diagnosis and interview for cases from the time-related 
variables (e.g., years of service) for controls because ALS cases and controls were asked to use the date of 
ALS diagnosis and the date of interview, respectively, as the reference date for all information they 
provided (100) (i.e., controls may have had more time than ALS cases for which they could have been 
exposed). For analyses involving military exposures, we calculated Spearman correlation coefficients to 
identify moderate to high correlations between exposures and then attempted to account for these 
correlations by adjusting for the exposure that was most strongly correlated with the exposure of interest. 
We performed all analyses via SAS version 9.3 (SAS Institute Inc., Cary, NC, 2011). 
RESULTS 
 Controls were closely matched to cases on age and use of the VA health care system (Table 4.1). 
After adjustment for the matching factors, women and veterans of a race/ethnicity other than non-
Hispanic White were significantly less likely to have ALS than men and non-Hispanic Whites, 
respectively. The odds of ALS decreased as the highest educational degree attained increased. This 
inverse trend was also apparent when evaluating years of schooling completed (linear trend OR = 0.70; 
95% CI = 0.61, 0.81 for a four year increase). Descriptive statistics for clinical characteristics of ALS 
cases are shown in Table 4.2. 
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 The large majority of the means of the truncated overall stabilized weights were approximately 
equal to one (Appendix F, Tables F.3–F.11). The exceptions were usually for time-related variables (e.g., 
end of most recent service or deployment) or some exposures incurred during deployment to the Gulf 
War. There were few extreme weights, but those that did occur did so when we evaluated the number of 
days of exposure or whether veterans felt ill after exposure incurred during deployment to the four major 
wars. 
There was no difference in the weighted odds of ALS among veterans of the Air Force, Army, 
Marines, and Navy (Table 4.3). The odds of ALS were lower, however, among veterans whose longest 
service was in branches other than the Air Force, Army, Marines, or Navy (e.g., Coast Guard, National 
Guard, Reserves) compared to the Army and among veterans who had been officers. There were 
significant inverse linear trends between ALS and number of service branches as well as years of and end 
of most recent service. Results from standard regression analyses were similar, although the magnitude of 
associations between the categories of end of most recent service and ALS was much larger. 
In the weighted analysis, ALS was significantly more common among veterans whose longest 
deployment was to WWII or the Korean War, but significantly less common among veterans whose 
longest deployment was to operations besides the four major wars, compared to those who were not 
deployed (Table 4.4). There were significant inverse linear trends between ALS and end of most recent 
deployment as well as total time of all periods of receipt of danger pay. Ever receiving danger pay was 
also inversely associated with ALS. Results from standard regression analyses were generally 
qualitatively similar. 
ALS was significantly, or nearly significantly, positively associated with direct contact with 
herbicides for military purposes; pyridostigmine bromide; exhaust from heaters or generators; high-
intensity radar waves; explosions; mixing and application of burning agents; Agent Orange in the field; 
and ground level fumigation, although the last one was based on four exposed cases and two exposed 
controls (Table 4.5). Several other exposures had elevated, but non-significant ORs for ALS, although 
many were based on fewer than five exposed cases or controls. Patterns and directions of results were 
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 generally similar, particularly linear trend tests, when we evaluated the number of days of exposure or 
whether veterans felt ill after exposure (Appendix F, Tables F.12-F.13). The linear trend test for total 
number of preventive vaccinations received was nearly significant (OR = 1.16; 95% CI = 0.99, 1.36), 
although the categorical version of this variable did not show a monotonically increasing relationship 
(Appendix F, Table F12). Using standard regression methods shifted results down and sometimes through 
the null (Table 4.5; Appendix F, Tables F.12-F.13). 
Analyses restricted to Vietnam War-deployed veterans generally showed similar results 
(Appendix F, Tables F.13-F.17) as did analyses restricted to cases who enrolled in GENEVA within two 
years of diagnosis or received a diagnosis of clinically definite, probable, or probable and lab supported 
ALS (data not shown). Restricting to participants who did not report a family history of ALS; did not ever 
visit or reside in the island of Guam, the islands of New Guinea, or the Kii Peninsula of Japan; were men; 
were non-Hispanic White men; or did not require a proxy for the telephone interview did not change 
results qualitatively (data not shown). Likewise, results were similar after excluding the average time 
between diagnosis and interview for cases from the time-related variables for controls (data not shown). 
The majority of exposures were either not or only weakly correlated (e.g., Spearman correlation 
coefficients ≤ 0.2) and results were similar after adjusting for the exposure that was most strongly 
correlated with the exposure of interest (data not shown). 
DISCUSSION 
We found no difference in the odds of ALS among veterans of the Air Force, Army, Marines, and 
Navy, but lower odds of ALS among veterans whose longest service was in branches other than the Air 
Force, Army, Marines, or Navy, who had been officers, and whose longest deployment was to operations 
besides the four major wars. We also found higher odds of ALS among veterans whose longest 
deployment was to WWII or the Korean War. ALS was more common among veterans who had direct 
contact with eight different exposures incurred during deployment to the four major wars. While these 
results were robust in several secondary analyses, at least some of the results should be interpreted 
cautiously for reasons explained below. 
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 Several studies have evaluated associations between branch of service and ALS: two case-control 
studies found no association (56, 59), a spatial analysis of Gulf War veterans observed significantly lower 
ALS incidence for members of the Marine Corps compared to members of the Army (53), and two other 
studies, one  prospective cohort (41) and one case-control (14), reported the association between military 
service and ALS did not vary by branch of service. Highest rank attained was not associated with ALS 
deaths in a case-control study (59). One cohort study reported no association between deployment to the 
Gulf War and ALS mortality (50), a case-control study reported no association between ALS deaths and 
service in the Korean War (59), and several cohort studies reported positive associations between 
deployment to the Gulf War and ALS incidence or mortality (36-38, 40, 51). In our study, the odds of 
ALS did not vary across the four major branches, but was lower among officers and higher among 
veterans whose longest deployment was to WWII or the Korean War. 
The several inverse associations we observed between ALS and military service and deployment 
variables suggest that our control group includes many career military veterans. For example, we 
observed significant inverse linear trends between ALS and number of branches as well as years of 
service. The odds of ALS were also lower among veterans who had been officers, who had more 
education than a high school diploma, and among veterans whose longest service was in branches other 
than the Air Force, Army, Marines, or Navy compared to the Army. The “other” category included 36 
cases and 168 controls whose longest branch of service was activated or inactivated National Guard or 
Reserves. Our effort to remove what we thought was a selection bias through the use of IPW gave similar 
results to those obtained via standard regression methods. In addition to residual selection bias that may 
have affected these results, it is possible that the inverse associations we observed are explained by bias 
from the healthy worker survivor effect (197, 198). 
The three component associations that must be present for bias from the healthy worker survivor 
effect to occur are between 1) prior exposure and employment status, 2) employment status and 
subsequent exposure, and 3) employment status and mortality (197, 198). The three necessary component 
associations may be present in our study because non-officers who were in the military for shorter periods 
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 of time may have been more highly exposed to many military-related factors than officers or reservists, 
who were more likely to be in the military longer or in supervisory roles (first component association; 
note that, in this case, years of service could represent cumulative exposure to being a soldier or military 
lifesyle rather than cumulative exposure to a specific agent). People who left military service were no 
longer exposed to military-related factors, whereas people who remained continued to be exposed (second 
component association). Finally, people who left military service, perhaps because of poor health, may 
have been more likely to die than those who continued in the service (third component association). The 
same phenomenon could affect years of deployment and has been called the “healthy warrior effect” 
(199). Thus, bias from the healthy worker survivor effect may be an explanation for inverse associations 
we observed between ALS and military service and deployment variables (197). Unfortunately, we are 
unaware of any statistical methods that are currently available to correct bias from the healthy worker 
survivor effect in case-control studies, particularly those that sampled cases and controls from those 
available at the end of follow-up as ours did. 
We found positive associations between ALS and direct contact during deployment to the four 
major wars with exposures to pesticides and related compounds (herbicides in general, Agent Orange in 
particular, fumigants, pyridostigmine bromide); chemicals (exhaust from heaters or generators, burning 
agents), high-intensity radar, and explosions within one mile. Several of these findings are corroborated 
by general population studies and meta-analyses of associations between ALS and exposure to pesticides 
(79, 80), chemicals or solvents (15, 83), and magnetic fields (i.e., non-ionizing radiation) (96). These 
findings also agree with a cohort study of male U.S. Army Chemical Corps Vietnam veterans who were 
responsible for mixing and applying herbicides (including Agent Orange), riot control substances, and 
burning agents during the Vietnam War; the study found these veterans to have a non-significantly 
elevated nervous system disease mortality rate relative to the entire U.S. male population (43). A cross-
sectional study of Vietnam veterans from Korea found a positive association between Agent Orange 
exposure and self-reported ALS when using a self-reported perceived Agent Orange exposure index 
(200). No association was observed when two separate geographic information system (GIS) models were 
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 used to assess exposure (200), and another study of the same population reported no association between 
GIS-based exposure to Agent Orange and ALS identified via health insurance claims data (201). In our 
study, we thought Agent Orange exposure could have been over-reported, particularly for those who 
reported exposure in the field, because of the publicity that Agent Orange exposure has received. 
Therefore, we explored the plausibility of veterans’ self-reported Agent Orange exposures in our study 
and found that 90% (cases: 88%; controls: 92%) and 94% (cases: 88%; controls: 99%) of veterans who 
reported mixing and applying or exposure in the field, respectively, reported being in Vietnam during the 
time Agent Orange was used (i.e., 1965-1970). In addition, setting implausible values to missing for these 
two exposures gave slightly attenuated, but qualitatively similar, results (data not shown). These results 
should be interpreted cautiously, however, because we could not directly validate self-reported Agent 
Orange exposure. 
Our finding of a positive association between ALS and explosions within one mile during 
deployment to the four major wars is difficult to interpret. It is possible this exposure is a marker of lower 
socioeconomic status or rank (e.g., because less educated non-officers are more likely to be exposed to 
explosions than more educated officers), correlated with other combat-related exposures, or a marker of 
stress. The first two explanations were not supported by our data because results were similar when we 
adjusted for highest degree attained, restricted to non-officers, or mutually-adjusted correlated exposures 
(data not shown). Furthermore, the largest partial Spearman correlation coefficient between explosions 
within one mile and the other war-specific exposures queried in this study was only 0.27 (combat-related 
injury). The last explanation, stress, may have some biological plausibility because previous small studies 
have found differences in hormone (e.g., cortisol) levels between ALS cases and controls (202-204). Our 
data did not support this explanation, however, because veterans who reported any other exposure or 
experience which they considered harmful or extremely stressful did not have increased odds of ALS (OR 
= 0.81; 95% CI: 0.48, 1.38), although there was substantial missing data for this exposure. Thus, 
explanations for a positive association between ALS and explosions within one mile are unknown. 
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 Our finding of a nearly significant linear trend test for total number of preventive vaccinations 
received coupled with our findings of no association between having ever received the anthrax or 
smallpox vaccines could mean that the association between total number of vaccinations and ALS is only 
present at high levels of exposure. A case-control study, however, reported no association between ALS 
deaths and immunizations during service (59). We found non-significantly elevated odds of ALS among 
veterans exposed to nerve gas during deployment to the Gulf War. Two cohort studies have evaluated 
associations between nerve gas exposure during deployment to the Gulf War and ALS incidence or 
mortality with a non-significant, positive association found in the incidence study (53) and no association 
found in the mortality study (50). We also observed no association between exposure to smoke from oil 
well fires and ALS during deployment to the Gulf War, which agrees with a cohort mortality study of 
veterans deployed to the Gulf War (50). 
The large majority of the truncated overall stabilized IPWs in our analysis were well-behaved. 
Among those that were less well-behaved, time-related variables were more likely to have mean weights 
that were further from one. Examination of the component weights for the poorly behaved IPWs revealed 
that missing covariate data weights were always well-behaved (data not shown). For selection weights, 
some of the weights for time-related variables were extreme, but their means were approximately equal to 
one (data not shown). For confounding weights, the means for time-related variables were almost always 
greater than one and some weights were extreme (data not shown). For time-related variables, cross 
tabulations of age and the affected exposure variables showed non-positivity, particularly in the extreme 
combinations of age and the exposure variables (data not shown). Many of these instances of non-
positivity are likely structural rather than random (179), because, for example, veterans who served in the 
Gulf War are extremely unlikely to have been > 79 years-old at the date of ALS diagnosis in 2005-2010, 
when GENEVA was conducted (98, 100). Collapsing categories of the affected exposure variables 
remedied the non-positivity problems and gave similar ORs and 95% CIs as the expanded versions (data 
not shown). 
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 A limitation of our IPW analyses is that we were only able to weight GENEVA cases to represent 
the Registry cases, so any veteran ALS case who died before Registry enrollment began (April 1, 2003) 
was not included (24). Furthermore, the median time from enrollment in the Registry to enrollment in 
GENEVA among GENEVA cases was nine (IQR = 11) months, which is a relatively short time compared 
to elapsed time since diagnosis for long-surviving cases. Additionally, the BIRLS sample of potential 
controls is likely missing a subset of veterans whose release of active duty date was before 1973 (100). 
The age distribution of the BIRLS sample is also different from that of the general veteran population 
because it was age-stratified. However, adding a stabilized selection weight to weight the BIRLS sample 
to the age distribution of all U.S. military veterans in 2005 using data from the American Community 
Survey (30) gave similar results. Nevertheless, residual selection bias could have affected our results, 
particularly because we did not have information on education level or military rank—two factors 
inversely associated with ALS in our study—for the BIRLS sample. 
While residual confounding by age could have affected our results, residual confounding by the 
other matching or adjustment factors seems unlikely because results were similar when we restricted 
analyses to men or non-Hispanic White men. It is possible, however, that associations between ALS and 
specific exposures incurred during deployment to the four major wars were confounded by exposure to 
other toxicants experienced during military service or civilian life. We were unable to adjust analyses for 
non-military exposures, but results were similar after adjusting for the war-specific exposure that was 
most strongly correlated with the exposure of interest. 
There are some limitations to enrolling ALS cases from the Registry. Despite a national recruiting 
effort (98), underascertainment of ALS cases seems likely, especially in light of the documented 
underascertainment of cases among non-deployed veterans in the VA’s previous Gulf War ALS study 
(36, 38). In addition, cases enrolled in the Registry are a mix of incident cases and long-surviving cases 
(100, 180). The fact that results were similar when we restricted analyses to cases who enrolled in 
GENEVA within two years of diagnosis, however, increases confidence in our results. 
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 While alternative exposure assessment methods, such as biomarkers or military databases, may 
have been preferable, insufficiently long half lives and lack of detail, respectively, made these approaches 
impractical. The validity and reliability of self-reported military service or military-related exposures 
have been evaluated by several studies, usually in comparison to data from the U.S. Department of 
Defense’s Defense Manpower Data Center, and found to be good (38, 128-136). None of these studies, 
however, was able to assess the validity or reliability of self-reported military service or military-related 
exposures extending back to WWII (the longest time between exposure and exposure assessment in these 
studies was about 10 years (38)) or whether the quality of self-report varied by war/time period. When we 
explored these issues in our study, we found some reporting errors for exposures with distinct time 
periods of use (e.g., a reported receipt of anthrax vaccination in the 1950s, which was 40 years too early). 
Importantly, however, there seems to be little evidence that cases of various diseases recall past 
occupational exposures and information differently than controls (101). Furthermore, efforts were made 
to improve recall in GENEVA by asking participants about exposures that can be sensed (e.g., explosions 
in the air; bathing in or drinking of contaminated water; petrochemical fumes; etc.), using general terms 
(e.g., flea collar instead of the names of specific pesticides or products), and providing a list of specific 
exposures and benchmarks against which respondents could compare their levels of exposure (e.g., 
feeling ill after exposure) (100). Finally, results were similar when we restricted to cases who did not 
require a proxy for the telephone interview. 
Strengths of our study include medical-record confirmed diagnoses and a large sample size, 
although the sample size available for analyses of some exposures, particularly those that were war-
specific, was small. We had extensive information on military service and deployment variables as well 
as on 40 specific exposures. Our results were robust to many secondary analyses. Finally, we used IPW to 
explore and control potential missing covariate data and selection biases resulting from studying cases 
who likely overrepresented long survivors and controls who may be different from U.S. military veterans 
at large. 
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 In conclusion, we observed several inverse associations between ALS and military service and 
deployment variables, but these may be due to uncontrolled bias from the healthy worker survivor effect. 
We also found higher odds of ALS among veterans whose longest deployment was to WWII or the 
Korean War compared to the odds among those who were not deployed. ALS was also more common 
among veterans who had direct contact with specific exposures incurred during deployment to the four 
major wars, exposures similar to those associated with ALS in other studies of military veterans or the 
general population. While we cannot exclude effects of uncontrolled selection bias or confounding by 
non-military exposures, our results provide clues to the potential causal factor(s) underlying the apparent 
increase of ALS among military veterans and, therefore, require replication and further study. 
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 Figure 4.1. Flow diagram depicting the ascertainment of GENEVA cases. Solid boxes or lines represent 
cases who advanced past each step shown. Small-dashed boxes or lines represent cases who were 
excluded after each step shown. Abbreviations: ALS, amyotrophic lateral sclerosis; GENEVA, Genes and 
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis. 
  
Final sample: n = 598 + 23 = 621 
Complete interview: n = 604 Partial interview: n = 26 
Withdrawal: n = 31 Deceased: n = 33 Passive refusal: n = 30 
Consented: n = 724 
Able to contact for GENEVA enrollment: n = 843 
Did not attempt to contact: n = 266 Unable to contact: n = 37 
Consented for DNA Bank: n = 1,346 
Missing: n = 75 Deceased: n = 214 
 
Permission to re-contact for further studies: n = 1,830 
No permission to re-contact for further studies: n = 26 
Enrolled in the National Registry of Veterans with ALS: n = 2,122 
Sporadic ALS: n = 1,856 
Not sporadic ALS: n = 248 Withdrawal: n = 18 
Refused: n = 195 
Deceased: n = 200 
 
Ineligible: n = 25 Passive refusal: n = 10 Active refusal: n = 84 
Missing covariate data: n = 6 + 3 = 9 
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 Figure 4.2. Flow diagram depicting the ascertainment of GENEVA controls. Solid boxes or lines 
represent potential controls who advanced past each step shown. Small-dashed boxes or lines represent 
potential controls who were excluded after each step shown. Abbreviations: GENEVA, Genes and 
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis.  
 
 
Partial interview: n = 16 
Beneficiary Identification and Records Locator System sample: n = 10,000 
Address available: n = 8,929 
No address available: n = 1,071 
Invitation mailed: n = 4,420 
No invitation mailed: n = 4,509 
Able to contact by telephone: n = 2,728 
Deceased: n = 106 Unable to contact by telephone: n = 1,586 
Eligibility status determined: n = 1,618 + 9 = 1,627 
Passive refusal: n = 36 Active refusal: n = 1,074 
Contacted GENEVA: n = 9 
Eligible: n = 1,536 
Ineligible: n = 91 
Consented: n = 1,055 
Deceased: n = 1 Passive refusal: n = 232 Active refusal: n = 248 
Complete interview: n = 959 
Withdrawal: n = 38 Deceased: n = 2 Passive refusal: n = 40 
Final sample: n = 942 + 16 = 958 
Missing covariate data: n = 17 + 0 = 17 
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 Table 4.1. Demographic characteristics of amyotrophic lateral sclerosis cases and controls in GENEVA. 
  Cases Controls Adjusteda 
Characteristic No. % No. % OR 95% CI 
Age (years)       ≤ 29 9 1 6 1   
30-39 33 5 47 5   
40-49 67 11 117 12   
50-59 170 27 280 29   
60-69 207 33 324 34   
70-79 121 19 171 18   
> 79 14 2 13 1   
Median ± IQR 61 ± 14  60 ± 15    Use of VA health care system       
No 363 58 564 59   
Yes 258 42 394 41   
Sex       Male 608 98 890 93 1.00 Referent 
Female 13 2 68 7 0.27 0.15, 0.49 
Race/Ethnicity       Non-Hispanic White 571 92 842 88 1.00 Referent 
Other 50 8 116 12 0.63 0.45, 0.90 
Ever applied for VA benefits of any type       No 99 18 151 16 1.00 Referent 
Yes 460 82 807 84 0.78 0.58, 1.05 
Missing 62  0    Highest degree attained       Grade school (grades 1-8) 20 3 17 2 1.40 0.71, 2.73 
High school diploma 261 42 311 32 1.00 Referent 
Technical or vocation school diploma or Associate degree 116 19 224 23 0.62 0.47, 0.82 
College or graduate school diploma or doctorate 219 35 343 36 0.76 0.60, 0.96 
Other 5 1 63 7 0.10 0.04, 0.24 
Cigarette smoking status       Never 212 35 350 37 1.00 Referent 
Past 307 51 464 49 1.11 0.88, 1.39 
Current 84 14 132 14 1.08 0.78, 1.49 
Missing 18   12       
Abbreviations: CI, confidence interval; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral 
Sclerosis; IQR, interquartile range; OR, odds ratio; VA, Department of Veterans Affairs. 
aAdjusted for the matching factors: age (centered at age 60—the median age among controls—and modeled with linear and 
quadratic terms) and use of the VA health care system. 
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 Table 4.2. Clinical characteristics of amyotrophic lateral sclerosis cases and controls in GENEVA. 
  Cases Controls Adjusteda 
Characteristic No. % No. % OR 95% CI 
Most recent ALS diagnosis       Clinically definite 148 24     Clinically probable 213 34     Clinically probable and lab supported 101 16     Clinically possible 48 8     Suspected (progressive bulbar palsy or progressive muscular atrophy) 111 18     Family history of ALS       No 579 97 935 99 1.00 Referent 
Yes 15 3 6 1 4.14 1.59, 10.73 
Missing 27  17    Site of symptom onset       Bulbar 89 14     Extremities 500 81     Otherb 31 5     Missing 1      Time from symptom onset to diagnosis (months)       ≤ 6 117 19     > 6-12 168 28     > 12-18 102 17     > 18-24 46 8     > 24 170 28     Missing 18      Median ± IQR 13 ± 18      Time from diagnosis to enrollment in the Registry (months)       ≤ 12 218 35     > 12-24 142 23     > 24-36 73 12     > 36-48 43 7     > 48 139 23     Missing 6      Median ± IQR 18 ± 32      Time from enrollment in the Registry to enrollment in the GENEVA study 
(months)       
≤ 6 180 29     > 6-12 205 33     > 12-18 97 16     > 18-24 74 12     > 24 65 10     Median ± IQR 9 ± 11      Baselinec ALSFRS-R score (possible range: 0-48)d       ≤ 16 135 22     > 16-23 118 19     > 23-30 137 22     > 30-35 110 18     > 35 121 19     Median ± IQR 27 ± 16      Currently using riluzole (baselinec)       No 301 50     Yes 304 50     Missing 16      
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   Cases Controls Adjusteda 
Characteristic No. % No. % OR 95% CI 
Currently using BiPAP to assist with breathing (baselinec)       No 485 79     Yes 130 21     Missing 6      Currently using CPAP to assist with breathing (baselinec)       No 596 96     Yes 24 4     Missing 1      Currently using a ventilator (≥ two weeks, 15 hours/day) to assist with 
breathing (baselinec)       
No 577 93     Yes 44 7     Currently using tracheostomy to assist with breathing (baselinec)       No 575 93     Yes 43 7     Missing 3      Currently using a feeding tube (baselinec)       No 433 80     Yes 110 20     Missing 78           
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BiPAP, Bi-level Positive 
Airway Pressure; CI = confidence interval; CPAP, Continuous Positive Airway Pressure; GENEVA, Genes and Environmental 
Exposures in Veterans with Amyotrophic Lateral Sclerosis; IQR, interquartile range; OR = odds ratio; VA = Department of 
Veterans Affairs. 
aAdjusted for the matching factors: age (centered at age 60—the median age among controls—and modeled with linear and 
quadratic terms) and use of the VA health care system. 
bIncludes “all over” (n = 4), “cramps/fasciculations” (n = 26), and “loss of appetite” (n = 1). 
cThe ALSFRS-R score or use status of riluzole, BiPAP, CPAP, ventilator, tracheostomy, or feeding tube that was measured 
closest to the time of enrollment (i.e., interview) in the GENEVA stud 
dCategory boundaries were set at quintiles of the ALSFRS-R score among all cases.
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 Table 4.3. Military service and amyotrophic lateral sclerosis in GENEVA. 
  Cases Controls Adjusteda Adjustedb IP-weightedc 
Variable No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Military branch of longest service           Air Force (including Army Air Force) 128 21 201 21 0.79 0.60, 1.05 0.79 0.59, 1.04 0.95 0.66, 1.37 
Army 252 41 316 33 1.00 Referent 1.00 Referent 1.00 Referent 
Marines (including Merchant Marines) 54 9 74 8 0.90 0.61, 1.33 0.87 0.59, 1.29 0.73 0.46, 1.17 
Navy 140 23 183 19 0.95 0.72, 1.25 0.95 0.72, 1.25 0.88 0.62, 1.26 
Otherd 45 7 182 19 0.30 0.21, 0.44 0.30 0.20, 0.43 0.35 0.23, 0.55 
Missing 2  2        Number of military branches of service           1 (Median = 1) 571 92 727 76 1.00 Referent 1.00 Referent 1.00 Referent 
2 (2) 44 7 197 21 0.28 0.20, 0.40 0.28 0.19, 0.39 0.32 0.20, 0.51 
> 2 (3) 6 1 32 3 0.24 0.10, 0.57 0.21 0.09, 0.52 0.17 0.06, 0.48 
Missing 0  2        Trende     0.34 0.25, 0.45 0.32 0.24, 0.43 0.35 0.24, 0.51 Officer or Warrant Officer           No 517 84 743 78 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 102 16 213 22 0.68 0.52, 0.89 0.70 0.53, 0.91 0.72 0.50, 1.02 
Missing 2  2        Years of military service           ≤ 1 (0.50) 15 2 23 2 0.66 0.34, 1.28 0.72 0.36, 1.41 1.29 0.48, 3.46 
> 1-5 (3.00) 418 68 429 45 1.00 Referent 1.00 Referent 1.00 Referent 
> 5-10 (6.74) 59 10 181 19 0.32 0.23, 0.44 0.33 0.23, 0.46 0.45 0.29, 0.70 
> 10-15 (12.00) 26 4 38 4 0.63 0.37, 1.08 0.61 0.36, 1.04 0.41 0.21, 0.83 
> 15 (22.06) 101 16 287 30 0.36 0.28, 0.47 0.36 0.28, 0.47 0.49 0.34, 0.69 
Missing 2  0        Trend (IQR = 16.91)e, f     0.44 0.35, 0.55 0.43 0.34, 0.55 0.56 0.41, 0.75 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Variable No. % No. % OR 95% CI OR 95% CI OR 95% CI 
End of most recent period of military service (month/year)g           ≤ 06/1950 (07/1946) 48 8 12 1 73.68 28.53, 190.29 79.34 30.48, 206.53 5.59 1.91, 16.41 
07/1950-01/1955 (05/1954) 56 9 29 3 20.92 10.63, 41.18 22.41 11.31, 44.39 5.63 1.29, 24.67 
02/1955-02/1961 (08/1957) 97 16 65 7 7.54 4.71, 12.08 7.92 4.92, 12.75 5.45 2.21, 13.42 
03/1961-07/1964 (01/1963) 44 7 35 4 3.85 2.27, 6.52 3.99 2.35, 6.78 5.63 1.31, 24.26 
08/1964-04/1975 (07/1970) 191 31 281 29 1.00 Referent 1.00 Referent 1.00 Referent 
05/1975-08/1980 (08/1978) 41 7 127 13 0.34 0.22, 0.52 0.35 0.23, 0.55 0.21 0.09, 0.50 
09/1980-07/1990 (03/1985) 54 9 170 18 0.30 0.20, 0.44 0.34 0.22, 0.50 0.39 0.18, 0.86 
08/1990-08/2001 (11/1995) 71 11 152 16 0.30 0.20, 0.45 0.33 0.22, 0.50 0.55 0.27, 1.11 
> 08/2001 (01/2006) 17 3 87 9 0.10 0.05, 0.18 0.10 0.05, 0.19 0.33 0.09, 1.22 
Missing 2  0        Trend (20 years, 11.63 months)e, f         0.17 0.13, 0.22 0.17 0.13, 0.22 0.32 0.22, 0.48 
Abbreviation: ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CI = 
confidence interval; GENEVA = Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; IP = inverse probability; IQR = interquartile range; OR = 
odds ratio; VA = Department of Veterans Affairs. 
aAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms) and use of the VA health care system. 
bAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, and race/ethnicity. 
cWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, 
race/ethnicity, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled 
with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 
23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA (for cases: conditional on 
race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score [modeled with a 
restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth [modeled with a 
restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care system, and their 
interaction). 95% CIs were calculated with robust variance estimates. 
dIncludes Coast Guard (cases: n = 8; controls: n = 11), Activated National Guard (cases: n = 6; controls = 28), Activated Reserves (cases: n = 17; controls = 37), Inactivated 
National Guard (cases: n = 4; controls = 30), Inactivated Reserves (cases: n = 9; controls = 73), Department of Defense (cases: n = 0; controls: n = 0), National Oceanic and 
Atmospheric Administration (cases: n = 1; controls = 0), and Public Health Service (cases: n = 0; controls = 3). 
eUsed within-category medians that were calculated using all controls. 
fScaled the OR to an IQR-unit increase in the exposure variable. IQRs were calculated using all controls. 
gCategory boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and May 1975) and followed (98, 100). 
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 Table 4.4. Military deployments or danger pay and amyotrophic lateral sclerosis in GENEVA. 
  Cases Controls Adjusteda Adjustedb IP-weightedc 
Variable No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Deployments           Ever deployed to any war/operationd           No 349 58 554 59 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 250 42 390 41 1.01 0.82, 1.25 0.90 0.72, 1.12 0.83 0.63, 1.09 
Missing 20  12        War/operation of longest deploymentd           Not deployed 349 59 554 59 1.00 Referent 1.00 Referent 1.00 Referent 
World War II 31 5 12 1 5.25 2.50, 10.99 5.46 2.56, 11.65 5.28 1.79, 15.57 
Korean War 32 5 35 4 1.77 1.03, 3.03 1.62 0.94, 2.79 3.10 0.94, 10.20 
Vietnam War 141 24 255 27 0.90 0.69, 1.16 0.74 0.57, 0.97 1.43 0.88, 2.34 
Gulf War 11 2 22 2 0.70 0.33, 1.48 0.77 0.35, 1.68 0.53 0.17, 1.61 
Othere 24 4 60 6 0.57 0.35, 0.95 0.55 0.32, 0.92 0.45 0.23, 0.89 
Missing 31  18        Ever deployed to any other country           No 312 52 394 42 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 285 48 548 58 0.66 0.54, 0.81 0.62 0.50, 0.76 0.81 0.62, 1.05 
Missing 22  14        Total time (years) of all periods of deployment to any war/operationd           Not deployed (0.00) 349 59 554 59 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 1 (0.67) 122 21 221 24 0.88 0.68, 1.14 0.78 0.60, 1.02 0.80 0.57, 1.10 
> 1-2 (1.33) 69 12 100 11 1.09 0.77, 1.53 0.95 0.67, 1.34 0.82 0.49, 1.37 
> 2-3 (2.09) 31 5 31 3 1.58 0.94, 2.65 1.39 0.82, 2.36 1.64 0.67, 3.99 
> 3-5 (3.58) 9 2 27 3 0.53 0.24, 1.14 0.47 0.22, 1.03 0.38 0.11, 1.36 
> 5 (5.67) 8 1 5 1 2.51 0.81, 7.78 2.74 0.86, 8.71 3.03 0.79, 11.54 
Missing 31  18        Trendf     1.04 0.93, 1.17 1.01 0.89, 1.14 1.13 0.96, 1.33 End of most recent period of deployment to any war/operation (month/year)d, g           Not deployed 349 59 554 59 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 12/1946 (12/1945) 28 5 9 1 6.47 2.86, 14.66 6.77 2.94, 15.60 5.46 1.75, 17.08 
01/1947-01/1955 (03/1953) 28 5 27 3 2.09 1.16, 3.78 1.94 1.06, 3.55 4.04 0.92, 17.68 
02/1955-07/1964 (10/1957) 12 2 15 2 1.46 0.67, 3.18 1.26 0.57, 2.79 5.79 1.26, 26.59 
08/1964-04/1975 (01/1970) 135 23 252 27 0.87 0.67, 1.12 0.71 0.55, 0.93 1.14 0.70, 1.85 
05/1975-08/1980 (04/1978) 5 1 12 1 0.64 0.22, 1.85 0.70 0.24, 2.05 0.29 0.06, 1.45 
09/1980-07/1990 (08/1984) 5 1 12 1 0.61 0.21, 1.76 0.61 0.21, 1.81 0.82 0.23, 2.92 
> 07/1990 (08/1993) 25 4 61 6 0.56 0.34, 0.93 0.56 0.33, 0.94 0.37 0.18, 0.74 
Missing 32  14        Trend (IQR = 6 years, 1.99 months)f, h     0.42 0.34, 0.51 0.44 0.36, 0.54 0.62 0.50, 0.76 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Variable No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Danger pay, hardship duty or combat zone tax exclusion benefits for 
deployment           
Ever received imminent danger pay, hardship duty or combat zone tax exclusion 
benefits for deployment           
No 414 72 564 60 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 161 28 369 40 0.59 0.47, 0.74 0.51 0.40, 0.65 0.66 0.49, 0.88 
Missing 44  23        Total time (years) of all periods of deployment to any countries or sea region(s) 
ever received imminent danger pay, hardship duty or combat zone tax exclusion 
benefits for deployment           
Never received imminent danger pay, hardship duty or combat zone tax 
exclusion benefits for deployment (0.00) 414 78 564 68 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 1 (0.83) 74 14 165 20 0.60 0.44, 0.81 0.51 0.37, 0.70 0.57 0.38, 0.85 
> 1-2 (1.09) 30 6 72 9 0.55 0.35, 0.86 0.47 0.30, 0.74 0.49 0.27, 0.86 
> 2 (2.66) 12 2 27 3 0.61 0.30, 1.21 0.52 0.26, 1.06 0.54 0.24, 1.23 
Missing 89  128        Trendf     0.69 0.55, 0.85 0.61 0.49, 0.77 0.73 0.55, 0.95 Abbreviation: ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CI = 
confidence interval; GENEVA = Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf = 1990-1991 Persian Gulf; IP = inverse probability; IQR 
= interquartile range; OR = odds ratio; VA = Department of Veterans Affairs; WWII = World War II. 
aAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms) and use of the VA health care system. 
bAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, race/ethnicity, and 
military branch of longest service. 
cWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). 95% CIs were calculated with robust variance estimates. 
dThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also asked "Ever 
deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, 
Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
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 eIncludes Grenada (cases: n = 0; controls: n = 1), Lebanon (cases: n = 5; controls: n = 8), Panama (cases: n = 8; controls: n = 29), Somalia (cases: n = 2; controls: n = 0), Bosnia 
(cases: n = 2; controls: n = 1), Kosovo (cases: n = 0; controls: n = 0), Rwanda (cases: n = 0; controls: n = 0), Afghanistan (cases: n = 1; controls: n = 2), and Iraq/Persian Gulf 
region (Gulf War II) (cases: n = 6; controls: n = 19). 
fUsed within-category medians that were calculated using all controls. 
gCategory boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and May 1975) and followed (98, 100). 
hScaled the OR to an IQR-unit increase in the exposure variable. IQRs were calculated using all controls except those in the reference category. Reference category excluded for 
linear trend test.  
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 Table 4.5. Military exposures and amyotrophic lateral sclerosis in GENEVA. 
  Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Ever received the anthrax vaccine prior to reference date           No 493 93 803 91 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 35 7 79 9 0.68 0.44, 1.05 0.76 0.48, 1.19 1.52 0.83, 2.78 
Missing 91  74        Ever received the smallpox vaccine           No 73 13 110 13 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 468 87 730 87 0.99 0.72, 1.37 0.99 0.71, 1.38 0.88 0.59, 1.31 
Missing 78  116        Prior to reference date, ever involved in testing, transporting or 
spraying herbicides for military purposes           
No 450 96 906 97 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 18 4 31 3 1.27 0.70, 2.31 1.27 0.69, 2.34 2.83 1.11, 7.22 
Missing 151  19        Prior to reference date, ever been treated with nasopharyngeal 
(NP) radium during military service           
No 458 99 930 99 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 5 1 5 1 2.09 0.60, 7.28 1.98 0.55, 7.15 4.07 0.90, 18.35 
Missing 156  21        Ever taken pyridostigmine bromide, or little white pills in foil packs, 
sometimes called NAPPs, which are used to protect against nerve 
agents           
No 531 97 882 97 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 19 3 23 3 1.37 0.73, 2.57 1.53 0.79, 2.97 2.50 0.96, 6.51 
Missing 69  51        Prior to reference date, ever visited or resided in the island of 
Guam, the islands of New Guinea, or the Kii Peninsula of Japan 
(including any time spent there in the military)           
No 492 84 748 80 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 92 16 187 20 0.74 0.56, 0.97 0.72 0.54, 0.96 0.77 0.51, 1.17 
Missing 35  21        
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
While you were in WWII, the Korean War, the Vietnam War, 
and/or the Gulf Ward: did you have direct contact with/were 
you exposed to           
Manufacture, testing, or use of chemical protective gear (for 
mustard gas, tear gas, etc.) Do not include training           
No 208 95 306 91 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 12 5 29 9 0.27 0.11, 0.67 0.29 0.12, 0.72 0.47 0.17, 1.28 
Missing 11  3        Ionizing radiation from nuclear weapon testing or occupation of 
Hiroshima/Nagasaki           
No 212 98 327 99 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 2 < 5 1 1.78e, f 0.32, 9.88e, f g g 1.71 0.31, 9.48 
Missing 15  7        Use of personal pesticides, like creams, sprays or flea collars           No 155 70 233 70 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 67 30 102 30 0.97 0.66, 1.43 0.96 0.64, 1.42 1.55 0.87, 2.78 
Missing 9  3        Use of pesticides on your clothing or bedding           No 161 77 243 74 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 49 23 86 26 0.82 0.54, 1.25 0.84 0.54, 1.29 1.09 0.57, 2.09 
Missing 21  9        Exhaust from heaters or generators (e.g., kerosene heaters, tent 
heaters)           
No 142 65 235 70 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 75 35 101 30 1.17 0.80, 1.70 1.21 0.83, 1.78 1.81 1.09, 3.00 
Missing 14  2        Exposure to diesel and/or other petrochemical fumes           No 75 34 118 36 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 145 66 214 64 1.01 0.69, 1.47 1.00 0.68, 1.46 1.06 0.62, 1.82 
Missing 11  6        Burning trash or burning feces/manure           No 146 66 202 61 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 74 34 130 39 0.75 0.51, 1.10 0.70 0.46, 1.06 1.13 0.61, 2.10 
Missing 11  6        Exposure to paint, solvents, or petrochemical substances           No 146 67 216 65 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 72 33 118 35 0.87 0.60, 1.27 0.74 0.49, 1.12 0.76 0.42, 1.38 
Missing 13  4        
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
High-intensity radar waves (e.g., as radar operator, radio 
operator, aviation electrician's mate)           
No 162 78 263 83 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 45 22 52 17 1.44 0.92, 2.27 1.43 0.89, 2.27 1.76 0.95, 3.26 
Missing 24  23        Food contaminated with smoke, oil, or other chemicals           No 185 93 269 89 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 15 8 33 11 0.70 0.37, 1.34 0.72 0.38, 1.40 1.40 0.65, 3.05 
Missing 31  36        Local food other than food provided by the Armed Forces           No 110 49 167 50 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 113 51 169 50 0.97 0.68, 1.37 0.98 0.68, 1.41 1.17 0.65, 2.11 
Missing 8  2        Bathing in or drinking of water contaminated with smoke, oil, 
dead animals or any chemicals           
No 175 89 274 88 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 21 11 37 12 0.97 0.54, 1.73 0.95 0.52, 1.73 1.27 0.30, 5.32 
Missing 35  27        Heat cramps, heat exhaustion, heat stroke or other heat illness           No 172 77 249 75 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 51 23 84 25 0.90 0.59, 1.36 0.92 0.60, 1.41 1.45 0.73, 2.89 
Missing 8  5        Heard chemical alarms sounding           No 208 93 301 90 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 15 7 33 10 0.42 0.20, 0.87 0.47 0.22, 0.99 1.04 0.47, 2.30 
Missing 8  4        Explosion in the air or on the ground within one mile of you (e.g., 
artillery, rockets, mortars)           
No 72 32 116 36 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 151 68 210 64 1.27 0.87, 1.86 1.30 0.88, 1.92 1.88 1.15, 3.07 
Missing 8  12        Have you suffered a combat-related injury that required medical 
attention during your deployment?           
No 177 78 257 77 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 50 22 77 23 1.01 0.66, 1.53 1.00 0.65, 1.55 1.56 0.76, 3.19 
Missing 4  4        
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
While you were in WWII, the Korean War, and/or the Vietnam 
Ward: did you have direct contact with/were you exposed to           
Mixing and application of herbicides           No 202 98 303 99 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 5 2 < 5 1 4.01e, f 0.63, 43.55e, f g g 4.14 0.65, 26.51 
Missing 12  9        Exposure to herbicides in the field           No 160 93 238 94 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 12 7 14 6 1.66 0.73, 3.78 1.73 0.75, 4.00 2.30 0.56, 9.36 
Missing 47  62        Mixing and application of riot control substances           No 213 99 307 98 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 1 7 2 0.58e, f 0.09, 2.63e, f g g 2.73 0.35, 21.30 
Missing 3  0        Exposure to riot control substances in the field           No 202 94 285 92 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 13 6 26 8 0.59 0.28, 1.26 0.62 0.29, 1.35 1.66 0.56, 4.90 
Missing 4  3        Mixing and application of burning agents           No 197 93 303 98 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 15 7 6 2 3.69 1.37, 10.00 3.66 1.35, 9.94 8.69 2.08, 36.29 
Missing 7  5        Exposure to burning agents in the field           No 176 84 277 90 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 34 16 31 10 1.71 0.98, 2.97 1.73 0.98, 3.06 1.64 0.51, 5.30 
Missing 9  6        While you were in the Korean War, the Vietnam War, and/or 
the Gulf Ward: did you have direct contact with/were you 
exposed to           
Microwave radiation           No 153 92 268 92 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 14 8 24 8 0.93 0.45, 1.91 0.93 0.44, 1.94 1.30 0.54, 3.11 
Missing 29  35        
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
While you were in the Vietnam Ward, h: did you have direct 
contact with/were you exposed to           
Mixing and application of Agent Orange           No 109 93 200 94 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 8 7 13 6 1.42 0.52, 3.85 1.54 0.55, 4.29 1.27 0.42, 3.86 
Missing 10  6        Exposure to Agent Orange in the field           No 41 41 98 56 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 58 59 77 44 2.91 1.57, 5.39 3.12 1.59, 6.09 2.55 1.28, 5.08 
Missing 28  44        While you were in the Gulf Ward: did you have direct contact 
with/were you exposed to           
Use of depleted uranium (DU) for munitions or armor           No 8 62 23 85 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 5 38 < 5 15 3.52e, f 0.50, 30.02e, f 3.81e, i 0.25, 214.20e, i 4.08 0.68, 24.62 
Missing 3  3        CARC (Chemical Agent Resistant Compound) paint           No 10 71 20 83 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 29 < 5 17 1.68e, f 0.22, 12.89e, f 2.44e, i 0.08, 232.81e, i 4.01 0.67, 23.97 
Missing 2  6        Scud missile explosion in the air or on the ground within one 
mile of you           
No 9 69 17 61 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 31 11 39 0.63e, f 0.10, 3.32e, f 1.56e, i 0.17, 19.59e, i 4.02 0.67, 24.04 
Missing 3  2        Smoke from oil well fires           No 5 36 9 31 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 9 64 20 69 1.12 0.23, 5.33 1.32 0.17, 10.30 1.20 0.24, 5.94 
Missing 2  1        Exposure to nerve gas (e.g., during munitions destruction)           No 11 79 21 95 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 21 < 5 5 5.06e, f 0.24, 369.48e, f 7.64e, i 0.19, 882.66e, i g g 
Missing 2  8        High levels of dust/sand           No < 5 19 < 5 7 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 13 81 28 93 0.21e, f 0.01, 2.31e, f 0.18e, i 0.01, 2.55e, i 0.75 0.10, 5.72 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Ground level fumigation           No 9 69 24 92 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 31 < 5 8 3.85e, f 0.45, 49.05e, f 3.57e, i 0.29, 85.96e, i 7.79 0.98, 61.68 
Missing 3  4        In any conflicts deployed to, any other exposure or experience not 
asked about which you consider harmful or extremely stressful           
No 239 76 244 69 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 75 24 108 31 0.74 0.52, 1.06 0.74 0.51, 1.06 0.81 0.48, 1.38 
Missing 305   604               
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CARC, 
Chemical Agent Resistant Compound; CI, confidence interval; DU, depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral 
Sclerosis; Gulf, 1990-1991 Persian Gulf; IP, inverse probability; NP, nasopharyngeal; OR, odds ratio; VA, Department of Veterans Affairs; WWII, World War II. 
aAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms) and use of the VA health care system. 
bAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, race/ethnicity, and 
military branch of longest service. War deployment-related exposures were not adjusted for sex because of model instability. 
cWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 95% CIs were calculated with robust variance estimates. 
dThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). 
eOR and 95% CI calculated using exact methods. 
fAdjusted for age (centered at age 60—the median age among controls—and modeled with a linear term) and use of the VA health care system. 
gUnable to estimate OR and 95% CI. 
hRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of the Vietnam War, or 1964-1975) because doing 
so drastically improved the behavior of the IP weights used for analysis. This restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls. 
iAdjusted for age (centered at age 60—the median age among controls—and modeled with a linear term), use of the VA health care system, race/ethnicity, and military branch of 
longest service.
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 CHAPTER FIVE: MILITARY SERVICE, DEPLOYMENTS, AND EXPOSURES IN 
RELATION TO AMYOTROPHIC LATERAL SCLEROSIS SURVIVAL 
 
INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease that involves 
motor neuron loss in the central nervous system (1-3). Half of individuals with ALS die within three years 
of diagnosis, but 4% survive at least ten years after diagnosis (1-3). Factors consistently associated with 
shorter ALS survival or progression include older age at diagnosis (16-24), bulbar onset (17-22, 24-26), 
clinical features (e.g., disease progression/disability status, respiratory function) (17-19, 21, 23, 27, 28), 
shorter time between symptom onset and diagnosis (17-19, 24-26, 29) and diagnosis category (definite, 
probable, etc.) (17). Few studies have considered modifiable prognostic factors, particularly those that are 
occupational or environmental in nature. 
Limited evidence suggests that ALS rates may be higher among military veterans, particularly 
those deployed to the 1990-1991 Persian Gulf War (hereafter “Gulf War”) (196). In addition, a few 
studies, although with conflicting results, have examined associations between military-related factors 
and ALS survival or progression (24, 26, 63, 64). A study based on the ALS Clinical Assessment, 
Research and Education (CARE) database found no association between U.S. military veteran status and 
ALS survival (63), whereas a study in Boston, Massachusetts, reported that both being a male veteran and 
a male veteran who had performed active duty were associated with faster ALS progression after one year 
of follow-up (26). Past deployment to the Gulf War was associated with shorter ALS survival in one 
study (64), but not another (24). The latter study, based on the U.S. National Registry of Veterans with 
ALS (hereafter “Registry”) (98), also found an association between shorter ALS survival and past 
deployment to Vietnam, but not with cumulative military service, branch, or deployment to Korea (24). 
The goal of the present analysis was to evaluate associations between military-related factors and ALS 
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 survival using data from the Genes and Environmental Exposures in Veterans with Amyotrophic Lateral 
Sclerosis (GENEVA) study (100). 
MATERIALS AND METHODS 
Study Population and Outcome Assessment 
The GENEVA study is a case-control study that enrolled 630 veteran ALS cases from the 
Registry (98) and 975 frequency-matched veteran controls identified via U.S. Department of Veterans 
Affairs (VA) databases from 2005-2010 (100). It was conducted to evaluate associations between ALS 
and environmental factors, genetic susceptibility, and their interactions (100). For the current analysis, we 
restricted the sample to ALS cases only. 
The methods used to enroll cases first in the Registry and later in GENEVA were published 
previously (98, 100). The ascertainment of GENEVA cases from the 2,122 veterans enrolled in the 
Registry is shown in Figure 5.1. Of the 248 veterans enrolled in the Registry who did not have a diagnosis 
of sporadic ALS, diagnoses were primary lateral sclerosis (PLS; n = 129), clinically definite and lab 
supported familial ALS (n = 3), no ALS (n = 20), indeterminate (n = 94), and other (n = 2). Of the 25 
ALS cases who were ineligible for GENEVA, reasons included dementia diagnosis (n = 9), change in 
diagnosis (e.g., to no ALS/MND; n = 2), withdrawal from the DNA bank (n = 3), or infeasibility of 
telephone interview for other reasons (n = 11). In total, 630 cases enrolled in the GENEVA study with 
604 providing a complete telephone interview and 26 providing partial interviews. For the current 
analysis, we restricted the sample to the 616 cases who had information on diagnosis date and had not 
died before enrollment. 
ALS specialist neurologists reviewed potential cases’ medical records and confirmed diagnoses in 
accordance with the gold standard World Federation of Neurology Revised El Escorial ALS Diagnostic 
Criteria (107, 108). The primary outcome measure in the current analysis was time (days) from the 
diagnosis date to the death date (survival) or the end of the follow-up period with late entry at the date of 
enrollment in GENEVA. Time since diagnosis was the most clinically meaningful time scale and 
accounting for late entry at the date of enrollment in GENEVA addressed concerns of immortal person-
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 time bias (72). Time to death has been recommended over other ALS survival outcomes, which 
incorporate time to tracheostomy, prolonged noninvasive ventilation, or permanent assisted ventilation, 
because these respiratory interventions are not uniformly defined or used across centers (122). Thus, 
death is the least variable and most easily identifiable measure of survival among ALS cases (122). 
Diagnosis date was available from the medical record and date of enrollment in GENEVA was 
available from the GENEVA telephone interview (Appendix B). Information on death, from the Austin 
Vital Status File (AVSF) housed at the Austin (Texas) Automation Center, was available through July 25, 
2013. The AVSF contains vital status information from several sources within the VA, including the 
Medicare Vital Status Files, Social Security Administration Death Master File, Veterans Benefits 
Administration’s Beneficiary Identification and Records Locator System Death File, and Veterans Health 
Administration Medical SAS Inpatient Datasets (123). Using the National Death Index (NDI) (124) as the 
gold standard, a VA Information Resource Center validation study found that the AVSF was 98.3% 
sensitive and 99.8% specific (κ = 0.981) for identifying deaths among veterans (123). No study has 
assessed the ability of the AVSF to accurately identify ALS deaths among veterans, but a non-military 
study of lead exposure and ALS survival that ascertained deaths from NDI Plus reported that 71% and 
17% of neurologist-confirmed ALS cases had perfect and partial matches, respectively (125). In addition, 
a validation study in the Cancer Prevention Study II cohort found that the NDI identified 93% of known 
deaths overall (not from ALS specifically) and 97% of known deaths when a social security number was 
available for the search (126). The NDI’s sensitivity varied by race and sex, but was highest among white 
males (95%) (126). Thus, it is likely that only a small proportion of deaths among GENEVA cases will be 
misclassified because the majority of cases (n = 571; 92%) are white males. 
GENEVA was approved by the Institutional Review Boards of the Durham VA Medical Center, 
Duke University Medical Center, and the National Institute of Environmental Health Sciences; the 
Institutional Review Board of the University of North Carolina at Chapel Hill approved this analysis. All 
participants gave written or oral informed consent before the telephone interview. 
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 Exposure Assessment 
Information on clinical characteristics (e.g., site of symptom onset, ALS functional rating scale-
revised [ALSFRS-R] score, etc.) was extracted from medical records or the Registry semi-annual 
telephone follow-up interviews. Extensive information on military service, deployments, and exposures, 
as well as on potential confounders, was collected for GENEVA via telephone interviews (Appendix B) 
(100). Cases were asked to use their diagnosis date as the reference date for all information they provided 
(100). 
Information on military service included branch and number of branches, officer, total time of 
service, and end of most recent service. Military deployment information was collected about World War 
II (WWII) and the Korean, Vietnam, and Gulf Wars as well as operations in Grenada, Lebanon, Panama, 
Somalia, Bosnia, Kosovo, Rwanda, Afghanistan, and the Iraq/Persian Gulf region (Gulf War II). 
Specifically, information included ever deployment to any war/operation, war/operation of longest 
deployment, total time of all deployments, and end of most recent deployment. Information was also 
collected on ever deployment to any other country, ever receiving imminent danger pay, hardship duty, or 
combat zone tax exclusion benefits for deployment to 17 foreign countries and/or five sea regions (plus 
fill-in options for locations not listed); and total time deployed to those countries/sea regions. 
Information was collected for 40 specific military exposures, 33 of which were queried in 
reference only to exposures incurred during deployment to WWII or the Korean, Vietnam, and/or Gulf 
Wars (228 cases were deployed to one of the four wars listed). For 32 of 33 war-specific exposures (the 
exception was number of vaccinations received), cases were asked if they had ever been exposed, number 
of days exposed (≤ 5 days, 6-30 days, > 30 days), and whether they felt ill after exposure. For the other 
seven exposures, information included ever exposure and, for some, exposure gradient (e.g., number of 
shots, pills, etc.). 
Statistical Analyses 
We identified the following prognostic factors for ALS survival from previous literature to 
consider as potential confounders: age at diagnosis, bulbar onset, clinical features (e.g., lower baseline 
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 ALSFRS-R score), time between symptom onset and diagnosis, diagnosis category, gender, psychosocial 
factors, therapeutic interventions (e.g., riluzole treatment, non-invasive positive pressure ventilation), 
agricultural occupation, and lead exposure. 
We used directed acyclic graphs (DAGs) (177, 178) to identify minimally sufficient adjustment 
sets (MSASs) among potential confounders (Appendix G, Figure G.1 and Explanation of Figure G.1). For 
analyses involving military service and deployment variables, the MSAS was age and sex. For analyses 
involving military exposure variables, the MSAS was age, sex, and wars/operations of deployment. We 
did not adjust for sex in our main models, however, due to the small number of female cases (n = 13) and 
deaths (n = 10) in our study. 
For our main analyses, we used Cox proportional hazards regression models to calculate hazard 
ratios (HRs) and 95% confidence intervals (CIs) for associations between military-related factors and 
ALS survival. We checked the proportional hazards assumption by evaluating the statistical significance 
of interactions between the covariate of interest and three versions (linear, natural logarithm of linear, and 
dichotomized at the median in separate models) of time since diagnosis (176). We calculated three types 
of stabilized inverse probability weights (IPW) (105, 179), a type of propensity score, to adjust 1) for the 
confounders in the MSASs, 2) for potential bias resulting from missing data in ALSFRS-R scores for 8% 
of cases enrolled in the Registry, and 3) for potential selection bias resulting from studying cases who 
likely represent long survivors (100) (Appendix G, Statistical Analyses: Inverse Probability Weights). We 
used linear, logistic, or polytomous logistic regression models, depending on the nature of the exposure 
variable, to calculate stabilized confounding weights for each exposure separately (179, 181). We used 
logistic regression models to calculate stabilized missing covariate data and selection weights (179, 181), 
which were informed by our analysis of relationships between clinical, demographic, and military 
characteristics and participation in GENEVA among the Registry cases (Appendix G, Table G.1). We 
multiplied the three types of weights to obtain the overall stabilized weights and applied them to Cox 
proportional hazards regression models containing the exposure of interest as the only explanatory 
variable in the same way sampling weights are applied when analyzing data from complex survey 
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 sampling designs (179, 181). We calculated 95% CIs using robust variance estimates because using 
weights for analysis induces within-subject correlation (182). The weighted HRs and 95% CIs apply to 
the population of 1,783 Registry cases who had diagnoses of clinically definite, probable, probable and 
lab supported, possible, or suspected (progressive bulbar palsy or progressive muscular atrophy) ALS; 
had not died before enrolling in the Registry (some cases were enrolled by proxy after they died); had 
diagnosis date available; and had no missing data on any covariates used to calculate the IPWs. 
We used four criteria to evaluate the appropriateness of the weights in our analyses: 1) nearness 
of the mean weight to one, 2) number of extreme weights (e.g., < 0.05 or > 20), 3) positivity, and 4) bias–
variance (validity–precision) tradeoff (179). To informally assess the bias-variance tradeoff (189, 190), 
we progressively truncated the overall stabilized weights by symmetrically resetting weights less or 
greater than a certain percentile (e.g., 1st and 99th, 5th and 95th, 10th and 90th, etc.) to the value of that 
percentile (179). Regarding the HRs derived from the untruncated weights as the “true” values, we 
informally evaluated bias-variance tradeoff by looking at how features of both the weights and the 
corresponding HRs changed with increasing truncation. Not truncating the overall stabilized weights 
appeared to be the best balance of validity and precision. 
We used category midpoints, and 50% above the lower bound of the top category, to separately 
assess linear exposure-response trends for number of days exposed to 32 military exposures incurred 
during deployment to WWII or the Korean, Vietnam, or Gulf Wars (summed over the four wars). We 
used ordinal scores to separately assess linear exposure-response trends for feeling ill after exposure to 
the same 32 exposures. For all other exposures, we used within-category medians, calculated using all 
cases, to assess linear exposure-response trends (191) and scaled many linear trend HRs to interquartile 
range (IQR) increases in the original continuous exposure variables, calculated using all cases. 
We also conducted several secondary analyses. We used standard regression methods to adjust 
for potential confounding but without adjustment for potential selection or missing covariate data bias. 
We separately analyzed deployment-specific exposures for veterans who were deployed to the Vietnam 
War (n = 145 of 228, 64%); there were too few veterans who were deployed to WWII (n = 35 of 228, 
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 15%), the Korean War (n = 38 of 228, 17%), or the Gulf War (n = 16 of 228, 7%) to analyze deployment-
specific exposures for these wars separately. To reduce heterogeneity in the sample, we restricted separate 
analyses to cases who enrolled in GENEVA within two years of diagnosis (n = 243 of 616, 39%); who 
received a diagnosis of clinically definite, probable, or probable and lab supported ALS (n = 459 of 616, 
75%); who did not report a family history of ALS (n = 571 of 588, 97%); or who did not ever visit or 
reside in the island of Guam, the islands of New Guinea, or the Kii Peninsula of Japan (n = 480 of 570, 
84%; there have been clusters of a form of ALS among individuals living in those areas (1-3)). For better 
control of confounding by sex, we restricted analyses to participants who were men (n = 603 of 616, 
98%). To mitigate potential bias from exposure misclassification, we restricted analyses to participants 
who did not require a proxy for the telephone interview (n = 589 of 616 [96%]). For analyses involving 
military exposures, we calculated Spearman correlation coefficients to identify moderate to high 
correlations between exposures and then attempted to account for these correlations by adjusting for the 
exposure that was most strongly correlated with the exposure of interest. We performed all analyses via 
SAS version 9.3 (SAS Institute Inc., Cary, NC, 2011). 
RESULTS 
At the end of follow-up (July 25, 2013), a total of 24,267 person-months (PM) had been observed 
since enrollment in GENEVA (Table 5.1). The median follow-up time was 28 months (IQR = 59) and 
there had been 446 (72%) deaths (median follow-up time = 17 months [IQR = 27]). HRs increased with 
increasing age (Table 5.1). No other demographic characteristic was associated with ALS survival. 
After adjustment for age, HRs for death were lower for clinically probable and lab supported ALS 
compared to clinically probable, but higher among cases who had a family history of ALS or who were 
currently using a feeding tube or Bi-level Positive Airway Pressure, a ventilator, or tracheostomy to assist 
with breathing at baseline (Table 5.2). HRs for death decreased with increases in time from symptom 
onset to diagnosis, time from diagnosis to enrollment in the Registry, and baseline ALSFRS-R score, but 
increased with increases in time from enrollment in the Registry to enrollment in GENEVA. 
129 
 The large majority of the means of the overall stabilized weights were approximately equal to one 
(Appendix G, Tables G.2–G.10). The exceptions were usually for time-related variables (e.g., end of most 
recent period of service, deployment, or receipt of danger pay). There were few extreme weights, but 
time-related variables had the highest occurrence of weights > 20 and weights < 0.05 occurred more 
frequently among individual exposures incurred during deployment to the four major wars. 
Weighted HRs were higher among cases who served ≤ one year in the military or before July 
1950 (Table 5.3). Similarly, cases who were deployed to WWII or before July 1950 were more likely to 
die during follow-up than those who were not deployed to one of the four major wars or nine conflicts 
queried (Table 4). There was a significant inverse linear trend between end of most recent period of 
deployment and mortality (HR = 0.65; 95% CI: 0.49, 0.88), although the category-specific associations 
were not monotonic. In general, results obtained standard regression methods were similar. 
In the weighted analysis, receipt of the anthrax vaccine; mixing and application of herbicides, riot 
control substances, or burning agents; and being exposed to Scud missile explosions during deployment 
to at least one of the four major wars were all associated with higher mortality, although only anthrax 
vaccine and burning agents had at least five exposed deaths (Table 5.5). In contrast, exposure to paint, 
solvents, or petrochemical substances; local food not provided by the Armed Forces; burning agents or 
Agent Orange in the field; use of depleted uranium for munitions or armor; smoke from oil well fires; and 
high levels of dust/sand were all associated with lower mortality, although only the first three of these 
exposures had at least five exposed deaths. Results using standard regression methods were generally 
similar with the exceptions of ever being treated with nasopharyngeal radium and ever being exposed to 
ionizing radiation or pesticide on clothing or bedding. Only ever being exposed to pesticide on clothing or 
bedding, however, had at least five exposed deaths. 
When evaluating associations between ALS survival and number of days of or feeling ill after 
direct contact with deployment-specific exposures (Appendix G, Tables G.11-G.12), number of days of 
hearing chemical alarms sounding was inversely associated with ALS survival, whereas feeling ill after 
explosions was positively associated. Other associations observed using these exposure metrics were also 
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 observed when using ever exposure (Table 5.5) or were limited by small numbers of exposed deaths in 
exposure categories. 
Analyses restricted to veterans who were deployed to the Vietnam War generally showed similar 
results (Appendix G, Tables G.13-G.16) as did restricting analyses to cases who enrolled in GENEVA 
within two years of diagnosis; who received a diagnosis of clinically definite, probable, or probable and 
lab supported ALS; who did not report a family history of ALS; who did not ever visit or reside in the 
island of Guam, the islands of New Guinea, or the Kii Peninsula of Japan; who were men; or who did not 
require a proxy for complete the telephone interview (data not shown). The majority of exposures were 
either not or only weakly correlated (e.g., Spearman correlation coefficients ≤ 0.2) and results were 
similar after adjusting for the exposure that was most strongly correlated with the exposure of interest 
(data not shown). 
DISCUSSION 
We found higher rates of mortality among cases who served or were deployed before July 1950 
or in WWII and among those who received the anthrax vaccine or who mixed and applied burning agents. 
In contrast, rates of mortality were lower among cases who were exposed to paint, solvents, or 
petrochemical substances; local food not provided by the Armed Forces; or burning agents and Agent 
Orange in the field. However, most military-related factors were not associated with ALS survival. These 
results persisted in several secondary analyses, for example after restricting to cases enrolled within two 
years of diagnosis, who had a diagnosis of definite or probable ALS, or who did not requiring a proxy.  
However, at least some of the results should be interpreted cautiously for reasons explained below. 
Evidence suggests that the rate of ALS may be increased among military veterans, particularly 
those deployed to the Gulf War (196). However few studies (see above) have evaluated associations 
between military-related factors and ALS survival or progression, and they all have limitations (24, 26, 
63, 64). The study based on the CARE database (63), a non-military database of ALS patients from North 
America (65), was published in abstract form only, so the robustness of the result is difficult to evaluate. 
The study in Boston, Massachusetts (26), did not adjust for age at diagnosis, which is one of the most 
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 consistently reported prognostic factors for ALS survival (16-24). The two studies of deployment to war 
(24, 64) were susceptible to immortal person-time bias (72, 73). The discrepancy in the results of these 
two studies may be due to that fact that the first—which found a positive association—was restricted to 
Gulf War-era veterans (64) whereas the other—with no association—included non-Gulf War-era veterans 
in the comparison group (24). Our study also included veterans of any era and found higher mortality 
among cases who were deployed to WWII, but not to other wars/conflicts, compared to cases who were 
not deployed to one of the four major wars or nine conflicts queried. 
Although several general population studies have evaluated associations between some of the 
exposures examined in our study and ALS mortality or etiology, we are aware of only two that studied 
these or related exposures and ALS survival or progression. A cohort study of ALS cases in the Boston, 
Massachussetts, reported that toxicant exposure (e.g., pesticides, lead, solvents, etc. evaluated as a group) 
was not associated with changes in disease progression or respiratory function after one year of follow-up 
(26). Similarly, agricultural work was not associated with one-year survival in a cohort of cases in Italy 
(22). Our finding of increased mortality among cases who mixed and applied burning agents contrasts 
with the decreased mortality we observed among cases who were exposed to burning agents in the field, 
although the former exposure may be greater than the latter. It is possible that the few associations we 
observed between ALS survival and specific exposures incurred during deployment to the four major 
wars were confounded by exposure to other toxicants experienced during military service or civilian life. 
We lacked the necessary data to adjust analyses for non-military exposures, but results were similar after 
adjusting for the military exposure that was most strongly correlated with the exposure of interest. 
The large majority of the overall stabilized IPWs in our analysis were well-behaved. Among 
those that were less well-behaved, time-related variables were more likely to have mean weights that were 
further from one or weights > 20 whereas weights < 0.05 occurred more frequently among exposures 
incurred during deployment to specific wars. Examination of the component weights for the poorly 
behave IPWs revealed that missing covariate data and selection weights were always well-behaved, but 
that confounding weights often were not (data not shown). Cross tabulations of age and the affected 
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 exposure variables showed non-positivity—empty cells (179, 183)—particularly in the extreme 
combinations of age and the exposure variables (data not shown). Many of these instances of non-
positivity are likely structural rather than random zeros (179), because, for example, veterans who served 
in the Gulf War are extremely unlikely to have been > 79 years-old in 2005-2010 when GENEVA was 
conducted (100). Collapsing categories of both age and the affected exposure variables remedied the non-
positivity problems and gave similar HRs and 95% CIs as the expanded versions (data not shown). Note, 
however, that we were only able to weight GENEVA cases to represent Registry cases, so any veteran 
ALS case who died before enrollment in the Registry began (April 1, 2003) was not included (24). 
Furthermore, the median time from enrollment in the Registry to enrollment in GENEVA among 
GENEVA cases was nine (IQR = 11) months, which is a relatively short time compared to elapsed time 
since diagnosis for long-surviving cases. Thus, residual selection bias could have affected our results. 
There are some limitations to enrolling ALS cases from the Registry. Despite a national recruiting 
effort (98), underascertainment of ALS cases seems likely, especially in light of the documented 
underascertainment of cases among non-deployed veterans in the VA’s previous Gulf War ALS study 
(36, 38). In addition, cases enrolled in the Registry are a mix of incident cases and long-surviving cases 
(100, 180). Despite these limitations, we observed associations between clinical and demographic 
characteristics and ALS survival that agreed with previous literature—e.g., HRs for death decreased with 
increases in time from symptom onset to diagnosis (17-19, 24-26, 29) and baseline ALSFRS-R score (17, 
21, 27) and were higher among cases who were older (16-24). While residual confounding by age may 
have affected our results, these similarities, as well as the fact that results were similar when we restricted 
analyses to men, increase confidence. 
While alternative exposure assessment methods, such as biomarkers or military databases, may 
have been preferable, insufficiently long half lives and lack of detail, respectively, made these approaches 
impractical. The validity and reliability of self-reported military service or military-related exposures 
have been evaluated by several studies, usually in comparison to data from the U.S. Department of 
Defense’s Defense Manpower Data Center, and found to be good (38, 128-136). None of these studies, 
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 however, was able to assess the validity or reliability of self-reported military service or military-related 
exposures extending back to WWII (the longest time between exposure and exposure assessment in these 
studies was about 10 years (38)) or whether the quality of self-report varied by war/time period. When we 
explored these issues in our study, we found some reporting errors for exposures with distinct time 
periods of use (e.g., a reported receipt of anthrax vaccination in the 1950s, which was 40 years too early). 
Nevertheless, efforts were made to improve recall in GENEVA by asking participants about exposures 
that can be sensed (e.g., explosions in the air; bathing in or drinking of contaminated water; petrochemical 
fumes; etc.), using general terms (e.g., flea collar instead of the names of specific pesticides or products), 
and providing a list of specific exposures and benchmarks against which respondents could compare their 
levels of exposure (e.g., feeling ill after exposure) (100). Finally, results were similar when we restricted 
to cases who did not require a proxy for the telephone interview. 
Strengths of our study include medical-record confirmed diagnoses and the relatively complete 
ascertainment of deaths from VA sources. We also had a large number of cases, although the sample size 
available for analyses of some exposures, particularly those that were war-specific, was small. We had 
extensive information on military service and deployment variables as well as on 40 specific exposures. 
Our results were robust to many secondary analyses. Finally, we used inverse probability weighting to 
explore and control potential missing covariate data and selection biases resulting from studying cases 
who likely overrepresented long survivors. 
In conclusion, previous studies of military-related factors and ALS survival have generated mixed 
results. We had more information on military-related factors than any previous study of this topic. We did 
not find strong evidence that military-related factors are associated with ALS survival. The few factors 
that appeared to be related to ALS survival may be explained by uncontrolled selection bias or 
confounding by non-military exposures. Thus, while our largely null results may be comforting to veteran 
ALS cases, more research is needed in this and other populations.
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 Figure 5.1. Flow diagram depicting the ascertainment of GENEVA cases. Solid boxes or lines represent 
cases who advanced past each step shown. Small-dashed boxes or lines represent cases who were 
excluded after each step shown. Abbreviations: ALS, amyotrophic lateral sclerosis; GENEVA, Genes and 
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis. 
 
Final sample: n = 590 + 26 = 616 
Complete interview: n = 604 Partial interview: n = 26 
Withdrawal: n = 31 Deceased: n = 33 Passive refusal: n = 30 
Consented: n = 724 
Able to contact for GENEVA enrollment: n = 843 
Did not attempt to contact: n = 266 Unable to contact: n = 37 
Consented for DNA Bank: n = 1,346 
Missing: n = 75 Deceased: n = 214 
 
Permission to re-contact for further studies: n = 1,830 
No permission to re-contact for further studies: n = 26 
Enrolled in the National Registry of Veterans with ALS: n = 2,122 
Sporadic ALS: n = 1,856 
Not sporadic ALS: n = 248 Withdrawal: n = 18 
Refused: n = 195 
Deceased: n = 200 
 
Ineligible: n = 25 Passive refusal: n = 10 Active refusal: n = 84 
Missing date of diagnosis: n = 7 + 0 = 7 Proxy interview: n = 7 + 0 = 7 
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 Table 5.1. Demographic characteristics of amyotrophic lateral sclerosis deaths and total casesa in 
GENEVA. 
  Deaths Total Crude Adjustedb 
Characteristic No. PMc No. PMc HRd 95% CId HRd 95% CId 
Total 446 10,558 616 24,267     Age (years)         ≤ 39 17 409 42 2,470 0.60 0.36, 1.02 NA NA 
40-49 35 1,150 68 3,853 0.74 0.50, 1.09 NA NA 
50-59 117 2,893 171 7,186 1.00 Referent NA NA 
60-69 165 3,624 203 6,708 1.45 1.14, 1.84 NA NA 
70-79 100 2,264 119 3,767 1.45 1.11, 1.90 NA NA 
> 79 12 219 13 283 1.98 1.09, 3.59 NA NA 
Median ± IQR 62 ± 14  60 ± 14  1.43
e 1.26, 1.63e NA NA 
Sex         Male 436 10,240 603 23,698 1.00 Referent 1.00 Referent 
Female 10 318 13 569 1.00 0.53, 1.87 1.26 0.66, 2.39 
Race/Ethnicity         Non-Hispanic White 413 9,491 561 21,419 1.00 Referent 1.00 Referent 
Other 29 1,009 48 2,569 0.68 0.47, 1.00 0.74 0.51, 1.09 
Missing 4  7      Use of VA health care system         No 254 5,920 361 14,502 1.00 Referent 1.00 Referent 
Yes 192 4,639 254 9,686 1.04 0.86, 1.25 1.00 0.82, 1.21 
Missing 0  1      Ever applied for VA benefits of any 
type         
No 73 1,536 100 3,741 1.00 Referent 1.00 Referent 
Yes 335 7,918 455 17,264 0.90 0.70, 1.16 0.92 0.71, 1.19 
Missing 38  61      Highest degree attained         Grade school (grades 1-8) 17 496 20 753 1.22 0.74, 2.00 1.00 0.61, 1.66 
High school diploma or other 191 4,455 266 10,474 1.00 Referent 1.00 Referent 
Technical or vocation school 
diploma or Associate degree 81 1,604 114 4,207 0.95 0.73, 1.24 0.96 0.73, 1.25 
College or graduate school 
diploma 145 3,692 199 8,152 0.98 0.79, 1.22 0.99 0.80, 1.24 
Doctorate 12 310 17 681 0.88 0.49, 1.59 0.84 0.47, 1.52 
Cigarette smoking status         Never 141 3,261 207 8,558 1.00 Referent 1.00 Referent 
Past 232 5,531 305 11,380 1.13 0.92, 1.40 1.04 0.84, 1.29 
Current 58 1,547 85 3,808 0.96 0.71, 1.31 1.02 0.75, 1.39 
Missing 15   19           
Abbreviations: ALS, amyotrophic lateral sclerosis; CI, confidence interval; GENEVA, Genes and Environmental Exposures in 
Veterans with Amyotrophic Lateral Sclerosis; HR, hazard ratio; IQR, interquartile range; NA, not applicable; PM, person-months; 
VA, Department of Veterans Affairs. 
aFourteen ALS cases were excluded from this analysis because 1) they were missing data on date of diagnosis (n = 7) or 2) they 
died before the interview (i.e., the interview was completed by a proxy after the case died; n = 7). 
bAdjusted for age (modeled with indicator variables corresponding to 5-year groups). 
cPerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 
2013). 
dHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
eScaled the HR to an IQR-unit increase in age among all cases. 
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 Table 5.2. Clinical characteristics of amyotrophic lateral sclerosis deaths and total casesa in GENEVA. 
  Deaths Total Crude Adjustedb 
Characteristic No. PMc No. PMc HRd 95% CId HRd 95% CId 
Most recent ALS diagnosis         Clinically definite 99 2,671 148 6,778 0.86 0.67, 1.12 0.90 0.69, 1.18 
Clinically probable 166 3,672 209 7,145 1.00 Referent 1.00 Referent 
Clinically probable and lab supported 66 1,467 102 4,377 0.68 0.51, 0.90 0.67 0.50, 0.89 
Clinically possible 37 854 47 1,681 1.04 0.73, 1.49 1.07 0.75, 1.54 
Suspected (progressive bulbar palsy or progressive muscular atrophy) 78 1,894 110 4,286 0.91 0.70, 1.20 0.86 0.65, 1.13 
Family history of ALS         No 412 9,885 571 22,748 1.00 Referent 1.00 Referent 
Yes 15 365 17 532 1.36 0.81, 2.29 1.65 0.97, 2.80 
Missing 19  28      Site of symptom onset         Bulbar 70 1,362 85 2,551 1.35 1.04, 1.75 1.23 0.94, 1.61 
Extremities 352 8,586 499 20,512 1.00 Referent 1.00 Referent 
Othere 23 579 31 1,171 0.84 0.55, 1.29 0.96 0.63, 1.48 
Missing 1  1      Time from symptom onset to diagnosis (months)         ≤ 6 90 2,299 116 4,483 0.85 0.65, 1.11 0.88 0.67, 1.15 
> 6-12 138 2,868 166 5,041 1.00 Referent 1.00 Referent 
> 12-18 73 1,434 104 3,869 0.74 0.56, 0.98 0.77 0.58, 1.03 
> 18-24 36 799 46 1,617 0.88 0.61, 1.28 0.85 0.59, 1.24 
> 24 104 2,940 172 8,426 0.56 0.43, 0.72 0.49 0.38, 0.64 
Missing 5  12      Median ± IQR 11 ± 15  13 ± 18  0.82
f 0.75, 0.91f 0.77f 0.70, 0.86f 
Time from diagnosis to enrollment in the Registry (months)         ≤ 12 185 3,372 216 5,699 1.00 Referent 1.00 Referent 
> 12-24 116 2,838 142 4,865 0.95 0.74, 1.21 0.86 0.67, 1.11 
> 24-36 47 1,091 75 3,347 0.76 0.53, 1.09 0.73 0.50, 1.05 
> 36-48 26 643 44 2,071 0.83 0.51, 1.32 0.76 0.47, 1.23 
> 48 72 2,614 139 8,284 0.73 0.44, 1.21 0.70 0.42, 1.17 
Median ± IQR 15 ± 25  19 ± 32  0.82
f 0.66, 1.03f 0.82f 0.65, 1.02f 
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   Deaths Total Crude Adjustedb 
Characteristic No. PMc No. PMc HRd 95% CId HRd 95% CId 
Time from enrollment in the Registry to enrollment in the GENEVA study 
(months)         
≤ 6 140 2,795 178 5,634 0.99 0.78, 1.26 1.01 0.79, 1.30 
> 6-12 142 3,101 204 8,157 1.00 Referent 1.00 Referent 
> 12-18 72 1,951 95 3,896 1.36 1.02, 1.81 1.30 0.97, 1.74 
> 18-24 51 1,526 71 3,286 1.34 0.96, 1.86 1.36 0.97, 1.90 
> 24 41 1,186 68 3,294 1.31 0.90, 1.90 1.34 0.92, 1.95 
Median ± IQR 9 ± 11  9 ± 11  1.16
f 1.01, 1.34f 1.18f 1.02, 1.37f 
Baselineg ALSFRS-R score (possible range: 0-48)h         ≤ 16 108 2,071 133 4,167 1.87 1.41, 2.47 2.09 1.57, 2.77 
> 16-23 94 1,815 116 3,674 1.50 1.13, 1.99 1.69 1.27, 2.25 
> 23-30 99 2,730 137 5,787 1.00 Referent 1.00 Referent 
> 30-35 77 1,792 111 4,466 0.88 0.65, 1.19 0.89 0.66, 1.21 
> 35 68 2,151 119 6,172 0.53 0.39, 0.73 0.56 0.41, 0.76 
Median ± IQR 26 ± 16  27 ± 16  0.54
f 0.47, 0.62f 0.51f 0.44, 0.59f 
Currently using riluzole (baselineg)         No 207 5,107 298 12,448 1.00 Referent 1.00 Referent 
Yes 229 5,200 302 11,166 1.08 0.90, 1.31 1.14 0.94, 1.39 
Missing 10  16      Currently using BiPAP to assist with breathing (baselineg)         No 332 8,593 482 20,656 1.00 Referent 1.00 Referent 
Yes 109 1,849 128 3,402 1.78 1.43, 2.22 1.83 1.46, 2.28 
Missing 5  6      Currently using CPAP to assist with breathing (baselineg)         No 431 10,174 591 23,087 1.00 Referent 1.00 Referent 
Yes 14 382 24 1,177 0.82 0.48, 1.40 0.74 0.43, 1.26 
Missing 1  1      Currently using a ventilator (≥ two weeks, 15 hours/day) to assist with breathing 
(baselineg)         
No 415 9,699 573 22,353 1.00 Referent 1.00 Referent 
Yes 31 859 43 1,914 1.31 0.89, 1.91 1.55 1.06, 2.28 
Currently using tracheostomy to assist with breathing (baselineg)         No 412 9,611 570 22,264 1.00 Referent 1.00 Referent 
Yes 31 872 43 1,928 1.33 0.91, 1.95 1.58 1.07, 2.33 
Missing 3  3      
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   Deaths Total Crude Adjustedb 
Characteristic No. PMc No. PMc HRd 95% CId HRd 95% CId 
Currently using a feeding tube (baselineg)         No 295 7,261 430 18,106 1.00 Referent 1.00 Referent 
Yes 89 1,815 108 3,390 1.74 1.37, 2.21 1.86 1.46, 2.38 
Missing 62   78           
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BiPAP, Bi-level Positive Airway Pressure; CI, confidence interval; CPAP, 
Continuous Positive Airway Pressure; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; HR, hazard ratio; IQR, interquartile range; 
PM, person-months. 
aFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) they died before the interview (i.e., the interview was 
completed by a proxy after the case died; n = 7). 
bAdjusted for age (modeled with indicator variables corresponding to 5-year groups). 
cPerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 2013). 
dHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
eIncludes “all over” (deaths: n = 4; total: n = 4), “cramps/fasciculations” (deaths: n = 18; total: n = 26), and “loss of appetite” (deaths: n = 1; total: n = 1). 
fScaled the HR and 95% CI to an IQR-unit increase in time from onset to diagnosis, time from diagnosis to enrollment in the Registry, time from enrollment in the Registry to 
enrollment in GENEVA, or baseline ALSFRS-R score among all cases. 
gThe ALSFRS-R score or use status of riluzole, BiPAP, CPAP, ventilator, tracheostomy, or feeding tube that was measured closest to the time of enrollment (i.e., interview) in 
GENEVA. 
hCategory boundaries were set at quintiles of the ALSFRS-R score among all cases. 
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 Table 5.3. Military service and amyotrophic lateral sclerosis survival in GENEVAa. 
  Deaths Total Adjustedb IP-weightedc 
Variable No. PMd No. PMd HRe 95% CIe HRe 95% CIe 
Military branch of longest service         Air Force (including Army Air Force) 97 2,124 129 4,784 1.11 0.86, 1.42 1.10 0.84, 1.45 
Army 182 4,403 249 9,775 1.00 Referent 1.00 Referent 
Marines (including Merchant Marines) 36 638 55 2,175 1.00 0.69, 1.43 0.84 0.51, 1.40 
Navy 98 2,570 136 5,616 0.93 0.72, 1.19 0.90 0.68, 1.19 
Otherf 32 816 45 1,815 0.94 0.64, 1.37 0.75 0.49, 1.15 
Missing 1  2      Number of military branches of service         1 (Median = 1) 411 9,774 565 22,300 1.00 Referent 1.00 Referent 
> 1 (2) 35 785 51 1,967 0.97 0.68, 1.38 1.01 0.75, 1.37 
Officer or Warrant Officer         No 373 8,685 514 20,110 1.00 Referent 1.00 Referent 
Yes 72 1,858 100 4,060 1.02 0.79, 1.32 0.93 0.69, 1.25 
Missing 1  2      Years of military service         ≤ 1 (0.50) 13 241 15 400 1.74 0.98, 3.07 1.81 1.12, 2.91 
> 1-5 (2.92) 305 7,022 414 15,896 1.00 Referent 1.00 Referent 
> 5-10 (7.92) 42 1,202 59 2,497 0.92 0.65, 1.28 0.83 0.56, 1.25 
> 10-15 (11.99) 14 436 26 1,398 0.92 0.52, 1.64 0.81 0.49, 1.32 
> 15-20 (18.92) 19 502 21 684 1.56 0.97, 2.52 0.83 0.64, 1.09 
> 20 (24.31) 52 1,147 79 3,290 0.83 0.62, 1.13 0.99 0.69, 1.42 
Missing 1  2      Trend (IQR = 6.00)g, h     0.97 0.89, 1.04 0.99 0.90, 1.09 End of most recent period of military service 
(month/year)i         
≤ 12/1946 (03/1946) 26 593 32 1,073 1.41 0.77, 2.58 1.60 0.97, 2.63 
01/1947-06/1950 (02/1948) 9 185 11 341 1.25 0.56, 2.78 2.23 1.08, 4.62 
07/1950-01/1955 (06/1953) 48 1,332 56 2,003 1.04 0.64, 1.67 1.05 0.71, 1.56 
02/1955-02/1961 (12/1957) 78 1,648 97 3,266 1.03 0.71, 1.48 1.21 0.84, 1.73 
03/1961-07/1964 (06/1963) 34 849 43 1,603 0.87 0.57, 1.33 1.06 0.68, 1.67 
08/1964-04/1975 (07/1969) 134 3,160 192 7,732 1.00 Referent 1.00 Referent 
05/1975-08/1980 (05/1978) 26 606 42 1,903 1.12 0.72, 1.74 0.89 0.52, 1.51 
09/1980-07/1990 (03/1986) 36 818 53 2,156 0.98 0.66, 1.45 0.84 0.59, 1.21 
08/1990-08/2001 (06/1994) 44 1,177 71 3,299 0.97 0.67, 1.40 0.96 0.64, 1.44 
> 08/2001 (10/2003) 10 182 17 789 0.89 0.45, 1.76 0.88 0.44, 1.75 
Missing 1  2      Trend (20 years, 11.99 months)g, h         0.94 0.76, 1.17 0.96 0.79, 1.16 
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI, confidence interval; 
GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; HR, hazard ratio; IP, inverse 
probability; IQR, interquartile range; PM, person-months. 
aFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) 
they died before the interview (i.e., the interview was completed by a proxy after the case died; n = 7). 
bAdjusted for age (modeled with indicator variables corresponding to 5-year groups). 
cWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data 
(conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical 
Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
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 dPerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 
2013). 
eHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
fIncludes Coast Guard (deaths: n = 6; total: n = 8), Activated National Guard (deaths: n = 5; total = 6), Activated Reserves 
(deaths: n = 11; total = 17), Inactivated National Guard (deaths: n = 2; total = 4), Inactivated Reserves (deaths: n = 8; total = 9), 
Department of Defense (deaths: n = 0; total: n = 0), National Oceanic and Atmospheric Administration (deaths: n = 0; total = 1), 
and Public Health Service (deaths: n = 0; total = 0). 
gUsed within-category medians that were calculated using all cases. 
hScaled the HR to an IQR-unit increase in the exposure variable. IQRs were calculated using all cases. 
iCategory boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and 
May 1975) and followed (98, 100). 
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 Table 5.4. Military deployments or danger pay and amyotrophic lateral sclerosis survival in GENEVAa. 
  Deaths Total Adjustedb IP-weightedc 
Variable No. PMd No. PMd HRe 95% CIe HRe 95% CIe 
Deployments         Ever deployed to any war/operationf         No 250 5,790 348 13,683 1.00 Referent 1.00 Referent 
Yes 179 4,472 247 9,986 0.99 0.81, 1.21 0.98 0.78, 1.23 
Missing 17  21      War/operation of longest deploymentf         Not deployed 250 5,790 348 13,683 1.00 Referent 1.00 Referent 
World War II 24 671 29 1,076 0.81 0.47, 1.42 1.60 1.07, 2.40 
Korean War 29 686 32 931 1.32 0.87, 2.00 0.92 0.46, 1.82 
Vietnam War 98 2,318 138 5,474 0.98 0.76, 1.27 0.88 0.62, 1.25 
Otherg 19 584 35 1,926 0.87 0.53, 1.43 0.54 0.33, 0.88 
Missing 26  34      Ever deployed to any other country         No 222 5,222 309 12,310 1.00 Referent 1.00 Referent 
Yes 205 5,014 283 11,254 0.96 0.79, 1.16 0.99 0.80, 1.24 
Missing 19  24      Total time (years) of all periods of 
deployment to any war/operationf         
Not deployed (0) 250 5,790 348 13,683 1.00 Referent 1.00 Referent 
≤ 1 (0.67) 88 2,206 120 4,834 1.05 0.82, 1.35 1.10 0.87, 1.41 
> 1-2 (1.25) 45 1,228 67 2,918 0.82 0.59, 1.14 0.80 0.58, 1.10 
> 2-4 (2.37) 29 643 36 1,238 1.46 0.98, 2.19 1.47 1.01, 2.12 
> 4 (6.00) 8 183 11 417 0.71 0.34, 1.45 0.62 0.18, 2.20 
Missing 26  34      Trendh     0.98 0.89, 1.08 0.87 0.70, 1.07 End of most recent period of deployment 
to any war/operation (month/year)f, i         
Not deployed 250 5,790 348 13,683 1.00 Referent 1.00 Referent 
≤ 06/1950 (01/1946) 23 656 28 1,061 0.80 0.46, 1.41 1.77 1.19, 2.64 
07/1950-01/1955 (01/1953) 24 539 26 702 1.25 0.79, 1.98 1.37 0.91, 2.04 
02/1955-02/1961 (02/1956) 7 165 8 247 1.86 0.85, 4.08 2.09 0.53, 8.18 
03/1961-04/1975 (02/1969) 98 2,362 136 5,348 1.00 0.78, 1.29 1.14 0.82, 1.58 
05/1975-07/1990 (08/1980) 6 147 10 491 1.02 0.45, 2.32 0.98 0.50, 1.94 
> 07/1990 (07/1992) 12 391 25 1,462 0.72 0.39, 1.33 0.57 0.30, 1.08 
Missing 26  35      Trend (IQR=14 years, 11.98 months)h, j     0.86 0.60, 1.24 0.65 0.49, 0.88 Danger pay, hardship duty or combat 
zone tax exclusion benefits for 
deployment         
Ever received imminent danger pay, 
hardship duty or combat zone tax 
exclusion benefits for deployment         
No 309 7,571 414 16,134 1.00 Referent 1.00 Referent 
Yes 103 2,267 157 6,498 0.94 0.74, 1.19 0.85 0.65, 1.13 
Missing 34  45      
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   Deaths Total Adjustedb IP-weightedc 
Variable No. PMd No. PMd HRe 95% CIe HRe 95% CIe 
Total time (years) of all periods of 
deployment to any countries or sea 
region(s) ever received imminent danger 
pay, hardship duty or combat zone tax 
exclusion benefits for deployment 
        
Never received imminent danger pay, 
hardship duty or combat zone tax 
exclusion benefits for deployment 
(0.00) 
309 7,571 414 16,134 1.00 Referent 1.00 Referent 
≤ 1 (0.83) 47 1,092 73 3,104 0.90 0.66, 1.24 0.79 0.51, 1.21 
> 1-2 (1.13) 21 447 30 1,172 1.03 0.66, 1.62 0.86 0.56, 1.33 
> 2 (2.50) 8 191 11 462 1.17 0.57, 2.39 0.99 0.47, 2.10 
Missing 61  88      Trendh     1.00 0.81, 1.25 0.98 0.78, 1.22 Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI, confidence interval; 
GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; 
HR, hazard ratio; IP, inverse probability; IQR, interquartile range; PM, person-months; WWII, World War II. 
aFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) 
they died before the interview (i.e., the interview was completed by a proxy after the case died; n = 7). 
bAdjusted for age (modeled with indicator variables corresponding to 5-year groups). 
cWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data 
(conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical 
Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
dPerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 
2013). 
eHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
fThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a 
separate question: World War II (defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined 
as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period from August 3, 1964, to May 7, 
1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also 
asked "Ever deployed..." to the following countries where each country was asked about with a separate question: Grenada, 
Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
gIncludes Grenada (cases: n = 0; controls: n = 1), Lebanon (cases: n = 5; controls: n = 9), Panama (cases: n = 8; controls: n = 
29), Somalia (cases: n = 2; controls: n = 0), Bosnia (cases: n = 2; controls: n = 1), Kosovo (cases: n = 0; controls: n = 0), Rwanda 
(cases: n = 0; controls: n = 0), Afghanistan (cases: n = 1; controls: n = 2), and Iraq/Persian Gulf region (Gulf War II) (cases: n = 
6; controls: n = 20). 
hUsed within-category medians that were calculated using all cases. 
iCategory boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and 
May 1975) and followed (98, 100). 
jScaled the HR to an IQR-unit increase in the exposure variable. IQRs were calculated using all cases except those in the 
reference category. Reference category excluded for linear trend test.
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 Table 5.5. Military exposures and amyotrophic lateral sclerosis survival in GENEVAa. 
  Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Ever received the anthrax vaccine prior to reference date           No 353 8,486 483 18,957 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 25 534 35 1,372 1.32 0.86, 2.03 1.47 0.92, 2.35 1.50 0.99, 2.27 
Missing 42  64        Ever received the smallpox vaccine           No 50 1,088 71 2,744 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 329 7,944 454 18,127 1.01 0.74, 1.37 1.02 0.75, 1.39 0.90 0.66, 1.24 
Missing 41  57        Prior to reference date, ever involved in testing, transporting 
or spraying herbicides for military purposes           
No 325 7,357 440 16,184 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 10 350 17 851 0.78 0.41, 1.48 0.79 0.41, 1.51 1.08 0.58, 2.00 
Missing 85  125        Prior to reference date, ever been treated with 
nasopharyngeal (NP) radium during military service           
No 331 7,615 452 16,877 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 96 < 5 179 1.43 0.44, 4.64 1.49 0.45, 4.91 0.98 0.59, 1.62 
Missing 86  126        Ever taken pyridostigmine bromide, or little white pills in foil 
packs, sometimes called NAPPs, which are used to protect 
against nerve agents           
No 379 9,072 523 20,649 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 10 296 18 940 0.90 0.47, 1.73 0.97 0.50, 1.88 1.12 0.37, 3.39 
Missing 31  41        Prior to reference date, ever visited or resided in the island of 
Guam, the islands of New Guinea, or the Kii Peninsula of 
Japan (including any time spent there in the military)           
No 347 8,190 480 18,911 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 66 1,619 90 3,550 1.00 0.76, 1.30 1.02 0.78, 1.35 0.97 0.74, 1.27 
Missing 7  12        
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
While you were in WWII, the Korean War, the Vietnam 
War, or the Gulf Warg: did you have direct contact 
with/were you exposed to           
Manufacture, testing, or use of chemical protective gear 
(for mustard gas, tear gas, etc.) Do not include training           
No 154 3,735 208 8,109 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 5 95 10 493 0.89 0.34, 2.30 1.05 0.39, 2.83 0.84 0.16, 4.43 
Missing 9  10        Ionizing radiation from nuclear weapon testing or 
occupation of Hiroshima/Nagasaki           
No 153 3,911 209 8,450 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 18 < 5 77 1.78 0.55, 5.77 2.18 0.66, 7.18 1.05 0.22, 5.03 
Missing 12  15        Use of personal pesticides, like creams, sprays or flea 
collars           
No 111 2,781 152 6,155 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 50 1,206 67 2,536 1.25 0.87, 1.78 1.29 0.89, 1.86 0.93 0.63, 1.37 
Missing 7  9        Use of pesticides on your clothing or bedding           No 114 3,090 159 6,770 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 36 675 49 1,673 1.43 0.94, 2.16 1.39 0.91 1.05 0.62, 1.80 
Missing 18  20        Exhaust from heaters or generators (e.g., kerosene 
heaters, tent heaters)           
No 102 2,484 140 5,525 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 52 1,213 74 3,035 0.94 0.66, 1.34 0.96 0.67, 1.37 0.80 0.54, 1.19 
Missing 14  14        Exposure to diesel and/or other petrochemical fumes           No 57 1,372 75 2,890 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 102 2,499 143 5,750 0.99 0.70, 1.41 1.03 0.72, 1.47 1.05 0.66, 1.67 
Missing 9  10        Burning trash or burning feces/manure           No 108 2,691 144 5,635 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 51 1,243 74 3,096 1.11 0.76, 1.61 1.08 0.74, 1.58 0.78 0.53, 1.17 
Missing 9  10        
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Exposure to paint, solvents, or petrochemical substances           No 110 2,730 143 5,461 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 45 1,132 72 3,264 0.74 0.52, 1.06 0.77 0.53, 1.10 0.70 0.49, 1.01 
Missing 13  13        High-intensity radar waves (e.g., as radar operator, radio 
operator, aviation electrician's mate)           
No 117 3,026 158 6,377 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 35 815 46 1,692 1.17 0.79, 1.75 1.27 0.84, 1.90 1.28 0.88, 1.85 
Missing 16  24        Food contaminated with smoke, oil, or other chemicals           No 130 3,291 181 7,414 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 11 267 15 580 1.01 0.53, 1.92 0.95 0.50, 1.81 0.68 0.36, 1.29 
Missing 27  32        Local food other than food provided by the Armed Forces           No 85 1,881 108 3,741 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 77 2,056 112 4,873 0.84 0.61, 1.17 0.84 0.60, 1.17 0.67 0.49, 0.92 
Missing 6  8        Bathing in or drinking of water contaminated with smoke, 
oil, dead animals or any chemicals           
No 131 3,186 174 6,641 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 12 188 20 801 0.89 0.48, 1.65 0.88 0.47, 1.63 0.83 0.33, 2.11 
Missing 25  34        Heat cramps, heat exhaustion, heat stroke or other heat 
Illness           
No 129 3,162 172 6,645 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 34 811 50 2,103 1.10 0.74, 1.65 1.11 0.74, 1.66 0.86 0.53, 1.38 
Missing 5  6        Heard chemical alarms sounding           No 154 3,722 206 7,944 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 7 169 15 810 0.60 0.28, 1.30 0.69 0.30, 1.57 0.59 0.24, 1.43 
Missing 7  7        Explosion in the air or on the ground within one mile of you 
(e.g., artillery, rockets, mortars)           
No 49 1,349 71 3,154 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 112 2,601 149 5,597 1.30 0.92, 1.86 1.26 0.88, 1.80 1.26 0.87, 1.84 
Missing 7  8        
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Have you suffered a combat-related injury that required 
medical attention during your deployment?           
No 126 2,958 175 6,965 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 38 1,015 49 1,871 1.03 0.71, 1.51 0.98 0.67, 1.45 0.87 0.53, 1.44 
Missing 4  4        While you were in WWII, the Korean War, or the Vietnam 
Warg: did you have direct contact with/were you exposed 
to           
Mixing and application of herbicides           No 150 3,661 201 7,744 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 87 < 5 87 2.41 0.85, 6.87 2.03 0.69, 6.02 1.57 0.98, 2.51 
Missing 10  11        Exposure to herbicides in the field           No 120 2,839 159 5,982 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 10 304 11 396 1.34 0.68, 2.62 1.29 0.65, 2.56 1.01 0.62, 1.65 
Missing 34  46        Mixing and application of riot control substances           No 159 3,911 211 8,084 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 9 < 5 9 4.54 1.01, 20.42 4.83 1.08, 21.61 4.11 2.32, 7.27 
Missing 3  3        Exposure to riot control substances in the field           No 152 3,654 200 7,537 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 9 267 12 490 0.96 0.48, 1.92 0.99 0.49, 2.00 0.65 0.32, 1.29 
Missing 3  4        Mixing and application of burning agents           No 145 3,601 195 7,594 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 13 193 14 284 2.22 1.19, 4.12 2.41 1.29, 4.49 2.75 1.38, 5.46 
Missing 6  7        Exposure to burning agents in the field           No 134 3,286 175 6,610 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 22 511 32 1,271 0.84 0.52, 1.35 0.87 0.54, 1.40 0.54 0.35, 0.85 
Missing 8  9        
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
While you were in the Korean War, the Vietnam War, or 
the Gulf Warg: did you have direct contact with/were you 
exposed to           
Microwave radiation           No 108 2,792 151 6,261 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 10 241 14 581 1.15 0.59, 2.25 1.14 0.57, 2.24 1.03 0.61, 1.75 
Missing 23  29        While you were in the Vietnam Warg: did you have direct 
contact with/were you exposed to           
Mixing and application of Agent Orange           No 91 2,145 128 5,050 1.00 Referent NA NA 1.00 Referent 
Yes 6 127 8 283 1.11 0.47, 2.61 NA NA 0.63 0.33, 1.22 
Missing 7  9        Exposure to Agent Orange in the field           No 40 841 51 1,729 1.00 Referent NA NA 1.00 Referent 
Yes 39 795 63 2,668 0.73 0.46, 1.17 NA NA 0.62 0.39, 0.99 
Missing 25  31        While you were in the Gulf Warg: did you have direct 
contact with/were you exposed to           
Use of depleted uranium (DU) for munitions or armor           No 5 213 8 495 1.00 Referent NA NA 1.00 Referent 
Yes < 5 43 5 389 0.35 0.04, 3.39 NA NA 0.47 0.10, 2.22 
Missing 2  3        CARC (Chemical Agent Resistant Compound) paint           No 5 205 10 663 1.00 Referent NA NA 1.00 Referent 
Yes < 5 69 < 5 240 1.56 0.19, 13.01 NA NA 1.36 0.30, 6.25 
Missing 1  2        Scud missile explosion in the air or on the ground within 
one mile of you           
No < 5 153 9 593 1.00 Referent NA NA 1.00 Referent 
Yes < 5 78 < 5 267 12.50 0.52, 298.52 NA NA 3.04 0.71, 13.08 
Missing 2  3        Smoke from oil well fires           No 5 206 5 206 1.00 Referent NA NA 1.00 Referent 
Yes < 5 68 9 665 0.12 0.01, 1.41 NA NA 0.18 0.04, 0.75 
Missing 1  2        
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Exposure to nerve gas (e.g., during munitions destruction)           No 7 246 11 593 1.00 Referent NA NA 1.00 Referent 
Yes 0 0 < 5 281 h h NA NA h h 
Missing 1  2        High levels of dust/sand           No < 5 86 < 5 86 1.00 Referent NA NA 1.00 Referent 
Yes 5 202 13 894 0.17 0.01, 2.33 NA NA 0.13 0.01, 1.11 
Ground level fumigation           No 6 204 9 468 1.00 Referent NA NA 1.00 Referent 
Yes 0 0 < 5 365 h h NA NA h h 
Missing 2  3        In any conflicts deployed to, any other exposure or 
experience not asked about which you consider harmful or 
extremely stressful           
No 162 3,904 231 9,744 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 52 1,420 68 2,692 1.06 0.77, 1.46 1.05 0.75, 1.48 0.82 0.54, 1.25 
Missing 206   283               
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CARC, Chemical Agent Resistant Compound; CI, confidence interval; DU, 
depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; HR, hazard ratio; IP, inverse 
probability; NA, not applicable; NP, nasopharyngeal; PM, person-months; WWII, World War II. 
aFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) they died before the interview (i.e., the interview was 
completed by a proxy after the case died; n = 7). 
bAdjusted for age (modeled with indicator variables corresponding to 5-year groups or, for exposures queried only in reference to deployment to the Gulf War, modeled with a 
linear term that was centered at age 60—the median age among all cases). 
cAdjusted for age (modeled with indicator variables corresponding to 5-year groups), war/operation of longest deployment, and the pairwise interaction between war/operation of 
longest deployment and the natural logarithm of time since diagnosis. 
dWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups or, for exposures queried only in reference to deployment to the Gulf War, 
modeled with a linear term that was centered at age 60—the median age among all cases), war/operation of longest deployment, not missing covariate data (conditional on most 
recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to 
enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the 
Registry cases not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS 
diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the 
Registry [months; modeled with a linear term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the 
distribution in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
ePerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 2013). 
fHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
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 gThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). 
hUnable to estimate HR and 95% CI. 
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 CHAPTER SIX: SUMMARY AND CONCLUSIONS 
 
REVIEW OF SPECIFIC AIMS 
ALS is a debilitating neurodegenerative disease that involves motor neuron loss in the central 
nervous system (1-3). Despite its rarity, ALS is an important public health problem because of the 
dramatic effect of motor neuron loss in the daily lives of individuals with ALS and their caregivers as 
well its often rapid and fatal, but extremely variable, progression. ALS rates have been reported to be 
higher among U.S. military veterans, of which there are currently more than 21 million (30), but the 
causal agents of military service have not been identified (196). Previous studies of military-related 
factors and ALS etiology or survival have been limited by reliance on mortality as a surrogate for 
incidence, a dearth of survival analyses, lack of clinical data, low statistical power, and limited exposure 
assessment (196). Therefore, we used data from the GENEVA study, a case-control study of 630 veteran 
ALS cases and 975 frequency-matched veteran controls (100) to 1) evaluate associations between aspects 
of military service, deployments, and 40 exposures and ALS etiology; and 2) evaluate associations 
between aspects of military service, deployments, and 40 exposures and ALS survival. We also used IPW 
(105) to evaluate and adjust for potential selection bias resulting from studying cases who likely represent 
long survivors and controls who may be different from U.S. military veterans at large (100, 180). 
SUMMARY OF RESULTS 
For Specific Aim 1 (etiology), there was no difference in the odds of ALS among veterans of the 
Air Force, Army, Marines, and Navy. The weighted odds of ALS were lower among veterans whose 
longest service was in branches other than the Air Force, Army, Marines, or Navy (e.g., Coast Guard, 
National Guard, Reserves) compared to the Army and among veterans who had been officers. There were 
significant inverse linear trends between ALS and number of branches of service as well as years of and 
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 end of most recent service. ALS was significantly more common among veterans whose longest 
deployment was to WWII or the Korean War, but significantly less common among veterans whose 
longest deployment was to operations besides the four major wars, than among those who were not 
deployed. There were significant inverse linear trends between ALS and end of most recent deployment 
as well as total time of all periods of receipt of danger pay. Ever receiving danger pay was also inversely 
associated with ALS. ALS was significantly or nearly significantly positively associated with direct 
contact with eight different exposures incurred during deployment to the four major wars: herbicides for 
military purposes; pyridostigmine bromide; exhaust from heaters or generators; high-intensity radar 
waves; explosions; mixing and application of burning agents; Agent Orange in the field; and ground level 
fumigation (although the last one was based on only four exposed cases and two exposed controls). 
Several other exposures had elevated, but non-significant ORs for ALS, although many were based on 
fewer than five exposed cases or controls. Patterns and directions of results were generally similar, 
particularly linear trend tests, when we evaluated the number of days of exposure or whether veterans felt 
ill after exposure. The linear trend test for total number of preventive vaccinations received was nearly 
significant, although the categorical version of this variable did not show a monotonically increasing 
relationship. Our results were robust to many secondary analyses and results were generally similar 
qualitatively when we used standard regression methods. 
For Specific Aim 2 (survival), weighted HRs were higher among cases who served no more than 
one year in the military or before July 1950. Similarly, cases who were deployed to WWII or before July 
1950 were more likely to die during follow-up than those who were not deployed to one of the four major 
wars or nine conflicts queried and there was a significant inverse linear trend between end of most recent 
deployment and mortality. Similar results were observed for end of most recent period of receipt of 
danger pay. Receipt of the anthrax vaccine; mixing and application of herbicides, riot control substances, 
or burning agents; and Scud missile explosions during deployment to the four major wars were all 
associated with higher mortality, although only receipt of anthrax vaccine and mixing and application of 
burning agents had at least five exposed deaths. In contrast, exposure to paint, solvents, or petrochemical 
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 substances; local food not provided by the Armed Forces; burning agents and Agent Orange in the field; 
use of depleted uranium for munitions or armor; smoke from oil well fires; and high levels of dust/sand 
were all associated with lower mortality, although the latter three each had less than five exposed deaths. 
Once again, our results were robust to many secondary analyses and results were generally similar 
qualitatively when we used standard regression methods. 
STRENGTHS AND LIMITATIONS 
We were able to address several of the limitations of previous studies by using data from the 
GENEVA study. Specifically, we were able to use the GENEVA study for both etiological and survival 
research because of the following features: 
• Living cases were identified via the Registry and ALS diagnoses were confirmed via medical 
record review (100). 
• Important and high quality clinical information, such as date of diagnosis, site of onset, disease 
progression/disability status, etc., was also available. 
• Controls were identified via VA databases and frequency-matched to cases on age and use of the 
VA health care system (100). 
• Information on the vital status of ALS cases was ascertained from VA sources and current 
through July 2013. 
• Formal survival analyses, with the appropriate mitigation of immortal person-time bias, were 
conducted. 
Thus, associations between military-related factors and ALS etiology or survival were evaluated 
more rigorously and with greater detail than in previous studies. In addition, having 630 ALS cases makes 
the GENEVA study one of the largest studies of military-related factors and ALS etiology or survival and 
provided better power for evaluating associations of interest. The GENEVA study collected extensive 
information on various aspects of military service and deployments as well as on 40 specific exposures 
related to military service (100), including pesticides, chemicals, paint, gas, diesel, solvents, ionizing and 
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 non-ionizing radiation, vaccines, and riot control substances, which was not available in any previous 
study of military exposures and ALS etiology or survival. Finally, our results were robust to many 
secondary analyses (e.g., after restricting to cases enrolled within two years of diagnosis, who had a 
diagnosis of definite or probable ALS, or who did not requiring a proxy, etc.). 
For Specific Aim 2 (survival), we observed several associations between clinical characteristics 
and ALS survival that agreed with previous literature—e.g., HRs for death decreased with increases in 
time from symptom onset to diagnosis (17-19, 24-26, 29) and baseline ALSFRS-R score (17, 21, 27) and 
were higher among cases who were older (16-24). 
The GENEVA study may also have some limitations. Recall bias may be possible, and 
differential by war of service, because the GENEVA study interview occurred up to 65 years after 
participants served in the military (98, 100). There seems to be little evidence, however, that cases of 
various diseases recall past exposures differently than controls (101). Another possible limitation of the 
GENEVA study is that associations between ALS etiology or survival and specific exposures incurred 
during deployment to the four major wars may have been confounded by exposure to other toxicants 
experienced during military service or civilian life. We were unable to adjust analyses for non-military 
exposures, but the majority of military exposures for which we had information were either not or only 
weakly correlated (e.g., Spearman correlation coefficients ≤ 0.2), and results were similar after adjusting 
for the exposure that was most strongly correlated with the exposure of interest. 
Potential selection bias arising from non-participation of potential controls and the fact that the 
fastest progressing cases likely died before they could enroll is another possible limitation of the 
GENEVA study. We used inverse probability weighting to explore and control potential missing 
covariate data and selection biases resulting from these sources and, for the most part, obtained results 
similar to those observed when we used standard regression methods. This may suggest the effect of 
missing covariate data and selection biases on our results was small. A limitation of our IPW analyses, 
however, is that we were only able to weight the GENEVA study cases to represent the Registry cases, so 
any veteran ALS case who died before enrollment in the Registry began (April 1, 2003) was not included 
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 (24). Furthermore, the median time from enrollment in the Registry to enrollment in the GENEVA study 
among the GENEVA study cases was nine (IQR = 11) months, which is a relatively short time compared 
to elapsed time since diagnosis for long-surviving cases. Additionally, the BIRLS sample of potential 
controls is likely missing a subset of veterans whose release of active duty date was before 1973 (100). 
The age distribution of the BIRLS sample is also different from that of the general veteran population 
because it was age-stratified. However, adding a stabilized selection weight to weight the BIRLS sample 
to the age distribution of all U.S. military veterans in 2005 using data from the American Community 
Survey (30) gave similar results. Nevertheless, residual selection bias could have affected our results, 
particularly because we did not have information on education level or military rank—two factors 
inversely associated with ALS etiology in our study—for the BIRLS sample. 
For Specific Aim 1 (etiology), the several inverse associations between ALS and military service 
and deployment variables that we observed suggest our control group includes many career military 
veterans. Our effort to remove what we thought was a selection bias through the use of IPW gave inverse 
associations similar to those obtained via standard regression methods. In addition to residual selection 
bias that may have affected the results from our IPW analysis, it is possible that the inverse associations 
we observed are explained by bias from the healthy worker survivor effect (197, 198). 
DIRECTIONS FOR FUTURE RESEARCH 
There are many directions for future research on military-related factors and ALS etiology and 
survival using the GENEVA study data and for the field at large. For the GENEVA study, the telephone 
interview included an extensive lifetime occupational history in which each participant was asked 
questions regarding every job he or she had held for at least six months since he or she was 16 years-old, 
including jobs in the military (Appendix B) (100). In addition to job title, information collected for each 
job included industry, job tasks, materials used (per task), protective equipment used (per job title), and 
level of physical activity (per job title) (Appendix B) (100). Industries were then assigned codes 
according to the U.S. Census Bureau’s North American Industry Classification System 2002 codes (205) 
and job titles were assigned codes according to the U.S. Department of Labor’s Standard Occupational 
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 Classification 2000 codes (100, 206). The occupational history information has also recently undergone 
industrial hygiene review to assign probability and intensity scores for exposure to toxicants of interest. 
Once the industrial hygiene data have been cleaned, they can be used as a second source of information 
on exposures incurred during military service. In addition, they may be able to be combined with the 
military information utilized in the current analyses to construct lifetime exposure histories for toxicants 
of interest or to adjust the current analyses for civilian exposures. 
The second future direction using the GENEVA study data would be to evaluate effect measure 
modification of the associations studied in the current analyses by head injury, genetic susceptibility, or 
other relevant factors. If these analyses involve exposures also found in non-military settings, then there 
may be opportunites to pool data with other studies. 
 For the field at large, the main future direction for research on military-related factors and ALS or 
ALS survival is to conduct more studies in U.S. military and other populations that address the limitations 
of previous studies outlined in Chapter 1. Such studies should identify incident cases of ALS to avoid 
potential selection bias resulting from studying prevalent cases who likely represent long survivors. A 
longer recruitment period would also be desirable to increase the number of cases and controls enrolled in 
studies thereby increasing the statistical power available to detect associations. Simulation studies and 
studies of outcome misclassification should also be conducted to determine the validity of using mortality 
as a surrogate for incidence in ALS association studies and to assess the magnitude of the bias introduced 
into estimates of associations between exposures and ALS incidence when mortality is used instead. 
Case-control studies will likely be necessary due to the rarity of ALS—incidence is about two per 
100,000 per year (1-3)—and the small sample sizes of other studies of military populations (e.g., the 
Millennium Cohort Study contains about 150,000 participants (172). Therefore, controls should be 
sampled from a sampling frame other than the BIRLS database because the BIRLS database contains 
records for only a subset of veterans with a RAD before 1973 (100). The DoD’s DMDC may be a suitable 
sampling frame and has been used by several previous studies of military-related factors and ALS (36, 
38-40, 50, 51, 53) or ALS survival (64). In addition, controls should be sampled via incidence density 
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 sampling instead of from the available non-cases at the end of follow-up to enable estimation of rate 
ratios. Finally, more information should be collected on factors related to control participation so that 
evaluations and adjustments for potential selection bias resulting from non-participation will be less prone 
to bias from unmeasured factors related both to participation and to the outcome or exposures under 
study. 
Exposure assessment could be improved by collecting and incorporating administrative data (e.g., 
deployment information from the DoD’s DMDC), biomarkers of ongoing (e.g., in blood and urine) and 
past (e.g., in toenails or from bone scans) exposures, monitored data (e.g., particulate matter in the air) 
and modeled data (e.g., via GIS). In addition, occupational histories should be collected via the National 
Cancer Institute/Parkinson’s Institute modules (207-210) instead of via open-ended questions as was done 
in the GENEVA study (industrial hygiene assignment of probability and intensity scores for exposure can 
be done once with the modules instead of separately for every person and job combination and so is much 
more cost- and labor-efficient). Additional studies to more fully establish the validity and reliability of 
self-reporting military-related factors, preferably over a long time period, are also needed. 
Future studies of military-related factors and ALS or ALS survival could also be improved by the 
use of sophisticated statistical methods. Specifically, Bayesian hierarchical models should be explored as 
an approach to control for confounding by exposure to other toxicants experienced during military service 
or civilian life. Latent class analysis might also prove useful to derive patterns of exposure because 
military personnel have contact with multiple exposures, often probably in predictable patterns, during the 
course of their service. We were unable to use Bayesian hierarchical models or latent class analysis in the 
current study because we had too much missing data in the exposure variables evaluated in our study. 
Finally, statistical methods to explore and control bias from the healthy worker survivor effect in case-
control studies need to be developed and implemented. 
Future studies should evaluate effet measure modification of the associations between military-
related factors and ALS or ALS survival by head injury, genetic susceptibility, or other relevant factors. 
These analyses, particularly those of gene by environment interactions, may require pooling data among 
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 multiple researchers. Finally, animal studies need to be conducted to identify mechanisms of action 
underlying associations between specific toxicant exposures incurred during military service and ALS or 
ALS survival. 
PUBLIC HEALTH IMPLICATIONS 
More than 21 million Americans, or about one in 11 of those at least 18 years-old, have served in 
the military in their lifetimes (30). Among American men, who comprise 92% of U.S. military veterans 
(31), this number jumps to about one in six (30). U.S. military personnel are exposed to a number of 
factors encountered in the unique circumstances of their jobs that may lead to health problems later in life 
(32). For example, U.S. military personnel are exposed to intensive physical activity, lifestyle factors 
(cigarette smoking, alcohol consumption), physical trauma (combat-related, fractures), psychological 
trauma, transmissible agents (viruses), toxic substances (lead, pesticides), and other environmental 
toxicants and exposures (33, 34). Concern regarding potential health effects of U.S. military service is 
demonstrated by the fact that typing “military OR veterans OR soldiers” into the search engine on the 
Institute of Medicine (IOM) website returns 103 reports published after 1998 (35). Unfortunately, one of 
the health consequences suspected to be associated with U.S. military service is ALS (34, 196). 
ALS is rare in the general population; incidence is about two per 100,000 per year and prevalence 
is about six per 100,000 population (1-3). Nevertheless, 2.7 of every 1,000 deaths in the United States 
(U.S.) were due to ALS in 2011 (4). In addition, the effect of motor neuron loss in the daily lives of 
individuals with ALS is dramatic and may include an inability to move, eat, talk, or complete other 
activities of daily living (1). ALS cases are unable to work, have expensive health bills, require intensive 
care, and are often depressed (2, 3). 
Half of individuals with ALS die within three years of diagnosis, but 4% survive at least ten years 
(1-3). The most common cause of death among ALS cases is respiratory failure (2). Riluzole is the only 
ALS therapy approved by the U.S. Food and Drug Administration, but a recent meta-analysis found that it 
extends survival by only two to three months (5). Treatments including physical therapy can relieve ALS 
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 symptoms (2, 3), but explanations for the extremely variable survival of ALS cases, particularly 
explanations that could lead to interventions or therapies, are sorely needed. 
The aims of the current study were to 1) evaluate associations between military service, 
deployments, and 40 exposures and ALS etiology; and 2) evaluate associations between military service, 
deployments, and 40 exposures and ALS survival. We also used IPW (105) to evaluate and adjust for 
potential selection bias resulting from studying cases who likely represent long survivors and controls 
who may be different from U.S. military veterans at large (100, 180). 
For Specific Aim 1 (etiology), we observed several inverse associations between ALS and 
military service and deployment variables, but these may be due to uncontrolled bias from the healthy 
worker survivor effect. We also found higher odds of ALS among veterans whose longest deployment 
was to WWII or the Korean War, but lower odds among veterans whose longest deployment was to 
operations besides the four major wars, compared to the odds among those who were not deployed. ALS 
was also more common among veterans who had direct contact with eight different exposures incurred 
during deployment to the four major wars, including pesticides, other chemicals, radar waves, and nearby 
explosions. While we cannot exclude the effects of uncontrolled selection bias or confounding by non-
military exposures on our results, they provide clues to the potential causal factor(s) underlying the 
apparent increase of ALS among military veterans and, therefore, require replication and further study. 
For Specific Aim 2 (survival), we did not find strong evidence that military-related factors are 
associated with shorter ALS survival. Our findings were robust to many secondary analyses. The few 
factors that appeared to be related to ALS survival may be due to uncontrolled selection bias or 
confounding by non-military exposures. Thus, while our largely null results for survival may be 
comforting to veteran ALS cases, more research is needed in this and other populations. 
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 APPENDIX A: SUPPLEMENTAL TABLE REFERENCED IN CHAPTER 12
2This appendix is a reprint of Web Table 1 in Beard JD, Kamel F. Military service, deployments, and exposures in 
relation to amyotrophic lateral sclerosis etiology and survival. Epidemiol Rev. 2015;37(1):55-70, and appears by 
permission of the Society for Epidemiologic Research. 
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 Table A.1. Studies of the Association Between Military Service, Deployments, or Exposures and ALS/MND Etiology Published Through the end 
of 2013 That did not Have at Least Five Exposed Cases or Controls or did not Report an Effect Measure Estimate or p-value for the Association(s) 
of Interest. 
First Author, Year 
(Reference No.) Study Population Sample Size Outcome Exposure 
Matching or Adjustment 
Factors Statistical Analysis Result 
Cohort 
Gibberd, 1980 (42) British WWII ex-
prisoners of war in 
the Far East 
followed since 1945 
4,684 ex-prisoners of 
war, 1 MND case 
MND NA None Prevalence Prevalence = 21.35 per 
100,000 (vs. 7-12 per 
100,000 in the general 
populations of the U.S. 
and the U.K.) 
Thomas, 1990 (43) Male U.S. Army 
Chemical Corps 
Vietnam veterans 
followed from date 
last served in 
Vietnam until death 
or 1987 
854 veterans (16,200 
person-years), 3 
deceased nervous 
system diseases 
cases (2 ALS, 1 MS) 
Nervous 
system 
disease 
death rate 
NA Age, race, calendar 
period 
SMR (using the entire 
U.S. male population 
as the standard) 
SMR = 4.16, p > 0.05 
Case-Control 
Gresham, 1986 (45) Center for 
Neurologic Center 
in San Diego, 
California, January-
May 1985 
66 cases; 66 controls 
(friends and neighbors 
of ALS cases, but not 
former co-workers, 
free of known 
neurologic disease) 
ALS Military experience Individually-matched on 
age, sex 
McNemar's test for 
matched pairs, odds 
ratio 
n = 23 cases, 22 
controls, no OR shown 
Chio, 1991 (44) Italy, 1960-1982 512 cases; 512 
hospital controls with 
other neurological 
diseases 
MND Occupation as a 
soldier 
Age, sex, province of 
residence, date of 
admission 
McNemar's test for 
matched pairs, odds 
ratio 
n = 2 cases, 4 controls, 
OR = 0.5; 95% CI: 0, 2.2 
Gunnarsson, 1991 (46) Sweden, 1970-1983 1,375 deceased cases; 
1,434 living controls 
from an age-stratified 
random sample of 
native Swedes 
ALS death Armed forces 
occupation 
Age Mantel-Haenszel odds 
ratio 
Males: n = 4 deceased 
cases, OR = 0.7 
Sutedja, 2007 (47) University Medical 
Center Utrecht, The 
Netherlands, 2001-
2005 
364 cases, 392 
controls 
(acquaintances of 
ALS cases who were 
not spouses, partners, 
or blood relatives) 
ALS Armed forces 
occupation 
Matched on age, sex; 
adjusted for age, 
cigarette smoking, level 
of education, major 
occupation group; 
stratified by sex 
Multiple logistic 
regression 
Males: n = 4 cases, 5 
controls, OR = 0.9; 95% 
CI = 0.2, 3.4; females: n 
= 0 cases, 0 controls 
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 First Author, Year 
(Reference No.) Study Population Sample Size Outcome Exposure 
Matching or Adjustment 
Factors Statistical Analysis Result 
Cross-Sectional 
Holloway, 1986 (48) Scotland, 1961-1981 161 cases MND Armed forces 
occupation 
None Chi-square test to 
compare observed 
and expected counts 
Males: n = 1 case (1.2% 
vs. 0.2% in the general 
population), no p-value 
shown 
Abbreviations: ALS, amyotrophic lateral sclerosis; CI, confidence interval; MND, motor neuron disease; MS, multiple sclerosis; NA, not available; OR, odds ratio; SMR, 
standardized mortality ratio; U.K., United Kingdom; U.S., United States; WWII, World War II.
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 APPENDIX B: ALS RISK FACTOR QUESTIONNAIRE3 
GENES AND ENVIRONMENTAL EXPOSURES IN VETERANS WITH AMYOTROPHIC 
LATERAL SCLEROSIS—THE GENEVA STUDY 
 
3This appendix appears by permission of Dr. Silke Schmidt, Department of Medicine, Duke University Medical 
Center; Dr. Lorene M. Nelson and Dr. Valerie McGuire, Department of Health Research and Policy, School of 
Medicine, Stanford University; Dr. Kelli D. Allen, Epidemiology Research and Information Center, Durham VA 
Medical Center, and Department of Medicine and Thurston Arthritis Research Center, University of North Carolina 
at Chapel Hill; and Dr. Eugene Z. Oddone and Dr. Dawn Provenzale, Epidemiology Research and Information 
Center, Durham VA Medical Center, and Department of Medicine, Duke University Medical Center. 
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ALS RISK FACTOR QUESTIONNAIRE        STUDY ID:               REFERENCE DATE  
_______________________________________________________________________________________________________________________________________ 
 
Date of Interview:  Interviewer: _________________________________ 
 
 
 
[INTRODUCTION] 
 
This is________________________ [NAME OF INTERVIEWER] calling for The Genetic Epidemiology of ALS in Veterans on behalf of the 
Durham VAMC and Duke University.  May I speak to ______________________________ [NAME OF STUDY PARTICIPANT]? 
 
 
 [IF NOT AVAILABLE, GET CONTACT TIME]  
 
 
 
 
 
[IF DECEASED, MENTALLY OR PHYSICALLY INCOMPETENT, ASK IF SOMEONE COULD PROVIDE THE ANSWERS IN PLACE OF 
THE PARTICIPANT [A PROXY RESPONDENT], OR BY COMMUNICATING WITH THE PARTICIPANT AS MUCH AS POSSIBLE] 
 
Rest of questionnaire not filled out because  1  Participant unwilling to do interview 
 2  Participant deceased, no proxy available 
 3  Participant mentally or physically  
 incompetent, no proxy available  
 
/ 
 
/ 
 
 
 
/ / 
am 
pm 
 (hrs) (mins) 
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 [IF RESPONDENT IS NOT STUDY PARTICIPANT, ASK THE FOLLOWING:] 
 
a) Name of person answering questions: _____________________________________________________   
 
Relationship to participant: 1  Spouse/partner 
 2  Son/daughter 
 3  Sibling 
 4  Parent 
 5  Other relative 
 6  Non-related caregiver/friend, 
 7  Health care provider 
 8  Other: specify ______________ 
 
b) Is this person providing the answers in place of the 1  Providing answers in place of participant 
participant (a proxy respondent) or is he/she   2  Communicating with participant to fill  
communicating with the participant to answer  out form 
the questions? 
 
[IF RESPONDENT IS A CASE, CONTROL OR PROXY, READ THE FOLLOWING:] 
 
As described in the material we sent you, we are conducting a study of Lou Gehrig’s disease (ALS) in US veterans and you have consented to 
complete a telephone interview.  Are you willing to proceed?  
 
Your participation in the study is of course voluntary, and if any questions seem too personal, you may choose not to answer them. 
I want to remind you before I begin that all of the information will be kept completely confidential. I do appreciate your willingness to speak with 
me, and if you are ready, we should begin the interview now.  
 
Some of the questions will ask you to recall events that occurred prior to or on a particular date. In your case, this date is [Reference Date =DATE 
OF ALS DIAGNOSIS FOR CASES, =INTERVIEW DATE FOR CONTROLS]. 
  
 
1. Could you confirm that you have been a member  YES 
of the US Army, Air Force, Navy, Marine Corps,   NO 
Coast Guard, activated Reserves or National Guard 
at some point in time?  (If no, ask if respondent otherwise meets the definition of a veteran and if so, check “yes” and specify under “other” in the 
next question) 
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 [IF YES:]  
 In which military branch did you serve during your  1  Air Force (Army Air Force) 
 most recent period of service, ie, prior to discharge? 2  Army 
  3  Marines (Merchant Marines) 
 4  Navy 
 5  Coast Guard  
 6  Activated Reserves 
 7  Activated National Guard 
 8  Other  
   (please specify)____________________________ 
 
 
2. What was your most recent period of service FROM or   DK  
 in the military?  
 [CAN ENTER DK FOR DAY] 
  TO or   DK  
  
 
3. Did you serve for more than one period of time? 
 
  
 [IF NO:] GO to 4:  [IF YES:] GO to 3a: 
 
3a. What was your other period of service  FROM      or   DK  
 in the military?  
 [CAN ENTER DK FOR DAY] 
  TO or   DK  
  
 
    In which military branch did you serve during this period of service?                 
            1.         Air Force (Army Air Force) 
            2.         Army 
            3.      Marines (Merchant Marines) 
            4.      Navy 
    5.     Coast Guard  
    6.     Activated Reserves 
    7.     Activated National Guard 
    8.     Other (please specify) 
                                                                                                                             
YES 
NO 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
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 3a. What was your other period of service        FROM  or   DK  
 in the military?  
 [CAN ENTER DK FOR DAY]                         TO                                                                or   DK  
                                                                                                
  In which military branch did you serve during this period of service?                 
                                                                                       1.         Air Force (Army Air Force) 
                                                                                       2.    Army 
                                                                           3.    Marines (Merchant Marines) 
                                                                                       4.    Navy 
                                                                                       5.    Coast Guard  
                                                                                       6.    Activated Reserves 
                                                                                       7.    Activated National Guard                        
                                                                                       8.    Other (please specify)_________________ 
                                                                                                    
Ok, we will go over the multiple periods of service when we review your occupational history in more detail. 
Note: A job should be entered in Section C for each period of service held for 6 months or longer.  
If the service period was not six months or longer, please add a comment of clarification in Section N. 
 
4. Have you used the VA Health care system   YES 
 prior to [Reference Date]?    NO 
                              DK 
       [IF YES, MUST PROVIDE YEAR IN QUESTION 5a] 
 
5. Have you ever applied for VA benefits of any type   YES  
 (disability benefits [compensation/pension],  NO 
 health care, education/training, life insurance,   DK 
 home loans, vocational, rehab/employment)? 
 
 [IF YES:] 
 5a. In which year did you first apply for… 
 
 Disability benefits (compensation/pension?    did apply but DK year  
  YEAR  did not apply 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
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 Education and training (Montgomery GI bill,  
 Veterans’ Educational Assistance Program?    did apply but DK year  
  YEAR  did not apply 
 
 Vocational rehabilitation and employment?    did apply but DK year  
  YEAR  did not apply 
 
 Home loans?   did apply but DK year  
  YEAR  did not apply 
 
 Veterans’ Group Life Insurance?   did apply but DK year  
  YEAR  did not apply 
 [ ASK FOR THOSE WHO  
 ANSWERED  YES TO  QUESTION 4 OR 5 ABOVE] 
    did apply but DK year 
 Health Care? YEAR  did not apply 
 
SECTION A: DEMOGRAPHICS AND BODY HABITUS  
 
First, I would like to begin with some background information about you. 
 
1.  [INDICATE GENDER OF THE SUBJECT] 1  Male 
  2  Female 
 
2.  What is your date of birth? 
 
  
 
3. What was your marital status on  1  never married 
[Reference Date]? 2  married 
  3  separated 
  4  divorced 
  5  widowed 
  6  living with partner 
 
/ / 
 (mm) (dd) (yyyy) 
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 4. How many years of schooling  
 have you completed prior to  
 [Reference Date]? #YEARS    DK 
 
5. What is the highest degree that   1   grade school (grades 1-8) 
 you have attained prior to  2  high school diploma (including GED)  
 [Reference Date]? 3  technical or vocation school diploma    
    Associates degree 
  4  college diploma (4 year degree) 
  5  graduate school diploma 
  6  doctorate 
  7  other 
 
6. What was your employment status on  1  full-time employed 
 [Reference Date] ? 2   part-time employed 
 [CHOOSE ALL THAT APPLY] 3  retired 
 4  Disabled 
 5  full-time student 
 6  part-time student  
 7  homemaker 
 8  unemployed 
 9  other 
 
7a. What do you consider your ethnic group? 1   Hispanic or Latino  
 [CHOOSE ONE ONLY] 2  Not Hispanic or Latino 
  3  Unknown (individuals not reporting ethnicity) 
 
7b. What is your racial category?  1  American Indian/Alaska Native  
 [CHOOSE ALL THAT APPLY] 2  Asian  
  3  Native Hawaiian/Pacific Islander 
 4  Black or African-American 
 5  White 
 6  Unknown or not reported 
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 7c. Which of the following reflects the population(s)  1  Western European 
 from which your family has descended  2  Eastern European 
 (eg, based on origin of four grandparents)?  3  Mediterranean 
 [CHOOSE ALL THAT APPLY] 4  Scandinavian (excluding Finland) 
 5  Finland 
 6  San Marino 
 7  Africa (excluding Tunisia)  
 8  Tunisia  
 9  Middle East  
 10  Pakistan  
 11  Japan  
 12  Caribbean  
 13  Mexico  
 14  Ashkenazi Jewish 
 15  Sephardic Jewish 
 16  Cherokee Indian 
 17  Lumbee Indian 
 18  Other  
  (please specify)______________________________ 
 
8. What was your height on                                                                                          . 
 [Reference Date]? FEET and INCHES   OR    DK 
 
   
9. What was your weight on  
 [Reference Date]? POUNDS OR   DK 
 
[IF CURRENT AGE/AGE ON REFERENCE DATE MORE THAN 25, ASK 10 and 11:] 
 
 10. What was your height at age 25?                                                                  . 
  FEET  and INCHES OR    DK 
 
  
11. What was your approximate weight at age 25? 
  POUNDS  OR   DK 
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 [IF CURRENT AGE/AGE ON REFERENCE DATE MORE THAN 40, ASK:]  
 
 12. What was your approximate weight at age 40? 
  POUNDS  OR   DK 
 
SECTION B. CONSTRUCTION OF LIFE TIMELINE 
 
We are going to look at the timeline of life events that should help your memory for questions that arise throughout the interview. In the 
mail, we sent you a life timeline that represents the period from your birth to the [Reference Date] (present  date for controls, date of 
diagnosis for cases).  This timeline is designed to help you when answering questions about your activities and residence history.    
[PLEASE NOTE: PRIOR TO CONDUCTING THE INTERVIEW, THE SUBJECT MAY HAVE ADDED THE FOLLOWING DATES 
ON THE LIFE TIMELINE IF AVAILABLE:  CALENDAR YEAR OF BIRTH ,  EVENTS THAT OCCURRED DURING THE 
CALENDAR YEARS THAT CORRESPOND TO 5 and 10-YEAR INTERVALS ON THE TIMELINE,AND DEPLOYMENT DATES 
THAT FALL WITHIN EACH OF THE FOLLOWING HISTORICAL DATES:  WORLD WAR I (1914-1918), THE DEPRESSION (1929-
1939), WORLD WAR II (1939-1945), THE KOREAN WAR (1950-1953), ASSASSINATION OF JOHN KENNEDY (1963), THE 
VIETNAM WAR (1950-1975), AND THE PERSIAN GULF WAR (1990-1991).] 
[FOR CASES ONLY: THE YEAR [REFERENCE YEAR] IS MARKED ON THE TIMELINE, SINCE OUR INTERVIEW WILL 
CONSIDER ONLY DATES UP UNTIL (REFERENCE MONTH/REFERENCE YEAR)].   
[FOR CASES and CONTROLS:]  
Now, if you have used the timeline, I would like you to tell me some of the important dates in your life that you wrote on the timeline, so 
that I can write them on my timeline  
[PLEASE USE THE “LIFE TIMELINE” AS NECESSARY TO ASSIST THE RESPONDENT IN RECALLING THE YEAR OR AGE AT 
WHICH A SPECIFIC EVENT TOOK PLACE. PLEASE RECORD THE UPDATES NEATLY ON YOUR OWN TIMELINE SO THAT 
YOU ARE BOTH REFERRING TO THE SAME INFORMATION.] 
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 SECTION C.    LIFETIME OCCUPATIONAL HISTORY 
 
We are interested in your occupational history for the period from age 15 up to (REFERENCE DATE), including seasonal or part-time 
employment, but only for jobs you held for 6 months or longer.  Please include positions you held while serving in the military.  If you stayed 
with the same employer but changed the type of work you did (for example, changed from grocery clerk to assistant manager) we will consider 
that two jobs even though you had the same employer. Before we begin, please answer the following questions:  
 
• While in the military, were you ever enlisted? (Y,N) ____ 
 
• While in the military were you an Officer or Warrant Officer?(Active Duty, Reserve, National Guard) (Y,N) _____ 
 
Ok. now let's begin with your most recent job and work backwards in time.  
 
(BEGINNING WITH THE MOST RECENT JOB, REPEAT THE QUESTIONING FOR EACH JOB HELD.  RECORD 
RESPONSES ON A SEPARATE JOB HISTORY PAGE FOR EACH JOB.) 
 
1. What was the name of the company where you held your (most recent/next most recent) job?    (COMPANY) 
 [PROMPT FOR NAME OF BRANCH/UNIT FOR JOBS HELD DURING MILITARY SERVICE] 
 
2. In what city and state was the company (unit) located?    (LOCATION)  
 
3. What industry or type of business was (COMPANY/UNIT) engaged in—that is, what did they make or what service did they provide? 
(INDUSTRY)  
 
4. What was the job title or position you held within (COMPANY/UNIT)?    (JOB TITLE) 
 
5. Did your company’s work involve the manufacture or production of some product?  (PRODUCT COMPANY) (Y,N,NA,DK) *(IF YES:) 
 5a.  What product or products were produced?  (PRODUCTS PRODUCED) 
 
6. In what year did you start working as (JOB TITLE) at (COMPANY/UNIT)?   (YEAR STARTED)or DK 
 
7. In what year did you stop working as (JOB TITLE) at (COMPANY/UNIT)?    (YEAR STOPPED) or DK 
8. On average, how many hours a week did you work at this job?    (HOURS/WEEK) or DK 
 
9. I would like you to describe in detail your specific tasks and duties in this job.  Try to describe what you did and how you did it.  (JOB TASKS) 
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 (AFTER THE SUBJECT HAS FINISHED REPORTING JOB TASKS, ASK:) 
Are there any other tasks or duties that you routinely carried out in the course of your job? 
 
SECTION C.    LIFETIME OCCUPATIONAL HISTORY (CONTINUED) 
 
10. Approximately what percentage of your time did you spend carrying out each of these duties or tasks?  Let's begin with (FIRST JOB TASK 
LISTED).  Please tell me the category that corresponds to the approximate percentage of time you spent in (JOB TASK). 
(ASK TIME SPENT FOR EACH TASK.) 
 
 (FOR JOBS LONGER THAN 10 YEARS, ASK THE FOLLOWING.) 
 This job lasted ___ years.  Did your job duties, or the amount or percentages of time spent with each job duty change over that time? 
(IF “YES” AND CHANGE RESULTED IN DIFFERENT FREQUENCY RATINGS FOR ONE  OR MORE JOB TASKS, RECORD 
A NEW JOB PAGE FOR THAT INTERVAL OF TIME).  
 
11. What materials did you use to carry out these tasks?  (MATERIALS) (ASK MATERIALS USED FOR EACH TASK)  
 
12. We are interested in the overall percentage of your work hours that were spent at different levels of physical activity. Please tell me what 
percentage of time, on average, was spent on…(PHYSICAL ACTIVITY) 
 
5=>Doing heavy physical activity that caused heavy breathing or sweating, such as lifting or carrying more than 25 lbs: ___  
4=> Doing moderate physical activity that caused heavy breathing or sweating, such as lifting or carrying less than 25 lbs 
3=>Doing light physical work that did not cause sweating, such as pushing or pulling light objects or reaching to stock shelves: ___  
2=>Walking: ___  
1=>Sedentary activities, such a sitting, standing or driving: ___  
(IF OCCUPATION WAS A WHITE-COLLAR OCCUPATION*, DO NOT QUESTION ABOUT .  PROTECTIVE EQUIPMENT. THIS 
WILL BE TRACKED AS NA. CONTINUE WITH QUESTION 1 FOR THE NEXT MOST RECENT JOB HELD.) 
         *CRITERIA  = no material exposures and no moderate and heavy physical activity 
 
13 Did you ever wear some type of protective equipment in this job, such as a paper dust mask, face shield, hearing protection, cartridge respirator, 
gloves or protective clothing? (Y, N DK) 
 IF YES, go to Q13a and 13 b 
 
13a. What type of protective equipment was this? ________________________________(free text plus field for internal code) 
 
13b.Approximately what percentage of time did you wear this protective equipment?____________ (See codes) 
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 14.  (IF SUBJECT EVER WORKED AS A PILOT DURING THEIR MILITARY SERVICE, OR OTHER JOB WHERE FLAME 
RETARDANT MATERIAL MAY BE USED i.e. firefighter, Air Force mechanic, worked with high temperatures, ASK) As best as you 
know, were you exposed to NOMEX suits?  
(NOMEX) (Y.N.DK, NA) ___ 
 *(IF YES:) 
 a.  Approximately what percentage of your work hours did you spend wearing these suits?  ___
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 SECTION C.    LIFETIME OCCUPATIONAL HISTORY (CONTINUED) 
1. COMPANY/UNIT:_______________________/__________________________  JOB NUMBER:    ___  ___ ___ ( number as 001, 002,)  
2. LOCATION:  (City or town, State/Country)_______________/_____________  6. YEAR  STARTED:  ___  ___ 
___  ___ 
3.INDUSTRY: (DATABASE AS FREE TEXT AND SIC CODE) or DK  
____________________________________________________________
_____ 
7. YEAR  STOPPED: ___  ___ 
___  ___ 
4.JOB TITLE: (DATABASE AS FREE TEXT AND SOC CODE) or DK  
___________________________________________________________
_______ 
8. HOURS/WEEK: ___  ___  
___ or DK___ 
5 . P R O D U C T  C O M P A N Y ?   ( Y  , N , D K ,  N A )   _ _ _ _ _ _ _  *IF YES: PRODUCTS PRODUCED: ________________________ 
(DATABASE AS FREE TEXT AND INTERNAL CODE) 
9. JOB TASKS 
(DATABASE AS FREE TEXT AND INTERNAL 
CODE) 
_____________________________________________
______ 
_____________________________________________
______ 
 
10.  FREQ.* 
or DK 
___ 
___ 
 
11.  MATERIALS, SUBSTANCES WORKED WITH: 
(DATABASE AS FREE TEXT AND INTERNAL CODE) 
_____________________________________________________
________ 
_____________________________________________________
________ 
 
12.*  FREQ OF HEAVY PHYSICAL ACTIVITY           ___    13. Did you ever wear some type of protective equipment in this job, such as a paper dust  
       FREQ OF MODERATE PHYSICAL ACTIVITY   ___             mask, face shield, hearing protection, cartridge respirator, gloves or 
protective  
       FREQ OF LIGHT PHYSICAL ACTIVITY             ___              clothing? (Y, N DK, NA) ( if Y go to Q 13a and 13b) 
       FREQ OF WALKING                                                 ___ 
       FREQ OF SEDENTARY ACTIVITY                       ___    13a.   What type of protective equipment was this?                                                                                                           
________________________________________ 
                                                                                                13b. Approximately what percentage of time did you wear this protective 
equipment?  
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 1 4 . *   E V E R  E X P O S E D  T O  N O M E X  I N  S U I T S ?  ( Y * ,  N ,  D K ,  N A )   _ _ _   
14a  IF YES: FREQ OF WEARING NOMEX SUITS: ___________________ 
1=> <1% time;   2=>1-4% time;   3=>5-24% time;   4=> 25-49% time;   5=>50-74% time;   6=> 75-100% time (questions 10, 12, 13b 14a) 
Supplemental page?  Y,N  ______( use supplemental page if needed for additional job tasks , materials- use same job number)
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 SECTION D.   HOME PESTICIDE USE 
Next, I will ask you some questions about the pesticides that you may have used to control insects, weeds, or plant diseases in your home or 
garden.  I am interested only in products that you personally handled, that is, products that you either prepared or applied, or products that 
you helped clean up after they were applied.  
 
[PRODUCT] 
 
 
 
 
 
(Did you use…) 
1. 
Prior to 
[Reference Date] 
Have you ever 
personally used 
(PRODUCT)? 
 
2. 
What was your 
age when 
you first used 
(PRODUCT)?  
3. 
What was your 
age when 
you last used 
(PRODUCT)?  
4. 
This is a total of 
____ years. 
Excluding any 
years you did 
not use it, what 
is the total 
number of years 
you used 
(PRODUCT)?  
5. 
During years 
when you used 
it, what is the 
average number 
of times per year 
you used 
(PRODUCT)?  
 
A. Insecticides to 
 control insects in 
 your home. 
 
 YES [2.]  
 NO [B]   
 DK [B]   
 
 
 
AGE 
 
 DK 
 
 
AGE  
 
 DK 
 
 
YEARS  
 
 DK 
 
 
# PER YEAR  
 
 DK 
 
B. Insecticides to 
 control insects in 
 your garden. 
 
 
 YES [2.]  
 NO [C]   
 DK [C]   
 
 
 
AGE  
 
 DK 
 
 
AGE  
 
 DK 
 
 
YEARS  
 
 DK 
 
 
# PER YEAR  
 
 DK 
 
C. Herbicides or 
 weed killers to 
 control weeds in 
 your garden or 
 other areas  around 
       the home. 
 
 
 YES [2.]  
 NO [D]   
 DK [D]   
 
 
 
AGE  
 
 DK 
 
 
AGE  
 
 DK 
 
 
YEARS  
 
 DK 
 
 
# PER YEAR  
 
 DK 
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D. Fungicides to 
 control plant mold 
 or mildew in your 
 home or garden. 
 
 
 YES [2.]  
 NO [6.]  
 DK [6.]  
 
 
 
AGE  
 
 DK 
 
 
AGE  
 
 DK 
 
 
YEARS  
 
 DK 
 
 
# PER YEAR  
 
 DK 
 
6. Prior to [Reference Date], have you ever    YES 
 been involved in testing, transporting or spraying   NO 
 herbicides for military purposes?       DK 
  
 [IF YES] 
 6a.  For how many years? 
 YEARS      or        DK 
 
SECTION E.  TOBACCO HISTORY: CIGARETTES. 
 
I will next ask you some questions about your use of tobacco products. 
 
1. Have you ever smoked one or more cigarettes   YES [GO TO 2.] 
 per day for six months or longer?    NO [GO TO 6.] 
   DK [GO TO 6.] 
  
 [IF YES:] 
 2. How old were you when you first began  
  smoking one or more cigarettes per day?  YEARS OR  DK 
 
 3. Were you still a cigarette smoker on    YES 
  [Reference Date]?     NO 
        DK 
 
  [IF NO:] 
  a. At what age did you stop smoking  
   cigarettes?    AGE  OR  DK 
   [ASK FOR LAST STOP DATE IF PARTICIPANT STOPPED MORE THAN ONCE)  
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  4. Thinking about the years between age   YES 
  (AGE FROM Q2) and age (AGE FROM Q 3a/  NO 
  REFERENCE AGE), was there ever a period of  DK 
  one year or more in which you did not smoke cigarettes? 
  
  [IF YES:] 
  a. For how many years between  
  [AGE FROM Q2 AND AGE FROM  YEARS OR  DK 
                            Q3a/REFERENCE AGE]   
   did you not smoke cigarettes?   
 
5. During periods when you smoked, how many  
 cigarettes (do/did) you usually smoke per day?    
      # CIGARETTES OR  DK 
 One pack contains 20 cigarettes. 
  
SECTION E.  TOBACCO HISTORY (CONTINUED): CIGARS 
 
6. Have you ever smoked one or more cigars    YES [GO TO 7.] 
 per week for six months or longer?    NO [GO TO 11.] 
   DK [GO TO 11.] 
  
 [IF YES:] 
 7. How old were you when you first began  
  smoking one or more cigars per week?  YEARS OR  DK 
 
 8. Were you still a cigar smoker on    YES 
  a [Reference Date]?     NO 
        DK 
 
  [IF NO:] 
  a. At what age did you stop smoking  
   cigars?    AGE  OR  DK 
   [ASK FOR LAST STOP DATE IF PARTICIPANT STOPPED MORE THAN ONCE)  
 
  
 
179 
 9. Thinking about the years between age   YES 
  (AGE FROM Q7) and age (AGE FROM Q8a/  NO 
  REFERENCE AGE), was there ever a period of  DK 
  one year or more in which you did not smoke cigars? 
  
  [IF YES:] 
  a. For how many years between  
  (AGE FROM Q7) AND (AGE FROM  YEARS OR  DK 
                            Q8a/REFERENCE AGE)   
   did you not smoke cigars?   
 
10. During periods when you smoked, how many  
 cigars (do/did) you usually smoke per week?   # CIGARS OR  DK 
 
SECTION E.  TOBACCO HISTORY (CONTINUED): PIPES 
 
11. Have you ever smoked one or more pipes    YES [GO TO 12.] 
 per week for six months or longer?    NO [GO TO SECTION F] 
   DK [GO TO SECTION F] 
  
 [IF YES:] 
 12. How old were you when you first began  
  smoking one or more pipes per week?  YEARS OR  DK 
 
 13. Were you still a pipe smoker on   YES 
  [Reference Date]?     NO 
        DK 
  [IF NO:] 
  a. At what age did you stop smoking  
   pipes?    AGE  OR  DK 
   [ASK FOR LAST STOP DATE IF PARTICIPANT STOPPED MORE THAN ONCE)  
 
 14. Thinking about the years between age   YES 
  (AGE FROM Q12) and age (AGE FROM Q13a/  NO 
  REFERENCE AGE), was there ever a period of  DK 
  one year or more in which you did not smoke pipes? 
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   [IF YES:] 
  a. For how many years between  
  (AGE FROM Q12) AND (AGE FROM  YEARS OR  DK 
                            Q13a/REFERENCE AGE)   
   did you not smoke pipes?   
 
15. During periods when you smoked, how many  
 pipes (do/did) you usually smoke per week?   # PIPES OR  DK 
 
SECTION F.    LIFETIME CONSUMPTION OF ALCOHOL AND CAFFEINATED DRINKS 
The next few questions pertain to your usual drinking habits as an adult. 
1. Before [Reference Date], did you ever   YES [GO TO a.] 
 drink alcoholic beverages such as wine, beer, or  NO [GO TO 4.] 
 other liquor at least once a week for 6 months or more?   DK [GO TO 4.] 
 
 [IF YES:] 
 a. At what age did you begin drinking alcoholic  
  beverages at least once a week?    AGE OR  DK 
 
 b.   On [Reference Date]  did you still drink   YES [GO TO 2.] 
 alcoholic beverages at least once a week?  NO [GO TO c.] 
      DK [GO TO 2.] 
[IF NO:] 
 c. How old were you when you quit drinking  
 alcoholic beverages at least once a week?  AGE          OR        DK 
 d.   What was the reason you quit drinking  _____________________________________ 
   alcoholic beverages at that time? 
   
 2. Between ages [AGE STARTED DRINKING - Q1aI    
  and  [AGE ON [Reference Date] or AGE QUIT  NUMBER OF TIMES DRANK 
  DRINKING -Q 1c], how often did you have at   - PER - 
  Least one drink of any kind of alcoholic  1  DAY        2   WEEK      3  MONTH       
beverage?   A drink is a 12 oz. beer or wine                                         4  YEAR       -1 DK 
  cooler, 4 ounces of wine, or a drink containing  
  1 oz. of liquor. 
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  3. Between ages [AGE STARTED DRINKING -Q 1a]  
  and [AGE ON (Reference Date) or AGE QUIT  NUMBER OF DRINKS PER DAY 
  DRINKING - Q1c], about how many drinks would     
  you usually have on days when you had a drink?     DK 
 
SECTION F.    LIFETIME CONSUMPTION OF ALCOHOL AND CAFFEINATED DRINKS 
 (CONTINUED) 
 
4. On average, how many 8-ounce cups of the following beverages did you consume per day prior to [Reference Date]? 
 
 a. Coffee (regular, not decaf)                           .  
    # CUPS   DK 
 
 b. Tea (regular, not decaf; hot or cold)                    .     
    # CUPS   DK 
 
 c. Soft drinks (caffeinated)                                      . 
    # CUPS   DK 
 
 
 
 
 
 
 
 
SECTION G: DEPLOYMENT-SPECIFIC EXPOSURE 
 
Next, we will ask you about some specific exposures you may have experienced during deployment to some major military conflicts the US 
Armed Forces have been engaged in. Please refer to the life timeline we constructed to help you recall if and when you may have experienced the 
events I will ask about.  
 
1. Were you deployed to World War II   YES 
 (defined as the period from   NO  [GO TO QUESTION G3] 
 December 7, 1941 to December 31, 1946) ?                               NA ( too young, not born or dead) 
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  [IF YES:] 
 Please tell me the theaters of operation to which you were deployed, for which period of time and in which unit.  
 
THEATER OF OPERATION 
 
 
PERIOD OF TIME 
 
UNIT 
 
 
 
 
 FROM  
 
 
 
TO 
 
 
 
 
 
 
 
 
 FROM 
 
 
 
 
TO 
 
 
 
 
2. Now we would like you to think back to the experiences while you were in WW II. 
         
A. 
While you were in WW II, (did you have direct  
contact with/were you exposed to…) 
[IF YES, ASK B AND C] 
B. 
How many days were 
you exposed? 
C.  
Did you feel 
ill? 
1. Manufacture, testing, or use of chemical protective  
 gear (for mustard gas, tear gas etc.).  
 Do not include training. 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
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 2. Ionizing radiation from nuclear weapon testing or  
 occupation of Hiroshima/Nagasaki 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
3. Use of personal pesticides, like creams, sprays or 
 flea collars 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
4. Use of pesticides on your clothing or bedding   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
5. Exhaust from heaters or generators (e.g. kerosene 
 heaters, tent heaters) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
6. Exposure to diesel and/or other petrochemical fumes   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
7. Burning trash or burning feces/manure   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
8. Exposure to paint, solvents, or petrochemical 
 substances 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
A. 
(While you were in WW II, did you have direct  
contact with/were you exposed to…) 
[IF YES, ASK B AND C] 
B. 
How many days were 
you exposed? 
C.  
Did you feel 
ill? 
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 9. High-intensity radar waves (eg, as radar operator, 
 radio operator, aviation electrician’s mate) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
10. Food contaminated with smoke, oil, or other  chemicals   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
11. Local food other than food provided by the Armed 
 Forces 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
12. Bathing in or drinking of water contaminated with 
 smoke, oil, dead animals or any chemicals 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
13. Heat cramps, heat exhaustion, heat stroke or other 
 heat illness                                 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
14. Heard chemical alarms sounding   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
15. Explosion in the air or on the ground within one mile 
 of you  (e.g. artillery, rockets, mortars) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
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 16. Mixing and application of herbicides   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
A. 
(While you were in WW II, did you have direct  
contact with/were you exposed to…) [IF YES, ASK B AND C] 
B. 
How many days were 
you exposed? 
C.  
Did you feel 
ill? 
17. Exposure to herbicides in the field   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
18. Mixing and application of riot control substances   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
19. Exposure to riot control substances in the field   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
20. Mixing and application of burning agents   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
21. Exposure to burning agents in the field   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
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 22. Have you suffered a combat-related injury that 
 required medical attention during your deployment? 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
 
NA 
 
[SECTION G: DEPLOYMENT-SPECIFIC EXPOSURE (CONTINUED)] 
 
3. Were you deployed to the Korean War   YES 
 (defined as the period from   NO     [GO TO QUESTION G5] 
 June 27, 1950 to January 31, 1955)?                                             NA ( too young, not born or dead) 
 [IF YES:] 
 Please tell me the theaters of operation to which you were deployed, for which period of time and in which unit. 
 
THEATER OF OPERATION 
 
 
PERIOD OF TIME 
 
UNIT 
 
 
 
 FROM  
 
 
 
TO 
 
 
 
 
 
 
 
 
 
 FROM  
 
 
 
TO 
 
 
 
 
 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
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 4. Now we would like you to think back to the experiences while you were in Korea. 
A.  While you were in Korea, (did you have direct  
contact with/were you exposed to…) [IF YES, ASK B AND C] 
B.  How many days were 
you exposed? 
C. Did you 
feel ill? 
1. Manufacture, testing, or use of chemical protective 
 gear (for mustard gas, tear gas etc)  
 Do not include training. 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
2.  Ionizing radiation from nuclear weapon testing   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
3.  Microwave radiation   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
4.  Use of personal pesticides, like creams, sprays or flea 
 collars 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
5.  Use of pesticides on your clothing or bedding   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
6.  Exhaust from heaters or generators (e.g. kerosene 
 heaters, tent heaters) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
7.  Exposure to diesel and/or other petrochemical fumes   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
8.  Burning trash or burning feces/manure   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
9.  Exposure to paint, solvents, or petrochemical 
 substances 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
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 A.  (While you were in Korea, did you have direct  
contact with/were you exposed to…)  [IF YES, ASK B AND C] 
B. How many days were 
you exposed? 
C. Did you 
feel ill? 
10. High-intensity radar waves (eg, as radar operator, 
 radio operator, aviation electrician’s mate) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
11. Food contaminated with smoke, oil, or other 
 chemicals 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
12. Local food other than food provided by the Armed 
 Forces 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
13. Bathing in or drinking of water contaminated with 
 smoke, oil, dead animals or any chemicals 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
14.  Heat cramps, heat exhaustion, heat stroke or other 
 heat illness 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
15.  Heard chemical alarms sounding       YES  
  NO    
  DK    
       5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
 YES  NO
  DK 
16. Explosion in the air or on the ground within one mile 
 of you (e.g. artillery, rockets, mortars) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
17. Mixing and application of herbicides   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
18. Exposure to herbicides in the field   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
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 A. 
(While you were in Korea, did you have direct  
contact with/were you exposed to…) 
[IF YES, ASK B AND C] 
B. 
How many days were you 
exposed? 
C.  
Did you feel 
ill? 
19. Mixing and application of riot control substances   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
20. Exposure to riot control substances in the field   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
21. Mixing and application of burning agents   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
 
22. Exposure to burning agents in the field 
  
      YES  
  NO    
  DK    
  
       5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  
 YES  NO
  DK 
23. Have you suffered a combat-related injury that 
 required medical attention during your deployment? 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
 
NA 
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 SECTION G: DEPLOYMENT-SPECIFIC EXPOSURE (CONTINUED) 
 
5. Were you deployed to the Vietnam War   YES 
 (defined as the period from   NO [GO TO QUESTION G7] 
 August 3, 1950 to May 7, 1975)?                                            NA ( too young, not born or dead) 
 
 [IF YES:] 
 Please tell me the theaters of operation to which you were deployed, for which period of time and in which unit. 
 
 
THEATER OF OPERATION 
 
 
PERIOD OF TIME 
 
UNIT 
 
 
 
 
 FROM  
 
 
 
TO 
 
 
 
 
 
 
 
 
 FROM  
 
 
 
TO 
 
 
 
 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
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 6. Now we would like you to think back to the experiences while you were in Vietnam.  
A. While you were in Vietnam, (did you have direct contact with/were 
you exposed to) [IF YES, ASK B AND C] 
B. How many days were you 
exposed? 
C. Did you feel 
ill? 
1. Mixing and application of Agent Orange   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
2. Exposure to Agent Orange in the field   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
3.  Mixing and application of other herbicides   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
4.  Exposure to other herbicides in the field   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
5.  Manufacture, testing, or use of chemical 
 protective gear  (for mustard gas, tear gas 
 etc) Do not include training. 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
6.  Ionizing radiation from nuclear weapon 
 testing  
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
7.  Microwave radiation   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
8.  Use of personal pesticides, like creams, 
 sprays or flea collars 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
9.  Use of pesticides on your clothing or bedding   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
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 A. (While you were in Vietnam, did you have direct contact with/were 
you exposed to)  [IF YES, ASK B AND C] 
B. How many days were you 
exposed? 
C. Did you feel 
ill? 
10.  Exhaust from heaters or generators 
 (e.g. kerosene heaters, tent heaters) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
11. Exposure to diesel and/or other 
 petrochemical fumes 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
12. Burning trash or burning feces/manure   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
13. Exposure to paint, solvents, or petrochemical 
 substances 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
14. High-intensity radar waves (eg, as radar 
 operator, radio operator, aviation 
 electrician’s mate) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
15. Food contaminated with smoke, oil, or other 
 chemicals 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
16. Local food other than food provided by the 
 Armed Forces 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
17. Bathing in or drinking of water contaminated 
 with smoke, oil, dead animals or any 
 chemicals 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
18. Heat cramps, heat exhaustion, heat stroke or 
 other heat illness 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
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 A. 
(While you were in Vietnam, did you have direct contact with/were 
you exposed to)  [IF YES, ASK B AND C] 
B. 
How many days were you 
exposed? 
C.  
Did you feel ill? 
19. Heard chemical alarms sounding   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
20. Explosion in the air or on the ground within 
 one mile of you  (e.g. artillery, rockets, 
 mortars) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
21. Mixing and application of riot control 
 substances 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
22. Exposure to riot control substances in the 
 field 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
23. Mixing and application of burning agents   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
24. Exposure to burning agents in the field   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
  YES
  NO
  DK 
25. Have you suffered a combat-related injury 
 that required medical attention during your 
 deployment? 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days 
  More than 30 days 
  DK 
 
NA 
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 SECTION G: DEPLOYMENT-SPECIFIC EXPOSURE (CONTINUED) 
 
7.  Were you deployed to the Persian Gulf War   YES 
 during the conflict or shortly thereafter   NO [GO TO QUESTION 9] 
 (period from August 2, 1990 to December 31,1991)?                 NA ( too young, not born or dead) 
 
 [IF YES:] 
 Please tell me the theaters of operation to which you were deployed, for which period of time and in which unit. 
 
 
THEATER OF OPERATION 
 
 
PERIOD OF TIME 
 
UNIT 
 
 
 
 
 FROM  
 
 
 
TO 
 
 
 
 
 
 
 
 
 FROM  
 
 
 
TO 
 
 
 
 
 
 
 
 
 
 
 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
/ / 
 (mm) (dd) (yyyy) 
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 8. Now we would like you to think back to the experiences while you were in the Persian Gulf.  
 
A. While you were in the Persian Gulf, (did you have direct contact 
with/were you exposed to) [IF YES, ASK B AND C] 
B. How many days were 
you exposed? 
C.  Did you feel 
ill? 
1.  Smoke from oil well fires   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
2.  Exhaust from heaters or generators (e.g. 
 kerosene heaters, tent heaters) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
3.  Exposure to diesel and/or other petrochemical 
 fumes  
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
4.  Burning trash or burning feces/manure   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
5.  CARC (Chemical Agent Resistant Compound) 
 Paint 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
6.  Exposure to other paint, solvents, or 
 petrochemical substances 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
7.  High-intensity radar waves (eg, as radar 
 operator, radio operator, aviation electrician’s 
 mate) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  
  YES
  NO
  DK 
8. Use of depleted uranium (DU) for munitions 
 or armor 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  
  YES
  NO
  DK 
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 9. Ionizing radiation from nuclear weapon testing   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
 
(While you were in the Persian Gulf, did you have direct contact with/were 
you exposed to) [IF YES, ASK B AND C] 
B. 
How many days were 
you exposed? 
C.  
Did you feel ill? 
10. Microwave radiation   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
11. Use of personal pesticides, like creams, sprays 
 or flea collars 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
12. Pesticides on your clothing or bedding   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
13. Manufacture, testing, or use of chemical 
 protective gear  (for mustard gas, tear gas etc) 
 Do not include training 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
14. Exposure to nerve gas (eg, during munitions 
 destruction) 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
15. Food contaminated with smoke, oil, or other 
 chemicals 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
16. Local food other than food provided by the 
 Armed Forces 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
17. High levels of dust/sand   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
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 18. Ground level fumigation   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
A. (While you were in the Persian Gulf, did you have direct contact 
with/were you exposed to) [IF YES, ASK B AND C] 
B. How many days were 
you exposed? 
C.  Did you feel 
ill? 
19. Bathing in or drinking of water contaminated 
 with smoke, oil, dead animals or any 
 chemicals 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
20.  Heat cramps, heat exhaustion, heat stroke or 
 other heat illness 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
21. Heard chemical alarms sounding   YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
22.  Scud missile explosion in the air or on the 
 ground within one mile of you 
  YES  
  NO    
  DK    
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
23. Explosion other than scud missile in the air or 
 on the ground within one mile of you (e.g. 
 artillery, rockets, mortars) 
  YES  
  NO    
  DK     
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
  YES
  NO
  DK 
24. Have you suffered a combat-related injury that 
 required medical attention during your 
 deployment?  
  YES  
  NO    
  DK     
  5 Days or Less 
  6 – 30 days  DK 
  More than 30 days 
 
NA 
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 SECTION G: DEPLOYMENT-SPECIFIC EXPOSURE (CONTINUED) 
 
[ASK THIS QUESTION IN RELATION TO ANY DEPLOYMENT PERIOD SERVED] 
 
9. In any of the conflicts you have been   YES 
 deployed to, have you had any other   NO 
 exposure or experience I did not ask   DK 
 you about which you consider harmful  
 or extremely stressful? 
 
 [IF YES:]  Please describe   
 _______________________________________________________________________________________  
 _______________________________________________________________________________________ 
SECTION G: DEPLOYMENT-SPECIFIC EXPOSURE (CONTINUED) 
10. Now I will ask you to think about the vaccines you may have received or taken yourself, either by injection (shots) or by mouth (orally). I 
will ask you about each conflict you have been deployed to and about two different time periods for each.  
While you were 
deployed during/to… 
a. How many 
preventive vaccinations 
did you receive by  
injection (shots) while 
in the US? 
b. How many preventive 
vaccinations did you 
receive by  mouth while 
in the US? 
c. How many 
preventive vaccinations 
did you receive by  
injection (shots) while 
outside the US? 
d. How many preventive 
vaccinations did you receive by  
mouth while outside the US? 
WW II 
 
 
 
# VACCINATIONS 
 DK 
   
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
Korea  
 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
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 Vietnam  
 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
Persian Gulf War 
 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
 
 
# VACCINATIONS 
 DK 
 
11. Have you ever taken pyridostigmine bromide,   YES 
 or little white pills in foil packs, sometimes called   NO 
 NAPPs, which are used to protect against nerve agents?   DK 
 
 [IF YES:] 
  11a. In which year did you take pyridostigmine pills? 
   YEAR    DK  
 
 11b. For how many days TOTAL did you take  
  pyridostigmine pills?  TOTAL DAYS   DK 
  [PROBE FOR BEST GUESS] 
 
 11c. In an average day, when you took them,  
  how many pills did you take?  # PILLS   DK 
 
12.  Have you ever received the anthrax vaccine   YES 
 prior to [Reference Date]?  NO 
 DK 
 
 [IF YES:] 
 12a. How many shots?  
   # SHOTS   DK 
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 13. Prior to [Reference Date], have you ever  YES  
 been treated with nasopharyngeal (NP) radium   NO 
 during military service?  DK 
14. Prior to the [Reference Date], have you ever received   YES 
 the smallpox vaccine?  NO    DK 
15. Prior to the [Reference Date], did you ever receive   YES [GO TO 16] 
 imminent danger pay, hardship duty pay or   NO   [GO TO 18] 
 combat zone tax exclusion benefits for deployment?    DK 
 
SECTION G: DEPLOYMENT-SPECIFIC EXPOSURE( CONTINUED) 
16. For which countries or region(s) did you receive imminent danger pay, hardship duty, or combat zone tax exclusion benefits? Please tell us the 
date (month and year) you arrived in the region and the date (month and year) that you departed from the region. 
If the participant does not recall the country or region for which they received imminent danger pay please prompt by reading list below: 
 
Country Codes: 
01 Afghanistan                                                  10 Philippines                                     19. Arabian Sea 
02 Bahrain                                                         11. Qatar                           20. Gulf of Aden 
03 Croatia                                                          12. Saudi Arabia   21. Gulf of Oman 
04 Kuwait or Iraq     13. Serbia (includes Kosovo)  22. Persian Gulf 
05 Kyrgyzstan      14. Tajikistan    23. Red Sea 
06 Macedonia      15. Turkey    24. Other Sea Area (please specify): 
07 Montenegro      16. United Arab Emirates       
08 Oman      17. Uzbekistan 
09 Pakistan      18. Other country( please specify):  
 
Location                                 Date Arrived  or DK                                         Date Departed or DK 
                      Month     / Year                                                     Month       /  Year 
a.                                          DK           TO                          DK 
 
b.                                          DK            TO                         DK 
 
c                                           DK           TO                          DK 
 
d                                           DK           TO                          DK 
 
e                                           DK            TO                         DK 
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 17. Did you receive imminent danger pay, hardship duty or combat zone tax exclusion benefits for greater than 5 regions/countries?  (Y, N, 
DK)___ 
 
SECTION G: DEPLOYMENT-SPECIFIC EXPOSURE( CONTINUED) 
18. I will now read to you a list of other operations the US Armed Forces have been involved in during the recent past. I will only ask whether 
you were deployed to any of the respective areas of conflict, and if so, when and for how long. 
 
Country a. Ever deployed b.  In which year were you first sent 
there? 
c. What is the total number of months you spent 
there? 
Grenada   YES  
  NO    
  DK    
 
  
 YEAR   DK 
 
  
 MONTHS   DK 
Lebanon   YES  
  NO    
  DK    
 
  
  
YEAR   DK 
 
  
  
MONTHS  DK 
Panama   YES  
  NO    
  DK    
 
  
 YEAR   DK 
 
  
  
MONTHS   DK 
Somalia   YES  
  NO    
  DK    
 
  
 YEAR   DK 
 
  
 MONTHS   DK 
Bosnia   YES  
  NO    
  DK    
 
  
 YEAR   DK 
 
  
 MONTHS   DK 
Kosovo   YES  
  NO    
  DK    
 
  
  
YEAR   DK 
 
  
  
MONTHS   DK 
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Rwanda 
  
       YES  
  NO    
  DK    
 
  
 YEAR   DK 
 
  
 MONTHS  DK 
Afghanistan   YES  
  NO    
  DK    
 
  
  
YEAR   DK 
 
  
  
MONTHS  DK 
Iraq/Persian 
Gulf region 
(Gulf War II) 
  YES  
  NO    
  DK    
 
  
  
YEAR   DK 
 
  
  
MONTHS  DK 
 
18d.  Were you ever deployed to any other country?   YES [SPECIFY] 
 NO  [SECTION H] 
 DK 
(Please Specify)______________________________________________________________________________ 
 
SECTION H  HOBBIES 
 
NOW I HAVE A FEW QUESTIONS ABOUT YOUR HOBBIES PRIOR TO (REFERENCE DATE). 
 
1  Prior to [Reference Date], have you done   YES 
 any outdoor hunting or shooting, either animals,   NO 
 skeet, trap or targets?   DK 
 [IF YES:] 
 a. For how many years have you done outdoor  
  hunting or shooting?  # YEARS   DK 
  [CODE AS 1  IF <= 1 YEAR] 
 
 b. What is the average number of hours per month   
  (or year) that you engaged in this hobby? 1 HOURS/MONTH   2  HOURS/YEAR     DK 
 
2. Prior to [Reference Date], have you done   YES 
 any gun shooting in an indoor pistol or rifle range?  NO 
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      DK 
 [IF YES:] 
 a. For how many years have you done indoor  
  gun shooting?   # YEARS   DK 
  [CODE AS 1  IF <= 1 YEAR] 
 
 b. What is the average number of hours per month  
  (or year) that you engaged in this hobby?  1 HOURS/MONTH   2  HOURS/YEAR     DK 
 
3. Prior to [Reference Date], have you done any   YES 
 casting of bullets or other lead casting?   NO 
     DK 
 [IF YES:] 
 a. For how many years have you done lead casting?  
  [CODE AS 1  IF <= 1 YEAR]  # YEARS   DK 
 
 b. What is the average number of hours per month  
  (or year) that you engaged in this hobby? 1 HOURS/MONTH   2  HOURS/YEAR     DK 
 
SECTION H HOBBIES (CONTINUED) 
4. Prior to [Reference Date], have you done any   YES 
 fishing using lead weights or sinkers?   NO 
     DK 
 [IF YES:] 
 a. For how many years have you been fishing  
  using lead weights or sinkers?   # YEARS   DK 
  [CODE AS 1  IF <= 1 YEAR] 
 
 b. What is the average number of hours per month  
  (or year) that you engaged in this hobby? 1 HOURS/MONTH   2  HOURS/YEAR     DK 
 
5. Have you ever had bullets or buckshot lodged   YES 
 in your body for more than a week?   NO 
     DK 
 [IF YES:] 
 a. At what age did this first happen?  
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     AGE           DK 
 
 b. What is the total amount of time you have  
  had bullets or buckshot in your body?  1  WEEKS 2  MONTHS 3  YEARS 
 
 c. Do you still have bullets or buckshot in your body?   YES 
     NO 
     DK 
 [IF YES:] 
 d.  Where is (are) the bullet(s) located in your body? _____________________________________ 
 
 
 
                         [CODE]                         [CODE]                              [CODE]                        [CODE]       
 
 
          
                         [CODE]                         [CODE]                               [CODE]                      [CODE]       
                    
 
            
                         [CODE]                        [CODE]       
   
  
SECTION I.  TRAUMA AND MEDICAL HISTORY 
 
Now I am going to ask you some questions about head injuries, fractures and electrical shocks you may have experienced prior to [Reference 
Date]. 
 
1. Before [Reference Date], have you  ever had  YES  
 a head injury where you lost consciousness or for   NO [GO TO 6.] 
 which you received medical care?   DK [GO TO 6.] 
 
 [IF YES: ] 
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 [ASK THE FOLLOWING QUESTIONS FOR EACH TRAUMA WHERE THE SUBJECT LOST CONSCIOUSNESS AND/OR RECEIVED 
MEDICAL CARE.] 
 
2. 
 How old were you at 
the time of your 
(first/next) head 
injury? 
3. 
Did you lose 
consciousness 
because of this 
injury? 
3a. 
How long were you unconscious?  
 
4. 
Did you see a 
doctor for this 
head injury? 
 
5. 
Were you 
hospitalized 
for this injury? 
 
 
 |__|__| 
 AGE     DK 
 
 YES  
 NO [GO TO 4.] 
 DK [GO TO 4.] 
 
|__|__|__|   |__|__| 
  HOURS          MINUTES     DK 
 
  YES  
  NO   
  DK 
 
  YES  
  NO   
  DK 
 
 |__|__| 
 AGE     DK 
 
 YES  
 NO [GO TO 4.] 
 DK [GO TO 4.] 
 
 
|__|__|__|   |__|__| 
  HOURS          MINUTES     DK 
 
  YES  
  NO   
  DK 
 
  YES  
  NO   
  DK 
 
 |__|__| 
 AGE     DK 
 
 YES  
 NO [GO TO 4.] 
 DK [GO TO 4.] 
 
|__|__|__|   |__|__| 
  HOURS          MINUTES     DK 
 
  YES  
  NO   
  DK 
 
  YES  
  NO   
  DK 
Total # Supplemental Pages     |__|__|  Supplemental page?   YES  NO 
 SECTION I.  TRAUMA AND MEDICAL HISTORY (CONTINUED) 
 
6.  Prior to [Reference Date], have you ever   YES 
 received a severe electrical shock that resulted   NO  [GO TO 7] 
 in unconsciousness?    DK  [GO TO 7] 
 
 [IF YES:] 
 a. Have you received more than one shock  1  YES 
  of this type?  2  NO 
    -1  DK 
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  b. At what age did you first receive a shock  
  that resulted in unconsciousness? AGE          DK 
7. Prior to [Reference Date], have you ever   YES 
 received a severe electrical shock that resulted    NO   [GO TO 8] 
 in a burn?   DK   [GO TO 8] 
 
 [IF YES:]    
 a. Have you received more than one shock  1  YES 
  of this type?  2  NO 
    -1  DK 
    
 b. At what age did you first receive  
  a shock that resulted in a burn?  AGE          DK 
 
8. Prior to [Reference Date], have you ever   YES 
 received a severe electrical shock, but one that   NO  [GO TO 9] 
 did not result in unconsciousness or a burn?   DK  [GO TO 9]  
 
 [IF YES:] 
 a. Have you received more than one shock  1  YES 
  of this type?  2  NO 
    -1  DK 
     
 b. At what age did you first receive  
  a shock that did not result in   AGE          DK 
  unconsciousness or a burn? 
9. Prior to (REFERENCE DATE), have you ever fractured or broken a bone? (Y*, N, DK)  
*(IF YES, CODE THE FOLLOWING INFORMATION FOR EACH BONE THAT WAS BROKEN) 
  a. In what year did the fracture occur? 
 
 b. What bone (body site) 
was broken? 
  1=>Head(not face) 
  2=>Clavicle/Collarbone  
  3=>Spine/Back/Neck  
  4=>Breastbone  
  5=>Ribs  
  6=>Arm 
  7=>Elbow 
  8=>Hand/Fingers/Wrist  
  10=>Pelvis/Hip  
  11=>Leg  
  12=>Knee  
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   13=>Feet/Toes/Ankle                    14=>Face   -1=>DK). 
 c. Did you receive medical attention for the fracture?  (Y, N, DK) 
 
a. 
YEAR 
b. 
BONE/SITE 
c. 
MEDICAL 
ATTENTION 
___ ___ ___ ___ ___ ___ ___ 
___ ___ ___ ___ ___ ___ ___ 
___ ___ ___ ___ ___ ___ ___ 
___ ___ ___ ___ ___ ___ ___ 
___ ___ ___ ___ ___ ___ ___ 
 
 
10. Prior to [Reference Date], has a doctor ever  YES 
 told you that you had lead poisoning?   NO   [SECTION J] 
       DK   [SECTION J] 
 
 [IF YES:] 
 a. How many episodes of lead poisoning   
  were you diagnosed with?  # EPISODES   DK 
 
[FOR EACH EPISODE, ASK QUESTIONS 10b-10f AND RECORD ANSWERS IN THE TABLE]] 
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10b. 
In what year were you 
(first/next) diagnosed with 
lead poisoning? 
 
10c. 
In this episode, 
were you 
hospitalized? 
 
10d. 
In this episode, 
was blood drawn 
to measure the 
lead level? 
10e. 
Can you recall the 
lead level in your 
blood? (in 
micrograms per 
deciliter) 
10f. 
In this episode, what 
kind of treatment did you 
receive? 
 
 
 
     YEAR  DK 
 
  
  YES 
  NO 
  DK 
 
  YES  
  NO  [10f.] 
  DK  [10f.] 
 
 
MG/DL 
 DK   
 
 
  no treatment 
  chelation therapy  
  EDTA, versenate  
  BAL  
  DMSA, Chemet,  
       Succimer 
  Penicillamine  
  DK 
 other (specify) 
 
 
 
     YEAR  DK 
 
  
  YES 
  NO 
  DK 
 
  YES  
  NO  [10f.] 
  DK  [10f.] 
 
 
MG/DL 
 DK   
  no treatment 
  chelation therapy  
  EDTA, versenate  
  BAL  
  DMSA, Chemet,  
       Succimer 
  Penicillamine  
  DK 
 other (specify) 
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 SECTION J: PTSD (POST-TRAUMATIC STRESS DISORDER)  
 
The next few questions pertain to stressful experiences you may have encountered during your lifetime, either related or not related to your 
military service.  
 
(Prior to [Reference Date], have you ever 
experienced…) 
if don’t know , please write DK in margin 
1 
Not at all 
2 
A little bit 
3 
Moderately 
4 
Quite a 
bit 
5 
Extremely 
1. Repeated, disturbing memories  
 of stressful experiences from the past… 
 
 
 
 
 
 
 
 
 
 
2. Repeated, disturbing dreams of stressful 
 experiences from the past… 
 
 
 
 
 
 
 
 
 
 
3.  Suddenly acting or feeling as if stressful 
 experiences were happening again… 
 
 
 
 
 
 
 
 
 
 
4.  Feeling very upset when something happened 
 that reminds you of stressful experiences from 
 the past… 
 
 
 
 
 
 
 
 
 
 
5.  Trouble remembering important parts of 
 stressful experiences from the past… 
 
 
 
 
 
 
 
 
 
 
6.  Loss of interest in activities that you used to 
 enjoy…. 
 
 
 
 
 
 
 
 
 
 
7.  Feeling distant or cut off from other people…  
 
 
 
 
 
 
 
 
 
8.  Feeling emotionally numb, or being unable to 
 have loving feelings for those close to you… 
 
 
 
 
 
 
 
 
 
 
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 9.  Feeling as if your future will somehow be cut 
 short… 
 
 
 
 
 
 
 
 
 
 
10. Trouble falling asleep or staying asleep…  
 
 
 
 
 
 
 
 
 
11. Feeling irritable or having angry outbursts….  
 
 
 
 
 
 
 
 
 
12. Difficulty concentrating…  
 
 
 
 
 
 
 
 
 
13. Feeling  “super alert” or watchful or on  
 guard… 
 
 
 
 
 
 
 
 
 
 
 
14. Feeling jumpy or easily startled…  
 
 
 
 
 
 
 
 
 
15. Physical reactions when something reminds  you of 
stressful experiences from the past… 
 
 
 
 
 
 
 
 
 
 
16. Efforts to avoid thinking about your stressful 
 experiences from the past or avoid having 
 feelings about them… 
 
 
 
 
 
 
 
 
 
 
17. Efforts to avoid activities or situations because 
 they remind you of stressful experiences from 
 the past… 
 
 
 
 
 
 
 
 
 
 
 
Optional comments: _________________________________________________________________________ 
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SECTION K.    FAMILY HISTORY 
 
I would like to ask some background information about your family members.  I am interested only in your immediate blood relatives, 
including your mother, father, children, full sisters and full brothers.  Do not include adopted or foster relatives, or half-siblings.  Please 
include all relatives, both living and deceased. 
 
1. a. How many sisters do you have?  
    # SISTERS  DK 
 
 b. Are any of your sisters deceased?  
    # SISTERS  DK 
 
2. a. How many brothers do you have? 
 # BROTHERS  DK 
 
 b. Are any of your brothers deceased? 
 # BROTHERS  DK 
 
3. a. How many daughters do you have? 
 # DAUGHTERS  DK 
 
 b. Are any of your daughters deceased? 
 # DAUGHTERS  DK 
 
4. a. How many sons do you have? 
 # SONS  DK 
 
 b. Are any of your sons deceased? 
 # SONS  DK 
 
Now I have a few questions about each of your immediate relatives with respect to particular medical  
conditions they may have had.  I realize that it can be tedious to go through each family member; however, it is very important that we do so 
in order to obtain the most complete information. 
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 [COMPLETE QUESTIONS 7-9b (5 AND 6 OMITTED) FOR BOTH PARENTS AND FOR ALL SIBLINGS AND CHILDREN NOTED IN 1-
4]. 
[PLEASE NOTE THAT FOR FAMILY MEMBERS OF LESS THAN 18 YEARS OF AGE NOW/AT [Reference Date], ASK ONLY 
THE DOWN’S SYNDROME INFORMATION ON 9a AND EXCLUDE THE OTHER DISEASES.] 
SECTION K.    FAMILY HISTORY (CONTINUED) 
[1 MOTHER] 
7. 
 
Is your mother 
living? 
8. 
What is your 
mother’s current age / 
What was your 
mother’s age at her 
death? 
9a. 
Before [Reference Date], was your mother ever 
diagnosed with… 
 
 YES NO DK 
9b. 
At what age was this 
diagnosis first given? 
 
  YES 
  NO 
  DK 
  
|__|__| 
AGE 
 
  DK  
 
Down’s syndrome    
|__|__| 
 AGE      DK 
*Was the respondent asked the following questions 
(family member 18 y.o. or more)? Yes  No 
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
Alzheimer’s disease    |__|__| 
  AGE      DK 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
 
|__|__| 
  AGE      DK 
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  [2 FATHER] 
7. 
 
Is your father 
living? 
8. 
 
What is your father’s 
current age /What 
was your father’s age 
at his death? 
9a. 
Before [Reference Date],was your father ever 
diagnosed with… 
 
 YES NO DK 
9b. 
At what age was he 
diagnosed with 
(disease) 
 
  YES 
  NO 
  DK 
  
|__|__| 
AGE 
 
  DK 
 
 Down’s syndrome    
 |__|__| 
 AGE      DK 
*Was the respondent asked the following questions 
(family member 18 y.o. or more)? Yes  No 
Parkinson’s disease    
 
 |__|__| 
 AGE  DK 
Alzheimer’s disease     |__|__| 
  AGE      DK 
ALS     
 (amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
 
 |__|__| 
  AGE      DK 
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 [3 SISTERS] 
 
[PLEASE NOTE THAT FOR FAMILY MEMBERS OF LESS THAN 18 YEARS OF AGE NOW/AT (REFERENCE DATE), ASK ONLY THE 
DOWN’S SYNDROME INFORMATION ON 9 AND EXCLUDE THE OTHER DISEASES.]* 
Next, I am going to ask you about all of your sisters/your sister, (starting with the oldest)… 
 
7. 
 
Is your sister/ first 
sister/next sister 
living? 
8. 
What is your 
sister’s current age 
/ What was your 
sister’s age at her 
death? 
9a. 
Before [Reference Date], was this sister ever 
diagnosed with… 
 
 YES NO DK 
9b. 
At what age was this 
diagnosis first given? 
 
  YES 
  NO 
  DK 
 
  
|__|__| 
AGE 
 
  DK  
 
Down’s syndrome    
|__|__| 
 AGE      DK 
 
*Was the respondent asked the following questions 
(family member 18 y.o. or more)? Yes  No 
Parkinson’s disease    
|__|__| 
 AGE  DK 
Alzheimer’s disease    |__|__| 
  AGE      DK 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
  YES 
  NO 
  DK 
|__|__| 
AGE 
  DK 
Down’s syndrome    |__|__| 
 AGE      DK 
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 *Was the respondent asked the following questions 
(family member 18 y.o. or more)? Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
 
Alzheimer’s disease    
 
|__|__| 
  AGE      DK 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
 
[3 SISTERS CONTINUED] 
[PLEASE NOTE THAT FOR FAMILY MEMBERS OF LESS THAN 18 YEARS OF AGE NOW/AT (REFERENCE DATE), ASK ONLY THE 
DOWN’S SYNDROME INFORMATION ON 9a AND EXCLUDE THE OTHER DISEASES.]* 
7. 
 
Is your sister/ first 
sister/next sister 
living? 
8. 
 
What is your 
sister’s current age 
/ What was your 
sister’s age at her 
death? 
9a. 
Before [Reference Date],was this sister ever 
diagnosed with… 
 
 
 YES NO DK 
9b. 
At what age was this 
diagnosis first given? 
 
  YES 
  NO 
  DK 
 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
 
*Was the respondent asked the following questions 
(family member 18 y.o. or more)? Yes  No 
  
Parkinson’s disease    
 
 
|__|__| 
 AGE  DK 
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 Alzheimer’s disease    
 
 
|__|__| 
  AGE      DK 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
 
|__|__| 
  AGE      DK 
 
  YES 
  NO 
  DK 
 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
 
*Was the respondent asked the following questions 
(family member 18 y.o. or more)? Yes  No 
Parkinson’s disease    
|__|__| 
 AGE      DK 
 
Alzheimer’s disease    |__|__| 
 AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
 AGE      DK 
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 [4 BROTHERS] 
[PLEASE NOTE THAT FOR FAMILY MEMBERS OF LESS THAN 18 YEARS OF AGE NOW/AT [Reference Date], ASK ONLY THE 
DOWN’S SYNDROME INFORMATION ON 9a AND EXCLUDE THE OTHER DISEASES.]*  
 
Next, I am going to ask you about all of your brothers/your brother, (starting with the oldest)… 
7. 
 
Is your brother/first 
brother/next brother 
living? 
8. 
What is your 
brother’s current age 
/ What was your 
brother’s age at his 
death? 
9a. 
Before [Reference Date],was  this brother ever 
diagnosed with… 
 
 
 YES NO DK 
9b. 
At what age was this 
diagnosis first given? 
 
  YES 
  NO 
  DK 
 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
|__|__| 
 AGE  DK 
Alzheimer’s disease    |__|__| 
  AGE      DK 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
  YES 
  NO 
  DK 
|__|__| 
AGE 
 
  DK 
Down’s syndrome     
|__|__| 
 AGE      DK 
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 *Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
 
Alzheimer’s disease    
|__|__| 
  AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
 
 
[4 BROTHERS CONTINUED] 
[PLEASE NOTE THAT FOR FAMILY MEMBERS OF LESS THAN 18 YEARS OF AGE NOW/AT [Reference Date], ASK ONLY THE 
DOWN’S SYNDROME INFORMATION ON 9a AND EXCLUDE THE OTHER DISEASES.]*  
 
7. 
 
Is your brother/first 
brother/next brother 
living? 
8. 
What is your 
brother’s current age 
/ What was your 
brother’s age at his 
death? 
9a. 
Before [Reference Date],was this brother ever 
diagnosed with… 
 
 
 YES NO DK 
9b. 
At what age was this 
diagnosis first given? 
 
  YES 
  NO 
 
|__|__| 
AGE 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
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   DK  
  DK 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
 
Alzheimer’s disease    
|__|__| 
  AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
 
 
  YES 
  NO 
  DK 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
 
Alzheimer’s disease    
|__|__| 
  AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
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 [5 DAUGHTERS] 
[PLEASE NOTE THAT FOR FAMILY MEMBERS OF LESS THAN 18 YEARS OF AGE NOW/AT (Reference Date), ASK ONLY 
THE DOWN’S SYNDROME INFORMATION ON 9a AND EXCLUDE THE OTHER DISEASES.]* 
 
Next, I am going to ask you about all of your daughters/your daughter, (starting with the oldest)… 
 
7. 
 
Is your 
daughter/first 
daughter/next 
daughter living? 
8. 
What is your 
daughter’s current 
age / What was your 
daughter’s age at her 
death? 
9a. 
Before [Reference Date],was  this daughter ever 
diagnosed with… 
 
 
 YES NO DK 
9b. 
At what age was this 
diagnosis first given? 
 
  YES 
  NO 
  DK 
 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
 
|__|__| 
 AGE      DK 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
 
Alzheimer’s disease    
|__|__| 
  AGE      DK 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
  YES 
  NO 
  DK 
|__|__| 
AGE 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
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 *Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
Alzheimer’s disease    |__|__| 
  AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
 
 
[5 DAUGHTERS CONTINUED] 
 
[PLEASE NOTE THAT FOR FAMILY MEMBERS OF LESS THAN 18 YEARS OF AGE NOW/AT (Reference Date), ASK ONLY 
THE DOWN’S SYNDROME INFORMATION ON 9a AND EXCLUDE THE OTHER DISEASES.]* 
 
7. 
 
Is your 
daughter/first 
daughter/next 
daughter living? 
8. 
What is your 
daughter’s current 
age / What was your 
daughter’s age at her 
death? 
9a. 
Before [Reference Date],was this daughter ever 
diagnosed with… 
 
 
 YES NO DK 
9b. 
At what age was this 
diagnosis first given? 
 
  YES 
  NO 
  DK 
 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
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Alzheimer’s disease    
|__|__| 
  AGE      DK 
 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
 
|__|__| 
  AGE      DK 
 
  YES 
  NO 
  DK 
 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
|__|__| 
 AGE  DK 
 
Alzheimer’s disease    
|__|__| 
  AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
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 [6 SONS] 
 
[PLEASE NOTE THAT FOR FAMILY MEMBERS OF LESS THAN 18 YEARS OF AGE NOW/AT [Reference Date], ASK ONLY 
THE DOWN’S SYNDROME INFORMATION ON 9a AND EXCLUDE THE OTHER DISEASES.]* 
 
Next, I am going to ask you about all of your sons/your son, (starting with the oldest)… 
 
7. 
 
Is your son/first 
son/next son living? 
8. 
What is your son’s 
current age / What 
was your son’s age at 
his death? 
9a. 
Before [Reference Date],was this son ever 
diagnosed with… 
 
 YES NO DK 
9b. 
At what age was this 
diagnosis first given? 
 
  YES 
  NO 
  DK 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
|__|__| 
 AGE  DK 
 
Alzheimer’s disease    
|__|__| 
  AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
 
|__|__| 
  AGE      DK 
 
  YES 
  NO 
 
|__|__| 
AGE 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
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   DK  
  DK 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
Alzheimer’s disease    |__|__| 
  AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
 
 
[6 SONS CONTINUED] 
[PLEASE NOTE THAT FOR FAMILY MEMBERS OF LESS THAN 18 YEARS OF AGE NOW/AT (Reference Date), ASK ONLY 
THE DOWN’S SYNDROME INFORMATION ON 9a AND EXCLUDE THE OTHER DISEASES.] 
 
7. 
 
Is your son/first 
son/next son living? 
8. 
What is your son’s 
current age / What 
was your son’s age at 
his death? 
9a. 
Before [Reference Date],was this son ever 
diagnosed with… 
 
 YES NO DK 
9b. 
At what age was this 
diagnosis first given? 
 
  YES 
  NO 
  DK 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
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Alzheimer’s disease    
|__|__| 
  AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
 
 
  YES 
  NO 
  DK 
 
|__|__| 
AGE 
 
  DK 
 
Down’s syndrome    
|__|__| 
 AGE      DK 
 
*Was the respondent asked the following 
questions (family member 18 y.o. or more)? 
Yes  No 
  
Parkinson’s disease    
 
|__|__| 
 AGE  DK 
 
Alzheimer’s disease    
|__|__| 
  AGE      DK 
 
ALS     
(amyotrophic lateral sclerosis or Lou Gehrig’s 
disease) 
|__|__| 
  AGE      DK 
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SECTION L: RESIDENCE HISTORY  
We are interested in the location of your residences for all places you lived for a period of 6 months or longer up to (REFERENCE DATE). 
Please include military residences. Starting with the place where you were born, please tell me the city and state of each place where you have 
lived for 6 months or longer.  If you lived on a farm, please give the name of the nearest city or town.  If you moved within the same city or 
town, do not give each address, but instead consider that to be one place of residence. Let’s begin with your birth.  In what town or city were 
you born?   
. FOR EACH RESIDENCE, ASK:) 
1. 
At what 
age did 
you move 
to your 
next 
residence 
of 6 
months or 
longer? 
2. 
In what 
city or 
town was 
this 
residence? 
3. 
In what 
state (or 
country) 
was this 
residence? 
4. 
Would you 
describe the area 
you lived in as 
being...  
1=>urban or city 
2=>suburban 
3=>rural 
4=>farming, 
ranching or 
agricultural 
8=>other 
9=>DK 
5. 
Was this 
residence 
within one 
mile of an 
agricultural 
area that 
was sprayed 
with 
pesticides 
or 
herbicides? 
(Y, N, DK) 
6. 
Was this 
residence a 
farm or a 
ranch? 
(Y, N, 
DK) 
6a. 
*(IF YES) 
While 
living 
there, did 
you work 
on the 
farm 
(ranch)? 
(Y, N, 
DK) 
7. 
Did your water 
come from a 
well or other 
non- treated 
source during 
any of the years 
you lived in this 
residence? 
(Y, N, DK) 
7a. 
*(IF YES) 
During which years 
did your water come 
from a well or other 
non- treated source? 
BIRTH 
(age 0) 
________
_ 
________
_ 
___ ___ ___ ___ ___ __ __ __ __ to 
__ __ __ __ 
___ ___ ________
_ 
________
_ 
___ ___ ___ ___ ___ __ __ __ __ to 
__ __ __ __ 
___ ___ ________
_ 
________
_ 
___ ___ ___ ___ ___ __ __ __ __ to  
__ __ __ __ 
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 L.    RESIDENCE HISTORY (CONTINUED) 
8.      Prior to (REFERENCE DATE), have you ever visited or resided in the South 
Pacific, including the island of Guam, the islands of New Guinea, and the Kii Peninsula of 
Japan?  Please include any time spent there in the military.   
(Y, N, DK) 
 
___ 
*(IF YES, ASK QUESTIONS a THROUGH d FOR EACH AREA.) 
a. How many times have you visited or resided in (AREA)?   
b. How old were you when you first visited or resided in (AREA)?  
c. How old were you when you last visited or resided in (AREA)?  
d. What is the total amount of time you spent in (AREA), excluding time periods between your age at first and last visit when you 
didn’t visit or reside in (AREA)?  
 
Area 
a. 
No.  
of Times 
Visits/ 
Resided  
(orDK) 
b.   
Age First 
Visited/ 
Resided 
(or DK) 
c. 
Age Last 
Visited/ 
Resided 
(or DK) 
d. 
Total 
Amount 
of Time 
Visited/ 
Resided 
(or DK) 
 
Time Unit 
(circle one) 
     DAYS  WEEKS  MOS  YRS 
Guam 
 
___ ___ ___ ___ ___ ___ ___ ___      1            2           3        4 
New Guinea 
 
___ ___ ___ ___ ___ ___ ___ ___      1            2           3        4 
Kii Peninsula 
 
___ ___ ___ ___ ___ ___ ___ ___      1            2           3        4 
Other (specify) ___ ___ ___ ___ ___ ___ ___ ___      1            2           3        4 
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 Comments:(enter names of “other” South Pacific  Islands visited here)______________________________ 
 ______________________________________________________________________________________ 
______________________________________________________________________________________ 
 
SECTION M. PHYSICAL ACTIVITY 
 
1. Have you ever participated in any leisure-time   YES 
 recreational physical activity similar to brisk walking,   NO 
 jogging, bicycling, aerobics etc on a regular basis   DK 
 (at least an hour a week for a year or longer) 
 
2. Have you ever played on a competitive, high school   YES 
 or intercollegiate team?   NO 
   DK 
 
3. Have you ever participated in an organized   YES 
 sport activity on a regular basis (at least an   NO 
 hour a week for a year or longer)?   DK 
 
 
 [IF 1, 2, OR 3 = YES:]  
Please name each recreational activity/sport that you participated in, along with your age at starting/stopping this activity, the total number of years 
you participated, and for those years, the typical number of hours per week, and the number of weeks per year, that you engaged in this activity.  
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 a. 
(Sport or recreational 
activity) 
b. 
What was your 
age when you 
first participated? 
 
c. 
What was your 
age when you 
last participated? 
 
d. 
Excluding any 
years you did not 
participate, what 
is the total 
number of years 
you participated? 
 
 
e. 
Number of 
hours  
per week 
 
 
f. 
Number of 
weeks  
per year 
[ASK #OF 
MONTHS AND 
TRANSLATE 
TO WEEKS] 
 
 
__________________ 
 
__________________ 
 
 
      |__|__| 
          AGE 
 
  DK 
 
      |__|__| 
          AGE 
 
  DK 
 
     |__|__| 
YEARS 
 
  DK 
 
  |__|__| 
HOURS 
 
  DK 
 
|__|__| 
WKS/YR 
 
  DK 
 
__________________ 
 
__________________ 
 
 
      |__|__| 
          AGE 
 
  DK 
 
      |__|__| 
          AGE 
 
  DK 
 
     |__|__| 
YEARS 
 
  DK 
 
  |__|__| 
HOURS 
 
  DK 
 
|__|__| 
WKS/YR 
 
  DK 
 
__________________ 
 
__________________ 
 
 
      |__|__| 
          AGE 
 
  DK 
 
      |__|__| 
          AGE 
 
  DK 
 
     |__|__| 
YEARS 
 
  DK 
 
  |__|__| 
HOURS 
 
  DK 
 
|__|__| 
WKS/YR 
 
  DK 
 
__________________ 
 
__________________ 
 
 
      |__|__| 
          AGE 
 
  DK 
 
      |__|__| 
          AGE 
 
  DK 
 
     |__|__| 
YEARS 
 
  DK 
 
  |__|__| 
HOURS 
 
  DK 
 
|__|__| 
WKS/YR 
 
  DK 
 
__________________ 
 
__________________ 
 
 
      |__|__| 
          AGE 
 
  DK 
 
      |__|__| 
          AGE 
 
  DK 
 
     |__|__| 
YEARS 
 
  DK 
 
  |__|__| 
HOURS 
 
  DK 
 
|__|__| 
WKS/YR 
 
  DK 
Please use supplemental page if needed. 
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 This is the end of the interview. I appreciate your taking the time to go through this interview with me. The information you have provided will be 
a valuable contribution to our research. Thanks again for your participation in this study.  
 
SECTION N.   INTERVIEWER'S COMMENTS 
 
Q1. Respondent was ...? 1  Subject 
   2  Proxy 
   3  Translator 
 
 
Q2. The respondent’s ability to communicate  1  Excellent 
 verbally in English was...? 2  Good 
  3  Fair 
  4  Poor 
 
 
Q3. Was there any other person present? 1  Yes, spouse present for part of interview 
 2  Yes, spouse present for most or all of  
   interview 
 3  Yes, other person present for part of  
   interview:_________ 
 
 4  Yes, other person present for most or all of  
   interview:_________________________ 
 
   5  No 
 
 [IF YES:] 
 a. How much influence did (person)  1  A considerable amount of influence 
  exert on the respondent’s answers? 2  Little or no influence 
 
Q4. In your opinion how reliable are the  1  Very reliable 
 respondent's responses?  2  Somewhat reliable 
   3  Hard to tell 
   4  Somewhat unreliable 
   5  Very unreliable 
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SECTION 
 
Q5. The quality of each section is: 
1. 
High 
quality 
2. 
Generally 
reliable 
3. 
Questionable 
4. 
Unsatisfactory 
5. 
Not 
Applicable 
A. Demographics and Body   
 
     
B. Construction of Life Timeline 
 
     
C. Lifetime Occupational History 
 
     
D. Home Pesticide Use 
 
     
E. Tobacco History 
 
     
F. Lifetime Consumption of  
 Alcohol and Caffeinated Drinks 
 
     
G. Deployment-Specific Exposure      
H. Hobbies      
I. Trauma and Medical History      
J. Post- Traumatic Stress Disorder      
K.         Family History      
L. Residence History      
M. Physical Activity      
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 Questionnaire not completed because: 
 Actively refused to continue 
 Passively refused to continue 
  Too sick to complete 
   Died before completion 
  Other (please specify reason in comments) 
 
(IF ONE OR MORE OF THE SECTIONS HAVE BEEN RATED AS 4=>UNSATISFACTORY OR 3=>QUESTIONABLE, COMPLETE 
Q5a.) 
 
SECTION N.   INTERVIEWER'S COMMENTS (CONTINUED) 
Q5a. The reason (s) for unreliable or questionable quality of information 
(was/were) because the respondent 
  
 
Did not know enough information regarding the topic 1   YES       2   NO 
Did not want to be more specific 1   YES       2   NO 
Was bored or uninterested 1   YES       2   NO 
Was upset, depressed or angry 1   YES       2   NO 
Had poor hearing or speech 1   YES       2   NO 
Was confused or distracted by frequent interruptions 1   YES       2   NO 
Was inhibited by others 1   YES       2   NO 
Was embarrassed by the subject matter 1   YES       2   NO 
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 Was emotionally unstable 1   YES       2   NO 
Was physically ill 1   YES       2   NO 
Other (specify)  ___________________________________________ 
 
1   YES       2   NO 
 
Q6. Was there an unusual situation or information? 1    YES 
  2  NO 
  -1  DK 
[IF YES:] 
a.  Indicate pertinent pages in questionnaire,  
     and comment below. 
 PAGE COMMENT 
 ________________________________________________________________________________ 
 
 ________________________________________________________________________________ 
 
 ________________________________________________________________________________ 
 
 ________________________________________________________________________________ 
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 APPENDIX C: ALS REGISTRY SCREENING FORM4 
NATIONAL REGISTRY OF VETERANS WITH AMYOTROPHIC LATERAL SCLEROSIS
4This appendix appears by permission of Dr. Kelli D. Allen, Epidemiology Research and Information Center, 
Durham VA Medical Center, and Department of Medicine and Thurston Arthritis Research Center, University of 
North Carolina at Chapel Hill; and Dr. Eugene Z. Oddone and Dr. Dawn Provenzale, Epidemiology Research and 
Information Center, Durham VA Medical Center, and Department of Medicine, Duke University Medical Center. 
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 ALS REGISTRY SCREENING FORM                               9/14/04 
 
Study ID: ___[ID]_______     Date:___ [ScrDate]________________ 
Initials of Screener: ___ [ScrInit] _________ 
 
Hello.  This is (NAME) from the Durham VA Medical Center.  May I speak to (name of individual who 
left the message on toll free phone line or name of veteran identified through medical records)? 
 
1. Name of Veteran: _____  [FName]  [MName]  [LName] ___________________________________ 
 
2. Name of Contact Person During Screening: ____________________[sContactPerson] ________ 
 
3.   Relationship of Contact Person to Veteran:  [sContactRelation] [sProxyScreener] 
____Self/Veteran     ____Spouse      _____Child     ____Sibling   ____Parent   ____Partner     _____Friend  
_____ Health Care Provider     _____Other (specify):______________________________________ 
 
I am a research assistant with the national VA ALS registry.  How may I help you today (if call is returned 
from phone line)? 
 
Provide information about the registry: 
We are currently developing a registry of U.S. veterans who have ALS, or Lou Gehrig’s Disease. This 
Registry is being developed by the Department of Veterans Affairs (VA) under the direction of Dr. Eugene 
Oddone and his research team.  The purpose of the registry is to identify as completely as possible all 
living veterans with ALS, and to follow the health status of these veterans.  The registry will also provide a 
way for the VA to inform veterans with ALS about clinical trials for which they may be eligible.  
(Enrolling in the Registry does not obligate you to participate in any future clinical trials.)  Any living 
veteran who has received a medical diagnosis of ALS is eligible to enroll in this registry.   
 
4.   With your permission, I would like to ask you some questions to determine your (the veteran’s) 
eligibility.  The information you provide today will be documented as part of our database of individuals 
we have spoken with about the registry, and all of the information you provide will be kept confidential.  
May I proceed? 
____ Yes     [sProceed] 
____ No  (Refuse) 
____ No (Don’t have ALS) 
____ No (Dead) 
____ Don’t Know    
____ Call back   
  If YES (veteran or proxy): Go to Eligibility Form 
 
  If NO (refuse): Go to Refused Script 
 
If NO (don’t have ALS):  Since you do not have ALS, I won’t ask you to answer any further 
questions.  Thank you for taking the time to speak with me today. (End call.) 
 
IF DON’T KNOW: 
The questionnaire will only take a few minutes, and the information you provide is 
confidential.  You can refuse to answer any question or terminate this phone call at any time.  
May I proceed? 
      If YES: Go to Eligibility Form 
      If NO: Go to Refused Script 
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 If CALL BACK: 
      When would be a good time to call you back? 
      Date        _____ / _____ / _____  Time        ______ (EST) 
                                    [sCallBackDate]                                            [sCallBackTime]  
 
ELIGIBILITY FORM 
1. Have you (or the person being considered for eligibility) ever served in the US Army, Navy, Marine 
Corps, Air Force, or activated Reserves or National Guard Unit?  [sServed] 
Ο YES – Go to Q2 Ο NO- Go to Ineligible Script (non-veteran) Ο DK-go to Q2 
  
2.  Were you (was the veteran) ever told by a health professional that you (he/she) might have ALS or Lou 
Gehrig’s disease?    [sHProALSYN] 
Ο YES  -Go to 2a. Ο NO - Go to Q3 Ο DK-go to Q3 
 
 2a.  Were you (was the veteran) clinically diagnosed with ALS?  [sClinALS] 
       Ο YES  -Go to Q5.  Ο NO - Go to Q3.   (DK go to Q5) 
 
3. Is there another current diagnosis given by a health professional?  [AnotherDx] 
      Ο YES  -Go to Q4.  Ο NO - Go to Q5.  .   (DK go to Q5) 
 
4. What was the diagnosis (check all that apply)? 
Ο Possibly ALS (not yet determined/diagnosed) If yes, go to Q5. [PossALS] 
Ο Primary lateral sclerosis   If yes, go to Q5 .[PrimLatSc] 
Ο Progressive bulbar palsy   If yes, go to Q5. [ProgBulbPalsy] 
Ο Progressive muscular atrophy   If yes, go to Q5. [ProgMuscAtrophy] 
                                                                                                            [Monomelic] 
Ο Other [OtherCurrDxYN] (please specify):   [OtherCurrDxTxt]  ________________ 
   Additional relevant/ “unusual” 
information:__[SuspiciousNote]_____________________________ 
  
If  “other” diagnosis and there is no other unusual information (for example, veteran has a family member 
with ALS who had similar symptoms) go to Ineligible Script (No ALS Diagnosis).   
If “other” and there is unusual information, continue with screener.  Then inform the veteran that we will 
discuss his/her case with our study neurologist and call them back to let them know whether we will 
proceed with the consent process.   
 
5. Have you been seen by a neurologist?  Ο YES   Ο NO  [sSeenNeuro] 
 
6. What was the date of diagnosis (if appropriate)? _____/_____/_____   [sDxMon] [sDxDay] 
[sDxYear] 
 
7. Please describe your current symptoms? (Check all that apply) 
Ο Weakness in upper limbs      [sWeakArms]   [sNoALSWeakArms] 
Ο Weakness in the legs   [sWeakLegs]   [sNoALSWeakLegs] 
Ο Difficulty chewing/swallowing    [sDiffChew] [sNoALSDiffChew] 
Ο Difficulty speaking   [sDiffSpk]  [sNoALSDiffSpk] 
Ο Other current symptoms:_____  [sOtherCurrYN]  [sOtherCurrTxt] 
[sNoALSOtherCurrYN]  [sNoALSOtherCurrTxt] 
_____________________________________________ 
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 8.  Have you had progression in muscle weakness?  Ο YES   Ο NO  [sProgressWeak] 
 
If diagnosis is NOT possible ALS, primary lateral sclerosis, progressive bulbar palsy, or progressive 
muscular atrophy and patient does NOT  have progression in muscles weakness, AND there is not 
unusual information, go to Ineligible Script (No ALS Diagnosis). 
9. When was the onset of progressive muscle weakness? _____/_____/_____  [sOnsetWeakMonth] 
[sOnsetWeakDay] [sOnsetWeakYear] 
 
10.  Where did the muscle weakness start? _____________ [sOnsetSite]   _____________________ 
 
11.  Has a family member/relative ever been diagnosed with ALS? Ο YES   Ο NO 
[sFamilyALS] 
 
 If Yes, Specify Family Member(s)_____________________________________________ 
Check Boxes 
[Mother] [MotherNote] 
[Father] [FatherNote] 
[Sister] [NumSisters] [SisterNote] 
[Brother] [NumBrothers] [BrotherNote] 
[MatGMother] [MatGMotherNote] 
[MatGFather] [MatGFatherNote] 
[PatGMother] [PatGMotherNote] 
[PatGFather] [PatGFatherNote] 
[OtherRelYN] [OtherRelTxt] [OtherRelNote] 
 
  - Complete Veteran/Proxy Information Form and go to Eligible Script 
VETERAN/PROXY INFORMATION FORM 
 
Multiple Addresses possibly recorded 
Stacked format 
[AUse] 
[AddType] 
 [AddSource] 
 
1.  Veteran’s Contact Information:   [AFName] [AMName] [ALName] 
     Street address    ___ [Str1] [Str2] [Str3] _____________________ 
 City ___ [City] ___________ State ____ [State] _________ Zip Code ___ [Zip] _________ 
 Home Phone: _____ [PhoneH] __________________________________ 
 Work Phone: ______ [PhoneW] _________________________________ 
 Cell Phone: ________[PhoneCell]_________________________________ 
                                                [AltPhone] 
 Email Address: _________________ [Email] _____________________ 
 
2. In case we are unable to reach you, who should we contact as your proxy? For example, this may be 
the person who has your health care power of attorney.  
ame of Proxy:______________________________________ 
 
Relationship of Proxy to Veteran: [AddRel] 
 
____Self/Veteran     ____Spouse      _____Child     ____Sibling   ____Parent   ____Partner     _____Friend  
_____ Health Care Provider     _____Other (specify):______________________________________ 
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 8. Proxy’s Contact Information  
     Street address    ________________________ 
 City _____________________ State ____________________ Zip Code _________________ 
 Home Phone: _______________________________________ 
 Work Phone: _______________________________________ 
 Cell Phone: _________________________________________ 
 Email Address: ______________________________________ 
 
9. Veteran’s date of birth: _____ [DOBDay] [DOBMonth] [DOBYear] [DOB] [AgeAtScreener 
 
5.   Veteran’s Social security number   ______-________-_______ [SSN] (text version0 [SSNNum] 
(numeric) 
 
6.   Veteran’s Gender :   Ο Male  Ο Female  [Gender]  [Greeting] 
[DemNote] 
 
7.   Veteran’s Ethnicity (mark all that apply): 
 Are you Spanish, Hispanic, or Latino? [HispanicYN] 
 Ο No 
 Ο Yes If Yes, Ο Mexican, Mexican American, or Chicano  [Mexican] 
   Ο Puerto Rican   [PuertoRican] 
   Ο Cuban  [Cuban] 
   Ο Other Spanish/Hispanic/Latino:  __[OtherHispanic] [OtherHispanicSpecify]  
 
8.   Veteran’s Race (check all that apply): 
Ο White   [White] 
Ο Black or African American,   [Black] 
Ο American Indian or Alaska Native [AmIndian] Principle Tribe___ [Tribe] __________ 
 Ο Asian  [AsianAny] 
 If Yes, Ο Asian Indian  [AsianIndian] 
  Ο Chinese   [Chinese] 
  Ο Filipino   [Filipino] 
  Ο Japanese   [Japanese] 
  Ο Korean   [Korean] 
  Ο Vietnamese   [Vietnamese] 
  Ο Other Asian: _____ [OtherAsianYN]   [SpecOtherAsianTxt ]_______________ 
  Ο Native Hawaiian or other Pacific Islander [PacIslanderAny] 
 If Yes, Ο Native Hawaiian   [NativeHawaiian] 
  Ο Guamanian or Chamorro   [Guamanian] 
  Ο Samoan  [Samoan] 
  Ο Other Pacific Islander: ____[OtherPacIslanderYN]   [OtherPacIslanderTxt] _____ 
 
9 Veteran’s Military History: 
 
9a.  Branch(es) of the Military (mark all the apply): 
   _____Army     _____Refused 
  _____Air Force     _____Don’t Know 
  _____Navy     _____Missing 
  _____Marines     _____Air National Guard 
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   _____Other     _____Army National Guard 
  _____Army Reserves    _____Army Guard 
  _____Navy Reserves    _____Coast Guard 
  _____Marine Reserves    _____Air Force Guard 
  _____Air Force Reserves 
 
9b.  Dates of service: 
 Branch    Type Duty    Begin Date  End Date 
             Active, ActiveReserves,  
            Ready/inactive Reserves 
 [DutyBranch]  [TypeDuty]   [BegDateMon]  [EndDateMon] 
                  [BegDateDay]  [EndDateDay] 
        [BegDateYear] 
 [EndDateYear] 
        [BegDate]  [EndDate] 
____________  ____________   ___/___/____  ___/___/___ 
 
 ____________  ____________   ___/___/____  ___/___/___ 
 
 ____________  ____________   ___/___/____  ___/___/___ 
 
 ____________  ____________   ___/___/____  ___/___/___ 
[InductionDischNote] 
 
9c.  Were you in the Gulf War ALS  Study? 
   Mark NA if dates do not overlap GW period (08/02/90-07/31/91). 
  ____Yes 
  ____No 
  ____NA 
  ____Refused 
  ____Don’t Know 
  ____Missing  
 9d.  Have you ever been stationed at or worked at Kelly Air Force Base?  [ServedKellyAFBase] 
   Ο YES   Ο NO   
 
9e.  While in the military, did you (did the veteran) serve outside the continental U.S.?   
  _____Yes   [OutsideContUS] 
  _____No   
   
If Yes,  
i.    Did you serve in: 
  Afghanistan  _____Yes _____No  [Afghanistan] [SpecifyAfghan] 
  Europe   _____Yes _____No [Europe] [Specify Europe] 
  Korea   _____Yes _____No [Korea]  [Specify Korea] 
  North Africa  _____Yes _____No           [NorthAfrica][SpecifyNAfrica] 
  Pacific Islands  _____Yes _____N           [PacificIslands][SpecifyIslands] 
  Persian Gulf  _____Yes _____No [PersianGulf]    
 If Yes: 
   In what location(s): __________________________________ [SpecifyPG] 
   Dates:  From ______/______/____[PGStartDay][PGStartMon][PGStartYear] 
                                                         to ______/______/_____ [PGEndDay]  [PGEndMon][PGEndYear] 
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   Vietnam  _____Yes _____No   [Vietnam]  [SpecifyVietnam] 
  Other   _____Yes _____No   
       Specify:  ________________________________ [SpecifyOther]  
 
ii. Number of months served outside the continental U.S.?  
[OutsideUSinMonTotal] 
10. Are you a current patient of a VAMC? (if so, list location of primary VA) _______________
 [CurrentVAPatient] 
 [VAList] 
 [SpecifyVA] 
 [DurhamVA] 
 
11.   How did you find out about this registry (if self-referred)?   (Mark all that apply.) 
Ο ALS Brochure- Specify source: ____________  [ALSBrochure] [ALSBrochureSource] 
Ο Muscular Dystrophy Association   [MDA] 
Ο ERIC Website   [ERICWeb] 
Ο Other Website -Specify ______ [OtherWebYN]    [OtherWebTxt]____________ 
Ο ALSA referral   [ALSA] 
Ο Neurologist    [Neurologist] 
Ο Friend or family member (word of mouth)  [FriendFamily] 
Ο Press release -Specify __________________ [PressReleaseYN]   [PressReleaseTxt] 
Ο Other – Specify ____________________  [OtherSourceYN]  [OtherSourceTxt] 
Ο DK 
If not self-referred: 
O Received Letter  [ReceivedLetter] 
Ο VA Database -Specify _______ [VADatabase]  [VADBTxt]___________ 
Ο VBA records   [VBAdatabase] 
Ο Other – Specify ________ [OtherDB]   [OtherDBTxt]____________ 
[GWDatabase  [GWId] 
[PTFFY01Ind]              
[PTFFY02Ind]            
[PTFFY03Ind]             
[SEFY01Ind]      
[SEFY02Ind]               
[SEFY03Ind]                           
[WebBasedRegistration]     
[AustinFy04Ind]            
[DSSPharmacy04]            
[AustinFY05Ind]            
[DSSPharmacy05]            
[AustinFY06Ind]            
[AustinFY07Ind]         
 
12. Are you a member of a Veterans’ Service Organization?  Yes______   [VSOYN] 
                       No______ 
 If Yes, please list__________________________________________________ 
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 SCRIPTS 
REFUSED SCRIPT: 
If you change your mind regarding your participation in our study, you can reach us at any time by calling 
1-877-DIAL-ALS (1-877-342-5257).   
 
INELIGIBLE SCRIPTS: 
  Not  Veteran: 
Because you are not a U.S. veteran, you are not eligible to enroll in this registry.  There are other 
studies dealing with ALS among non-veterans, and we would encourage you to contact the ALS 
Association (1-800-782-4747 or www.alsa.org) for more information.  Thank you for taking the 
time to answer our questions.  
 
 No ALS diagnosis:  
Because you have not been diagnosed with ALS by a physician, you are not eligible to enroll in 
this registry at this time. If you are diagnosed with ALS at a later date, please re-contact us via the 
toll-free ALS call line (1-877-342-5257).  Thank you for taking the time to answer our questions.   
 
ELIGIBLE SCRIPT: 
We would like to send you a packet that will contain a copy of the verbal consent form for you to 
keep, and a Release of Medical Information form.  We will need you to sign and date the medical release 
form and return it to us in the postage paid envelope included so we may obtain a copy of your medical 
records.   
Once we have received the form back from you, we will request a copy of your medical records 
from your physician(s).  A study neurologist who is an expert in ALS and other motor neuron diseases 
will then review your records to confirm your diagnosis.   
If veteran reports diagnosis of ALS, Possible ALS, PLS, PBP, PMA, say:  If the neurologist confirms 
your diagnosis, you will be eligible to participate in the Registry and we will contact you by telephone to 
conduct a brief interview.   
If veteran has no specific diagnosis but has progressive muscular weakness, say: If the neurologist 
believes you may have ALS, you may be eligible to participate in the Registry immediately, or we may 
request that we review your medical records again in six months to determine whether you are eligible to 
participate.  If you are eligible to participate, we will contact you by telephone for a brief interview. 
 
 This interview will include basic questions about your health.  We will also contact you every six months 
to complete a similar interview and monitor your health status.   
You should be receiving the information packet from us soon.  If you have any questions about 
these materials or the registry, please call us on our toll-free line:  1-877-DIAL-ALS (1-877-342-5257).  
Thank you for taking the time to speak with me today. 
 
9/15/2004 
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 APPENDIX D: NEUROLOGICAL SUMMARY SHEET5 
NATIONAL REGISTRY OF VETERANS WITH AMYOTROPHIC LATERAL SCLEROSIS
5This appendix appears by permission of Dr. Kelli D. Allen, Epidemiology Research and Information Center, 
Durham VA Medical Center, and Department of Medicine and Thurston Arthritis Research Center, University of 
North Carolina at Chapel Hill; and Dr. Eugene Z. Oddone and Dr. Dawn Provenzale, Epidemiology Research and 
Information Center, Durham VA Medical Center, and Department of Medicine, Duke University Medical Center. 
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ALS REGISTRY – NEUROLOGICAL SUMMARY SHEET 
Patient Name_____________________               Id___________ 
 
         /         / 6. Date of Onset  
  
         /         / 7. Minimum (Earliest) Date of Onset Range 
  
         /         / 8. Maximum (Latest) Date of Onset Range 
  
 9. Site of Onset 
  
         /         / 10. Date of ALS Diagnosis  - First Mention,  Dr.__________________ 
  
/         / 11. Date of ALS Diagnosis – 2nd Opinion,  Dr.___________________ 
  
/         / 12.  Date of Other MND Diagnosis (PLS, PBP, PMA) 
  
         /         / 13. Date of Onset of Muscle Cramps  (Earliest) 
  
         /         / 14.  Date of Onset of Fasciculations  (Earliest) 
 
Mark all that apply: 
 Bulbar Upper Extremities Trunk Lower Extremities 
Upper Motor 
Neuron 
15. 16. 17. 18. 
EMG Lower 
Motor Neuron 
19. 20. 21. 22. 
Clinical Lower 
Motor Neuron 
23. 24. 25. 26. 
 
27.  Progression? Yes       No 
 
28.  Atypical Features  Yes       No 
 
If Yes, then check all 
that apply: 
 
                                
_________ 
28a. Extrapyramidal  
                                
_________ 
28b. Ocular   
                                
_________ 
28c. Dementia   
                                
_________ 
28d. Autonomic  
                                
_________ 
28e. Sensory  
                                
_________ 
28f. Other - Specify:  
 1. Abstractor   3.  MD Reviewer  5.  Review #   
       /       / 2.  Abstraction Date          /       / 4.  MD Review Date    
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 29.  Please circle only one numbered diagnosis below.       Study ID# _____________  
 
 
    Weakness / Atrophy / Hyper-reflexia / Spasticity 
Progression 
EMG/Imaging 
Neuropathology 
        
                 
 
LMN + 
UMN 
3 or 4 
regions 
  
LMN + 
UMN 
2 regions 
  
LMN + UMN 
1 region 
  
LMN and/or 
UMN 
1 region 
  
LMN + UMN 
1 region 
or UMN 
>/= 1 region 
  
LMN only > 
1 region 
  
UMN only > 
1 region 
    
                 
 
1.  
Clinically 
Definite 
ALS 
  
2.  
Clinically 
Probable 
ALS 
  
3.  Clinically 
Possible ALS 
  
Identified 
ALS Mutation 
 
  
EMG acute 
denervation 
>/= 2 limbs 
 
  
Suspected ALS 
  
Suspected 
ALS 
    
                 
       
4.  Clinically 
Definite 
Familial ALS 
– Laboratory 
Supported 
 
  
5.  Clinically 
Probable 
ALS – 
Laboratory 
Supported 
  
6.  Progressive 
Muscular 
Atrophy 
 
7.  Progressive 
Bulbar Palsy 
  
8.  Primary 
Lateral 
Sclerosis 
 9.Indeterminate 
  
 10. No 
ALS 
 
 
 
9a.  Indeterminate: More current medical records needed.  
Specify records to obtain: 
 
 
9b.  Indeterminate:  Follow-up for new medical records in 6 months 
 
 
9c.  Indeterminate: Do you think this patient will evolve to ALS over time?  
 
     Yes            No 
9d.  Indeterminate: Does this patient need to be seen by an ALS expert? 
 
     Yes            No 
10a. Correct Diagnosis If Known 
11.  Any EMG Available? 
 
YES  NO 
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 30.  If ALS, mark one of the below: 
 
  
1. Sporadic ALS 
 
  
2. Familial ALS 
 
 If familial, what family member(s) (check all that apply and indicate if more 
than one in any category): 
                                             ______ 2a. Mother  
                                             ______ 2b. Father 
                                             ______ 2c. Sister 
                                             ______ 2d. Brother  
                                             ______ 2e. Maternal Grandmother 
                                             ______ 2f. Maternal Grandfather 
                                             ______ 2g. Paternal Grandmother  
                                             ______ 2h. Paternal Grandfather 
                                             ______ 2i. Other   
Specify__________________ 
 
31. Notes/Comments: 
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 Laboratory Data Test Done 1.  Yes    2.  No 
(Circle Yes or No for All Items) 
Result 
    
1. Total CK (numeric values- note up to 3) 1.      Yes         No  
    
2. GM1 Ganglioside Antibody 2.      Yes         No  
    
3. HIV testing (+/-; circle one) 3.      Yes         No        Positive     Negative      
    
4.  HTLV I testing (+/-; circle one) 4.      Yes         No        Positive     Negative      
    
5. T3/T4/TSH (numeric – time of diagnosis) 5.      Yes         No                  /            / 
    
6.  Parathyroid Hormone (numeric) 6.        Yes         No  
    
6a.  Vitamin B-12 
 
6b.  Uric Acid 
6a. 
 
6b. 
     Yes         No 
 
     Yes         No 
 
 
    
7. Heavy Metal Screen (numeric) 7.      Yes         No  
    
   7a. Urine Hg 7a.      Yes         No  
    
   7b. Urine Pb 7b.      Yes         No  
    
   7c.  Serum Pb 7c.      Yes         No  
    
8. SOD1 Genetic Testing (name mutation) 8.      Yes         No  
    
9.  Kennedy’s   9.      Yes         No  
    
10. Survival Motor Neuron 10. Yes         No  
    
11.  Other Genetic Testing 11. Yes         No  
     Specify: _________________________    
12. CSF Analysis (numeric) 12.        Yes         No  
    
 12a. Protein (CSF) 12a.      Yes         No  
    
 12b. Glucose 12b.      Yes         No  
    
 12c. WBC 12c.      Yes         No  
    
 12d. RBC 12d.      Yes         No  
13.  Hexosaminidase A 13.      Yes         No  
    
14.  Lyme Disease (+/-; circle one) 14.      Yes         No Positive     Negative 
    
15.  Paraneoplastic Antibodies 15.      Yes         No     Positive     Negative 
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 16. CT of : 16.      Yes         No  
    
                    16a.  Chest    16a. Yes         No Normal     Cancer     Other 
    
                    16b.  Abdomen 16b. Yes         No Normal     Cancer     Other 
    
                         16c.  Pelvis 16c. Yes         No Normal     Cancer     Other 
    
17.  MRI of: 17. Yes         No  
    
                     17a.  Brain 17a. Yes         No    Normal         Abnormal 
    
                     17b.  Cervical Spine 17b. Yes         No    Normal         Abnormal 
    
                     17c.  Thoracic Spine 17c. Yes         No    Normal         Abnormal 
    
                     17d.  Lumbar Spine 17d. Yes         No    Normal         Abnormal 
18. Other Lab Tests 18.      Yes         No  
(Specify)__________________    
              __________________    
19. Electrophoresis  19.      Yes         No  
    
     19a. IgG 19a.      Yes         No  
    
     19b. IgA 19b.      Yes         No  
    
     19c. IgM 19c.      Yes         No  
    
     19d. Total Protein 19d.      Yes         No  
    
     19e. Albumin 19e.      Yes         No  
    
     19f. Alpha-1-glob 19f.      Yes         No  
    
     19g. Alpha-2-glob 19g.      Yes         No  
    
     19h. Beta glob 19h.      Yes         No  
    
     19i. Gamma glob 19i.      Yes         No  
    
     19j. M-Spike 19j.      Yes         No  
    
     19k. Total glob 19k.      Yes         No  
    
     19l. A/G Ratio 19l.      Yes         No  
    
     19m. IFE Result 19m.      Yes         No Normal       Abnormal 
  If Abnormal, describe: 
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    Date 
    
20. BiPAP 17.      Yes         No  
    
21. Vent 18.     Yes         No  
    
22. PEG 19.     Yes         No  
    
 
Pulmonary Function Tests  ALSFRS 
 Date Type 
FVC, VC 
Value   Date Type 
FRS, FRSR 
Value 
1.   
 
  1.    
2.   
 
  2.    
3.   
 
  3.    
4.   
 
  4.    
5.   
 
  5.    
6.   
 
  6.    
7.   
 
  7.    
8.   
 
  8.    
 
Weights 
 Date Value 
1.  
 
 
2.  
 
 
3.  
 
 
4.  
 
 
5.  
 
 
6.  
 
 
7.  
 
 
8.  
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 OTHER MEDICAL HISTORY 
      1.  Yes    2.  No 
     (Circle Yes or No) 
1.  Myocardial infarction 1.       Yes        No 
2.  Congestive heart failure 2.       Yes        No 
3.  Peripheral vascular disease 3.       Yes        No 
   
4.  Cerebrovascular disease 4.       Yes        No 
5.  Ulcer Disease 5.       Yes        No 
   
6.  Diabetes (mild to Moderate) 6.       Yes        No 
7.  Diabetes (end-organ damage) 7.       Yes        No 
8.  Hemiplegia 8.       Yes        No 
   
9.  Moderate/severe renal disease 9.       Yes        No 
10.  Any tumor 10.       Yes        No 
11.  Metastatic tumor 11.       Yes        No 
   
12.  Leukemia 12.       Yes        No 
13.  Lymphoma 13.       Yes        No 
14.  AIDS 14.       Yes        No 
   
15.  Autoimmune Disease(s) 15.      Yes        No 
       15b. Specify   
       15b. Specify   
16.  Connective tissue disease 16.       Yes        No 
17.  Other 17.       Yes        No 
          17a.  Specify   
          17b.  Specify   
          17c.  Specify   
          17d.  Specify   
          17e.  Specify   
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TRAUMA HISTORY 
 Type of Trauma Date 
1.  
 
 
2.  
 
 
3.  
 
 
4.  
 
 
5.  
 
 
 
 
Surgical History 
 Type of Surgery Date 
1.  
 
 
2.  
 
 
3.  
 
 
4.  
 
 
5.  
 
 
 
 
 
General Notes or Comments: 
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 APPENDIX E: VETERANS ALS REGISTRY QUESTIONNAIRE6 
NATIONAL REGISTRY OF VETERANS WITH AMYOTROPHIC LATERAL SCLEROSIS 
6This appendix appears by permission of Dr. Kelli D. Allen, Epidemiology Research and Information Center, 
Durham VA Medical Center, and Department of Medicine and Thurston Arthritis Research Center, University of 
North Carolina at Chapel Hill; and Dr. Eugene Z. Oddone and Dr. Dawn Provenzale, Epidemiology Research and 
Information Center, Durham VA Medical Center, and Department of Medicine, Duke University Medical Center. 
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 Veterans ALS Registry Questionnaire 
 
Registry ID #____________  [Id] [IdNum] Interviewer Name: ___________ 
[InterviewerInit]   
Date of Interview: _____/_____/_____ [InterviewDt] Time of Interview:  ________ AM   PM  
[InterviewTime]  
Survey Interval:   [SurveyInt]   [StudyPer] 
_____ Baseline  _____ 18-month  _____ 36-month 
_____ 6-month  _____ 24-month   
_____ 12-month _____ 30-month  
 
Hello.  This is (NAME) from the National Registry of Veterans with ALS.  May I speak to (name of 
veteran, or proxy who provided information on the previous interview)?  
I am calling to ask you a few questions about your (the veteran’s) health as part of our regular follow-up 
for the registry.  Is this a good time to talk?  (If no, note a day and time when you should call back: 
_______________) 
 
If participant has died, note death date:   _____/_____/_____ (In Dead file [DeadMon] [DeadDay] 
[DeadYear] [DeathDt]) 
 
Proxy Respondent?  _____Yes _____No [InterviewProxy]   
 
[IntProxyRel]   
 If yes, specify  ____Spouse      _____Child     ____Sibling   ____Parent   ____Partner     _____Friend  
_____ Health Care Provider     _____Other (specify):______________________________________ 
Name of proxy respondent:  __________________________________ [ProxyName] [ProxyNote]   
(If new proxy, get contact information)   [ReferenceToProxyAdd ]   
                                                                  (Address fields are in  
       PrimaryAddress and AllAddresses data set)                                 
                             Address ____________________ [Str1]  
                              ____________________ [Str2]  [Str3]  
  ____________________ [City]  [State]  [Zip]  
Phone   (         )__ ____________ [PhoneH] [PhoneW] [PhoneCell]    
 
A. Only ask if:  Suspected ALS, or an Indeterminate diagnosis.  (All others, skip to ALSFRS) 
We would like to ask you about your current diagnosis, since we know that diagnoses can change 
over time.   
1. What is your (the veteran’s) current diagnosis? (Check all that apply) 
Ο ALS (confirmed by a physician) [CurDxALS]   
Ο Maybe/Possibly ALS (not yet determined/diagnosed) [CurDxPossALS]   
Ο Primary lateral sclerosis [CurDx_PLS]   
Ο Progressive bulbar palsy [CurDxBulbPals]   
Ο Progressive muscular atrophy  [CurDxMuscAtrphy]   
Ο Other   [CurDxOther]  (please specify):    __________________________ [CurDxOthSpec]   
 
2.  Have you seen a neurologist or had any medical tests since the last time we spoke with you 
(insert date here in database if possible)?   Ο YES   Ο NO [SeenNeuro]   
If No, skip to Section B 
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 3. We would like to request copies of these new medical records so we can add them to your 
medical record file with the Registry. What is the name of the neurologist you saw or the 
medical facility where you had tests? (variables in Medical Request Log) 
a.  Neurologist Name (if applicable) :_ [Dr. Seen] ______________________________ 
 
     Medical Facility (if applicable): ___ [MRFacility]  __________________________ 
 
 Is this a neurologist you have seen before or a medical facility you have visited before? 
 Ο YES   Ο NO 
 If Yes, skip to next neurologist/facility (if applicable) or Section B 
 If NO, obtain address of neurologist of facility: (variables in Lookup Facility) 
 __ [FacId] __ [FacName] _ [FacContact] _ [FacPhone1] _ [FacStr1] _  
      __ [FacStr2] _ [FacCity] __ [FacState] _ [FacZip] _ [FacFax] _______ 
___________________________________________________________ 
 
b.  Neurologist Name (if applicable) :___ [Dr. Seen] ____________________________ 
 
     Medical Facility (if applicable): ______[MRFacility]_________________________ 
 
 Is this a neurologist you have seen before or a medical facility you have visited before? 
 Ο YES   Ο NO 
 If Yes, skip to next neurologist/facility (if applicable) or Section B 
 If NO, obtain address of neurologist of facility: 
 __ [FacId] __ [FacName] _ [FacContact] _ [FacPhone1] _ [FacStr1] _  
      __ [FacStr2] _ [FacCity] __ [FacState] _ [FacZip] _ [FacFax] _______ 
___________________________________________________________ 
 
c.  Neurologist Name (if applicable) :____ [Dr. Seen] _________________________ 
 
     Medical Facility (if applicable): ___[MRFacility]__________________________ 
 
 Is this a neurologist you have seen before or a medical facility you have visited before? 
 Ο YES   Ο NO 
 If Yes, skip to Section B 
 If NO, obtain address of neurologist of facility: 
 __ [FacId] __ [FacName] _ [FacContact] _ [FacPhone1] _ [FacStr1] _  
      __ [FacStr2] _ [FacCity] __ [FacState] _ [FacZip] _ [FacFax] _______ 
___________________________________________________________ 
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 B.  ALS Functional Rating Scale (For all participants) 
These following questions ask you about limitations due to your health (the veteran’s  health).  For each 
item, please indicate the category that most describes your current state of health. 
 
1.  Speech  [Speech]    
 ___ (4) Normal speech processes 
 ___ (3) Detectable speech disturbance 
 ___ (2) Intelligible with repeating 
 ___ (1) Speech combined with non-vocal communication 
 ___ (0) Loss of usual speech 
 
2.  Salivation [Salivation]   
 ___ (4) Normal 
 ___ (3) Slight but definite excess of saliva in mouth, may have nighttime drooling 
 ___ (2) Moderately excessive saliva, may have minimal drooling 
 ___ (1) Marked excess of saliva with some drooling 
 ___ (0) Marked drooling, requires constant tissue or handkerchief 
 
3.  Swallowing  [Swallowing]   
 ___ (4) Normal eating habits 
 ___ (3) Early eating problems – occasional choking 
 ___ (2) Dietary consistency changes 
 ___ (1) Needs supplemental tube feeding 
 ___ (0) Nothing taken by mouth (exclusively parenteral or enteral feeding) 
 
4.  Handwriting (with dominant hand) [Handwriting]   
 ___ (4) Normal 
 ___ (3) Slow or sloppy:  all words are legible 
 ___ (2) Not all words are legible 
 ___ (1) Able to grip pen but unable to write 
 ___ (0) Unable to grip pen 
 
Uses a feeding tube:    No- go to Q. 5a  [FeedingTub]   
     Yes- go to Q. 5b  
 
5a.  Cutting food and handling utensils (patients without gastrostomy)  [Utensils]  
 ___ (4) Normal 
 ___ (3) Somewhat slow and clumsy but no help needed 
 ___ (2) Can cut most foods, although clumsy and slow; some help needed 
 ___ (1) Food must be cut by someone, but can still feed slowly 
 ___ (0) Needs to be fed 
 
5b.  Use of feeding tube (for patients with gastrostomy) [FeedingTubeAbility]   
 ___ (4) Normal 
 ___ (3) Clumsy but able to perform all manipulations independently 
 ___ (2) Some help needed with closures and fasteners 
 ___ (1) Provide minimal assistance to caregiver 
 ___ (0) Unable to perform any aspect of task 
 
 
 
255 
 6.  Dressing and hygiene  [DressHygiene]   
 ___ (4) Normal function 
 ___ (3) Independent and complete self-care with effort or decreased efficiency 
 ___ (2) Intermittent assistance or substitute methods 
 ___ (1) Need attendant for self-care 
 ___ (0) Total dependence 
 
7.  Turning in bed and adjusting bed clothes  [Bed]   
 ___ (4) Normal 
 ___ (3) Somewhat slow and clumsy, but no help needed 
 ___ (2) Can turn alone or adjust sheets, but with great difficulty 
 ___ (1) Can initiate, but not turn or adjust sheets alone 
 ___ (0) Unable to do 
 
8.  Walking  [Walking]   
 ___ (4) Normal 
 ___ (3) Early ambulation difficulties (any assistive devices including AFOs) 
 ___ (2) Walk with assistance 
 ___ (1) Non-ambulatory functional movement only 
 ___ (0) No purposeful leg movement 
 
9.  Climbing stairs  [Stairs]   
 ___ (4) Normal 
 ___ (3) Slow 
 ___ (2) Mild unsteadiness or fatigue 
 ___ (1) Need assistance (including handrails) 
 ___ (0) Cannot do 
 
10a.  Dyspnea  [Dyspnea]   
 ___ (4) None 
 ___ (3) Occurs when walking 
 ___ (2) Occurs with one or more of the following:  eating, bathing, dressing (ADL) 
 ___ (1) Occurs at rest, difficulty breathing when either sitting or lying 
 ___ (0) Significant difficulty, considering using mechanical respiratory support 
 
10b. Orthopnea   [Orthopnea]   
 ___ (4) None 
___ (3) Some difficulty sleeping at night due to shortness of breath, does not routinely use    
more than two pillows 
 ___ (2) Needs extra pillows in order to sleep (more than two) 
 ___ (1) Can only sleep sitting up 
 ___ (0) Unable to sleep 
 
10c.  Respiratory insufficiency  [RespInsuff]   
___ (4) None 
___ (3) Intermittent use of BiPAP or CPAP 
 ___ (2) Continuous use of BiPAP or CPAP during the night  
 ___ (1) Continuous use of BiPAP or CPAP during the night and day 
 ___ (0) Invasive mechanical ventilation by intubation or tracheostomy 
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 C.  Questions about health and medical care 
These following questions ask you about your current medical care for ALS.   
 
1. Please name each of the medications (prescription, over the counter, or experimental) that you are 
(the veteran is) currently using.  We are interested in medications you are using to treat ALS 
symptoms, and also medications you are using for other health conditions you may have. 
__ [MedName] [MedNum] ________          _______________________________ 
_______________________________          _______________________________ 
_______________________________          _______________________________ 
_______________________________          _______________________________ 
_______________________________          _______________________________ 
 
2. Please name any dietary products, herbal products, or vitamins you are (the veteran is) currently 
using. 
[OtherProdNum]  [OtherProdTxt]           _______________________________ 
_______________________________          _______________________________ 
_______________________________          _______________________________ 
_______________________________          _______________________________ 
_______________________________          _______________________________ 
_______________________________          _______________________________ 
 
3. Are you (is the veteran) using any of the following to assist with breathing? 
_____ CPAP (Continuous Positive Airway Pressure)  [CPAP] 
 
           Start date of use: (M/D/Y)__________ [CPAPMon] [CPAPDay] [CPAPYear] 
                                               [CPAPNote] 
  
_____ BiPAP (Bi-level Positive Airway Pressure) [BIPAP] 
     
          Start date of use: (M/D/Y)_____________ [BIPAPMon] [BIPAPDay] [BIPAPYear] 
                                                    [BIPAPNote] 
 
_____ Ventilator   [VENTILATOR] 
 
           Start date of use (M/D/Y)______________(at least 2 weeks, 15 hours per day) 
 [VENTILATORMon] [VENTILATORDay] [VENTILATORYear] 
                                           [VENTILATORNote] 
 
_____ Trach [TRACH]  
       
           Start date of use (M/D/Y) _____________ [TRACHMon] [TRACHDay] [TRACHYear] 
                                                     [TRACHNote] 
 
4. Are you (is the veteran) using a feeding tube? [FeedingTub]  Ο YES   Ο  NO            Ο  NA 
[PEGMon] [PEGDay] [PegYear] [PEGNote] 
 
 
 
5. What is your (the veteran’s) current weight (in pounds) _ [Wt] _____________________ 
If don’t know, ask for best estimate.  If no idea, leave blank. 
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 D.  Questions about Previous Trauma  (Ask only at baseline interview) 
 
1. Have you (has the veteran) ever had a major physical trauma?  [MajPhysTrauma ]  
Ο YES   Ο NO 
 
(Specifics in TraumaDetails dataset – Could have multiple per id) 
 If yes, please specify the type of trauma: __ [SpecifyTrauma] ____________________________ 
 _______________________________________________________________________ 
 Did this trauma require hospitalization? [HospitalYN]   Ο YES   Ο NO 
 
2.  Have you (has the veteran) ever had any fractures?  [Fractures] Ο YES   Ο NO 
 
E.  Questions about Smoking (Ask only at baseline interview) 
 1.  Have you (has the veteran) ever smoked cigarettes? [SmkCigarettes]  Ο YES       Ο NO    
    If NO, stop smoking questionnaire here. 
 2.  Have you (has the veteran) ever smoked at least 100 cigarettes (or the equivalent amount of 
tobacco) in your lifetime?  [SmkGE100]  Ο YES   Ο NO  
 3.  Have you (has the veteran) ever smoked daily?  [SmkDaily] Ο YES   Ο NO 
 4.  Do you (does the veteran) now smoke daily, occasionally, or not at all?  [SmkAmtNow] 
    (indicate category)________________________ 
    If daily or occasionally, skip to Q.6 
 5.  If “not at all”, at what age did you stop smoking? ____ [StopSmkAge] _________________  
 6.  For how many years have you smoked/did you smoke? __  [NumSmkYears] (Option to record 
year patient stopped smoking [StopSmkYear] then would calculate NumSmkYears)   ___________ 
 7. On the days that you (did) smoke, what was the average number of cigarettes that you smoked?                
     ____ [AvgNumCig] ________________________________________________________                  
Thank you very much for taking time to answer these questions today.  We greatly appreciate your 
involvement in the National Registry of Veterans with ALS.  We will contact you again in approximately 
six months to ask you this same series of questions.  Should you have any questions before then, please 
contact us at 1-877-342-5257 (1-877-DIAL-ALS). 
 
Ineligible Script (New diagnosis, not ALS or related MND):  
Because you have received a new diagnosis that is not ALS or a related disease, we will not ask you to 
continue with the 6-month follow-up interviews for the Registry.  Thank you very much for your 
participation in the Veterans ALS Registry.  If you have any questions about the Registry in the future, 
please contact us via the toll-free ALS call line (1-877-342-5257).   
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 APPENDIX F: AIM 1 SUPPLEMENTAL MATERIAL  
REFERENCED IN CHAPTER 4 
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 Figure F.1. Directed acyclic graphs for: (a) military service variables and ALS etiology in the GENEVA 
study (100) and (b) military deployment and exposure variables and ALS etiology in the GENEVA study 
(100). Abbreviations: ALS, amyotrophic lateral sclerosis; GENEVA, Genes and Environmental 
Exposures in Veterans with Amyotrophic Lateral Sclerosis. 
 
 
EXPLANATION OF FIGURE F.1. 
The directed acyclic graph (DAG) (177, 178) shown in panel (a) of Figure F.1 corresponds to all 
analyses involving military service variables. The arrows from age, sex, and race/ethnicity to military 
service variables and ALS etiology depict relationships between each covariate and military service 
variables and ALS etiology, respectively. We did not include family history of ALS or other 
neurodegenerative diseases and geographic residence in the DAG because they have not been associated 
with military service, deployment, and/or exposure variables in previous studies. Similarly, we thought 
that the following covariates were potentially affected by and/or more likely to occur temporally after 
military service, deployment, and/or exposure variables, so we did not include them in our DAG: cigarette 
smoking, electrical injury, magnetic fields, lead, occupation, pesticides, physical activity/professional 
sports, solvents, and trauma/head injury. 
260 
 The DAG shown in panel (b) of Figure F.1 corresponds to all analyses involving military 
deployment and exposure variables. The addition of branch of service is the only difference between the 
DAGs shown in panels (a) and (b) of Figure F.1. Branch of service is related to both military deployments 
and exposures and ALS etiology. 
STATISTICAL ANALYSES: INVERSE PROBABILITY WEIGHTS 
We calculated the numerators of the stabilized confounding weights as predicted probabilities of 
exposure from an intercept only model and the denominators of these weights as predicted probabilities of 
exposure from a model including the matching factors (age, use of VA health care system) and the 
covariates in the pertinent MSAS as independent variables. For the denominator models, we centered age 
at 60—the median age among controls—and modeled it with linear and quadratic terms because this form 
gave the lowest value of the Akaike Information Criterion (AIC) (187, 188). We modeled use of VA 
health care system, sex, race/ethnicity, and branch of longest service (for military deployment and 
exposure variables only) as shown in Tables 4.1 and 4.3. 
We calculated stabilized selection weights for ALS cases and controls separately because cases 
were enrolled from the Registry whereas controls were enrolled from the BIRLS database and these two 
sampling frames contained different types and breadths of data (100). Furthermore, the causes of 
participation in the GENEVA study and factors related to it likely differed among cases and controls. For 
example, the main causes of participation among cases were likely vital status and the progression of the 
disease and, therefore, factors related to ALS progression and survival were also likely related to 
participation. For controls, the main causes of participation were likely the matching strategy employed 
by the study design and other causes present in typical epidemioligcal studies (e.g., altruism). Therefore, 
the matching factors and other demographic factors were likely related to participation among controls 
(100, 180). 
For the numerators of the ALS case selection weights, we calculated the predicted probabilities of 
participation from an intercept only model; and, for the denominators of the weights, we calculated the 
predicted probabilities conditional on race/ethnicity, being a current patient of a VA Medical Center, most 
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 recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis, time from diagnosis 
to enrollment in the Registry, and baseline (i.e., at enrollment in the Registry) ALSFRS-R score. We did 
not include the exposures of interest in the numerator or denominator models for the case selection 
weights because data on the exposures of interest were available for only the 630 ALS cases who enrolled 
in the GENEVA study. For the denominator model, we modeled race/ethnicity the same way as for the 
confounding weights and being a current patient of a VA Medical Center, most recent ALS diagnosis, and 
site of symptom onset as shown in Table 4.2 and Appendix F, Table F.1. We modeled time from 
symptom onset to diagnosis with linear, quadratic, and cubic terms; time from diagnosis to enrollment in 
the Registry with a linear term; and baseline ALSFRS-R score with a restricted, quadratic spline with 
knots at 12, 34, and 44 based on percentiles of the distribution in the GENEVA study cases (we used SAS 
code from (188) to create the splines) because these forms gave the lowest values of the AIC (187, 188). 
For controls, we calculated the numerators of the stabilized selection weights as predicted 
probabilities of participation from an intercept only model and the denominators of these weights as 
predicted probabilities of participation from a model including year of birth, use of VA health care 
system, and their interaction as independent variable. We did not include the exposures of interest in the 
numerator or denominator models for the control selection weights because data on the exposures of 
interest were available only for the 975 controls who enrolled in the GENEVA study. For the 
denominator model, we modeled use of VA health care system the same way as for the confounding 
weights and year of birth with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on 
percentiles of the distribution in the BIRLS potential controls (we used SAS code from (188) to create the 
splines) because this form gave the lowest value of the AIC (187, 188). 
Eight percent of ALS cases enrolled in the Registry were missing data in baseline (i.e., at 
enrollment in the Registry) ALSFRS-R scores, which was included as a covariate in the denominator 
models of the ALS case stabilized selection weights. Therefore, for cases only, we also calculated 
stabilized missing covariate data weights to account for this potential bias. For the numerators of these 
weights, we calculated the predicted probabilities of not missing data in baseline ALSFRS-R score from 
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 an intercept only model; and, for the denominators of the weights, we calculated the predicted 
probabilities conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis, and time from diagnosis to enrollment in the Registry. We did not include the exposures of 
interest in the numerator or denominator models for the missing covariate data weights because data on 
the exposures of interest were available for only the 630 ALS cases who enrolled in the GENEVA study. 
For the denominator model, we modeled most recent ALS diagnosis and site of symptom onset as shown 
in Table 4.2. We modeled time from symptom onset to diagnosis with the natural logarithm of a linear 
term and time from diagnosis to enrollment in the Registry with a restricted, quadratic spline with knots at 
7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not 
missing covariate data (we used SAS code from (188) to create the splines) because these forms gave the 
lowest values of the AIC (187, 188). 
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 Table F.1. Demographic, clinical, and military characteristics of ALS cases in GENEVA and the Registry. All information shown in this table 
came from medical records or the Registry screening or semi-annual telephone follow-up interviews. 
  GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Total 630 100 1,856 100     Year of birth         ≤ 1920 5 1 35 2 0.40 0.17, 0.90 NA NA 
1921-1930 93 15 305 16 0.85 0.69, 1.03 NA NA 
1931-1940 194 31 573 31 0.94 0.80, 1.10 NA NA 
1941-1950 227 36 630 34 1.00 Referent 1.00 Referent 
1951-1960 74 12 214 12 0.96 0.78, 1.19 NA NA 
1961-1970 32 5 87 5 1.02 0.76, 1.37 NA NA 
> 1970 5 1 11 1 1.26 0.65, 2.43 NA NA 
Missing 0  1      Median ± IQR 1942 ± 14 yr.  1941 ± 16 yr.      Sex         Male 617 98 1,820 98 1.00 Referent 1.00 Referent 
Female 13 2 35 2 1.10 0.71, 1.69 1.12 0.73, 1.73 
Missing 0  1      Race/Ethnicity         Non-Hispanic White 581 92 1,674 90 1.00 Referent 1.00 Referent 
Other 48 8 179 10 0.77 0.60, 0.99 0.75 0.58, 0.96 
Missing 1  3      Cigarette smoking statusb         Never 217 35 552 33 1.00 Referent 1.00 Referent 
Past 339 54 942 56 0.92 0.80, 1.05 0.89 0.78, 1.02 
Current 70 11 195 12 0.91 0.74, 1.13 0.88 0.71, 1.09 
Missing 4  167      Being a current patient at a VA Medical Center         No 295 47 786 42 1.00 Referent 1.00 Referent 
Yes 335 53 1,068 58 0.84 0.74, 0.95 0.85 0.75, 0.96 
Missing 0  2      Most recent ALS diagnosisc         Clinically definite 99 16 333 18 0.89 0.73, 1.08 0.87 0.71, 1.05 
Clinically probable 244 39 728 39 1.00 Referent 1.00 Referent 
Clinically probable and lab supported 113 18 277 15 1.22 1.02, 1.45 1.22 1.02, 1.45 
Clinically possible 54 9 162 9 0.99 0.78, 1.27 1.02 0.80, 1.30 
Suspected (progressive bulbar palsy or progressive muscular atrophy) 118 19 336 18 1.05 0.88, 1.25 1.08 0.91, 1.29 
Other < 5 < 1 20 1 0.30 0.08, 1.12 0.29 0.08, 1.09 
Missing 0  0      
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   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Family history of ALS         No 490 96 1,435 95 1.00 Referent 1.00 Referent 
Yes 22 4 78 5 0.83 0.58, 1.19 0.81 0.56, 1.16 
Missing 118  343      Site of symptom onset         Bulbar 89 14 407 22 0.59 0.49, 0.72 0.59 0.49, 0.72 
Extremities 509 81 1374 74 1.00 Referent 1.00 Referent 
Otherc 31 5 71 4 1.18 0.90, 1.55 1.16 0.88, 1.52 
Missing 1  4      Time from symptom onset to diagnosis (months)         ≤ 6 118 19 410 23 0.95 0.78, 1.16 0.95 0.78, 1.16 
> 6-12 168 27 556 31 1.00 Referent 1.00 Referent 
> 12-18 105 17 301 17 1.15 0.95, 1.41 1.20 0.99, 1.47 
> 18-24 47 8 157 9 0.99 0.76, 1.30 1.05 0.80, 1.37 
> 24 173 28 378 21 1.51 1.28, 1.79 1.59 1.35, 1.88 
Missing 19  54      Median ± IQR 13 ± 18  11 ± 14      Time from diagnosis to enrollment in the Registry (months)         ≤ 12 220 35 664 36 1.00 Referent 1.00 Referent 
> 12-24 144 23 476 26 0.91 0.77, 1.09 0.92 0.77, 1.09 
> 24-36 75 12 241 13 0.94 0.76, 1.17 0.98 0.79, 1.22 
> 36-48 44 7 109 6 1.22 0.95, 1.57 1.21 0.94, 1.56 
> 48 140 22 343 19 1.23 1.04, 1.46 1.24 1.05, 1.46 
Missing 7  23      Median ± IQR 18 ± 32  18 ± 27      Baselined ALSFRS-R score (possible range: 0-48)e         ≤ 16 58 9 309 18 0.66 0.49, 0.87 0.64 0.48, 0.85 
> 16-23 67 11 284 17 0.82 0.63, 1.07 0.82 0.63, 1.06 
> 23-30 104 17 363 21 1.00 Referent 1.00 Referent 
> 30-35 135 21 292 17 1.61 1.32, 1.98 1.59 1.30, 1.95 
> 35 265 42 454 27 2.04 1.70, 2.44 1.99 1.66, 2.38 
Missing 1  154      Median ± IQR 34 ± 12  29 ± 16      Currently using riluzole (baselined)         No 277 47 763 48 1.00 Referent 1.00 Referent 
Yes 315 53 843 52 1.03 0.91, 1.17 1.02 0.89, 1.15 
Missing 38  250      
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   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Currently using BiPAP to assist with breathing (baselined)         No 531 86 1,336 79 1.00 Referent 1.00 Referent 
Yes 89 14 351 21 0.64 0.53, 0.77 0.63 0.52, 0.76 
Missing 10  169      Currently using CPAP to assist with breathing (baselined)         No 603 97 1,620 96 1.00 Referent 1.00 Referent 
Yes 17 3 59 4 0.77 0.52, 1.16 0.76 0.51, 1.14 
Missing 10  177      Currently using a ventilator (≥ two weeks, 15 hours/day) to assist with breathing 
(baselined)         
No 595 95 1,568 93 1.00 Referent 1.00 Referent 
Yes 30 5 123 7 0.64 0.47, 0.88 0.63 0.46, 0.87 
Missing 5  165      Currently using tracheostomy to assist with breathing (baselined)         No 555 95 1,389 92 1.00 Referent 1.00 Referent 
Yes 32 5 120 8 0.67 0.49, 0.90 0.67 0.49, 0.91 
Missing 43  347      Currently using a feeding tube (baselined)         No 469 88 1,162 78 1.00 Referent 1.00 Referent 
Yes 64 12 321 22 0.49 0.39, 0.62 0.49 0.39, 0.61 
Missing 97  373      Military branch of longest service         Air Force (including Army Air Force) 126 20 350 19 1.06 0.90, 1.26 1.05 0.89, 1.25 
Army 260 42 768 43 1.00 Referent 1.00 Referent 
Marines (including Merchant Marines) 54 9 155 9 1.03 0.81, 1.30 1.04 0.82, 1.31 
Navy 133 21 404 22 0.97 0.82, 1.15 0.98 0.83, 1.17 
Otherf 47 8 125 7 1.11 0.87, 1.42 1.09 0.86, 1.40 
Missing 10  54      Number of military branches of service         1 564 90 1,672 90 1.00 Referent 1.00 Referent 
2 63 10 163 9 1.15 0.93, 1.41 1.12 0.91, 1.37 
> 2 < 5 < 1 18 1 0.49 0.18, 1.39 0.52 0.18, 1.45 
Missing 0  3      Type duty (Active/Reserve) of longest service         Active 541 88 1,586 88 1.00 Referent 1.00 Referent 
Active Reserves 33 5 84 5 1.15 0.88, 1.52 1.11 0.84, 1.46 
Ready/Inactive Reserves or Reserves (unknown) 44 7 124 7 1.04 0.81, 1.33 1.02 0.80, 1.31 
Missing 12  62      
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   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Number of duty types during service         1 501 80 1,502 81 1.00 Referent 1.00 Referent 
2 117 19 325 18 1.08 0.92, 1.27 1.04 0.89, 1.23 
3 9 1 17 1 1.59 1.01, 2.50 1.55 0.99, 2.43 
Missing 3  12      Number of periods of military service         1 484 77 1,441 78 1.00 Referent 1.00 Referent 
2 124 20 344 19 1.07 0.92, 1.26 1.04 0.89, 1.22 
3 19 3 53 3 1.07 0.74, 1.54 1.10 0.76, 1.58 
> 3 < 5 < 1 16 1 0.56 0.20, 1.55 0.54 0.19, 1.50 
Missing 0  2      Years of military service         ≤ 1 18 3 58 3 0.92 0.62, 1.36 0.95 0.64, 1.41 
> 1-5 368 59 1,088 60 1.00 Referent 1.00 Referent 
> 5-10 97 16 308 17 0.93 0.77, 1.12 0.89 0.74, 1.07 
> 10-15 22 4 65 4 1.00 0.71, 1.42 0.96 0.67, 1.36 
> 15 115 19 283 16 1.20 1.02, 1.41 1.18 1.00, 1.39 
Missing 10  54      Median ± IQR 4.00 ± 6.67  4.00 ± 5.33      End of most recent period of military service (year)g         ≤ 1949 46 7 173 10 0.78 0.60, 1.03 1.19 0.75, 1.89 
1950-1954 52 8 159 9 0.96 0.75, 1.24 1.08 0.78, 1.50 
1955-1960 79 13 248 14 0.94 0.76, 1.16 0.95 0.72, 1.23 
1961-1964 64 10 166 9 1.14 0.91, 1.42 1.08 0.84, 1.39 
1965-1974 193 31 569 32 1.00 Referent 1.00 Referent 
1975-1980 47 8 137 8 1.01 0.78, 1.31 1.05 0.81, 1.36 
1981-1990 59 10 173 10 1.01 0.79, 1.27 1.06 0.83, 1.35 
1991-2001 62 10 136 8 1.34 1.08, 1.67 1.44 1.12, 1.84 
> 2001 16 3 38 2 1.24 0.84, 1.83 1.37 0.89, 2.11 
Missing 12  57      Median ± IQR 1968 ± 21 yr.  1968 ± 19 yr.      While in the military, served outside continental U.S.         No 134 21 378 20 1.00 Referent 1.00 Referent 
Yes 496 79 1,473 80 0.95 0.81, 1.11 0.95 0.82, 1.11 
Missing 0  5      
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   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Number of years served outside continental U.S.         0 135 23 384 22 1.00 Referent 1.00 Referent 
≤ 1 129 22 407 23 0.90 0.74, 1.10 0.89 0.73, 1.09 
> 1-2 181 30 518 30 0.99 0.83, 1.19 1.00 0.83, 1.19 
> 2-3 44 7 162 9 0.77 0.58, 1.03 0.78 0.58, 1.03 
> 3-5 49 8 126 7 1.11 0.85, 1.43 1.10 0.85, 1.43 
> 5 61 10 157 9 1.11 0.87, 1.40 1.10 0.86, 1.39 
Missing 31  102      Served in Afghanistan         No 490 100 1,454 100 1.00 Referent 1.00 Referent 
Yes < 5 < 1 6 < 1 0.99 0.32, 3.07 1.05 0.34, 3.21 
Missing 138  396      Served in Europe         No 281 57 850 58 1.00 Referent 1.00 Referent 
Yes 213 43 615 42 1.05 0.91, 1.21 1.03 0.89, 1.19 
Missing 136  391      Served in Korea         No 393 80 1,185 81 1.00 Referent 1.00 Referent 
Yes 100 20 279 19 1.08 0.91, 1.29 1.08 0.90, 1.30 
Missing 137  392      Served in North Africa         No 464 95 1,378 94 1.00 Referent 1.00 Referent 
Yes 27 5 82 6 0.98 0.71, 1.34 1.00 0.73, 1.37 
Missing 139  396      Served in Pacific Islands         No 334 68 1,039 71 1.00 Referent 1.00 Referent 
Yes 158 32 424 29 1.16 1.00, 1.35 1.21 1.04, 1.40 
Missing 138  393      Served in Persian Gulf         No 388 90 1,179 91 1.00 Referent 1.00 Referent 
Yes 42 10 118 10 1.08 0.84, 1.40 0.98 0.73, 1.31 
Missing 200  559      
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   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Served in Vietnam         No 358 72 1,059 72 1.00 Referent 1.00 Referent 
Yes 137 28 410 28 0.99 0.84, 1.16 0.93 0.78, 1.12 
Missing 135   387           
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BiPAP, Bi-level Positive Airway Pressure; CI, confidence interval; CPAP, 
Continuous Positive Airway Pressure; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; IQR, interquartile range; NA, not 
applicable; Registry, National Registry of Veterans with Amyotrophic Lateral Sclerosis; RR, risk ratio; U.S., United States; VA, Department of Veterans Affairs. 
aAdjusted for year of birth (modeled with a restricted, quadratic spline with three unequally spaced knots at 1925, 1942, and 1962 based on the 5th, 50th, and 95th percentiles of 
the distribution in all GENEVA cases). 
bCigarette smoking was defined as having ever smoked at least 100 cigarettes (or the equivalent amount of tobacco) in cases’ lifetimes. 
cIncludes “all over” (GENEVA: n = 4, Registry: n = 11), “cramps/fasciculations” (GENEVA: n = 26; Registry: n = 57), “dementia” (GENEVA: n = 0; Registry: n = 2), and “loss of 
appetite” (GENEVA: n = 1; Registry: n = 1). 
dThe most recent diagnosis, ALSFRS-R score, or use status of riluzole, BiPAP, CPAP, ventilator, tracheostomy, or feeding tube that was measured closest to the time of 
enrollment in the Registry. 
eCategory boundaries were set at quintiles of the ALSFRS-R score among all cases. 
fIncludes Coast Guard (GENEVA: n = 7; Registry: n = 21), Air Force Reserves (GENEVA: n = 5; Registry: n = 8), Army Reserves (GENEVA: n = 9; Registry: n = 33), Marines 
Reserves (GENEVA: n = 2; Registry: n = 4), Navy Reserves (GENEVA: n = 8; Registry: n = 17), Air National Guard (GENEVA: n = 3; Registry: n = 8), Army National Guard 
(GENEVA: n = 0; Registry: n = 0), Air Force Guard (GENEVA: n = 1; Registry: n = 2), Army Guard (GENEVA: n = 11; Registry: n = 31), and Other (GENEVA: n = 1; Registry: n = 
1). 
gCategory boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and May 1975) and followed (98, 100). 
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 Table F.2. Demographic and military characteristics of controls in GENEVA and potential controls in the BIRLS age-stratified sample. All 
information shown in this table came from the BIRLS database. 
 GENEVA Controls VBA Potential Controls Crude Adjusted
a 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Total 975 100 10,009 100     Year of birth         ≤ 1920 < 5 < 1 527 5 0.02 0.01, 0.09 0.02 0.01, 0.09 
1921-1930 39 4 1,473 15 0.16 0.11, 0.22 0.16 0.11, 0.22 
1931-1940 246 25 2,000 20 0.73 0.63, 0.85 0.73 0.63, 0.85 
1941-1950 338 35 2,003 20 1.00 Referent 1.00 Referent 
1951-1960 227 23 2,002 20 0.67 0.57, 0.79 0.66 0.57, 0.78 
1961-1970 83 9 1,174 12 0.42 0.33, 0.53 0.41 0.33, 0.52 
> 1970 40 4 829 8 0.29 0.21, 0.39 0.26 0.19, 0.36 
Missing 0  1      Median ± IQR 1947 ± 16 yr.  1947 ± 26 yr.      Sex         Male 616 93 6,449 94 1.00 Referent 1.00 Referent 
Female 43 7 439 6 1.03 0.76, 1.38 1.24 0.92, 1.67 
Missing 316  3,121      Use of VA health care system         No 664 69 6,795 68 1.00 Referent 1.00 Referent 
Yes 305 31 3,205 32 0.97 0.86, 1.11 0.91 0.80, 1.04 
Missing 6  9      Military branch of most recent active duty service         Air Force (including Army Air Force) 196 24 1,568 20 1.33 1.13, 1.57 1.21 1.03, 1.43 
Army 347 43 3,701 47 1.00 Referent 1.00 Referent 
Marines (including Merchant Marines) 71 9 816 10 0.93 0.73, 1.18 0.96 0.76, 1.22 
Navy 180 22 1,644 21 1.17 0.98, 1.38 1.11 0.94, 1.32 
Otherb 13 2 114 1 1.22 0.72, 2.05 1.24 0.75, 2.06 
Missing 168  2,166      
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  GENEVA Controls VBA Potential Controls Crude Adjusted
a 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Most recent release of active duty date (year)c         ≤ 1949 < 5 < 1 788 10 0.03 0.01, 0.08 0.22 0.06, 0.81 
1950-1954 11 1 340 4 0.22 0.12, 0.40 0.44 0.23, 0.85 
1955-1960 55 6 598 7 0.63 0.48, 0.83 0.68 0.50, 0.92 
1961-1964 52 6 374 5 0.95 0.72, 1.25 0.81 0.61, 1.08 
1965-1974 295 35 2,019 25 1.00 Referent 1.00 Referent 
1975-1980 150 18 1,249 16 0.82 0.68, 0.99 1.10 0.91, 1.33 
1981-1990 163 19 1,399 17 0.80 0.67, 0.95 1.37 1.13, 1.65 
1991-2001 94 11 1,031 13 0.62 0.50, 0.78 1.48 1.16, 1.89 
> 2001 27 3 245 3 0.75 0.52, 1.09 2.22 1.50, 3.28 
Missing 125  1,966      Median ± IQR 1975 ± 15 yr.  1974 ± 21 yr.      Abbreviations: BIRLS, Beneficiary Identification and Records Locator System; CI, confidence interval; GENEVA, Genes and Environmental Exposures in Veterans with 
Amyotrophic Lateral Sclerosis; IQR, interquartile range; RR, risk ratio; VA, Department of Veterans Affairs. 
aAdjusted for year of birth (modeled with a restricted, quadratic spline with three unequally spaced knots at 1920, 1947, and 1974 based on the 5th, 50th, and 95th percentiles of 
the distribution in all the BIRLS potential controls) and use of the VA health care system. 
bIncludes Coast Guard (GENEVA: n = 9; VBA: n = 97), Air National Guard (GENEVA: n = 1; VBA: n = 1), Army National Guard (GENEVA: n = 1; VBA: n = 3), Public Health 
Service (GENEVA: n = 2; VBA: n = 7), and Other (GENEVA: n = 0; VBA: n = 6). 
cCategory boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and May 1975) and followed (98, 100). 
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 Table F.3. Summary statistics for the truncated (at the 0.5th and 99.5th percentiles) overall stabilized 
inverse probability weightsa for models in Table 4.3. 
      Percentiles 
Variable Mean Standard Deviation 0.5 5 50 95 99.5 
Military branch of longest service 0.96 0.77 0.36 0.4
 
0.7
 
2.26 6.72 
Number of military branches of service        Categorical 0.96 0.77 0.39 0.4
 
0.7
 
2.14 7.16 
Trendb 0.96 0.77 0.41 0.4
 
0.7
 
2.14 7.23 
Officer or Warrant Officer 0.97 0.79 0.29 0.4
 
0.7
 
2.22 6.70 
Years of military service        Categorical 0.97 0.87 0.24 0.4
 
0.7
 
2.43 7.50 
Trendb 0.97 0.78 0.37 0.4
 
0.7
 
2.16 7.24 
End of most recent period of military service 
(month/year)        
Categorical 0.98 2.86 0.06 0.2
 
0.5
 
2.14 34.11 
Trendb 0.93 1.91 0.11 0.2
 
0.5
 
2.37 22.18 
Abbreviations: ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating Scale-Revised; BIRLS, Beneficiary 
Identification and Records Locator System; GENEVA = Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis; VA = Department of Veterans Affairs. 
aWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic 
terms), use of the VA health care system, sex, race/ethnicity, not missing covariate data (for cases: conditional on most recent 
ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a 
linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots 
at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate 
data]), and participating in GENEVA (for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, 
most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]; for controls: conditional on year of birth [modeled with a restricted, quadratic spline with knots at 1920, 1947, 
and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care system, and their 
interaction). 
bUsed within-category medians that were calculated using all controls.  
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 Table F.4. Summary statistics for the truncated (at the 0.5th and 99.5th percentiles) overall stabilized inverse probability weightsa for models in 
Table 4.4. 
      Percentiles 
Variable Mean Standard Deviation 0.5 5 50 95 99.5 
Deployments        Ever deployed to any war/operationb 0.96 0.82 0.33 0.42 0.71 2.30 7.09 
War/operation of longest deploymentb 0.89 1.24 0.05 0.24 0.66 2.11 14.23 
Ever deployed to any other country 0.95 0.73 0.37 0.46 0.72 2.17 6.27 
Total time (years) of all periods of deployment to any war/operationb        Categorical 0.97 0.96 0.28 0.39 0.70 2.19 9.97 
Trendc 0.95 0.76 0.30 0.47 0.71 2.16 6.59 
End of most recent period of deployment to any war/operation (month/year)b        Categorical 0.89 1.23 0.06 0.20 0.64 2.06 13.96 
Trendc, d 1.03 3.25 0.07 0.14 0.42 2.47 34.40 
Danger pay, hardship duty or combat zone tax exclusion benefits for deployment        Ever received imminent danger pay, hardship duty or combat zone tax exclusion benefits for deployment 0.94 0.74 0.34 0.40 0.73 2.16 6.02 
Total time (years) of all periods of deployment to any countries or sea region(s) ever received imminent danger pay, 
 hardship duty or combat zone tax exclusion benefits for deployment        
Categorical 0.95 0.77 0.27 0.36 0.73 2.17 6.80 
Trendc 0.95 0.76 0.34 0.45 0.72 2.11 7.10 
Abbreviations: ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; GENEVA 
= Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf = 1990-1991 Persian Gulf; VA = Department of Veterans Affairs; WWII = World War 
II. 
aWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA  
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). 
bThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also asked "Ever 
deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, 
Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
cUsed within-category medians that were calculated using all controls. 
dReference category excluded for linear trend test.  
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 Table F.5. Summary statistics for the truncated (at the 0.5th and 99.5th percentiles) overall stabilized inverse probability weightsa for models in 
Table 4.5. 
      Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
Ever received the anthrax vaccine prior to reference date 0.96 0.94 0.24 0.46 0.67 2.25 8.79 
Ever received the smallpox vaccine 0.96 0.85 0.36 0.48 0.70 2.15 8.01 
Prior to reference date, ever involved in testing, transporting or spraying herbicides for military purposes 0.96 0.82 0.27 0.48 0.71 2.05 7.94 
Prior to reference date, ever been treated with nasopharyngeal (NP) radium during military service 0.96 0.81 0.38 0.49 0.71 2.08 7.91 
Ever taken pyridostigmine bromide, or little white pills in foil packs, sometimes called NAPPs, which are used to 
protect against nerve agents 0.96 0.82 0.22 0.48 0.70 2.12 7.66 
Prior to reference date, ever visited or resided in the island of Guam, the islands of New Guinea, or the Kii Peninsula 
of Japan (including any time spent there in the military) 0.95 0.85 0.28 0.38 0.70 2.20 8.51 
While you were in WWII, the Korean War, the Vietnam War, and/or the Gulf Warb: did you have direct contact 
with/were you exposed to        
Manufacture, testing, or use of chemical protective gear (for mustard gas, tear gas, etc.) Do not include training 0.98 1.51 0.10 0.46 0.65 2.21 17.54 
Ionizing radiation from nuclear weapon testing or occupation of Hiroshima/Nagasaki 1.01 1.58 0.15 0.48 0.64 2.26 18.25 
Use of personal pesticides, like creams, sprays or flea collars 0.99 1.37 0.33 0.39 0.67 2.22 14.45 
Use of pesticides on your clothing or bedding 0.99 1.47 0.33 0.39 0.65 2.27 15.39 
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters) 0.99 1.49 0.41 0.46 0.66 2.11 17.29 
Exposure to diesel and/or other petrochemical fumes 0.96 1.36 0.30 0.42 0.62 2.13 15.73 
Burning trash or burning feces/manure 0.98 1.43 0.27 0.32 0.62 2.46 13.27 
Exposure to paint, solvents, or petrochemical substances 0.99 1.43 0.23 0.32 0.62 2.47 14.44 
High-intensity radar waves (e.g., as radar operator, radio operator, aviation electrician's mate) 0.96 1.15 0.26 0.44 0.64 2.36 12.13 
Food contaminated with smoke, oil, or other chemicals 0.99 1.52 0.25 0.44 0.66 2.03 16.92 
Local food other than food provided by the Armed Forces 1.02 1.76 0.30 0.40 0.65 2.46 21.05 
Bathing in or drinking of water contaminated with smoke, oil, dead animals or any chemicals 1.03 1.79 0.22 0.38 0.67 2.12 18.40 
Heat cramps, heat exhaustion, heat stroke or other heat illness 0.99 1.44 0.30 0.37 0.66 2.16 14.62 
Heard chemical alarms sounding 0.98 1.48 0.12 0.45 0.64 2.05 17.18 
Explosion in the air or on the ground within one mile of you (e.g., artillery, rockets, mortars) 0.94 1.01 0.25 0.41 0.65 2.46 9.98 
Have you suffered a combat-related injury that required medical attention during your deployment? 1.02 1.57 0.22 0.32 0.66 2.36 16.63 
While you were in WWII, the Korean War, and/or the Vietnam Warb: did you have direct contact with/were you 
exposed to        
Mixing and application of herbicides 1.01 1.65 0.39 0.49 0.64 2.20 18.56 
Exposure to herbicides in the field 1.05 1.71 0.20 0.44 0.66 2.57 17.44 
Mixing and application of riot control substances 1.01 1.62 0.10 0.49 0.65 2.32 18.31 
Exposure to riot control substances in the field 1.00 1.61 0.15 0.44 0.65 2.28 18.01 
Mixing and application of burning agents 1.00 1.60 0.28 0.47 0.64 2.40 17.88 
Exposure to burning agents in the field 1.01 1.74 0.23 0.37 0.65 2.33 18.18 
 
274 
       Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
While you were in the Korean War, the Vietnam War, and/or the Gulf Warb: did you have direct contact 
with/were you exposed to        
Microwave radiation 0.83 0.55 0.34 0.48 0.64 1.92 4.10 
While you were in the Vietnam Warb, c: did you have direct contact with/were you exposed to        Mixing and application of Agent Orange 0.95 0.48 0.32 0.49 0.87 1.58 4.62 
Exposure to Agent Orange in the field 0.96 0.73 0.28 0.38 0.79 2.15 6.87 
While you were in the Gulf Warb: did you have direct contact with/were you exposed to        Use of depleted uranium (DU) for munitions or armor 1.00 0.52 0.37 0.44 0.77 2.06 2.44 
CARC (Chemical Agent Resistant Compound) paint 0.97 0.61 0.35 0.36 0.79 2.62 2.92 
Scud missile explosion in the air or on the ground within one mile of you 0.97 0.99 0.28 0.35 0.55 2.89 5.47 
Smoke from oil well fires 0.91 0.80 0.23 0.35 0.60 2.38 4.03 
Exposure to nerve gas (e.g., during munitions destruction) 0.92 0.54 0.37 0.38 0.71 2.18 2.28 
High levels of dust/sand 0.95 0.57 0.16 0.32 0.75 1.90 2.91 
Ground level fumigation 0.86 0.46 0.20 0.31 0.81 1.99 2.27 
In any conflicts deployed to, any other exposure or experience not asked about which you consider harmful or 
extremely stressful 0.98 1.23 0.36 0.43 0.68 2.18 13.15 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CARC, 
Chemical Agent Resistant Compound; DU, depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 
Persian Gulf; NP, nasopharyngeal; VA, Department of Veterans Affairs; WWII, World War II. 
aWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 
bThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also asked "Ever 
deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, 
Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
cRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of the Vietnam War, or 1964-1975) because doing so 
drastically improved the behavior of the IP weights used for analysis. This restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls.
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 Table F.6. Summary statistics for the truncated (at the 0.5th and 99.5th percentiles) overall stabilized 
inverse probability weightsa for models in Appendix F, Table F.12. 
      Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
Number of anthrax vaccine shots received prior to reference date        Categorical 0.94 0.85 0.15 0.46 0.67 2.09 7.47 
Trendb 0.99 1.13 0.06 0.46 0.66 2.42 10.42 
Prior to reference date, number of years involved in testing, 
transporting or spraying herbicides for military purposes        
Categorical 0.96 0.87 0.20 0.48 0.71 2.03 9.11 
Trendb 0.96 0.81 0.26 0.48 0.71 2.04 7.81 
Year in which pyridostigmine bromide pills taken        Categorical 0.95 0.80 0.17 0.48 0.70 2.12 7.67 
Trendb, c 1.18 1.18 0.37 0.39 0.78 5.08 5.63 
Total days taken pyridostigmine bromide pills        Categorical 0.95 0.80 0.23 0.48 0.71 2.09 7.71 
Trendb 0.96 0.81 0.17 0.49 0.71 2.15 7.75 
Number of pills taken in an average day on days pyridostigmine 
bromide pills taken        
Categorical 0.95 0.82 0.20 0.49 0.71 2.07 7.74 
Trendb 0.96 0.80 0.36 0.49 0.71 2.14 7.78 
Total number of pyridostigmine bromide pills taken 
       Categorical 0.95 0.81 0.17 0.49 0.71 2.11 7.73 
Trendb, d 0.96 0.81 0.35 0.49 0.71 2.16 7.77 
Prior to reference date, number of times visited or resided in the 
island of Guam, the islands of New Guinea, or the Kii Peninsula of 
Japan        
Categorical 0.94 0.79 0.20 0.36 0.70 2.18 6.99 
Trendb 0.95 0.83 0.30 0.45 0.70 2.13 8.50 
Prior to reference date, total amount of time (months) spent in the 
island of Guam, the islands of New Guinea, or the Kii Peninsula of 
Japan, excluding time periods between age at first and last visits 
when you didn’t visit or reside in the island of Guam, the islands of 
New Guinea, or the Kii Peninsula of Japan 
       
Categorical 0.95 0.94 0.19 0.37 0.70 2.11 10.43 
Trendb, d 0.95 0.74 0.25 0.48 0.70 2.08 6.70 
While you were in WWII, the Korean War, the Vietnam War, 
and/or the Gulf Ware:        
Total number of preventive vaccinations received by injection 
 (shots) or by mouth while inside or outside the U.S.        
Categorical 0.99 1.48 0.22 0.30 0.64 2.43 14.56 
Trendb, d 1.02 1.74 0.26 0.38 0.66 2.29 18.65 
While you were in WWII, the Korean War, the Vietnam War, 
and/or the Gulf Ware: number of days exposed to        
Manufacture, testing, or use of chemical protective gear (for 
 mustard gas, tear gas, etc.) Do not include training        
Categorical 1.01 1.55 0.43 0.48 0.65 2.41 17.95 
Trendf 1.00 1.55 0.04 0.47 0.64 2.36 17.97 
Ionizing radiation from nuclear weapon testing or occupation of 
 Hiroshima/Nagasaki        
Categorical 1.00 1.58 0.12 0.48 0.64 2.24 18.25 
Trendf 1.01 1.59 0.03 0.49 0.64 2.27 18.28 
Use of personal pesticides, like creams, sprays or flea collars        Categorical 1.00 1.53 0.22 0.34 0.66 2.24 16.06 
Trendf 1.00 1.47 0.30 0.37 0.68 2.25 15.46 
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       Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
Use of pesticides on your clothing or bedding        Categorical 1.00 1.52 0.26 0.38 0.64 2.28 15.23 
Trendf 0.99 1.48 0.34 0.40 0.65 2.15 16.08 
Exhaust from heaters or generators (e.g., kerosene heaters, tent 
 heaters)        
Categorical 0.98 1.49 0.22 0.43 0.65 2.07 17.17 
Trendf 1.00 1.54 0.37 0.46 0.67 2.14 17.90 
Exposure to diesel and/or other petrochemical fumes        Categorical 0.97 1.43 0.23 0.37 0.65 2.40 15.97 
Trendf 0.96 1.43 0.30 0.42 0.64 2.19 16.56 
Burning trash or burning feces/manure        Categorical 0.97 1.46 0.18 0.28 0.59 2.63 13.37 
Trendf 0.98 1.44 0.24 0.31 0.66 2.51 14.92 
Exposure to paint, solvents, or petrochemical substances        Categorical 0.97 1.37 0.21 0.28 0.63 2.35 14.56 
Trendf 0.99 1.37 0.17 0.33 0.65 2.50 15.03 
High-intensity radar waves (e.g., as radar operator, radio operator, 
 aviation electrician's mate)        
Categorical 0.96 1.15 0.20 0.40 0.64 2.38 11.87 
Trendf 0.96 1.17 0.20 0.45 0.65 2.34 12.16 
Food contaminated with smoke, oil, or other chemicals        Categorical 1.00 1.53 0.24 0.44 0.66 2.20 16.95 
Trendf 1.01 1.60 0.18 0.47 0.66 2.15 17.77 
Local food other than food provided by the Armed Forces        Categorical 1.00 1.70 0.28 0.37 0.64 2.20 19.92 
Trendf 1.01 1.77 0.31 0.40 0.64 2.30 21.04 
Bathing in or drinking of water contaminated with smoke, oil, dead 
 animals or any chemicals        
Categorical 1.00 1.53 0.14 0.33 0.66 2.33 16.82 
Trendf 1.00 1.56 0.16 0.43 0.67 2.09 17.32 
Heat cramps, heat exhaustion, heat stroke or other heat illness        Categorical 0.98 1.40 0.22 0.35 0.67 2.16 14.59 
Trendf 0.99 1.49 0.23 0.43 0.66 2.16 16.92 
Heard chemical alarms sounding        Categorical 0.98 1.49 0.12 0.44 0.64 2.07 17.19 
Trendf 1.01 1.55 0.08 0.47 0.64 2.26 17.83 
Explosion in the air or on the ground within one mile of you (e.g., 
 artillery, rockets, mortars)        
Categorical 0.93 1.03 0.25 0.37 0.65 2.23 10.10 
Trendf 0.97 1.29 0.31 0.39 0.65 2.27 14.17 
Have you suffered a combat-related injury that required medical 
 attention during your deployment?        
Categorical 1.02 1.59 0.15 0.29 0.65 2.45 16.66 
Trendf 1.03 1.66 0.09 0.36 0.66 2.39 18.56 
While you were in WWII, the Korean War, and/or the Vietnam 
Ware: number of days exposed to        
Mixing and application of herbicides        Categorical 1.01 1.68 0.36 0.49 0.64 2.22 18.91 
Trendf 1.01 1.65 0.37 0.49 0.65 2.23 18.57 
Exposure to herbicides in the field        Categorical 1.03 1.72 0.10 0.41 0.65 2.45 17.58 
Trendf 1.05 1.78 0.15 0.45 0.65 2.47 18.24 
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       Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
Mixing and application of riot control substances        Categorical 1.01 1.62 0.14 0.48 0.65 2.32 18.41 
Trendf 1.02 1.62 0.36 0.49 0.64 2.33 18.30 
Exposure to riot control substances in the field        Categorical 1.01 1.58 0.37 0.48 0.66 2.34 17.87 
Trendf 1.01 1.59 0.06 0.47 0.65 2.26 17.85 
Mixing and application of burning agents        Categorical 1.00 1.60 0.38 0.49 0.64 2.33 18.07 
Trendf 1.01 1.62 0.14 0.48 0.65 2.38 18.24 
Exposure to burning agents in the field        Categorical 0.99 1.57 0.19 0.36 0.64 2.36 16.42 
Trendf 1.00 1.58 0.23 0.46 0.65 2.40 17.63 
While you were in the Korean War, the Vietnam War, and/or the 
Gulf Ware: number of days exposed to        
Microwave radiation        Categorical 0.83 0.52 0.38 0.49 0.64 1.92 3.71 
Trendf 0.84 0.57 0.29 0.49 0.64 1.93 4.35 
While you were in the Vietnam Ware, g: number of days exposed 
to        
Mixing and application of Agent Orange        Categorical 0.96 0.47 0.38 0.52 0.90 1.59 4.56 
Trendf 0.95 0.47 0.11 0.49 0.89 1.59 4.58 
Exposure to Agent Orange in the field        Categorical 0.96 0.77 0.25 0.35 0.76 2.19 6.95 
Trendf 0.94 0.52 0.30 0.38 0.84 2.04 3.46 
While you were in the Gulf Ware: number of days exposed to        Use of depleted uranium (DU) for munitions or armor        Categorical 0.95 0.60 0.10 0.14 0.73 2.34 2.77 
Trendf 1.05 0.63 0.32 0.39 0.81 2.44 2.96 
CARC (Chemical Agent Resistant Compound) paint        Categorical 0.84 0.55 0.06 0.14 0.67 2.05 2.28 
Trendf 1.02 0.63 0.10 0.27 0.77 2.45 2.81 
Scud missile explosion in the air or on the ground within one mile 
 of you        
Categorical 0.90 1.16 0.09 0.19 0.49 2.52 6.37 
Trendf 0.97 0.65 0.08 0.48 0.75 2.46 3.07 
Smoke from oil well fires        Categorical 1.35 1.84 0.36 0.40 0.95 2.43 12.22 
Trendf 0.88 0.44 0.27 0.37 0.68 1.82 1.85 
Exposure to nerve gas (e.g., during munitions destruction)        Categorical 0.82 0.50 0.04 0.05 0.68 2.18 2.24 
Trendf 1.03 0.72 0.00 0.42 0.80 2.50 3.76 
High levels of dust/sand        Categorical 3.67 8.19 0.26 0.29 1.00 16.09 47.64 
Trendf 0.92 0.50 0.23 0.39 0.77 1.88 2.14 
Ground level fumigation        Categorical 0.83 0.55 0.14 0.14 0.73 2.20 2.91 
Trendf 0.91 0.60 0.04 0.09 0.70 2.38 2.79 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary 
Identification and Records Locator System; CARC, Chemical Agent Resistant Compound; DU, depleted uranium; GENEVA, 
Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; U.S., United 
States of America; VA, Department of Veterans Affairs; WWII, World War II. 
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 aWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic 
terms), use of the VA health care system, sex, race/ethnicity, military branch of longest service, not missing covariate data (for 
cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; 
modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with 
a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the 
Registry cases not missing covariate data]), and participating in GENEVA (for cases: conditional on race/ethnicity, being a 
current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to 
diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; 
modeled with a linear term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 
44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth [modeled with a restricted, 
quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use 
of the VA health care system, and their interaction). War deployment-related exposures were not adjusted for sex because of 
model instability. 
bUsed within-category medians that were calculated using all controls. 
cReference category excluded for linear trend test. 
dReference category included for linear trend test. 
eThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a 
separate question: World War II (defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined 
as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period from August 3, 1964, to May 7, 
1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also 
asked "Ever deployed..." to the following countries where each country was asked about with a separate question: Grenada, 
Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
fUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5). Reference category included 
for linear trend test. 
gRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of 
the Vietnam War, or 1964-1975) because doing so drastically improved the behavior of the IP weights used for analysis. This 
restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls.
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 Table F.7. Summary statistics for the truncated (at the 0.5th and 99.5th percentiles) overall stabilized inverse probability weightsa for models in 
Appendix F, Table F.13. 
      Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
While you were in WWII, the Korean War, the Vietnam War, and/or the Gulf Warb: did you feel ill from 
exposure to        
Manufacture, testing, or use of chemical protective gear (for mustard gas, tear gas, etc.) Do not include training        Categorical 0.97 1.51 0.12 0.46 0.65 2.21 17.50 
Trendc 1.03 1.69 0.02 0.45 0.64 2.51 18.39 
Ionizing radiation from nuclear weapon testing or occupation of Hiroshima/Nagasaki        Categorical 1.01 1.59 0.39 0.49 0.64 2.28 18.28 
Trendc 1.02 1.61 0.08 0.49 0.64 2.33 18.47 
Use of personal pesticides, like creams, sprays or flea collars        Categorical 0.98 1.38 0.26 0.37 0.67 2.22 14.81 
Trendc 1.01 1.51 0.29 0.40 0.67 2.24 16.01 
Use of pesticides on your clothing or bedding        Categorical 0.98 1.46 0.09 0.38 0.65 2.31 15.48 
Trendc 0.99 1.47 0.23 0.42 0.65 2.33 16.09 
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)        Categorical 0.99 1.51 0.28 0.44 0.67 2.13 17.40 
Trendc 0.99 1.50 0.30 0.45 0.66 2.10 17.18 
Exposure to diesel and/or other petrochemical fumes        Categorical 0.95 1.32 0.29 0.40 0.63 2.12 15.01 
Trendc 0.94 1.22 0.27 0.42 0.62 2.09 12.92 
Burning trash or burning feces/manure        Categorical 0.97 1.40 0.21 0.31 0.61 2.53 13.54 
Trendc 0.97 1.47 0.22 0.34 0.63 2.41 14.82 
Exposure to paint, solvents, or petrochemical substances        Categorical 0.99 1.44 0.21 0.31 0.63 2.50 14.59 
Trendc 1.00 1.43 0.13 0.33 0.63 2.63 14.76 
High-intensity radar waves (e.g., as radar operator, radio operator, aviation electrician's mate)        Categorical 0.96 1.18 0.24 0.42 0.64 2.37 12.42 
Trendc 0.96 1.16 0.24 0.44 0.65 2.40 12.17 
Food contaminated with smoke, oil, or other chemicals        Categorical 1.00 1.53 0.17 0.44 0.65 2.19 17.03 
Trendc 1.01 1.59 0.31 0.46 0.65 2.11 17.69 
Local food other than food provided by the Armed Forces        Categorical 1.02 1.79 0.28 0.38 0.66 2.47 21.37 
Trendc 1.01 1.63 0.30 0.42 0.64 2.27 19.24 
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       Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
Bathing in or drinking of water contaminated with smoke, oil, dead animals or any chemicals        Categorical 1.02 1.76 0.20 0.33 0.66 2.15 18.49 
Trendc 1.00 1.57 0.16 0.40 0.67 2.19 17.17 
Heat cramps, heat exhaustion, heat stroke or other heat illness        Categorical 0.99 1.50 0.29 0.37 0.66 2.19 14.80 
Trendc 0.98 1.42 0.30 0.39 0.66 2.07 15.48 
Heard chemical alarms sounding        Categorical 0.98 1.48 0.10 0.45 0.64 2.05 17.16 
Trendc 1.00 1.51 0.05 0.45 0.64 2.41 16.95 
Explosion in the air or on the ground within one mile of you (e.g., artillery, rockets, mortars)        Categorical 0.94 1.03 0.25 0.38 0.65 2.44 10.14 
Trendc 0.94 1.04 0.24 0.38 0.65 2.22 10.37 
While you were in WWII, the Korean War, and/or the Vietnam Warb: did you feel ill from exposure to        Mixing and application of herbicides        Categorical 1.01 1.65 0.39 0.49 0.64 2.27 18.56 
Trendc 1.01 1.66 0.39 0.49 0.64 2.23 18.65 
Exposure to herbicides in the field        Categorical 1.04 1.72 0.09 0.44 0.65 2.44 17.55 
Trendc 1.05 1.76 0.19 0.45 0.65 2.47 18.09 
Mixing and application of riot control substances        Categorical 1.01 1.62 0.11 0.49 0.65 2.33 18.38 
Trendc 1.02 1.62 0.04 0.48 0.65 2.32 18.26 
Exposure to riot control substances in the field        Categorical 1.01 1.66 0.14 0.43 0.65 2.21 17.89 
Trendc 1.02 1.69 0.11 0.46 0.66 2.28 18.46 
Mixing and application of burning agents        Categorical 1.00 1.60 0.19 0.47 0.64 2.40 17.88 
Trendc 1.01 1.62 0.36 0.48 0.64 2.36 18.21 
Exposure to burning agents in the field        Categorical 1.01 1.74 0.17 0.37 0.65 2.39 18.33 
Trendc 1.00 1.56 0.17 0.43 0.66 2.39 17.08 
While you were in the Korean War, the Vietnam War, and/or the Gulf Warb: did you feel ill from exposure to        Microwave radiation        Categorical 0.84 0.59 0.18 0.48 0.63 1.95 4.72 
Trendc 0.84 0.55 0.29 0.49 0.64 1.96 3.76 
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       Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
While you were in the Vietnam Warb, d: did you feel ill from exposure to        Mixing and application of Agent Orange        Categorical 0.94 0.48 0.22 0.49 0.89 1.57 4.70 
Trendc 0.95 0.47 0.26 0.49 0.89 1.57 4.63 
Exposure to Agent Orange in the field        Categorical 0.93 0.68 0.20 0.35 0.80 2.02 6.01 
Trendc 0.95 0.73 0.25 0.34 0.80 1.92 6.33 
While you were in the Gulf Warb: did you feel ill from exposure to        Use of depleted uranium (DU) for munitions or armor        Categorical 0.96 0.74 0.02 0.21 0.75 2.22 4.10 
Trendc 1.05 0.56 0.18 0.44 0.88 2.40 2.41 
CARC (Chemical Agent Resistant Compound) paint        Categorical 0.91 0.62 0.02 0.21 0.78 2.55 2.88 
Trendc 1.02 0.59 0.04 0.40 0.90 2.39 2.57 
Scud missile explosion in the air or on the ground within one mile of you        Categorical 0.95 1.24 0.03 0.31 0.53 2.72 7.70 
Trendc 0.92 0.71 0.33 0.39 0.64 2.34 3.42 
Smoke from oil well fires        Categorical 0.77 0.50 0.21 0.31 0.62 1.76 2.48 
Trendc 0.96 0.76 0.25 0.31 0.75 2.35 4.36 
Exposure to nerve gas (e.g., during munitions destruction)        Categorical 0.77 0.46 0.05 0.08 0.64 1.83 2.18 
Trendc 1.02 0.72 0.04 0.06 0.78 3.11 3.20 
High levels of dust/sand        Categorical 0.90 0.58 0.09 0.22 0.71 1.77 2.94 
Trendc 1.00 0.59 0.08 0.26 0.82 2.08 2.52 
Ground level fumigation        Categorical 0.83 0.50 0.03 0.10 0.74 2.13 2.25 
Trendc 0.93 0.56 0.03 0.08 0.86 2.11 2.92 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CARC, 
Chemical Agent Resistant Compound; DU, depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 
Persian Gulf; VA, Department of Veterans Affairs; WWII, World War II. 
aWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
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 [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 
bThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also asked "Ever 
deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, 
Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
cUsed ordinal scores (0, 1, 2). Reference category included for linear trend test. 
dRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of the Vietnam War, or 1964-1975) because doing 
so drastically improved the behavior of the IP weights used for analysis. This restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls.
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 Table F.8. Summary statistics for the truncated (at the 0.5th and 99.5th percentiles) overall stabilized 
inverse probability weightsa, b for models in Appendix F, Table F.14. 
      Percentiles 
Variable Mean Standard Deviation 0.5 5 50 95 99.5 
Total number of theaters of operation for the Vietnam Warc        Categorical 0.95 0.62 0.27 0.38 0.78 2.17 3.98 
Trendd 0.95 0.47 0.33 0.48 0.86 1.61 4.65 
Total length (years) of deployment to all theaters of operation 
for the Vietnam Warc        
Categorical 0.95 0.63 0.22 0.35 0.79 2.20 4.21 
Trendd 0.95 0.47 0.24 0.48 0.91 1.66 4.27 
End of most recent period of deployment to the Vietnam War 
(year)c        
Categorical 0.95 0.72 0.19 0.30 0.77 2.22 5.43 
Trendd 0.94 0.62 0.23 0.44 0.81 1.99 5.42 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary 
Identification and Records Locator System; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis; VA, Department of Veterans Affairs. 
aWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic 
terms), use of the VA health care system, sex, race/ethnicity, military branch of longest service, not missing covariate data (for 
cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; 
modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with 
a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the 
Registry cases not missing covariate data]), and participating in GENEVA (for cases: conditional on race/ethnicity, being a 
current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to 
diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; 
modeled with a linear term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 
44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth [modeled with a restricted, 
quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use 
of the VA health care system, and their interaction). 
bRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of 
the Vietnam War, or 1964-1975) because doing so drastically improved the behavior of the IP weights used for analysis. This 
restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls. 
cThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a 
separate question: World War II (defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined 
as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period from August 3, 1964, to May 7, 
1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also 
asked "Ever deployed..." to the following countries where each country was asked about with a separate question: Grenada, 
Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
dUsed within-category medians that were calculated using all controls. Individuals in the categories labeled "Not deployed to any 
war/operation" and "Not deployed to the Vietnam War" were excluded for the linear trend test.  
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 Table F.9. Summary statistics for the truncated (at the 0.5th and 99.5th percentiles) overall stabilized 
inverse probability weightsa, b for models in Appendix F, Table F.15. 
      Percentiles 
Did you have direct contact with/were you exposed to Mean Standard Deviation 0.5 5 50 95 99.5 
Mixing and application of Agent Orangec 0.95 0.48 0.32 0.49 0.87 1.58 4.62 
Exposure to Agent Orange in the fieldc 0.96 0.73 0.28 0.38 0.79 2.15 6.87 
Mixing and application of other herbicides 0.94 0.44 0.38 0.51 0.87 1.63 4.57 
Exposure to other herbicides in the field 0.95 0.60 0.30 0.40 0.89 1.53 6.46 
Manufacture, testing, or use of chemical protective gear (for mustard gas, tear 
gas, etc.) Do not include training 0.94 0.47 0.30 0.47 0.88 1.58 4.84 
Ionizing radiation from nuclear weapon testing 0.93 0.44 0.12 0.50 0.89 1.51 4.48 
Microwave radiation 0.94 0.46 0.37 0.51 0.89 1.61 4.42 
Use of personal pesticides, like creams, sprays or flea collars 0.96 0.57 0.35 0.45 0.86 1.58 5.41 
Use of pesticides on your clothing or bedding 0.93 0.45 0.32 0.45 0.87 1.45 4.59 
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters) 0.95 0.45 0.34 0.50 0.87 1.55 4.28 
Exposure to diesel and/or other petrochemical fumes 0.94 0.48 0.26 0.52 0.86 1.80 4.30 
Burning trash or burning feces/manure 0.96 0.74 0.28 0.36 0.71 1.97 6.62 
Exposure to paint, solvents, or petrochemical substances 0.93 0.56 0.26 0.40 0.80 2.09 4.08 
High-intensity radar waves (e.g., as radar operator, radio operator, aviation 
electrician's mate) 0.97 0.64 0.33 0.50 0.90 1.53 7.26 
Food contaminated with smoke, oil, or other chemicals 0.95 0.43 0.34 0.49 0.90 1.54 4.00 
Local food other than food provided by the Armed Forces 0.95 0.52 0.33 0.48 0.83 1.80 4.43 
Bathing in or drinking of water contaminated with smoke, oil, dead animals or 
any chemicals 0.93 0.44 0.30 0.42 0.86 1.57 3.29 
Heat cramps, heat exhaustion, heat stroke or other heat illness 0.92 0.42 0.36 0.46 0.83 1.49 3.48 
Heard chemical alarms sounding 0.94 0.46 0.12 0.48 0.89 1.61 4.52 
Explosion in the air or on the ground within one mile of you (e.g., artillery, 
rockets, mortars) 0.95 0.49 0.24 0.45 0.86 1.75 3.85 
Mixing and application of riot control substances 0.95 0.48 0.14 0.51 0.88 1.64 4.52 
Exposure to riot control substances in the field 0.94 0.50 0.29 0.47 0.88 1.57 4.81 
Mixing and application of burning agents 0.94 0.47 0.36 0.52 0.88 1.64 4.58 
Exposure to burning agents in the field 0.95 0.50 0.25 0.45 0.90 1.57 5.08 
Have you suffered a combat-related injury that required medical attention 
during your deployment? 0.98 0.75 0.25 0.37 0.82 2.09 6.58 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary 
Identification and Records Locator System; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis; VA, Department of Veterans Affairs. 
aWeights adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), 
use of VA health care system, race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional 
on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with the natural 
logarithm of a linear term], and time from diagnosis to enrollment in Registry [months; modeled with a restricted, quadratic spline 
with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing 
covariate data]), and participating in GENEVA (for cases: conditional on race/ethnicity, being a current patient of a VA Medical 
Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]; for controls: conditional on year of birth [modeled with a restricted, quadratic spline with knots at 1920, 1947, 
and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care system, and their 
interaction). War deployment-related exposures were not adjusted for sex because of model instability. 
bRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of 
the Vietnam War, or 1964-1975) because doing so drastically improved the behavior of the IP weights used for analysis. This 
restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls. 
cRepeated from Appendix F, Table F.5.  
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 Table F.10. Summary statistics for the truncated (at the 0.5th and 99.5th percentiles) overall stabilized 
inverse probability weightsa for models in Appendix F, Table F.16. 
      Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
Total number of preventive vaccinations received by injection (shots) 
or by mouth while inside or outside the U.S.        
Categorical 0.95 0.74 0.26 0.44 0.85 1.60 7.83 
Trendc 0.92 0.46 0.29 0.50 0.89 1.37 4.74 
Number of days exposed to        Mixing and application of Agent Oranged        Categorical 0.96 0.47 0.38 0.52 0.90 1.59 4.56 
Trende 0.95 0.47 0.11 0.49 0.89 1.59 4.58 
Exposure to Agent Orange in the fieldd        Categorical 0.96 0.77 0.25 0.35 0.76 2.19 6.95 
Trende 0.94 0.52 0.30 0.38 0.84 2.04 3.46 
Mixing and application of other herbicides        Categorical 0.94 0.47 0.16 0.51 0.87 1.62 4.87 
Trende 0.94 0.44 0.07 0.52 0.88 1.62 4.63 
Exposure to other herbicides in the field        Categorical 0.96 0.46 0.36 0.52 0.92 1.58 4.44 
Trende 0.93 0.39 0.17 0.47 0.90 1.57 3.19 
Manufacture, testing, or use of chemical protective gear (for 
mustard gas, tear gas, etc.) Do not include training        
Categorical 0.93 0.46 0.28 0.48 0.88 1.58 4.84 
Trende 0.94 0.44 0.36 0.50 0.88 1.62 4.69 
Ionizing radiation from nuclear weapon testing        Categorical 0.93 0.45 0.07 0.50 0.89 1.57 4.48 
Trende 0.94 0.44 0.03 0.51 0.90 1.58 4.48 
Microwave radiation        Categorical 0.95 0.44 0.37 0.52 0.90 1.57 4.41 
Trende 0.95 0.46 0.32 0.51 0.89 1.64 4.44 
Use of personal pesticides, like creams, sprays or flea collars        Categorical 0.96 0.56 0.34 0.43 0.86 1.76 5.40 
Trende 0.96 0.57 0.33 0.43 0.87 1.63 5.50 
Use of pesticides on your clothing or bedding        Categorical 0.92 0.41 0.32 0.44 0.87 1.52 3.51 
Trende 0.93 0.48 0.37 0.48 0.88 1.49 5.16 
Exhaust from heaters or generators (e.g., kerosene heaters, tent 
 heaters)        
Categorical 0.95 0.51 0.31 0.46 0.86 1.56 5.16 
Trende 0.94 0.44 0.34 0.50 0.88 1.55 4.42 
Exposure to diesel and/or other petrochemical fumes        Categorical 0.94 0.51 0.26 0.44 0.83 1.89 4.16 
Trende 0.94 0.49 0.30 0.49 0.84 1.78 4.21 
Burning trash or burning feces/manure        Categorical 0.94 0.69 0.18 0.34 0.74 2.02 5.63 
Trende 0.95 0.59 0.21 0.40 0.84 1.80 5.57 
Exposure to paint, solvents, or petrochemical substances        Categorical 0.94 0.64 0.21 0.37 0.80 2.13 5.77 
Trende 0.94 0.54 0.20 0.34 0.85 1.78 4.38 
High-intensity radar waves (e.g., as radar operator, radio operator, 
 aviation electrician's mate)        
Categorical 0.98 0.65 0.20 0.43 0.91 1.77 7.24 
Trende 0.98 0.64 0.25 0.50 0.91 1.66 7.21 
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       Percentiles 
Exposure Mean Standard Deviation 0.5 5 50 95 99.5 
Food contaminated with smoke, oil, or other chemicals        Categorical 0.94 0.44 0.31 0.45 0.90 1.57 3.95 
Trende 0.95 0.42 0.30 0.49 0.90 1.60 3.94 
Local food other than food provided by the Armed Forces        Categorical 0.94 0.52 0.12 0.43 0.82 1.70 4.56 
Trende 0.93 0.47 0.33 0.49 0.86 1.52 4.34 
Bathing in or drinking of water contaminated with smoke, oil, dead 
 animals or any chemicals        
Categorical 0.94 0.49 0.27 0.43 0.86 1.57 3.80 
Trende 0.93 0.42 0.25 0.46 0.85 1.59 3.22 
Heat cramps, heat exhaustion, heat stroke or other heat illness        Categorical 0.92 0.46 0.30 0.44 0.82 1.55 3.56 
Trende 0.92 0.40 0.27 0.45 0.87 1.51 3.16 
Heard chemical alarms sounding        Categorical 0.93 0.47 0.04 0.47 0.87 1.64 4.53 
Trende 0.94 0.44 0.22 0.51 0.89 1.64 4.53 
Explosion in the air or on the ground within one mile of you (e.g., 
 artillery, rockets, mortars)        
Categorical 0.94 0.58 0.18 0.41 0.76 1.79 4.76 
Trende 0.94 0.54 0.28 0.43 0.82 1.73 4.97 
Mixing and application of riot control substances        Categorical 0.95 0.48 0.14 0.51 0.89 1.64 4.51 
Trende 0.97 0.48 0.37 0.51 0.90 1.63 4.50 
Exposure to riot control substances in the field        Categorical 0.96 0.49 0.38 0.51 0.90 1.62 4.70 
Trende 0.96 0.50 0.04 0.48 0.87 1.64 4.52 
Mixing and application of burning agents        Categorical 0.95 0.46 0.37 0.52 0.88 1.60 4.65 
Trende 0.94 0.46 0.24 0.50 0.89 1.62 4.60 
Exposure to burning agents in the field        Categorical 0.94 0.45 0.24 0.41 0.88 1.61 3.85 
Trende 0.94 0.42 0.26 0.50 0.88 1.59 3.72 
Have you suffered a combat-related injury that required medical 
 attention during your deployment?        
Categorical 0.97 0.94 0.18 0.32 0.81 1.95 9.47 
Trende 0.95 0.67 0.12 0.42 0.83 1.88 5.69 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary 
Identification and Records Locator System; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis; U.S., United States of America; VA, Department of Veterans Affairs. 
aWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic 
terms), use of the VA health care system, race/ethnicity, military branch of longest service, not missing covariate data (for cases: 
conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (for cases: conditional on race/ethnicity, being a current patient of a 
VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled 
with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], 
and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of 
the distribution in GENEVA cases]; for controls: conditional on year of birth [modeled with a restricted, quadratic spline with knots 
at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 
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 bRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of 
the Vietnam War, or 1964-1975) because doing so drastically improved the behavior of the IP weights used for analysis. This 
restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls. 
cUsed within-category medians that were calculated using all controls. Reference category included for linear trend test. 
dRepeated from Appendix F, Table F.6. 
eUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5). Reference category included 
for linear trend test.  
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 Table F.11. Summary statistics for the truncated (at the 0.5th and 99.5th percentiles) overall stabilized 
inverse probability weightsa for models in Appendix F, Table F.17. 
      Percentiles 
Did you feel ill from exposure to Mean Standard Deviation 0.5 5 50 95 99.5 
Mixing and application of Agent Orangec        Categorical 0.94  0.48  0.22  0.49  0.89  1.57  4.70  
Trendd 0.95  0.47  0.26  0.49  0.89  1.57  4.63  
Exposure to Agent Orange in the fieldc        Categorical 0.93  0.68  0.20  0.35  0.80  2.02  6.01  
Trendd 0.95  0.73  0.25  0.34  0.80  1.92  6.33  
Mixing and application of other herbicides        Categorical 0.94  0.44  0.38  0.51  0.87  1.59  4.57  
Trendd 0.94  0.43  0.37  0.52  0.87  1.62  4.60  
Exposure to other herbicides in the field        Categorical 0.92  0.40  0.08  0.41  0.90  1.53  3.56  
Trendd 0.95  0.54  0.16  0.46  0.90  1.55  5.75  
Manufacture, testing, or use of chemical protective gear (for mustard gas, tear 
gas, etc.) Do not include training        
Categorical 0.93  0.47  0.16  0.48  0.88  1.58  4.86  
Trendd 0.94  0.46  0.23  0.48  0.89  1.58  4.97  
Ionizing radiation from nuclear weapon testing        Categorical 0.94  0.43  0.37  0.53  0.90  1.50  4.49  
Trendd 0.94  0.44  0.08  0.51  0.89  1.57  4.49  
Microwave radiation        Categorical 0.94  0.46  0.36  0.50  0.87  1.66  4.43  
Trendd 0.94  0.46  0.34  0.48  0.89  1.65  4.45  
Use of personal pesticides, like creams, sprays or flea collars        Categorical 0.96  0.58  0.33  0.44  0.87  1.59  5.38  
Trendd 0.96  0.57  0.36  0.46  0.86  1.52  5.56  
Use of pesticides on your clothing or bedding        Categorical 0.92  0.46  0.12  0.41  0.85  1.51  4.06  
Trendd 0.93  0.44  0.23  0.46  0.87  1.52  4.24  
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)        Categorical 0.94  0.46  0.35  0.49  0.87  1.54  4.45  
Trendd 0.94  0.44  0.34  0.49  0.88  1.52  4.28  
Exposure to diesel and/or other petrochemical fumes        Categorical 0.95  0.56  0.26  0.48  0.84  1.89  4.79  
Trendd 0.95  0.52  0.28  0.50  0.86  1.73  4.50  
Burning trash or burning feces/manure        Categorical 0.96  0.78  0.23  0.34  0.73  2.11  6.53  
Trendd 0.96  0.75  0.28  0.38  0.74  2.13  5.71  
Exposure to paint, solvents, or petrochemical substances        Categorical 0.93  0.58  0.25  0.37  0.79  2.03  4.38  
Trendd 0.94  0.60  0.14  0.34  0.81  2.30  4.06  
High-intensity radar waves (e.g., as radar operator, radio operator, aviation 
electrician's mate)        
Categorical 0.97  0.64  0.32  0.50  0.91  1.58  7.29  
Trendd 0.97  0.59  0.29  0.51  0.91  1.59  6.48  
Food contaminated with smoke, oil, or other chemicals        Categorical 0.94  0.47  0.29  0.47  0.88  1.60  4.01  
Trendd 0.95  0.42  0.36  0.51  0.89  1.59  4.03  
Local food other than food provided by the Armed Forces        Categorical 0.95  0.51  0.31  0.47  0.85  1.81  4.44  
Trendd 0.95  0.51  0.33  0.50  0.84  1.70  4.55  
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       Percentiles 
Did you feel ill from exposure to Mean Standard Deviation 0.5 5 50 95 99.5 
Bathing in or drinking of water contaminated with smoke, oil, dead animals or 
any chemicals        
Categorical 0.93  0.45  0.30  0.43  0.85  1.64  3.22  
Trendd 0.93  0.42  0.24  0.46  0.86  1.52  3.24  
Heat cramps, heat exhaustion, heat stroke or other heat illness        Categorical 0.92  0.46  0.30  0.46  0.83  1.49  3.66  
Trendd 0.92  0.42  0.36  0.47  0.84  1.48  3.51  
Heard chemical alarms sounding        Categorical 0.94  0.46  0.10  0.47  0.88  1.63  4.50  
Trendd 0.95  0.46  0.05  0.48  0.88  1.62  4.52  
Explosion in the air or on the ground within one mile of you (e.g., artillery, 
rockets, mortars)        
Categorical 0.96  0.65  0.24  0.45  0.85  1.69  6.69  
Trendd 0.94  0.49  0.27  0.45  0.88  1.83  4.09  
Mixing and application of riot control substances        Categorical 0.95  0.48  0.08  0.50  0.89  1.69  4.50  
Trendd 0.96  0.48  0.06  0.52  0.90  1.63  4.51  
Exposure to riot control substances in the field        Categorical 0.94  0.50  0.23  0.44  0.88  1.60  4.80  
Trendd 0.95  0.51  0.17  0.45  0.88  1.67  4.85  
Mixing and application of burning agents        Categorical 0.94  0.48  0.09  0.48  0.89  1.60  4.56  
Trendd 0.94  0.47  0.34  0.50  0.89  1.66  4.61  
Exposure to burning agents in the field        Categorical 0.94  0.48  0.23  0.41  0.90  1.59  4.28  
Trendd 0.94  0.45  0.29  0.42  0.90  1.56  4.33  
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary 
Identification and Records Locator System; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis; VA, Department of Veterans Affairs. 
aWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic 
terms), use of the VA health care system, race/ethnicity, military branch of longest service, not missing covariate data (for cases: 
conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (for cases: conditional on race/ethnicity, being a current patient of a 
VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled 
with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], 
and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of 
the distribution in GENEVA cases]; for controls: conditional on year of birth [modeled with a restricted, quadratic spline with knots 
at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 
bRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of 
the Vietnam War, or 1964-1975) because doing so drastically improved the behavior of the IP weights used for analysis. This 
restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls. 
cRepeated from Appendix F, Table F.7. 
dUsed ordinal scores (0, 1, 2). Reference category included for linear trend test.
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 Table F.12. Dose-response for military exposures and amyotrophic lateral sclerosis in GENEVA. 
  Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Number of anthrax vaccine shots received prior to reference date           0 (Median = 0) 493 95 803 93 1.00 Referent 1.00 Referent 1.00 Referent 
1 (1) 8 2 20 2 0.60 0.26, 1.40 0.79 0.33, 1.89 1.89 0.55, 6.45 
2-3 (3) 7 1 23 3 0.47 0.20, 1.11 0.54 0.22, 1.32 0.65 0.23, 1.86 
> 3 (5) 9 2 21 2 0.63 0.28, 1.42 0.62 0.26, 1.46 1.08 0.31, 3.74 
Missing 102  89        Trendd     0.87 0.75, 1.01 0.88 0.76, 1.03 1.07 0.82, 1.41 Prior to reference date, number of years involved in testing, transporting or 
spraying herbicides for military purposes           
0 (0) 450 96 908 97 1.00 Referent 1.00 Referent 1.00 Referent 
1 (1) 10 2 17 2 1.30 0.59, 2.89 1.17 0.52, 2.61 3.86 0.86, 17.45 
> 1 (2) 8 2 12 1 1.44 0.58, 3.55 1.65 0.65, 4.17 2.40 0.84, 6.84 
Missing 151  19        Trendd     1.22 0.82, 1.82 1.25 0.83, 1.88 1.58 0.88, 2.85 Year in which pyridostigmine bromide pills taken           Never taken pyridostigmine bromide pills 531 97 882 97 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 1990 (1978) 10 2 11 1 1.54 0.65, 3.67 1.57 0.64, 3.88 e e 
> 1990 (1991) 5 1 12 1 0.67 0.23, 1.93 0.83 0.27, 2.57 e e 
Missing 73  51        Trend (IQR = 13)d, f     0.22 0.04, 1.18 0.07 < 0.01, 1.10 0.14 0.03, 0.69 Total days taken pyridostigmine bromide pills           0 (0.0) 531 98 882 98 1.00 Referent 1.00 Referent 1.00 Referent 
1-4 (2.5) 7 1 8 1 1.49 0.54, 4.14 1.54 0.54, 4.40 6.38 1.87, 21.71 
> 4 (14.0) 6 1 11 1 0.91 0.33, 2.51 1.13 0.38, 3.35 0.53 0.15, 1.88 
Missing 75  55        Trendd     1.00 0.93, 1.07 1.01 0.94, 1.09 0.98 0.89, 1.07 Number of pills taken in an average day on days pyridostigmine bromide pills 
taken           
0 (0) 531 98 882 98 1.00 Referent 1.00 Referent 1.00 Referent 
1 (1) 5 1 9 1 0.92 0.31, 2.79 1.35 0.41, 4.45 4.58 0.83, 25.30 
> 1 (3) 5 1 9 1 0.95 0.31, 2.85 1.01 0.32, 3.19 1.88 0.39, 9.15 
Missing 78  56        Trendd     0.98 0.69, 1.39 1.03 0.72, 1.48 1.26 0.80, 2.00 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Total number of pyridostigmine bromide pills taken           0 (0) 531 98 882 98 1.00 Referent 1.00 Referent 1.00 Referent 
1-20 (7) 5 1 11 1 0.79 0.27, 2.29 0.92 0.30, 2.77 1.54 0.30, 8.01 
> 20 (75) < 5 1 6 1 1.10 0.31, 3.96 1.46 0.35, 6.02 0.72 0.15, 3.44 
Missing 79  57        Trend (45)d, g     1.04 0.48, 2.24 1.24 0.53, 2.89 0.67 0.24, 1.89 Prior to reference date, number of times visited or resided in the island of Guam, 
the islands of New Guinea, or the Kii Peninsula of Japan           
0 (0) 492 84 749 80 1.00 Referent 1.00 Referent 1.00 Referent 
1 (1) 45 8 91 10 0.74 0.51, 1.08 0.70 0.47, 1.03 0.76 0.45, 1.27 
2 (2) 17 3 45 5 0.56 0.32, 0.99 0.53 0.30, 0.95 0.65 0.27, 1.60 
3 (3) 14 2 14 1 1.50 0.71, 3.18 1.69 0.77, 3.69 2.64 0.91, 7.65 
4-5 (4) 7 1 19 2 0.54 0.22, 1.30 0.53 0.22, 1.30 0.24 0.06, 0.90 
> 5 (10) 8 1 17 2 0.73 0.31, 1.70 0.70 0.29, 1.65 0.27 0.08, 0.93 
Missing 36  21        Trendd     0.95 0.88, 1.02 0.94 0.87, 1.02 0.88 0.79, 0.99 Prior to reference date, total amount of time (months) spent in the island of Guam, 
the islands of New Guinea, or the Kii Peninsula of Japan, excluding time periods 
between age at first and last visits when you didn’t visit or reside in the island of 
Guam, the islands of New Guinea, or the Kii Peninsula of Japan 
          
0 (0.00) 492 84 749 80 1.00 Referent 1.00 Referent 1.00 Referent 
> 0-6 (0.16) 70 12 150 16 0.70 0.51, 0.95 0.67 0.49, 0.93 0.63 0.40, 1.00 
> 6-12 (9.00) 6 1 15 2 0.58 0.22, 1.52 0.51 0.19, 1.35 0.72 0.19, 2.74 
> 12-24 (24.00) 10 2 8 1 1.85 0.72, 4.73 1.93 0.73, 5.12 4.77 0.97, 23.41 
> 24 (48.00) 5 1 14 1 0.54 0.19, 1.52 0.55 0.19, 1.57 0.61 0.20, 1.88 
Missing 36  20        Trend (3.03)d, g     0.99 0.93, 1.04 0.99 0.93, 1.04 1.03 0.95, 1.10 While you were in WWII, the Korean War, the Vietnam War, and/or the Gulf 
Warh:           
Total number of preventive vaccinations received by injection (shots) or by 
 mouth while inside or outside the U.S.           
0 (0) 57 33 82 28 1.00 Referent 1.00 Referent 1.00 Referent 
1-10 (5) 68 39 127 44 0.68 0.43, 1.09 0.67 0.42, 1.08 0.96 0.50, 1.85 
11-20 (13) 25 14 39 13 0.81 0.43, 1.53 0.80 0.42, 1.52 0.69 0.25, 1.90 
21-30 (24) 6 3 11 4 0.68 0.23, 1.99 0.59 0.20, 1.77 1.62 0.36, 7.25 
> 30 (99) 17 10 30 10 0.72 0.35, 1.46 0.73 0.35, 1.51 2.36 0.62, 8.92 
Missing 58  49        Trend (13)d, g     0.98 0.90, 1.07 0.98 0.90, 1.08 1.16 0.99, 1.36 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
While you were in WWII, the Korean War, the Vietnam War, and/or the Gulf 
Warh: number of days exposed to           
Manufacture, testing, or use of chemical protective gear (for mustard gas, tear 
 gas, etc.) Do not include training           
Not exposed or ≤ 5 211 96 324 97 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 8 4 11 3 0.62 0.21, 1.81 0.76 0.26, 2.20 2.78 0.94, 8.27 
Missing 12  3        Trendi     0.54 0.25, 1.16 0.60 0.28, 1.28 0.93 0.37, 2.34 Ionizing radiation from nuclear weapon testing or occupation of 
 Hiroshima/Nagasaki           
Not exposed 212 98 327 99 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 1 < 5 < 1 5.18 0.53, 50.47 5.08 0.49, 53.08 8.03 0.78, 82.73 
> 5 < 5 < 1 < 5 1 0.59 0.06, 5.73 0.48 0.05, 4.88 0.56 0.06, 5.49 
Missing 15  7        Trendi     0.57 0.14, 2.32 0.50 0.12, 2.18 3.51 0.07, 178.23 Use of personal pesticides, like creams, sprays or flea collars           Not exposed 155 70 233 70 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 9 4 7 2 1.89 0.67, 5.31 2.12 0.73, 6.15 5.45 1.50, 19.76 
6-30 8 4 14 4 0.88 0.35, 2.19 0.83 0.33, 2.09 3.17 1.07, 9.38 
> 30 48 22 78 23 0.89 0.58, 1.37 0.88 0.56, 1.38 1.16 0.56, 2.43 
Missing 11  6        Trendi     0.94 0.78, 1.13 0.94 0.77, 1.13 1.11 0.83, 1.50 Use of pesticides on your clothing or bedding           Not exposed 161 77 243 75 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 5 2 11 3 0.59 0.19, 1.81 0.60 0.19, 1.87 0.35 0.07, 1.72 
6-30 9 4 7 2 1.59 0.55, 4.57 1.58 0.53, 4.68 2.53 0.48, 13.36 
> 30 34 16 65 20 0.79 0.49, 1.27 0.81 0.50, 1.32 1.16 0.53, 2.54 
Missing 22  12        Trendi     0.91 0.75, 1.12 0.93 0.75, 1.14 1.12 0.82, 1.53 Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)           Not exposed 142 68 235 70 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 6 3 17 5 0.59 0.23, 1.55 0.61 0.23, 1.62 0.62 0.18, 2.18 
6-30 12 6 14 4 1.31 0.57, 2.98 1.50 0.64, 3.48 3.12 0.96, 10.09 
> 30 50 24 69 21 1.12 0.72, 1.73 1.14 0.73, 1.78 1.71 0.98, 3.00 
Missing 21  3        Trendi     1.06 0.88, 1.28 1.08 0.89, 1.30 1.29 1.02, 1.65 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Exposure to diesel and/or other petrochemical fumes           Not exposed 75 35 118 36 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 8 4 25 8 0.48 0.20, 1.15 0.50 0.20, 1.21 0.45 0.17, 1.19 
6-30 14 7 20 6 1.08 0.51, 2.30 1.09 0.51, 2.35 2.14 0.59, 7.75 
> 30 118 55 165 50 1.05 0.71, 1.55 1.04 0.69, 1.55 1.02 0.58, 1.82 
Missing 16  10        Trendi     1.06 0.90, 1.25 1.05 0.89, 1.24 1.04 0.82, 1.33 Burning trash or burning feces/manure           Not exposed 146 67 202 62 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 12 6 32 10 0.48 0.23, 1.00 0.48 0.23, 1.03 0.49 0.19, 1.23 
6-30 13 6 30 9 0.65 0.32, 1.30 0.61 0.30, 1.24 1.15 0.31, 4.26 
> 30 46 21 64 20 0.91 0.58, 1.45 0.83 0.51, 1.36 0.89 0.43, 1.87 
Missing 14  10        Trendi     0.98 0.81, 1.20 0.96 0.78, 1.18 1.05 0.78, 1.43 Exposure to paint, solvents, or petrochemical substances           Not exposed 146 67 216 65 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 7 3 28 8 0.42 0.18, 0.99 0.37 0.15, 0.90 0.18 0.05, 0.64 
6-30 19 9 35 11 0.77 0.42, 1.43 0.65 0.35, 1.23 0.90 0.34, 2.36 
> 30 45 21 53 16 1.17 0.73, 1.86 0.99 0.61, 1.64 1.29 0.72, 2.33 
Missing 14  6        Trendi     1.08 0.88, 1.31 1.02 0.83, 1.26 1.18 0.91, 1.53 High-intensity radar waves (e.g., as radar operator, radio operator, aviation 
 electrician's mate)           
Not exposed 162 79 263 84 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 7 3 13 4 0.91 0.35, 2.35 1.00 0.38, 2.63 1.74 0.51, 5.96 
> 30 37 18 38 12 1.61 0.98, 2.66 1.54 0.92, 2.58 1.91 0.94, 3.87 
Missing 25  24        Trendi     1.20 0.97, 1.49 1.18 0.95, 1.47 1.29 0.96, 1.75 Food contaminated with smoke, oil, or other chemicals           Not exposed 185 93 269 89 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 6 3 12 4 0.74 0.27, 2.03 0.78 0.28, 2.18 2.14 0.57, 8.07 
> 30 9 5 20 7 0.71 0.31, 1.60 0.73 0.32, 1.67 1.43 0.54, 3.79 
Missing 31  37        Trendi     0.87 0.62, 1.23 0.88 0.62, 1.25 1.22 0.80, 1.84 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Local food other than food provided by the Armed Forces           Not exposed 110 50 167 50 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 32 15 41 12 1.04 0.60, 1.79 1.07 0.61, 1.87 1.58 0.78, 3.19 
6-30 32 15 46 14 1.00 0.59, 1.68 1.00 0.58, 1.70 1.27 0.65, 2.46 
> 30 46 21 78 23 0.90 0.58, 1.41 0.92 0.58, 1.45 1.00 0.44, 2.27 
Missing 11  6        Trendi     0.95 0.79, 1.15 0.96 0.79, 1.16 0.97 0.69, 1.36 Bathing in or drinking of water contaminated with smoke, oil, dead animals or 
 any chemicals           
Not exposed 175 89 274 88 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 10 5 15 5 1.17 0.51, 2.68 1.14 0.49, 2.64 3.23 0.87, 12.04 
> 30 11 6 21 7 0.86 0.40, 1.88 0.86 0.39, 1.91 1.11 0.36, 3.47 
Missing 35  28        Trendi     0.95 0.68, 1.32 0.94 0.67, 1.32 1.29 0.83, 1.99 Heat cramps, heat exhaustion, heat stroke or other heat illness           Not exposed 172 77 249 75 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 22 10 44 13 0.75 0.43, 1.31 0.75 0.43, 1.33 1.23 0.51, 2.94 
6-30 17 8 19 6 1.27 0.62, 2.58 1.32 0.64, 2.74 1.46 0.61, 3.48 
> 30 12 5 21 6 0.87 0.41, 1.86 0.92 0.42, 1.99 1.99 0.52, 7.62 
Missing 8  5        Trendi     0.99 0.73, 1.35 1.01 0.74, 1.39 1.47 0.91, 2.39 Heard chemical alarms sounding           Not exposed 208 93 301 90 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 6 3 22 7 0.21 0.07, 0.64 0.22 0.07, 0.68 0.54 0.16, 1.77 
> 5 9 4 10 3 0.91 0.34, 2.45 1.18 0.42, 3.29 2.02 0.55, 7.37 
Missing 8  5        Trendi     0.76 0.42, 1.36 0.83 0.46, 1.49 0.89 0.40, 1.96 Explosion in the air or on the ground within one mile of you (e.g., artillery, 
 rockets, mortars)           
Not exposed 72 33 116 36 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 33 15 62 19 0.87 0.51, 1.04 0.93 0.54, 1.60 1.67 0.85, 3.27 
6-30 37 17 49 15 1.30 0.76, 2.22 1.30 0.75, 2.26 1.69 0.79, 3.63 
> 30 75 35 96 30 1.46 0.94, 2.27 1.49 0.95, 2.36 2.11 1.15, 3.87 
Missing 14  15        Trendi     1.20 1.01, 1.43 1.20 1.00, 1.44 1.28 0.98, 1.68 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Have you suffered a combat-related injury that required medical attention 
 during your deployment?           
Not exposed 177 78 257 77 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 22 10 25 8 1.32 0.72, 2.45 1.30 0.69, 2.45 1.24 0.52, 2.95 
6-30 11 5 18 5 0.93 0.42, 2.03 0.95 0.42, 2.13 1.68 0.47, 6.01 
> 30 16 7 33 10 0.77 0.40, 1.49 0.74 0.38, 1.47 0.94 0.27, 3.30 
Missing 5  5        Trendi     0.89 0.68, 1.16 0.87 0.66, 1.16 1.08 0.68, 1.73 While you were in WWII, the Korean War, and/or the Vietnam Warh: number 
of days exposed to           
Mixing and application of herbicides           Not exposed 202 98 303 99 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 1 < 5 < 1 2.08 0.17, 25.95 2.36 0.20, 27.88 0.49 0.03, 8.03 
> 5 < 5 1 < 5 < 1 5.91 0.60, 58.02 5.03 0.51, 49.98 5.29 0.47, 59.49 
Missing 12  9        Trendi     2.12 0.72, 6.21 1.99 0.68, 5.82 2.35 0.33, 16.68 Exposure to herbicides in the field           Not exposed 160 94 238 95 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 5 3 5 2 2.16 0.60, 7.76 3.04 0.77, 11.93 11.45 2.29, 57.14 
> 30 5 3 8 3 1.10 0.35, 3.53 1.02 0.32, 3.29 1.87 0.40, 8.83 
Missing 49  63        Trendi     1.07 0.66, 1.74 1.04 0.64, 1.70 1.44 0.78, 2.67 Mixing and application of riot control substances           Not exposed 213 99 307 98 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 < 1 < 5 1 0.67 0.06, 7.88 0.85 0.07, 9.93 2.96 0.26, 33.30 
> 5 < 5 1 5 2 0.53 0.09, 3.00 0.73 0.13, 4.14 1.73 0.18, 16.65 
Missing 3  0        Trendi     0.47 0.11, 1.97 0.59 0.14, 2.47 0.85 0.23, 3.20 Exposure to riot control substances in the field           Not exposed or ≤ 5 206 96 295 95 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 9 4 16 5 0.65 0.27, 1.60 0.73 0.29, 1.84 1.41 0.50, 3.99 
Missing 4  3        Trendi     0.76 0.43, 1.33 0.86 0.48, 1.56 1.43 0.67, 3.01 Mixing and application of burning agents           Not exposed or ≤ 5 199 94 304 98 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 13 6 5 2 4.06 1.37, 12.00 3.95 1.33, 11.71 8.13 2.53, 26.15 
Missing 7  5        Trendi     1.97 1.06, 3.65 1.94 1.04, 3.60 3.60 1.24, 10.49 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Exposure to burning agents in the field           Not exposed 176 85 277 90 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 14 7 11 4 1.97 0.85, 4.56 1.95 0.83, 4.58 1.46 0.28, 7.46 
6-30 7 3 9 3 1.26 0.44, 3.63 1.24 0.42, 3.62 1.87 0.51, 6.85 
> 30 10 5 11 4 1.36 0.54, 3.45 1.49 0.58, 3.86 1.60 0.35, 7.40 
Missing 12  6        Trendi     1.15 0.79, 1.69 1.19 0.81, 1.77 1.45 0.78, 2.69 While you were in the Korean War, the Vietnam War, and/or the Gulf Warh: 
number of days exposed to           
Microwave radiation           Not exposed or ≤ 5 155 93 276 95 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 12 7 15 5 1.33 0.59, 3.00 1.34 0.58, 3.09 2.08 0.89, 4.86 
Missing 29  36        Trendi     1.15 0.79, 1.68 1.16 0.78, 1.70 1.44 0.89, 2.34 While you were in the Vietnam Warh, j: number of days exposed to           Mixing and application of Agent Orange           Not exposed or ≤ 5 111 96 202 95 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 5 4 11 5 0.98 0.29, 3.30 0.99 0.28, 3.47 1.04 0.30, 3.60 
Missing 11  6        Trendi     0.94 0.48, 1.83 0.96 0.48, 1.92 0.93 0.42, 2.05 Exposure to Agent Orange in the field           Not exposed 41 44 98 58 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 10 11 13 8 2.30 0.83, 6.36 2.37 0.81, 6.99 2.12 0.71, 6.32 
6-30 8 9 16 10 2.01 0.66, 6.13 1.77 0.56, 5.63 3.05 0.82, 11.30 
> 30 34 37 41 24 3.14 1.53, 6.42 3.29 1.50, 7.22 2.25 1.03, 4.90 
Missing 34  51        Trendi     1.55 1.15, 2.09 1.56 1.13, 2.16 1.42 1.06, 1.90 While you were in the Gulf Warh: number of days exposed to           Use of depleted uranium (DU) for munitions or armor           Not exposed 8 62 23 85 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 < 5 15 < 5 4 8.00 0.35, 183.75 2.82 0.08, 100.26 2.10 0.16, 27.80 
> 30 < 5 23 < 5 11 2.85 0.37, 21.79 14.71 0.17, 1272.73 9.27 1.21, 70.83 
Missing 3  3        Trendi     1.63 0.69, 3.87 3.17 0.52, 19.52 2.18 0.88, 5.35 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
CARC (Chemical Agent Resistant Compound) paint           Not exposed 10 77 20 87 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 < 5 8 < 5 9 1.06 0.07, 15.38 e e 0.44 0.03, 5.62 
> 30 < 5 15 < 5 4 2.80 0.17, 45.05 17.86 0.03, 10140.86 1.99 0.15, 25.66 
Missing 3  7        Trendi     1.69 0.52, 5.52 3.53 0.22, 55.80 1.48 0.43, 5.12 Scud missile explosion in the air or on the ground within one mile of you           Not exposed 9 69 17 61 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 23 9 32 0.60 0.10, 3.47 1.63 0.16, 16.76 5.74 0.73, 45.33 
6-30 < 5 8 < 5 7 0.41 0.02, 7.97 0.76 0.01, 100.75 1.71 0.12, 23.76 
> 30 0 0 0 e e e e e e e 
Missing 3  2        Trendi     0.33 0.01, 8.94 0.89 < 0.01, 159.63 2.54 0.06, 109.44 Smoke from oil well fires           Not exposed or ≤ 5 8 62 15 52 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 5 38 14 48 0.55 0.12, 2.59 0.58 0.09, 3.83 0.36 0.07, 1.85 
Missing 3  1        Trendi     0.69 0.29, 1.64 0.56 0.18, 1.78 0.68 0.32, 1.44 Exposure to nerve gas (e.g., during munitions destruction)           Not exposed 11 79 21 96 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 7 < 5 4 1.50 0.04, 57.58 e e e e 
6-30 < 5 7 0 0 e e e e e e 
> 30 < 5 7 0 0 e e e e e e 
Missing 2  8        Trendk     1.35 0.72, 2.51 
e e e e 
High levels of dust/sand           Not exposed or ≤ 30 8 53 10 33 1.00 Referent 1.00 Referent 1.00 Referent 
> 30 7 47 20 67 0.17 0.03, 0.90 0.14 0.02, 1.06 1.36 0.21, 8.94 
Missing 1  0        Trendi     0.29 0.11, 0.77 0.27 0.09, 0.83 0.70 0.32, 1.51 Ground level fumigation           Not exposed 9 69 24 92 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 < 5 15 < 5 4 5.46 0.42, 71.73 19.29 0.20, 1854.70 9.41 0.71,123.78 
> 30 < 5 15 < 5 4 4.07 0.24, 68.81 2.33 0.07, 78.43 13.99 0.96, 203.86 
Missing 3  4        Trendi         1.91 0.58, 6.28 1.68 0.39, 7.28 3.24 0.83, 12.64 
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CARC, 
Chemical Agent Resistant Compound; CI, confidence interval; DU, depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral 
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 Sclerosis; Gulf, 1990-1991 Persian Gulf; IP, inverse probability; IQR, interquartile range; OR, odds ratio; U.S., United States of America; VA, Department of Veterans Affairs; 
WWII, World War II. 
aAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms) and use of the VA health care system. 
bAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, race/ethnicity, and 
military branch of longest service. War deployment-related exposures were not adjusted for sex because of model instability. 
cWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 95% CIs were calculated with robust variance estimates. 
dUsed within-category medians that were calculated using all controls. 
eUnable to estimate OR and 95% CI. 
fScaled the OR to an IQR-unit increase in the exposure variable. IQRs were calculated using all controls except those in the reference category. Reference category excluded for 
linear trend test. 
gScaled the OR to an IQR-unit increase in the exposure variable. IQRs were calculated using all controls except those in the reference category. Reference category included for 
linear trend test. 
hThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). 
iUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5) and scaled the OR to a 20 day increase in the exposure variable. Reference 
category included for linear trend test. 
jRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of the Vietnam War, or 1964-1975) because doing so 
drastically improved the behavior of the IP weights used for analysis. This restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls. 
kUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5). OR corresponds to a one day increase in the exposure variable. Reference 
category included for linear trend test.  
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 Table F.13. Feel ill from military exposures and amyotrophic lateral sclerosis in GENEVA. 
  Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
While you were in WWII, the Korean War, the Vietnam War, and/or the Gulf 
Ward: did you feel ill from exposure to           
Manufacture, testing, or use of chemical protective gear (for mustard gas, 
 tear gas, etc.) Do not include training           
Not exposed 208 95 306 92 1.00 Referent 1.00 Referent 1.00 Referent 
No 6 3 24 7 0.11 0.03, 0.41 0.13 0.04, 0.47 0.21 0.05, 0.83 
Yes 6 3 < 5 1 1.41 0.35, 5.76 1.27 0.31, 5.21 1.67 0.34, 8.14 
Missing 11  4        Trende     0.56 0.30, 1.04 0.57 0.31, 1.07 0.94 0.40, 2.20 Ionizing radiation from nuclear weapon testing or occupation of 
 Hiroshima/Nagasaki           
Not exposed 212 98 327 99 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 2 < 5 1 2.30 0.51, 10.49 2.16 0.45, 10.42 2.51 0.52, 12.08 
Yes 0 0 0 0 f f f f f f 
Missing 15  8        Trende     2.30 0.51, 10.49 2.16 0.45, 10.42 1.22 0.17, 8.91 Use of personal pesticides, like creams, sprays or flea collars           Not exposed 155 72 233 71 1.00 Referent 1.00 Referent 1.00 Referent 
No 54 25 86 26 0.90 0.59, 1.36 0.85 0.56, 1.31 1.46 0.78, 2.74 
Yes 5 2 7 2 1.34 0.41, 4.36 1.39 0.41, 4.66 3.72 0.95, 14.47 
Missing 17  12        Trende     0.97 0.68, 1.39 0.94 0.65, 1.36 1.24 0.66, 2.31 Use of pesticides on your clothing or bedding           Not exposed 161 79 243 75 1.00 Referent 1.00 Referent 1.00 Referent 
No 39 19 69 21 0.81 0.51, 1.28 0.81 0.50, 1.29 1.10 0.54, 2.26 
Yes 5 2 10 3 0.74 0.24, 2.28 0.98 0.30, 3.24 4.39 1.14, 16.90 
Missing 26  16        Trende     0.83 0.57, 1.21 0.87 0.59, 1.28 1.38 0.83, 2.31 Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)           Not exposed 142 67 235 71 1.00 Referent 1.00 Referent 1.00 Referent 
No 57 27 77 23 1.15 0.76, 1.74 1.16 0.76, 1.76 1.56 0.91, 2.68 
Yes 14 7 19 6 1.22 0.58, 2.57 1.48 0.69, 3.19 2.18 0.80, 5.94 
Missing 18  7        Trende     1.12 0.84, 1.51 1.19 0.88, 1.61 1.54 1.04, 2.27 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Exposure to diesel and/or other petrochemical fumes           Not exposed 75 36 118 36 1.00 Referent 1.00 Referent 1.00 Referent 
No 109 52 174 53 0.92 0.62, 1.36 0.91 0.60, 1.35 0.88 0.50, 1.55 
Yes 24 12 35 11 0.99 0.53, 1.86 1.02 0.54, 1.94 1.50 0.72, 3.12 
Missing 23  11        Trende     0.97 0.73, 1.29 0.98 0.73, 1.31 1.15 0.79, 1.67 Burning trash or burning feces/manure           Not exposed 146 67 202 62 1.00 Referent 1.00 Referent 1.00 Referent 
No 58 27 96 30 0.78 0.52, 1.18 0.74 0.47, 1.14 1.22 0.62, 2.40 
Yes 13 6 27 8 0.64 0.31, 1.32 0.56 0.26, 1.20 0.78 0.29, 2.11 
Missing 14  13        Trende     0.79 0.59, 1.07 0.74 0.54, 1.03 1.15 0.74, 1.79 Exposure to paint, solvents, or petrochemical substances           Not exposed 146 69 216 65 1.00 Referent 1.00 Referent 1.00 Referent 
No 60 28 98 30 0.85 0.57, 1.27 0.71 0.46, 1.10 0.69 0.36, 1.32 
Yes 7 3 16 5 0.73 0.29, 1.84 0.58 0.23, 1.50 1.16 0.37, 3.62 
Missing 18  8        Trende     0.85 0.62, 1.17 0.73 0.52, 1.04 0.89 0.54, 1.48 High-intensity radar waves (e.g., as radar operator, radio operator, aviation 
 electrician's mate)           
Not exposed 162 79 263 84 1.00 Referent 1.00 Referent 1.00 Referent 
No 41 20 48 15 1.43 0.90, 2.28 1.39 0.86, 2.26 1.70 0.89, 3.23 
Yes < 5 1 < 5 < 1 2.90 0.25, 33.07 2.29 0.20, 26.45 2.00 0.18, 22.44 
Missing 26  26        Trende     1.46 0.94, 2.26 1.41 0.89, 2.21 1.70 0.95, 3.04 Food contaminated with smoke, oil, or other chemicals           Not exposed 185 93 269 90 1.00 Referent 1.00 Referent 1.00 Referent 
No 8 4 24 8 0.51 0.22, 1.17 0.53 0.23, 1.24 1.46 0.54, 3.96 
Yes 6 3 7 2 1.35 0.44, 4.13 1.30 0.42, 4.03 2.52 0.67, 9.41 
Missing 32  38        Trende     0.88 0.55, 1.42 0.88 0.55, 1.43 1.35 0.77, 2.38 Local food other than food provided by the Armed Forces           Not exposed 110 50 167 50 1.00 Referent 1.00 Referent 1.00 Referent 
No 98 44 128 38 1.10 0.76, 1.58 1.13 0.77, 1.65 1.39 0.79, 2.44 
Yes 13 6 38 11 0.53 0.27, 1.05 0.50 0.25, 1.01 0.64 0.18, 2.29 
Missing 10  5        Trende     0.87 0.66, 1.14 0.86 0.65, 1.13 0.98 0.60, 1.61 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Bathing in or drinking of water contaminated with smoke, oil, dead animals or 
 any chemicals           
Not exposed 175 91 274 88 1.00 Referent 1.00 Referent 1.00 Referent 
No 14 7 25 8 0.97 0.48, 1.94 0.97 0.48, 1.97 0.60 0.13, 2.74 
Yes < 5 2 12 4 0.55 0.17, 1.77 0.52 0.16, 1.70 1.43 0.29, 7.05 
Missing 38  27        Trende     0.82 0.53, 1.29 0.81 0.51, 1.28 1.05 0.54, 2.03 Heat cramps, heat exhaustion, heat stroke or other heat illness           Not exposed 172 77 249 75 1.00 Referent 1.00 Referent 1.00 Referent 
No 8 4 8 2 1.54 0.55, 4.32 1.76 0.61, 5.06 4.53 1.15, 17.79 
Yes 42 19 76 23 0.81 0.52, 1.27 0.82 0.52, 1.29 1.28 0.58, 2.83 
Missing 9  5        Trende     0.91 0.73, 1.14 0.92 0.74, 1.15 1.17 0.84, 1.63 Heard chemical alarms sounding           Not exposed 208 93 301 90 1.00 Referent 1.00 Referent 1.00 Referent 
No 15 7 32 10 0.43 0.21, 0.89 0.49 0.23, 1.03 1.07 f 
Yes 0 0 < 5 < 1 f f f f f f 
Missing 8  4        Trende     0.42 0.21, 0.86 0.47 0.23, 0.98 0.69 0.30, 1.57 Explosion in the air or on the ground within one mile of you (e.g., artillery, 
 rockets, mortars)           
Not exposed 72 33 116 36 1.00 Referent 1.00 Referent 1.00 Referent 
No 135 61 187 58 1.27 0.87, 1.87 1.30 0.87, 1.93 1.77 1.07, 2.94 
Yes 13 6 19 6 1.19 0.55, 2.61 1.17 0.52, 2.61 2.36 0.79, 7.07 
Missing 11  16        Trende     1.18 0.86, 1.61 1.19 0.86, 1.64   While you were in WWII, the Korean War, and/or the Vietnam Ward: did you feel 
ill from exposure to           
Mixing and application of herbicides           Not exposed 202 98 303 99 1.00 Referent 1.00 Referent 1.00 Referent 
No 5 2 < 5 1 3.88 0.72, 20.94 3.64 0.68, 19.40 5.77 0.83, 40.30 
Yes 0 0 0 0 f f f f f f 
Missing 12  9        Trende     3.88 0.72, 20.94 3.64 0.68, 19.40 3.62 0.58, 22.71 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Exposure to herbicides in the field           Not exposed 160 94 238 95 1.00 Referent 1.00 Referent 1.00 Referent 
No 10 6 9 4 2.01 0.78, 5.15 2.14 0.82, 5.63 1.79 0.45, 7.12 
Yes < 5 1 < 5 2 0.58 0.06, 5.38 0.59 0.06, 5.56 0.56 0.06, 5.36 
Missing 48  63        Trende     1.27 0.65, 2.48 1.31 0.66, 2.59 1.97 0.68, 5.69 Mixing and application of riot control substances           Not exposed 213 99 307 98 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 1 5 2 0.83 0.18, 3.77 1.09 0.24, 4.95 2.60 f 
Yes 0 0 < 5 1 f f f f f f 
Missing 3  0        Trende     0.53 0.16, 1.80 0.66 0.20, 2.22 1.67 0.26, 10.66 Exposure to riot control substances in the field           Not exposed 202 94 285 92 1.00 Referent 1.00 Referent 1.00 Referent 
No 9 4 14 5 0.86 0.35, 2.10 0.93 0.37, 2.31 1.73 0.60, 5.00 
Yes < 5 2 12 4 0.29 0.07, 1.15 0.28 0.07, 1.16 3.97 0.52, 30.37 
Missing 4  3        Trende     0.63 0.37, 1.08 0.64 0.37, 1.11 1.82 0.78, 4.27 Mixing and application of burning agents           Not exposed 197 93 303 98 1.00 Referent 1.00 Referent 1.00 Referent 
No 12 6 5 2 3.39 1.13, 10.18 3.32 1.10, 9.99 6.49 1.26, 33.40 
Yes < 5 1 < 5 < 1 5.24 0.52, 52.71 5.48 0.54, 55.10 52.73 3.78, 736.29 
Missing 7  5        Trende     2.85 1.24, 6.55 2.84 1.24, 6.50 5.53 2.09, 14.61 Exposure to burning agents in the field           Not exposed 176 85 277 91 1.00 Referent 1.00 Referent 1.00 Referent 
No 26 13 20 7 2.12 1.11, 4.02 2.06 1.08, 3.95 1.45 0.37, 5.68 
Yes 6 3 9 3 1.02 0.34, 3.07 1.09 0.35, 3.40 2.97 0.75, 11.74 
Missing 11  8        Trende     1.37 0.89, 2.10 1.39 0.90, 2.15 2.07 1.08, 3.96 While you were in the Korean War, the Vietnam War, and/or the Gulf Ward: did 
you feel ill from exposure to           
Microwave radiation           Not exposed 153 92 268 92 1.00 Referent 1.00 Referent 1.00 Referent 
No 12 7 20 7 0.92 0.42, 2.02 0.90 0.41, 2.01 1.51 0.56, 4.06 
Yes < 5 1 < 5 1 1.15 0.10, 13.17 1.40 0.12, 15.96 0.72 0.06, 8.01 
Missing 30  37        Trende     0.96 0.49, 1.88 0.97 0.49, 1.93 1.24 0.56, 2.73 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
While you were in the Vietnam Ward,g: did you feel ill from exposure to           Mixing and application of Agent Orange           Not exposed 109 94 200 94 1.00 Referent 1.00 Referent 1.00 Referent 
No 7 6 12 6 1.47 0.54, 4.01 1.60 0.57, 4.51 1.67 f 
Yes 0 0 < 5 < 1 f f f f f f 
Missing 11  6        Trende     1.35 0.52, 3.51 1.44 0.54, 3.81 1.11 0.39, 3.17 Exposure to Agent Orange in the field           Not exposed 41 44 98 60 1.00 Referent 1.00 Referent 1.00 Referent 
No 43 46 58 35 3.07 1.58, 5.95 3.20 1.58, 6.47 2.50 1.23, 5.10 
Yes 9 10 8 5 2.88 0.85, 9.76 3.46 0.86, 13.96 8.73 2.19, 34.83 
Missing 34  55        Trende     2.23 1.34, 3.70 2.46 1.39, 4.37 2.69 1.51, 4.77 While you were in the Gulf Ward: did you feel ill from exposure to           Use of depleted uranium (DU) for munitions or armor           Not exposed 8 62 23 88 1.00 Referent 1.00 Referent 1.00 Referent 
No 5 38 < 5 8 6.00 0.83, 43.54 6.06 0.35, 105.73 1.19 f 
Yes 0 0 < 5 4 f f f f f f 
Missing 3  4        Trende     2.68 0.63, 11.48 5.17 0.38, 71.03 5.63 0.88, 36.04 CARC (Chemical Agent Resistant Compound) paint           Not exposed 10 77 20 87 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 23 < 5 9 2.07 0.26, 16.53 12.67 0.03, 5631.99 2.00 f 
Yes 0 0 < 5 4 f f f f f f 
Missing 3  7        Trende     1.32 0.26, 6.71 9.12 0.05, 1520.11 4.58 0.52, 40.20 Scud missile explosion in the air or on the ground within one mile of you           Not exposed 9 69 17 61 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 23 11 39 0.46 0.09, 2.42 1.38 0.14, 13.38 4.87 f 
Yes < 5 8 0 0 f f f f f f 
Missing 3  2        Trende     0.73 0.19, 2.85 1.52 0.18, 12.78 2.44 0.55, 10.87 Smoke from oil well fires           Not exposed 5 38 9 31 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 23 16 55 0.45 0.07, 2.96 0.18 0.01, 4.49 0.25 0.04, 1.50 
Yes 5 38 < 5 14 2.56 0.35, 18.59 4.80 0.30, 76.22 1.20 0.18, 8.15 
Missing 3  1        Trende     1.51 0.54, 4.26 1.99 0.51, 7.72 1.62 0.45, 5.77 
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   Cases Controls Adjusteda Adjustedb IP-weightedc 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Exposure to nerve gas (e.g., during munitions destruction)           Not exposed 11 79 21 95 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 7 < 5 5 4.70 0.21, 106.17 109.13 0.19, 61891.75 f f 
Yes < 5 14 0 0 f f f f f f 
Missing 2  8        Trende     5.45 0.35, 84.96 109.15 0.19, 61833.68 
f f 
High levels of dust/sand           Not exposed 3 20 2 7 1.00 Referent 1.00 Referent 1.00 Referent 
No 12 80 25 83 0.20 0.03, 1.63 0.13 0.01, 1.78 0.87 f 
Yes 0 0 < 5 10 f f f f f f 
Missing 1  0        Trende     0.17 0.02, 1.18 0.07 0.01, 0.81 1.03 0.18, 5.98 Ground level fumigation           Not exposed 9 69 24 92 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 23 < 5 4 7.48 0.56, 99.67 52.62 0.48, 5747.99 4.15 0.34, 50.57 
Yes < 5 8 < 5 4 2.41 0.12, 50.42 0.77 0.02, 30.53 0.73 0.04, 13.48 
Missing 3  4        Trende         2.41 0.61, 9.49 1.96 0.37, 10.45 13.04 1.32, 128.58 
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CARC, 
Chemical Agent Resistant Compound; CI, confidence interval; DU, depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral 
Sclerosis; Gulf, 1990-1991 Persian Gulf; IP, inverse probability; OR, odds ratio; VA, Department of Veterans Affairs; WWII, World War II. 
aAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms) and use of the VA health care system. 
bAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, race/ethnicity, and 
military branch of longest service. War deployment-related exposures were not adjusted for sex because of model instability. 
cWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 95% CIs were calculated with robust variance estimates. 
dThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). 
eUsed ordinal scores (0, 1, 2). Reference category included for linear trend test. 
fUnable to estimate OR and 95% CI. 
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 gRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of the Vietnam War, or 1964-1975) because doing 
so drastically improved the behavior of the IP weights used for analysis. This restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls.  
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 Table F.14. Military deployments to the Vietnam Wara and amyotrophic lateral sclerosis in GENEVA. 
  Cases Controls Adjustedc Adjustedd IP-weightede 
Variable No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Total number of theaters of operation for the Vietnam War           Not deployed to any war/operationf 169 55 320 56 1.00 Referent 1.00 Referent 1.00 Referent 
Not deployed to the Vietnam War 12 4 29 5 0.58 0.27, 1.25 0.61 0.28, 1.32 0.48 0.22, 1.04 
1 (Median = 1) 93 30 154 27 1.64 1.15, 2.34 1.39 0.96, 2.00 1.62 1.09, 2.41 
2 (2) 24 8 47 8 1.56 0.89, 2.76 1.39 0.78, 2.48 1.32 0.66, 2.67 
> 2 (3) 10 3 18 3 1.68 0.70, 4.00 1.43 0.59, 3.47 2.32 0.90, 5.99 
Missing 6  8        Trendg     1.06 0.71, 1.59 1.05 0.70, 1.59 1.06 0.71, 1.60 Total length (years) of deployment to all theaters of operation for the Vietnam War           Not deployed to any war/operationf 169 55 320 57 1.00 Referent 1.00 Referent 1.00 Referent 
Not deployed to the Vietnam War 12 4 29 5 0.58 0.27, 1.25 0.61 0.28, 1.32 0.48 0.22, 1.04 
≤ 1 (0.92) 63 21 133 24 1.28 0.87, 1.89 1.08 0.72, 1.61 1.18 0.75, 1.87 
> 1-2 (1.17) 42 14 60 11 2.09 1.29, 3.38 1.78 1.08, 2.93 2.39 1.37, 4.18 
> 2-3 (2.09) 12 4 12 2 2.67 1.13, 6.33 2.13 0.88, 5.12 2.26 0.66, 7.66 
> 3 (3.38) 7 2 11 2 2.07 0.75, 5.74 2.21 0.80, 6.12 0.57 0.17, 1.91 
Missing 9  11        Trendg     1.36 0.90, 2.05 1.44 0.95, 2.19 1.17 0.75, 1.82 End of most recent period of deployment to the Vietnam War (year)           Not deployed to any war/operationf 169 55 320 56 1.00 Referent 1.00 Referent 1.00 Referent 
Not deployed to the Vietnam War 12 4 29 5 0.56 0.26, 1.22 0.58 0.27, 1.28 0.48 0.23, 1.04 
≤ 1966 (1966) 14 5 13 2 5.54 2.42, 12.69 5.60 2.40, 13.09 4.25 1.58, 11.47 
1967-1968 (1968) 34 11 53 9 2.24 1.34, 3.76 1.82 1.07, 3.10 2.28 1.18, 4.38 
1969-1970 (1969) 43 14 78 14 1.61 1.02, 2.54 1.35 0.84, 2.17 1.74 0.98, 3.10 
1971-1972 (1971) 27 9 53 9 1.20 0.70, 2.07 1.04 0.60, 1.81 1.51 0.77, 2.96 
> 1972 (1974) 6 2 22 4 0.39 0.14, 1.11 0.34 0.12, 0.98 0.59 0.09, 3.85 
Missing 9  8        Trendg         0.55 0.46, 0.67 0.53 0.43, 0.65 0.75 0.65, 0.88 
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CI, confidence 
interval; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; IP, inverse probability; OR, odds ratio; VA, Department of Veterans 
Affairs. 
aThe GENEVA study questionnaire asked "Were you deployed to..." the Vietnam War (defined as the period from August 3, 1964, to May 7, 1975). 
bRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of the Vietnam War, or 1964-1975) because doing 
so drastically improved the behavior of the IP weights used for analysis. This restriction resulted in the exclusion of 305 (49%) cases and 380 (40%) controls. 
cAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms) and use of the VA health care system. 
dAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, race/ethnicity, and 
military branch of longest service. 
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 eWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, sex, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). 95% CIs were calculated with robust variance estimates. 
fThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also asked "Ever 
deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, 
Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
gUsed within-category medians that were calculated using all controls. Individuals in the categories labeled "Not deployed to any war/operation" and "Not deployed to the Vietnam 
War" were excluded for the linear trend test.  
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 Table F.15. Military exposures during deployment to the Vietnam Wara, b and amyotrophic lateral sclerosis in GENEVA. 
  Cases Controls Adjustedc Adjustedd IP-weightede 
Did you have direct contact with/were you exposed to No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Mixing and application of Agent Orangef           No 109 93 200 94 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 8 7 13 6 1.42 0.52, 3.85 1.54 0.55, 4.29 1.27 0.42, 3.86 
Missing 10  6        Exposure to Agent Orange in the fieldf           No 41 41 98 56 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 58 59 77 44 2.91 1.57, 5.39 3.12 1.59, 6.09 2.55 1.28, 5.08 
Missing 28  44        Mixing and application of other herbicides           No 116 97 211 99 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 3 < 5 1 3.88 0.53, 28.33 3.69 0.53, 25.68 2.52 0.26, 24.81 
Missing 8  6        Exposure to other herbicides in the field           No 80 91 165 93 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 8 9 12 7 3.24 1.11, 9.45 3.27 1.08, 9.94 4.84 1.34, 17.47 
Missing 39  42        Manufacture, testing, or use of chemical protective gear (for mustard gas, tear gas, etc.) 
Do not include training           
No 114 94 205 94 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 7 6 13 6 0.75 0.25, 2.28 0.79 0.26, 2.38 0.39 0.11, 1.38 
Missing 6  1        Ionizing radiation from nuclear weapon testing           No 114 98 212 99 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 2 < 5 1 1.56 0.24, 10.35 1.94 0.27, 13.82 0.97 0.14, 6.60 
Missing 11  4        Microwave radiation           No 97 90 184 92 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 11 10 15 8 1.78 0.69, 4.60 1.88 0.70, 5.00 1.38 0.55, 3.47 
Missing 19  20        Use of personal pesticides, like creams, sprays or flea collars           No 74 61 140 35 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 48 39 76 35 1.17 0.69, 1.99 1.15 0.67, 1.98 1.34 0.75, 2.38 
Missing 5  3        Use of pesticides on your clothing or bedding           No 76 66 153 72 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 39 34 60 28 1.60 0.91, 2.79 1.52 0.85, 2.70 1.69 0.92, 3.10 
Missing 12  6        
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   Cases Controls Adjustedc Adjustedd IP-weightede 
Did you have direct contact with/were you exposed to No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)           No 76 63 158 73 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 44 37 59 27 1.63 0.94, 2.81 1.69 0.97, 2.96 2.14 1.22, 3.74 
Missing 7  2        Exposure to diesel and/or other petrochemical fumes           No 30 25 70 32 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 92 75 147 68 1.51 0.84, 2.68 1.47 0.81, 2.64 1.37 0.75, 2.51 
Missing 5  2        Burning trash or burning feces/manure           No 62 51 114 53 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 60 49 100 47 1.10 0.66, 1.84 1.07 0.60, 1.89 1.09 0.60, 1.98 
Missing 5  5        Exposure to paint, solvents, or petrochemical substances           No 76 63 133 61 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 44 37 84 39 0.83 0.49, 1.42 0.75 0.42, 1.35 0.95 0.54, 1.68 
Missing 7  2        High-intensity radar waves (e.g., as radar operator, radio operator, aviation electrician's 
mate)           
No 83 75 172 84 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 28 25 33 16 1.77 0.93, 3.40 1.91 0.98, 3.72 1.85 0.87, 3.95 
Missing 16  14        Food contaminated with smoke, oil, or other chemicals           No 97 88 174 88 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 13 12 24 12 1.08 0.48, 2.41 1.12 0.49, 2.58 1.39 0.58, 3.31 
Missing 17  21        Local food other than food provided by the Armed Forces           No 56 46 113 52 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 67 54 106 48 1.23 0.74, 2.03 1.13 0.67, 1.91 1.05 0.61, 1.80 
Missing 4  0        Bathing in or drinking of water contaminated with smoke, oil, dead animals or any 
chemicals           
No 88 83 169 84 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 18 17 33 16 1.08 0.53, 2.21 1.15 0.55, 2.43 0.93 0.42, 2.09 
Missing 21  17        Heat cramps, heat exhaustion, heat stroke or other heat illness           No 84 69 152 70 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 38 31 64 30 1.07 0.61, 1.87 1.09 0.61, 1.93 1.26 0.73, 2.19 
Missing 5  3        
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   Cases Controls Adjustedc Adjustedd IP-weightede 
Did you have direct contact with/were you exposed to No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Heard chemical alarms sounding           No 117 96 200 93 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 5 4 16 7 0.54 0.18, 1.65 0.59 0.19, 1.83 0.63 0.18, 2.23 
Missing 5  3        Explosion in the air or on the ground within one mile of you (e.g., artillery, rockets, 
mortars)           
No 28 22 60 28 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 97 78 151 72 1.57 0.85, 2.87 1.63 0.87, 3.07 1.91 1.02, 3.59 
Missing 2  8        Mixing and application of riot control substances           No 123 98 213 97 1.00 Referent 1.00 Referent 1.00 Referent 
Yes < 5 2 6 3 0.51 0.08, 3.17 0.75 0.13, 4.43 0.24 0.03, 2.21 
Missing 2  0        Exposure to riot control substances in the field           No 115 93 198 91 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 9 7 19 9 0.64 0.25, 1.64 0.64 0.25, 1.69 0.58 0.22, 1.57 
Missing 3  2        Mixing and application of burning agents           No 110 91 212 98 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 11 9 5 2 5.00 1.53, 16.31 5.13 1.54, 17.14 5.05 1.37, 18.61 
Missing 6  2        Exposure to burning agents in the field           No 90 75 188 88 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 30 25 26 12 3.07 1.58, 5.94 3.22 1.63, 6.37 2.79 1.34, 5.83 
Missing 7  5        Have you suffered a combat-related injury that required medical attention during your 
deployment?           
No 94 76 156 72 1.00 Referent 1.00 Referent 1.00 Referent 
Yes 30 24 61 28 0.72 0.40, 1.31 0.78 0.42, 1.47 0.66 0.30, 1.43 
Missing 3   2               
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CI, confidence 
interval; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; IP, inverse probability; OR, odds ratio; VA, Department of Veterans 
Affairs. 
aThe GENEVA study questionnaire asked "Were you deployed to..." the Vietnam War (defined as the period from August 3, 1964, to May 7, 1975). 
bRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of the Vietnam War, or 1964-1975) because doing 
so drastically improved the behavior of the IP weights used for analysis. This restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls. 
cAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms) and use of the VA health care system. 
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 dAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, race/ethnicity, and 
military branch of longest service. War deployment-related exposures were not adjusted for sex because of model instability. 
eWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 95% CIs were calculated with robust variance estimates. 
fRepeated from Table 4.5.  
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 Table F.16. Dose-response for military exposures during deployment to the Vietnam Wara and amyotrophic lateral sclerosis in GENEVA. 
  Cases Controls Adjustedc Adjustedd IP-weightede 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Total number of preventive vaccinations received by injection (shots) or by mouth while 
inside or outside the U.S.           
0 (Median = 0) 29 29 48 26 1.00 Referent 1.00 Referent 1.00 Referent 
1-10 (5) 32 32 80 43 0.61 0.30, 1.25 0.61 0.29, 1.28 0.68 0.32, 1.44 
11-20 (13) 16 16 21 11 1.22 0.49, 3.03 1.23 0.48, 3.16 1.30 0.53, 3.19 
21-30 (25) 5 5 9 5 0.71 0.18, 2.79 0.72 0.18, 2.83 1.50 0.41, 5.40 
> 30 (99) 17 17 27 15 1.03 0.43, 2.45 1.08 0.44, 2.64 2.22 0.69, 7.20 
Missing 28  34        Trend (IQR = 13)f     1.03 0.93, 1.14 1.04 0.93, 1.15 1.09 0.96, 1.23 Number of days exposed to           Mixing and application of Agent Orangeg           Not exposed or ≤ 5 111 96 202 95 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 5 4 11 5 0.98 0.29, 3.30 0.99 0.28, 3.47 1.04 0.30, 3.60 
Missing 11  6        Trendh     0.94 0.48, 1.83 0.96 0.48, 1.92 0.93 0.42, 2.05 Exposure to Agent Orange in the fieldg           Not exposed 41 44 98 58 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 10 11 13 8 2.30 0.83, 6.36 2.37 0.81, 6.99 2.12 0.71, 6.32 
6-30 8 9 16 10 2.01 0.66, 6.13 1.77 0.56, 5.63 3.05 0.82, 11.30 
> 30 34 37 41 24 3.14 1.53, 6.42 3.29 1.50, 7.22 2.25 1.03, 4.90 
Missing 34  51        Trendh     1.55 1.15, 2.09 1.56 1.13, 2.16 1.42 1.06, 1.90 Mixing and application of other herbicides           Not exposed 116 97 211 99 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 < 5 2 < 5 < 1 3.11 0.22, 43.31 3.20 0.25, 40.51 3.80 0.23, 61.54 
> 30 < 5 1 < 5 < 1 5.04 0.28, 91.83 4.43 0.24, 81.42 1.77 0.11, 28.64 
Missing 8  6        Trendh     2.40 0.71, 8.13 2.28 0.67, 7.73 16.94 0.81, 356.45 Exposure to other herbicides in the field           Not exposed or ≤ 5 82 94 167 94 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 5 6 10 6 2.35 0.66, 8.41 2.10 0.57, 7.73 1.82 0.46, 7.17 
Missing 40  42        Trendh     1.44 0.79, 2.62 1.34 0.73, 2.45 1.23 0.65, 2.31 
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   Cases Controls Adjustedc Adjustedd IP-weightede 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Manufacture, testing, or use of chemical protective gear (for mustard gas, tear gas, 
 etc.) Do not include training           
Not exposed 114 94 205 94 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 2 9 4 0.49 0.11, 2.13 0.54 0.13, 2.23 0.15 0.03, 0.78 
> 5 < 5 3 < 5 2 1.43 0.27, 7.66 1.51 0.27, 8.49 0.96 0.17, 5.48 
Missing 6  1        Trendh     0.76 0.23, 2.45 0.79 0.24, 2.62 1.06 0.35, 3.23 Ionizing radiation from nuclear weapon testing           Not exposed 114 98 212 99 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 2 < 5 < 1 5.63 0.45, 71.09 5.82 0.44, 76.49 9.08 i 
6-30 0 0 < 5 1 i i i i i i 
> 30 0 0 < 5 1 i i i i i i 
Missing 11  4        Trendh     0.33 0.02, 7.32 0.40 0.02, 9.34 1.38 0.13, 14.99 Microwave radiation           Not exposed or ≤ 5 98 91 189 95 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 10 9 10 5 2.20 0.77, 6.29 2.36 0.80, 6.92 2.02 0.78, 5.24 
Missing 19  20        Trendh     1.48 0.91, 2.42 1.54 0.93, 2.54 1.23 0.74, 2.07 Use of personal pesticides, like creams, sprays or flea collars           Not exposed 74 61 140 66 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 9 7 13 6 1.43 0.52, 3.97 1.36 0.48, 3.89 2.65 0.88, 7.95 
> 30 38 31 60 28 1.17 0.66, 2.08 1.17 0.65, 2.12 1.12 0.62, 2.02 
Missing 6  6        Trendh     1.06 0.83, 1.35 1.06 0.82, 1.36 1.04 0.82, 1.33 Use of pesticides on your clothing or bedding           Not exposed 76 67 153 72 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 8 7 9 4 1.89 0.61, 5.83 1.69 0.53, 5.38 2.78 0.84, 9.17 
> 30 30 26 50 24 1.51 0.82, 2.76 1.46 0.79, 2.72 1.48 0.78, 2.80 
Missing 13  7        Trendh     1.20 0.93, 1.55 1.18 0.91, 1.54 1.21 0.91, 1.60 Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)           Not exposed 76 64 158 73 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 12 10 19 9 1.57 0.66, 3.76 1.62 0.66, 3.96 2.29 0.87, 6.02 
> 30 30 25 40 18 1.64 0.88, 3.05 1.72 0.91, 3.24 1.82 0.95, 3.47 
Missing 9  2        Trendh     1.26 0.97, 1.64 1.29 0.98, 1.69 1.36 1.04, 1.78 
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   Cases Controls Adjustedc Adjustedd IP-weightede 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Exposure to diesel and/or other petrochemical fumes           Not exposed 30 25 70 33 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 5 4 19 9 0.58 0.17, 1.97 0.58 0.17, 2.03 0.37 0.12, 1.15 
6-30 9 7 17 8 1.34 0.48, 3.79 1.29 0.45, 3.72 1.28 0.44, 3.78 
> 30 77 64 109 51 1.69 0.93, 3.07 1.65 0.89, 3.05 1.55 0.83, 2.88 
Missing 6  4        Trendh     1.30 1.02, 1.65 1.29 1.00, 1.65 1.29 1.00, 1.67 Burning trash or burning feces/manure           Not exposed 62 52 114 54 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 10 8 25 12 0.67 0.27, 1.66 0.69 0.27, 1.78 0.37 0.14, 0.96 
6-30 9 8 29 14 0.73 0.30, 1.77 0.70 0.28, 1.75 0.91 0.31, 2.69 
> 30 38 32 44 21 1.47 0.79, 2.73 1.35 0.69, 2.68 1.34 0.68, 2.63 
Missing 8  7        Trendh     1.20 0.92, 1.56 1.18 0.89, 1.56 1.16 0.87, 1.56 Exposure to paint, solvents, or petrochemical substances           Not exposed 76 63 133 62 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 17 14 45 21 0.69 0.34, 1.41 0.60 0.28, 1.28 0.72 0.32, 1.62 
> 30 27 23 38 18 1.04 0.54, 2.01 0.95 0.47, 1.93 0.99 0.49, 1.97 
Missing 7  3        Trendh     1.06 0.80, 1.40 1.04 0.77, 1.40 1.10 0.82, 1.48 High-intensity radar waves (e.g., as radar operator, radio operator, aviation 
 electrician's mate)           
Not exposed 83 75 172 84 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 5 5 10 5 1.29 0.39, 4.29 1.47 0.41, 5.24 0.95 0.25, 3.62 
> 30 23 21 23 11 1.98 0.95, 4.10 2.07 0.98, 4.34 2.33 0.99, 5.46 
Missing 16  14        Trendh     1.32 0.96, 1.80 1.35 0.98, 1.85 1.40 0.96, 2.03 Food contaminated with smoke, oil, or other chemicals           Not exposed 97 88 174 88 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 5 5 9 5 1.02 0.29, 3.57 1.09 0.29, 4.06 1.52 0.32, 7.18 
> 30 8 7 14 7 1.13 0.41, 3.11 1.17 0.41, 3.29 1.41 0.47, 4.26 
Missing 17  22        Trendh     1.10 0.72, 1.68 1.11 0.72, 1.72 1.23 0.77, 1.96 
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   Cases Controls Adjustedc Adjustedd IP-weightede 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Local food other than food provided by the Armed Forces           Not exposed 56 46 113 52 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 17 14 26 12 0.78 0.33, 1.87 0.71 0.29, 1.73 0.75 0.32, 1.76 
6-30 18 15 30 14 1.28 0.61, 2.67 1.22 0.57, 2.59 0.69 0.32, 1.47 
> 30 31 25 49 22 1.42 0.76, 2.65 1.31 0.69, 2.50 1.33 0.67, 2.63 
Missing 5  1        Trendh     1.19 0.92, 1.54 1.16 0.88, 1.51 1.15 0.87, 1.54 Bathing in or drinking of water contaminated with smoke, oil, dead animals or any 
 chemicals           
Not exposed 88 83 169 84 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 7 7 12 6 1.48 0.53, 4.15 1.48 0.51, 4.27 2.35 0.68, 8.14 
> 30 11 10 20 10 0.90 0.36, 2.27 1.03 0.40, 2.66 1.04 0.34, 3.14 
Missing 21  18        Trendh     0.97 0.66, 1.43 1.02 0.68, 1.53 1.04 0.66, 1.65 Heat cramps, heat exhaustion, heat stroke or other heat illness           Not exposed 84 69 152 70 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 15 12 31 14 0.89 0.41, 1.91 0.86 0.39, 1.88 0.77 0.37, 1.61 
6-30 13 11 15 7 1.54 0.62, 3.86 1.57 0.61, 4.05 1.33 0.53, 3.35 
> 30 10 8 18 8 0.99 0.39, 2.50 1.11 0.42, 2.92 1.71 0.62, 4.75 
Missing 5  3        Trendh     1.05 0.72, 1.54 1.10 0.74, 1.64 1.29 0.86, 1.92 Heard chemical alarms sounding           Not exposed 117 96 200 93 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 2 9 4 0.58 0.14, 2.52 0.62 0.14, 2.72 0.81 0.12, 5.58 
6-30 < 5 1 < 5 1 0.67 0.06, 7.60 1.04 0.08, 13.83 5.07 0.45, 56.80 
> 30 < 5 1 < 5 2 0.47 0.04, 5.00 0.41 0.04, 4.69 0.13 0.01, 1.27 
Missing 5  4        Trendh     0.69 0.26, 1.84 0.70 0.26, 1.86 0.50 0.17, 1.45 Explosion in the air or on the ground within one mile of you (e.g., artillery, rockets, 
 mortars)           
Not exposed 28 23 60 29 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 23 19 41 20 1.36 0.61, 3.04 1.51 0.66, 3.45 1.90 0.84, 4.33 
6-30 22 18 36 17 1.41 0.62, 3.18 1.36 0.59, 3.14 1.64 0.72, 3.75 
> 30 50 41 73 35 1.70 0.87, 3.31 1.76 0.87, 3.57 2.49 1.24, 5.01 
Missing 4  9        Trendh     1.19 0.93, 1.53 1.20 0.92, 1.56 1.27 0.97, 1.66 
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   Cases Controls Adjustedc Adjustedd IP-weightede 
Exposure No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Mixing and application of riot control substances           Not exposed 123 98 213 97 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 1 < 5 1 0.77 0.06, 10.56 1.00 0.08, 13.29 2.44 i 
> 5 < 5 1 < 5 2 0.36 0.03, 4.77 0.59 0.05, 6.73 i i 
Missing 2  0        Trendh     0.37 0.03, 4.02 0.53 0.07, 4.20 0.01 < 0.01, 13.22 Exposure to riot control substances in the field           Not exposed or ≤ 5 116 94 206 95 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 8 6 11 5 0.87 0.29, 2.55 0.96 0.32, 2.94 1.27 0.42, 3.91 
Missing 3  2        Trendh     0.90 0.46, 1.74 1.03 0.51, 2.05 1.20 0.53, 2.72 Mixing and application of burning agents           Not exposed or ≤ 5 111 92 213 98 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 10 8 < 5 2 6.64 1.83, 24.06 6.90 1.84, 25.89 4.52 1.25, 16.36 
Missing 6  2        Trendh     2.52 1.14, 5.58 2.62 1.17, 5.88 4.40 1.61, 12.02 Exposure to burning agents in the field           Not exposed 90 77 188 88 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 12 10 10 5 3.05 1.17, 7.98 3.05 1.15, 8.06 3.02 0.98, 9.30 
6-30 7 6 8 4 2.40 0.71, 8.10 2.40 0.67, 8.56 1.98 0.50, 7.77 
> 30 8 7 8 4 2.55 0.82, 7.91 2.99 0.93, 9.68 4.60 1.45, 14.60 
Missing 10  5        Trendh     1.56 0.98, 2.48 1.66 1.02, 2.68 1.96 1.18, 3.24 Have you suffered a combat-related injury that required medical attention during 
 your deployment?           
Not exposed 94 76 156 72 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 16 13 16 7 1.08 0.47, 2.49 1.13 0.48, 2.70 0.91 0.38, 2.16 
6-30 6 5 16 7 0.54 0.17, 1.71 0.61 0.19, 2.01 1.76 0.35, 8.87 
> 30 8 6 29 13 0.53 0.20, 1.39 0.57 0.21, 1.56 0.17 0.05, 0.52 
Missing 3  2        Trendh         0.73 0.49, 1.10 0.76 0.50, 1.16 0.59 0.37, 0.92 
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI, confidence interval; BIRLS, Beneficiary Identification and Records Locator 
System; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; IP, inverse probability; IQR, interquartile range; OR, odds ratio; U.S., 
United States of America; VA, Department of Veterans Affairs. 
aThe GENEVA study questionnaire asked "Were you deployed to..." the Vietnam War (defined as the period from August 3, 1964, to May 7, 1975). 
bRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of the Vietnam War, or 1964-1975) because doing 
so drastically improved the behavior of the IP weights used for analysis. This restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls. 
cAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms) and use of the VA health care system. 
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 dAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, race/ethnicity, and 
military branch of longest service. War deployment-related exposures were not adjusted for sex because of model instability. 
eWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 95% CIs were calculated with robust variance estimates. 
fUsed within-category medians that were calculated using all controls. Scaled the OR to an IQR-unit increase in the exposure variable. IQRs were calculated using all controls 
except those in the reference category. Reference category included for linear trend test. 
gRepeated from Appendix F, Table F.12. 
hUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5) and scaled the OR to a 20 day increase in the exposure variable. Reference 
category included for linear trend test. 
iUnable to estimate OR and 95% CI.  
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 Table F.17. Feel ill from military exposures during deployment to the Vietnam Wara,b and amyotrophic lateral sclerosis in GENEVA. 
  Cases Controls Adjustedc Adjustedd IP-weightede 
Did you feel ill from exposure to No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Mixing and application of Agent Orangef           Not exposed 109 94 200 94 1.00 Referent 1.00 Referent 1.00 Referent 
No 7 6 12 6 1.47 0.54, 4.01 1.60 0.57, 4.51 1.67 g 
Yes 0 0 < 5 < 1 g g g g g g 
Missing 11  6        Trendh     1.35 0.52, 3.51 1.44 0.54, 3.81 1.11 0.39, 3.17 Exposure to Agent Orange in the fieldf           Not exposed 41 44 98 60 1.00 Referent 1.00 Referent 1.00 Referent 
No 43 46 58 35 3.07 1.58, 5.95 3.20 1.58, 6.47 2.50 1.23, 5.10 
Yes 9 10 8 5 2.88 0.85, 9.76 3.46 0.86, 13.96 8.73 2.19, 34.83 
Missing 34  55        Trendh     2.23 1.34, 3.70 2.46 1.39, 4.37 2.69 1.51, 4.77 Mixing and application of other herbicides           Not exposed 116 97 211 99 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 3 < 5 1 3.88 0.53, 28.33 3.69 0.53, 25.68 3.04 0.35, 26.61 
Yes 0 0 0 0 g g g g g g 
Missing 8  6        Trendh     3.88 0.53, 28.33 3.69 0.53, 25.68 2.30 0.25, 20.91 Exposure to other herbicides in the field           Not exposed 80 92 165 94 1.00 Referent 1.00 Referent 1.00 Referent 
No 7 8 7 4 3.89 1.17, 13.00 3.94 1.13, 13.79 3.99 g 
Yes 0 0 < 5 2 g g g g g g 
Missing 40  43        Trendh     1.81 0.74, 4.46 1.88 0.73, 4.79 3.02 0.74, 12.25 Manufacture, testing, or use of chemical protective gear (for mustard gas, tear gas, etc.) Do not include 
training           
Not exposed 114 94 205 94 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 3 10 5 0.61 0.15, 2.41 0.73 0.19, 2.81 0.23 0.05, 1.15 
Yes < 5 2 < 5 1 1.13 0.18, 7.00 0.92 0.14, 5.83 1.00 0.13, 7.81 
Missing 6  1        Trendh     0.89 0.41, 1.94 0.88 0.40, 1.91 0.61 0.23, 1.64 Ionizing radiation from nuclear weapon testing           Not exposed 114 98 212 99 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 2 < 5 1 2.21 0.28, 17.71 3.08 0.36, 26.45 1.47 0.20, 11.07 
Yes 0 0 0 0 g g g g g g 
Missing 11  5        Trendh     2.21 0.28, 17.71 3.08 0.36, 26.45 0.76 0.09, 6.43 
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   Cases Controls Adjustedc Adjustedd IP-weightede 
Did you feel ill from exposure to No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Microwave radiation           Not exposed 97 91 184 93 1.00 Referent 1.00 Referent 1.00 Referent 
No 9 8 13 7 1.61 0.57, 4.53 1.68 0.58, 4.86 1.41 0.50, 3.96 
Yes < 5 1 < 5 1 6.57 0.29, 150.37 11.63 0.63, 214.15 0.79 0.05, 12.83 
Missing 20  21        Trendh     1.85 0.77, 4.43 2.11 0.86, 5.15 1.30 0.54, 3.11 Use of personal pesticides, like creams, sprays or flea collars           Not exposed 74 64 140 67 1.00 Referent 1.00 Referent 1.00 Referent 
No 38 33 66 32 1.03 0.59, 1.82 0.98 0.55, 1.75 1.16 0.62, 2.19 
Yes < 5 3 < 5 1 2.54 0.45, 14.29 1.95 0.33, 11.32 5.05 0.79, 32.25 
Missing 12  10        Trendh     1.16 0.70, 1.91 1.08 0.65, 1.80 1.39 0.81, 2.37 Use of pesticides on your clothing or bedding           Not exposed 76 68 153 73 1.00 Referent 1.00 Referent 1.00 Referent 
No 31 28 49 23 1.58 0.86, 2.89 1.46 0.79, 2.72 1.63 0.84, 3.18 
Yes < 5 4 7 3 1.08 0.25, 4.68 1.38 0.27, 7.01 5.79 1.20, 27.86 
Missing 16  10        Trendh     1.33 0.82, 2.17 1.35 0.81, 2.27 1.79 1.08, 2.96 Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)           Not exposed 76 65 158 74 1.00 Referent 1.00 Referent 1.00 Referent 
No 31 27 45 21 1.35 0.73, 2.50 1.38 0.73, 2.59 1.81 0.96, 3.39 
Yes 10 9 11 5 2.74 0.97, 7.72 3.13 1.06, 9.21 3.15 1.06, 9.37 
Missing 10  5        Trendh     1.53 0.99, 2.34 1.59 1.02, 2.48 1.79 1.16, 2.77 Exposure to diesel and/or other petrochemical fumes           Not exposed 30 25 70 33 1.00 Referent 1.00 Referent 1.00 Referent 
No 70 59 123 57 1.35 0.74, 2.44 1.29 0.70, 2.38 1.22 0.65, 2.30 
Yes 18 15 21 10 2.19 0.90, 5.31 2.24 0.89, 5.60 2.23 0.85, 5.88 
Missing 9  5        Trendh     1.45 0.95, 2.21 1.44 0.93, 2.23 1.40 0.89, 2.22 Burning trash or burning feces/manure           Not exposed 62 52 114 55 1.00 Referent 1.00 Referent 1.00 Referent 
No 45 38 73 35 1.09 0.63, 1.90 1.08 0.59, 1.98 1.10 0.56, 2.14 
Yes 13 11 22 11 1.15 0.49, 2.71 1.08 0.43, 2.72 1.00 0.36, 2.78 
Missing 7  10        Trendh     1.08 0.74, 1.58 1.05 0.69, 1.60 1.04 0.65, 1.67 
           
           
 
320 
   Cases Controls Adjustedc Adjustedd IP-weightede 
Did you feel ill from exposure to No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Exposure to paint, solvents, or petrochemical substances           Not exposed 76 66 133 62 1.00 Referent 1.00 Referent 1.00 Referent 
No 35 30 70 33 0.73 0.41, 1.30 0.62 0.33, 1.18 0.83 0.44, 1.55 
Yes 5 4 11 5 1.01 0.31, 3.30 0.82 0.24, 2.82 1.11 0.30, 4.07 
Missing 11  5        Trendh     0.85 0.54, 1.33 0.75 0.45, 1.24 0.91 0.53, 1.56 High-intensity radar waves (e.g., as radar operator, radio operator, aviation electrician's mate)           Not exposed 83 76 172 85 1.00 Referent 1.00 Referent 1.00 Referent 
No 24 22 30 15 1.66 0.84, 3.28 1.78 0.88, 3.60 1.70 0.75, 3.86 
Yes < 5 2 < 5 < 1 2.04 0.13, 32.54 1.52 0.10, 23.43 1.40 0.12, 15.86 
Missing 18  16        Trendh     1.62 0.87, 3.02 1.66 0.87, 3.17 1.70 0.85, 3.40 Food contaminated with smoke, oil, or other chemicals           Not exposed 97 89 174 88 1.00 Referent 1.00 Referent 1.00 Referent 
No 7 6 17 9 0.90 0.32, 2.52 0.98 0.34, 2.85 1.97 0.65, 5.95 
Yes 5 5 6 3 1.42 0.36, 5.60 1.44 0.35, 5.92 1.86 0.40, 8.55 
Missing 18  22        Trendh     1.10 0.61, 1.96 1.13 0.62, 2.06 1.21 0.65, 2.25 Local food other than food provided by the Armed Forces           Not exposed 56 46 113 52 1.00 Referent 1.00 Referent 1.00 Referent 
No 57 47 77 35 1.50 0.88, 2.56 1.39 0.80, 2.41 1.16 0.66, 2.04 
Yes 8 7 28 13 0.42 0.15, 1.16 0.39 0.14, 1.09 0.64 0.22, 1.84 
Missing 6  1        Trendh     0.91 0.62, 1.34 0.86 0.58, 1.27 0.91 0.60, 1.37 Bathing in or drinking of water contaminated with smoke, oil, dead animals or any chemicals           Not exposed 88 85 169 84 1.00 Referent 1.00 Referent 1.00 Referent 
No 12 12 23 11 1.20 0.52, 2.77 1.32 0.56, 3.10 0.83 0.29, 2.38 
Yes < 5 4 10 5 0.63 0.16, 2.40 0.65 0.16, 2.57 1.20 0.25, 5.86 
Missing 23  17        Trendh     0.92 0.54, 1.57 0.96 0.55, 1.67 1.02 0.55, 1.92 Heat cramps, heat exhaustion, heat stroke or other heat illness           Not exposed 84 69 152 70 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 3 5 2 2.47 0.54, 11.23 2.95 0.61, 14.16 0.80 0.15, 4.17 
Yes 33 27 59 27 0.94 0.52, 1.68 0.93 0.51, 1.70 1.18 0.65, 2.13 
Missing 6  3        Trendh     0.98 0.73, 1.31 0.98 0.73, 1.32 1.09 0.82, 1.46 
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   Cases Controls Adjustedc Adjustedd IP-weightede 
Did you feel ill from exposure to No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Heard chemical alarms sounding           Not exposed 117 96 200 93 1.00 Referent 1.00 Referent 1.00 Referent 
No 5 4 15 7 0.56 0.18, 1.70 0.61 0.19, 1.92 0.69 g 
Yes 0 0 < 5 < 1 g g g g g g 
Missing 5  3        Trendh     0.54 0.18, 1.61 0.58 0.19, 1.76 0.61 0.20, 1.86 Explosion in the air or on the ground within one mile of you (e.g., artillery, rockets, mortars)           Not exposed 28 23 60 29 1.00 Referent 1.00 Referent 1.00 Referent 
No 87 71 133 63 1.64 0.89, 3.03 1.71 0.90, 3.24 1.95 1.02, 3.73 
Yes 8 7 16 8 0.92 0.28, 2.98 0.87 0.26, 2.96 1.22 0.33, 4.49 
Missing 4  10        Trendh     1.21 0.75, 1.96 1.22 0.74, 2.01 1.56 0.97, 2.51 Mixing and application of riot control substances           Not exposed 123 98 213 97 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 2 < 5 2 0.88 0.12, 6.66 1.27 0.19, 8.39 0.36 g 
Yes 0 0 < 5 1 g g g g g g 
Missing 2  0        Trendh     0.49 0.11, 2.22 0.62 0.15, 2.63 0.24 0.03, 1.77 Exposure to riot control substances in the field           Not exposed 115 93 198 91 1.00 Referent 1.00 Referent 1.00 Referent 
No 7 6 9 4 1.13 0.35, 3.64 1.21 0.38, 3.92 1.38 0.42, 4.61 
Yes < 5 2 10 5 0.22 0.04, 1.40 0.19 0.03, 1.29 0.12 0.02, 0.59 
Missing 3  2        Trendh     0.63 0.32, 1.23 0.62 0.31, 1.22 0.61 0.31, 1.17 Mixing and application of burning agents           Not exposed 110 91 212 98 1.00 Referent 1.00 Referent 1.00 Referent 
No 9 7 < 5 2 5.59 1.48, 21.06 5.84 1.49, 22.83 8.41 1.96, 36.09 
Yes < 5 2 < 5 < 1 3.25 0.27, 38.86 3.18 0.27, 37.99 9.31 0.72, 120.24 
Missing 6  2        Trendh     3.33 1.20, 9.24 3.36 1.20, 9.45 3.93 1.15, 13.40 
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   Cases Controls Adjustedc Adjustedd IP-weightede 
Did you feel ill from exposure to No. % No. % OR 95% CI OR 95% CI OR 95% CI 
Exposure to burning agents in the field           Not exposed 90 76 188 88 1.00 Referent 1.00 Referent 1.00 Referent 
No 22 19 17 8 3.88 1.80, 8.39 4.01 1.82, 8.83 2.82 1.18, 6.76 
Yes 6 5 8 4 1.86 0.56, 6.13 2.06 0.60, 7.06 3.62 0.93, 14.11 
Missing 9  6        Trendh         1.98 1.21, 3.23 2.08 1.25, 3.47 2.35 1.31, 4.22 
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BIRLS, Beneficiary Identification and Records Locator System; CI, confidence 
interval; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; IP, inverse probability; OR, odds ratio; U.S., United States of America; 
VA, Department of Veterans Affairs. 
aThe GENEVA study questionnaire asked "Were you deployed to..." the Vietnam War (defined as the period from August 3, 1964, to May 7, 1975). 
bRestricted analyses to veterans who were born between 1939 and 1957 inclusive (i.e., they were 18-25 years old at the time of the Vietnam War, or 1964-1975) because doing 
so drastically improved the behavior of the IP weights used for analysis. This restriction resulted in the exclusion of 21 (14%) cases and 51 (19%) controls. 
cAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms) and use of the VA health care system. 
dAdjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, race/ethnicity, and 
military branch of longest service. War deployment-related exposures were not adjusted for sex because of model instability. 
eWeights were adjusted for age (centered at age 60—the median age among controls—and modeled with linear and quadratic terms), use of the VA health care system, 
race/ethnicity, military branch of longest service, not missing covariate data (for cases: conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset 
to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic 
spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in GENEVA 
(for cases: conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis 
[months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score 
[modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]; for controls: conditional on year of birth 
[modeled with a restricted, quadratic spline with knots at 1920, 1947, and 1974 based on percentiles of the distribution in the BIRLS potential controls], use of the VA health care 
system, and their interaction). War deployment-related exposures were not adjusted for sex because of model instability. 95% CIs were calculated with robust variance estimates. 
fRepeated from Appendix F, Table F.13. 
gUnable to estimate OR and 95% CI. 
hUsed ordinal scores (0, 1, 2). Reference category included for linear trend test. 
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 APPENDIX G: AIM 2 SUPPLEMENTAL MATERIAL  
REFERENCED IN CHAPTER 5 
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 Figure G.1. Directed acyclic graphs for: (a) military service and deployment variables and ALS survival 
in the GENEVA study (100) and (b) military exposure variables and ALS survival in the GENEVA study 
(100). Abbreviations: ALS, amyotrophic lateral sclerosis; GENEVA, Genes and Environmental 
Exposures in Veterans with Amyotrophic Lateral Sclerosis. 
 
EXPLANATION OF FIGURE G.1 
 The directed acyclic graph (DAG) (177, 178) shown in panel (a) of Figure G.1 corresponds to all 
analyses involving military service and deployment variables. The arrows from age and sex to military 
service and deployment variables and ALS survival depict relationships between each covariate and 
military service and deployment variables and ALS survival, respectively. We did not include the 
following covariates in the DAG because they have not been associated with military service, 
deployments, and/or exposures in previous studies: agricultural occupation, baseline ALS Functional 
Rating Scale-Revised (ALSFRS-R), bulbar onset, diagnosis category, therapeutic interventions, and time 
between symptom onset and diagnosis. Similarly, we thought that lead exposure and psychosocial factors 
were potentially affected by and/or more likely to occur temporally after military service, deployment, 
and/or exposure variables, so we did not include them in our DAG. 
325 
 The DAG shown in panel (b) of Figure G.1 corresponds to all analyses involving military 
exposure variables. The only difference between the DAGs shown in panels (a) and (b) of Figure G.1 is 
the addition of wars/operations of deployment. Wars/operations of deployment is related to both military 
exposure variables and ALS survival. 
STATISTICAL ANALYSES: INVERSE PROBABILITY WEIGHTS 
We calculated the numerators of the stabilized confounding weights as predicted probabilities of 
exposure from an intercept only model and the denominators of these weights as predicted probabilities of 
exposure from a model including age as the only independent variable. We modeled age with indicator 
variables corresponding to five-year groups. 
For the numerators of the stablized selection weights, we calculated the predicted probabilities of 
participation from an intercept only model; and, for the denominators of the weights, we calculated the 
predicted probabilities conditional on race/ethnicity, being a current patient of a VA Medical Center, most 
recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis, time from diagnosis 
to enrollment in the Registry, and baseline (i.e., at enrollment in the Registry) ALSFRS-R score. We did 
not include the exposures of interest in the numerator or denominator models for the selection weights 
because data on the exposures of interest were available for only the 616 ALS cases who enrolled in the 
GENEVA study. For the denominator model, we modeled race/ethnicity the same way as for the 
confounding weights and being a current patient of a VA Medical Center, most recent ALS diagnosis, and 
site of symptom onset as shown in Tables 5.2 and Appendix G, Table G.1. We modeled time from 
symptom onset to diagnosis with linear, quadratic, and cubic terms; time from diagnosis to enrollment in 
the Registry with a linear term; and baseline ALSFRS-R score with a restricted, quadratic spline with 
knots at 12, 34, and 44 based on percentiles of the distribution in the GENEVA study cases (we used SAS 
code from (188) to create the splines) because these forms gave the lowest values of the Akaike 
Information Criterion (AIC) (187, 188). 
Eight percent of ALS cases enrolled in the Registry were missing data in baseline (i.e., at 
enrollment in the Registry) ALSFRS-R scores, which was included as a covariate in the denominator 
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 models of the stabilized selection weights. Therefore, we also calculated stabilized missing covariate data 
weights to account for this potential bias. For the numerators of these weights, we calculated the predicted 
probabilities of not missing data in baseline ALSFRS-R from an intercept only model; and, for the 
denominators of the weights, we calculated the predicted probabilities conditional on most recent ALS 
diagnosis, site of symptom onset, time from symptom onset to diagnosis, and time from diagnosis to 
enrollment in the Registry. We did not include the exposures of interest in the numerator or denominator 
models for the missing covariate data weights because data on the exposures of interest were available for 
only the 616 ALS cases who enrolled in the GENEVA study. For the denominator model, we modeled 
most recent ALS diagnosis and site of symptom onset as shown in Table 5.2. We modeled time from 
symptom onset to diagnosis with the natural logarithm of a linear term and time from diagnosis to 
enrollment in the Registry with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 
months based on percentiles of the distribution in the Registry cases not missing covariate data (we used 
SAS code from (188) to create the splines) because these forms gave the lowest values of the AIC (187, 
188). 
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 Table G.1. Demographic, clinical, and military characteristics of ALS cases in GENEVA and the Registry. All information shown in this table 
came from medical records or the Registry screening or semi-annual telephone follow-up interviews. 
  GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Total 630 100 1,856 100     Year of birth         ≤ 1920 5 1 35 2 0.40 0.17, 0.90 NA NA 
1921-1930 93 15 305 16 0.85 0.69, 1.03 NA NA 
1931-1940 194 31 573 31 0.94 0.80, 1.10 NA NA 
1941-1950 227 36 630 34 1.00 Referent 1.00 Referent 
1951-1960 74 12 214 12 0.96 0.78, 1.19 NA NA 
1961-1970 32 5 87 5 1.02 0.76, 1.37 NA NA 
> 1970 5 1 11 1 1.26 0.65, 2.43 NA NA 
Missing 0  1      Median ± IQR 1942 ± 14 yr.  1941 ± 16 yr.      Sex         Male 617 98 1,820 98 1.00 Referent 1.00 Referent 
Female 13 2 35 2 1.10 0.71, 1.69 1.12 0.73, 1.73 
Missing 0  1      Race/Ethnicity         Non-Hispanic White 581 92 1,674 90 1.00 Referent 1.00 Referent 
Other 48 8 179 10 0.77 0.60, 0.99 0.75 0.58, 0.96 
Missing 1  3      Cigarette smoking statusb         Never 217 35 552 33 1.00 Referent 1.00 Referent 
Past 339 54 942 56 0.92 0.80, 1.05 0.89 0.78, 1.02 
Current 70 11 195 12 0.91 0.74, 1.13 0.88 0.71, 1.09 
Missing 4  167      Being a current patient at a VA Medical Center         No 295 47 786 42 1.00 Referent 1.00 Referent 
Yes 335 53 1,068 58 0.84 0.74, 0.95 0.85 0.75, 0.96 
Missing 0  2      Most recent ALS diagnosisc         Clinically definite 99 16 333 18 0.89 0.73, 1.08 0.87 0.71, 1.05 
Clinically probable 244 39 728 39 1.00 Referent 1.00 Referent 
Clinically probable and lab supported 113 18 277 15 1.22 1.02, 1.45 1.22 1.02, 1.45 
Clinically possible 54 9 162 9 0.99 0.78, 1.27 1.02 0.80, 1.30 
Suspected (progressive bulbar palsy or progressive muscular atrophy) 118 19 336 18 1.05 0.88, 1.25 1.08 0.91, 1.29 
Other < 5 < 1 20 1 0.30 0.08, 1.12 0.29 0.08, 1.09 
Missing 0  0      
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   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Family history of ALS         No 490 96 1,435 95 1.00 Referent 1.00 Referent 
Yes 22 4 78 5 0.83 0.58, 1.19 0.81 0.56, 1.16 
Missing 118  343      Site of symptom onset         Bulbar 89 14 407 22 0.59 0.49, 0.72 0.59 0.49, 0.72 
Extremities 509 81 1374 74 1.00 Referent 1.00 Referent 
Otherc 31 5 71 4 1.18 0.90, 1.55 1.16 0.88, 1.52 
Missing 1  4      Time from symptom onset to diagnosis (months)         ≤ 6 118 19 410 23 0.95 0.78, 1.16 0.95 0.78, 1.16 
> 6-12 168 27 556 31 1.00 Referent 1.00 Referent 
> 12-18 105 17 301 17 1.15 0.95, 1.41 1.20 0.99, 1.47 
> 18-24 47 8 157 9 0.99 0.76, 1.30 1.05 0.80, 1.37 
> 24 173 28 378 21 1.51 1.28, 1.79 1.59 1.35, 1.88 
Missing 19  54      Median ± IQR 13 ± 18  11 ± 14      Time from diagnosis to enrollment in the Registry (months)         ≤ 12 220 35 664 36 1.00 Referent 1.00 Referent 
> 12-24 144 23 476 26 0.91 0.77, 1.09 0.92 0.77, 1.09 
> 24-36 75 12 241 13 0.94 0.76, 1.17 0.98 0.79, 1.22 
> 36-48 44 7 109 6 1.22 0.95, 1.57 1.21 0.94, 1.56 
> 48 140 22 343 19 1.23 1.04, 1.46 1.24 1.05, 1.46 
Missing 7  23      Median ± IQR 18 ± 32  18 ± 27      Baselined ALSFRS-R score (possible range: 0-48)e         ≤ 16 58 9 309 18 0.66 0.49, 0.87 0.64 0.48, 0.85 
> 16-23 67 11 284 17 0.82 0.63, 1.07 0.82 0.63, 1.06 
> 23-30 104 17 363 21 1.00 Referent 1.00 Referent 
> 30-35 135 21 292 17 1.61 1.32, 1.98 1.59 1.30, 1.95 
> 35 265 42 454 27 2.04 1.70, 2.44 1.99 1.66, 2.38 
Missing 1  154      Median ± IQR 34 ± 12  29 ± 16      Currently using riluzole (baselined)         No 277 47 763 48 1.00 Referent 1.00 Referent 
Yes 315 53 843 52 1.03 0.91, 1.17 1.02 0.89, 1.15 
Missing 38  250      
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   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Currently using BiPAP to assist with breathing (baselined)         No 531 86 1,336 79 1.00 Referent 1.00 Referent 
Yes 89 14 351 21 0.64 0.53, 0.77 0.63 0.52, 0.76 
Missing 10  169      Currently using CPAP to assist with breathing (baselined)         No 603 97 1,620 96 1.00 Referent 1.00 Referent 
Yes 17 3 59 4 0.77 0.52, 1.16 0.76 0.51, 1.14 
Missing 10  177      Currently using a ventilator (≥ two weeks, 15 hours/day) to assist with breathing (baselined)         No 595 95 1,568 93 1.00 Referent 1.00 Referent 
Yes 30 5 123 7 0.64 0.47, 0.88 0.63 0.46, 0.87 
Missing 5  165      Currently using tracheostomy to assist with breathing (baselined)         No 555 95 1,389 92 1.00 Referent 1.00 Referent 
Yes 32 5 120 8 0.67 0.49, 0.90 0.67 0.49, 0.91 
Missing 43  347      Currently using a feeding tube (baselined)         No 469 88 1,162 78 1.00 Referent 1.00 Referent 
Yes 64 12 321 22 0.49 0.39, 0.62 0.49 0.39, 0.61 
Missing 97  373      Military branch of longest service         Air Force (including Army Air Force) 126 20 350 19 1.06 0.90, 1.26 1.05 0.89, 1.25 
Army 260 42 768 43 1.00 Referent 1.00 Referent 
Marines (including Merchant Marines) 54 9 155 9 1.03 0.81, 1.30 1.04 0.82, 1.31 
Navy 133 21 404 22 0.97 0.82, 1.15 0.98 0.83, 1.17 
Otherf 47 8 125 7 1.11 0.87, 1.42 1.09 0.86, 1.40 
Missing 10  54      Number of military branches of service         1 564 90 1,672 90 1.00 Referent 1.00 Referent 
2 63 10 163 9 1.15 0.93, 1.41 1.12 0.91, 1.37 
> 2 < 5 < 1 18 1 0.49 0.18, 1.39 0.52 0.18, 1.45 
Missing 0  3      Type duty (Active/Reserve) of longest service         Active 541 88 1,586 88 1.00 Referent 1.00 Referent 
Active Reserves 33 5 84 5 1.15 0.88, 1.52 1.11 0.84, 1.46 
Ready/Inactive Reserves or Reserves (unknown) 44 7 124 7 1.04 0.81, 1.33 1.02 0.80, 1.31 
Missing 12  62      
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   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Number of duty types during service         1 501 80 1,502 81 1.00 Referent 1.00 Referent 
2 117 19 325 18 1.08 0.92, 1.27 1.04 0.89, 1.23 
3 9 1 17 1 1.59 1.01, 2.50 1.55 0.99, 2.43 
Missing 3  12      Number of periods of military service         1 484 77 1,441 78 1.00 Referent 1.00 Referent 
2 124 20 344 19 1.07 0.92, 1.26 1.04 0.89, 1.22 
3 19 3 53 3 1.07 0.74, 1.54 1.10 0.76, 1.58 
> 3 < 5 < 1 16 1 0.56 0.20, 1.55 0.54 0.19, 1.50 
Missing 0  2      Years of military service         ≤ 1 18 3 58 3 0.92 0.62, 1.36 0.95 0.64, 1.41 
> 1-5 368 59 1,088 60 1.00 Referent 1.00 Referent 
> 5-10 97 16 308 17 0.93 0.77, 1.12 0.89 0.74, 1.07 
> 10-15 22 4 65 4 1.00 0.71, 1.42 0.96 0.67, 1.36 
> 15 115 19 283 16 1.20 1.02, 1.41 1.18 1.00, 1.39 
Missing 10  54      Median ± IQR 4.00 ± 6.67  4.00 ± 5.33      End of most recent period of military service (year)g         ≤ 1949 46 7 173 10 0.78 0.60, 1.03 1.19 0.75, 1.89 
1950-1954 52 8 159 9 0.96 0.75, 1.24 1.08 0.78, 1.50 
1955-1960 79 13 248 14 0.94 0.76, 1.16 0.95 0.72, 1.23 
1961-1964 64 10 166 9 1.14 0.91, 1.42 1.08 0.84, 1.39 
1965-1974 193 31 569 32 1.00 Referent 1.00 Referent 
1975-1980 47 8 137 8 1.01 0.78, 1.31 1.05 0.81, 1.36 
1981-1990 59 10 173 10 1.01 0.79, 1.27 1.06 0.83, 1.35 
1991-2001 62 10 136 8 1.34 1.08, 1.67 1.44 1.12, 1.84 
> 2001 16 3 38 2 1.24 0.84, 1.83 1.37 0.89, 2.11 
Missing 12  57      Median ± IQR 1968 ± 21 yr.  1968 ± 19 yr.      While in the military, served outside continental U.S.         No 134 21 378 20 1.00 Referent 1.00 Referent 
Yes 496 79 1,473 80 0.95 0.81, 1.11 0.95 0.82, 1.11 
Missing 0  5      
         
         
         
 
331 
   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Number of years served outside continental U.S.         0 135 23 384 22 1.00 Referent 1.00 Referent 
≤ 1 129 22 407 23 0.90 0.74, 1.10 0.89 0.73, 1.09 
> 1-2 181 30 518 30 0.99 0.83, 1.19 1.00 0.83, 1.19 
> 2-3 44 7 162 9 0.77 0.58, 1.03 0.78 0.58, 1.03 
> 3-5 49 8 126 7 1.11 0.85, 1.43 1.10 0.85, 1.43 
> 5 61 10 157 9 1.11 0.87, 1.40 1.10 0.86, 1.39 
Missing 31  102      Served in Afghanistan         No 490 100 1,454 100 1.00 Referent 1.00 Referent 
Yes < 5 < 1 6 < 1 0.99 0.32, 3.07 1.05 0.34, 3.21 
Missing 138  396      Served in Europe         No 281 57 850 58 1.00 Referent 1.00 Referent 
Yes 213 43 615 42 1.05 0.91, 1.21 1.03 0.89, 1.19 
Missing 136  391      Served in Korea         No 393 80 1,185 81 1.00 Referent 1.00 Referent 
Yes 100 20 279 19 1.08 0.91, 1.29 1.08 0.90, 1.30 
Missing 137  392      Served in North Africa         No 464 95 1,378 94 1.00 Referent 1.00 Referent 
Yes 27 5 82 6 0.98 0.71, 1.34 1.00 0.73, 1.37 
Missing 139  396      Served in Pacific Islands         No 334 68 1,039 71 1.00 Referent 1.00 Referent 
Yes 158 32 424 29 1.16 1.00, 1.35 1.21 1.04, 1.40 
Missing 138  393      Served in Persian Gulf         No 388 90 1,179 91 1.00 Referent 1.00 Referent 
Yes 42 10 118 10 1.08 0.84, 1.40 0.98 0.73, 1.31 
Missing 200  559      
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   GENEVA Cases Registry Cases Crude Adjusteda 
Characteristic No. % No. % RR 95% CI RR 95% CI 
Served in Vietnam         No 358 72 1,059 72 1.00 Referent 1.00 Referent 
Yes 137 28 410 28 0.99 0.84, 1.16 0.93 0.78, 1.12 
Missing 135   387           
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; BiPAP, Bi-level Positive Airway Pressure; CI, confidence interval; CPAP, 
Continuous Positive Airway Pressure; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; IQR, interquartile range; NA, not 
applicable; Registry, National Registry of Veterans with Amyotrophic Lateral Sclerosis; RR, risk ratio; U.S., United States; VA, Department of Veterans Affairs. 
aAdjusted for year of birth (modeled with a restricted, quadratic spline with three unequally spaced knots at 1925, 1942, and 1962 based on the 5th, 50th, and 95th percentiles of 
the distribution in all GENEVA cases). 
bCigarette smoking was defined as having ever smoked at least 100 cigarettes (or the equivalent amount of tobacco) in cases’ lifetimes. 
cIncludes “all over” (GENEVA: n = 4, Registry: n = 11), “cramps/fasciculations” (GENEVA: n = 26; Registry: n = 57), “dementia” (GENEVA: n = 0; Registry: n = 2), and “loss of 
appetite” (GENEVA: n = 1; Registry: n = 1). 
dThe most recent diagnosis, ALSFRS-R score, or use status of riluzole, BiPAP, CPAP, ventilator, tracheostomy, or feeding tube that was measured closest to the time of 
enrollment in the Registry. 
eCategory boundaries were set at quintiles of the ALSFRS-R score among all cases. 
fIncludes Coast Guard (GENEVA: n = 7; Registry: n = 21), Air Force Reserves (GENEVA: n = 5; Registry: n = 8), Army Reserves (GENEVA: n = 9; Registry: n = 33), Marines 
Reserves (GENEVA: n = 2; Registry: n = 4), Navy Reserves (GENEVA: n = 8; Registry: n = 17), Air National Guard (GENEVA: n = 3; Registry: n = 8), Army National Guard 
(GENEVA: n = 0; Registry: n = 0), Air Force Guard (GENEVA: n = 1; Registry: n = 2), Army Guard (GENEVA: n = 11; Registry: n = 31), and Other (GENEVA: n = 1; Registry: n = 
1). 
gCategory boundaries aligned with the occurrence of the major wars (e.g., the Vietnam War occurred between August 1964 and May 1975) and followed (98, 100). 
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 Table G.2. Summary statistics for the untruncated overall stabilized inverse probability weightsa for 
models in Table 5.3. 
    Percentiles 
Variable Mean Standard Deviation Min 5 50 95 Max 
Military branch of longest service 1.00 0.76 0.20 0.40 0.76 2.38 7.69 
Number of military branches of service        Categorical 1.89 2.60 0.21 0.31 0.93 6.53 25.58 
Trendb 0.99 0.71 0.20 0.44 0.74 2.32 6.29 
Officer or Warrant Officer 1.00 0.71 0.25 0.45 0.77 2.46 6.48 
Years of military service        Categorical 0.95 0.80 0.06 0.25 0.70 2.46 7.82 
Trendb 1.00 0.72 0.21 0.44 0.74 2.26 6.40 
End of most recent period of military service (month/year)        Categorical 0.78 1.10 0.05 0.14 0.44 2.62 10.74 
Trendb 1.05 2.42 0.06 0.16 0.54 2.91 41.06 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; GENEVA, Genes and 
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; VA, Department of Veterans Affairs. 
aWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data 
(conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical 
Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
bUsed within-category medians that were calculated using all cases. 
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 Table G.3. Summary statistics for the untruncated overall stabilized inverse probability weightsa for models in Table 5.4. 
    Percentiles 
Variable Mean Standard Deviation Min 5 50 95 Max 
Deployments        Ever deployed to any war/operationb 0.98 0.72 0.28 0.41 0.72 2.37 6.31 
War/operation of longest deploymentb 1.16 3.09 0.03 0.17 0.65 2.61 52.08 
Ever deployed to any other country 0.99 0.71 0.30 0.43 0.74 2.36 7.19 
Total time (years) of all periods of deployment to any war/operationb        Categorical 0.98 0.73 0.12 0.38 0.71 2.31 6.45 
Trendc 1.01 1.00 0.01 0.44 0.72 2.21 17.61 
End of most recent period of deployment to any war/operation (month/year)b        Categorical 0.94 1.35 0.10 0.23 0.64 2.28 23.52 
Trendc, d 1.12 2.98 0.05 0.08 0.43 3.90 36.92 
Danger pay, hardship duty or combat zone tax exclusion benefits for deployment        Ever received imminent danger pay, hardship duty or combat zone tax exclusion benefits for 
deployment 0.98 0.75 0.23 0.39 0.71 2.43 5.90 
Total time (years) of all periods of deployment to any countries or sea region(s) ever received imminent 
danger pay, hardship duty or combat zone tax exclusion benefits for deployment        
Categorical 0.95 0.71 0.20 0.38 0.70 2.16 6.30 
Trendc 0.96 0.67 0.31 0.42 0.70 2.25 4.85 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; GENEVA, Genes and Environmental Exposures in Veterans with 
Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; VA, Department of Veterans Affairs; WWII, World War II. 
aWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data (conditional on most recent ALS diagnosis, site of 
symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry 
[months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing 
covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, 
time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear 
term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]). 95% CIs 
were calculated with robust variance estimates. 
bThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also asked "Ever 
deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, 
Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
cUsed within-category medians that were calculated using all cases. 
dReference category excluded for linear trend test. 
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 Table G.4. Summary statistics for the untruncated overall stabilized inverse probability weightsa for models in Table 5.5. 
      Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
Ever received the anthrax vaccine prior to reference date 0.98 0.87 0.05 0.39 0.71 2.26 10.29 
Ever received the smallpox vaccine 1.00 0.74 0.23 0.43 0.74 2.26 6.75 
Prior to reference date, ever involved in testing, transporting or spraying herbicides for military purposes 0.98 0.81 0.13 0.45 0.73 2.26 10.79 
Prior to reference date, ever been treated with nasopharyngeal (NP) radium during military service 0.97 0.69 0.02 0.47 0.73 2.28 6.46 
Ever taken pyridostigmine bromide, or little white pills in foil packs, sometimes called NAPPs, which are used to 
protect against nerve agents 0.96 0.72 0.06 0.45 0.73 2.19 6.90 
Prior to reference date, ever visited or resided in the island of Guam, the islands of New Guinea, or the Kii 
Peninsula of Japan (including any time spent there in the military) 0.97 0.68 0.13 0.38 0.74 2.33 5.68 
While you were in WWII, the Korean War, the Vietnam War, and/or the Gulf Warb: did you have direct 
contact with/were you exposed to        
Manufacture, testing, or use of chemical protective gear (for mustard gas, tear gas, etc.) Do not include 
training 0.95 0.74 0.04 0.41 0.73 2.40 6.56 
Ionizing radiation from nuclear weapon testing or occupation of Hiroshima/Nagasaki 0.97 0.71 0.03 0.45 0.75 2.40 6.45 
Use of personal pesticides, like creams, sprays or flea collars 0.97 0.79 0.28 0.35 0.73 2.36 6.84 
Use of pesticides on your clothing or bedding 0.93 0.78 0.26 0.36 0.70 2.37 7.14 
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters) 0.97 0.76 0.27 0.39 0.73 2.26 6.15 
Exposure to diesel and/or other petrochemical fumes 0.95 0.76 0.24 0.35 0.71 2.56 5.42 
Burning trash or burning feces/manure 0.94 0.87 0.24 0.32 0.67 2.36 8.95 
Exposure to paint, solvents, or petrochemical substances 0.96 0.74 0.26 0.40 0.74 2.31 7.11 
High-intensity radar waves (e.g., as radar operator, radio operator, aviation electrician's mate) 0.97 0.79 0.16 0.36 0.73 2.44 6.78 
Food contaminated with smoke, oil, or other chemicals 0.95 0.71 0.15 0.40 0.73 2.42 6.57 
Local food other than food provided by the Armed Forces 0.97 0.78 0.28 0.36 0.74 2.48 5.40 
Bathing in or drinking of water contaminated with smoke, oil, dead animals or any chemicals 0.96 0.70 0.20 0.43 0.73 2.35 6.54 
Heat cramps, heat exhaustion, heat stroke or other heat illness 0.95 0.78 0.16 0.37 0.70 2.69 6.90 
Heard chemical alarms sounding 0.92 0.67 0.05 0.39 0.74 2.18 6.18 
Explosion in the air or on the ground within one mile of you (e.g., artillery, rockets, mortars) 0.96 0.77 0.17 0.35 0.69 2.54 5.27 
Have you suffered a combat-related injury that required medical attention during your deployment? 0.94 0.84 0.17 0.36 0.73 2.27 7.03 
While you were in WWII, the Korean War, and/or the Vietnam Warb: did you have direct contact 
with/were you exposed to        
Mixing and application of herbicides 0.95 0.70 0.02 0.43 0.76 2.26 6.30 
Exposure to herbicides in the field 0.94 0.70 0.15 0.40 0.75 2.17 6.41 
Mixing and application of riot control substances 0.96 0.70 0.21 0.45 0.75 2.27 6.36 
Exposure to riot control substances in the field 0.95 0.69 0.12 0.44 0.75 2.18 6.45 
Mixing and application of burning agents 0.96 0.85 0.27 0.40 0.75 2.22 8.05 
Exposure to burning agents in the field 0.93 0.72 0.30 0.37 0.73 2.29 7.09 
 
336 
       Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
While you were in the Korean War, the Vietnam War, and/or the Gulf Warb: did you have direct contact 
with/were you exposed to        
Microwave radiation 0.97 0.75 0.13 0.45 0.73 2.24 6.45 
While you were in the Vietnam Warb: did you have direct contact with/were you exposed to        Mixing and application of Agent Orange 1.00 0.77 0.20 0.43 0.77 2.53 6.46 
Exposure to Agent Orange in the field 1.05 0.99 0.16 0.32 0.72 2.50 6.74 
While you were in the Gulf Warb: did you have direct contact with/were you exposed to        Use of depleted uranium (DU) for munitions or armor 1.05 0.61 0.43 0.43 0.73 2.30 2.30 
CARC (Chemical Agent Resistant Compound) paint 1.00 0.59 0.43 0.43 0.73 2.18 2.18 
Scud missile explosion in the air or on the ground within one mile of you 1.05 1.16 0.42 0.42 0.60 4.60 4.60 
Smoke from oil well fires 1.05 0.71 0.43 0.43 0.68 2.64 2.64 
Exposure to nerve gas (e.g., during munitions destruction) 1.00 0.80 0.42 0.42 0.63 2.73 2.73 
High levels of dust/sand 1.02 0.68 0.25 0.25 0.71 2.81 2.81 
Ground level fumigation 0.86 0.41 0.43 0.43 0.69 1.86 1.86 
In any conflicts deployed to, any other exposure or experience not asked about which you consider harmful or 
extremely stressful 0.92 0.71 0.17 0.34 0.70 2.35 6.22 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CARC, Chemical Agent Resistant Compound; DU, depleted uranium; 
GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; NP, nasopharyngeal; VA, Department of Veterans 
Affairs; WWII, World War II. 
aWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups or, for exposures queried only in reference to deployment to the Gulf War, 
modeled with a linear term that was centered at age 60—the median age among all cases), war/operation of longest deployment, not missing covariate data (conditional on most 
recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to 
enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the 
Registry cases not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS 
diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the 
Registry [months; modeled with a linear term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the 
distribution in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
bThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also asked "Ever 
deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, 
Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
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 Table G.5. Summary statistics for the untruncated overall stabilized inverse probability weightsa for 
models in Appendix G, Table G.11. 
      Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
Number of anthrax vaccine shots received prior to reference date        Categorical 0.93 0.67 0.03 0.40 0.70 2.18 6.15 
Trendb 2.38 16.18 0.00 0.41 0.67 2.78 317.78 
Prior to reference date, number of years involved in testing, transporting 
or spraying herbicides for military purposes        
Categorical 0.98 0.77 0.10 0.45 0.72 2.25 8.99 
Trendb 0.99 0.75 0.00 0.46 0.74 2.45 7.33 
Year in which pyridostigmine bromide pills taken        Categorical 0.95 0.69 0.02 0.44 0.73 2.20 6.38 
Trendb, c 1.04 1.35 0.20 0.20 0.62 5.41 5.41 
Total days taken pyridostigmine bromide pills        Categorical 0.95 0.66 0.01 0.46 0.73 2.18 6.48 
Trendb 0.98 0.72 0.00 0.45 0.75 2.30 6.22 
Number of pills taken in an average day on days pyridostigmine bromide 
pills taken        
Categorical 0.95 0.66 0.02 0.46 0.73 2.19 6.41 
Trendb 1.08 1.93 0.00 0.45 0.73 2.22 37.83 
Total number of pyridostigmine bromide pills taken        Categorical 0.95 0.65 0.01 0.46 0.73 2.19 6.43 
Trendb, d 0.97 0.71 0.00 0.45 0.75 2.23 6.19 
Prior to reference date, number of times visited or resided in the island 
of Guam, the islands of New Guinea, or the Kii Peninsula of Japan        
Categorical 0.94 0.68 0.02 0.33 0.74 2.24 5.88 
Trendb 0.99 0.75 0.01 0.40 0.76 2.39 7.43 
Prior to reference date, total amount of time (months) spent in the island 
of Guam, the islands of New Guinea, or the Kii Peninsula of Japan, 
excluding time periods between age at first and last visits when you 
didn’t visit or reside in the island of Guam, the islands of New Guinea, or 
the Kii Peninsula of Japan 
       
Categorical 0.97 0.71 0.11 0.34 0.74 2.30 5.72 
Trendb, d 0.98 0.70 0.08 0.46 0.75 2.21 6.59 
While you were in WWII, the Korean War, the Vietnam War, and/or 
the Gulf Ware:        
Total number of preventive vaccinations received by injection 
 (shots) or by mouth while inside or outside the U.S.        
Categorical 0.94 0.94 0.16 0.26 0.65 2.51 8.05 
Trendb, d 0.94 0.65 0.27 0.40 0.76 2.34 4.31 
While you were in WWII, the Korean War, the Vietnam War, and/or 
the Gulf Ware: number of days exposed to        
Manufacture, testing, or use of chemical protective gear (for 
 mustard gas, tear gas, etc.) Do not include training        
Categorical 0.95 0.74 0.03 0.41 0.74 2.41 6.62 
Trendf 1.54 4.68 0.00 0.42 0.68 3.32 53.00 
Ionizing radiation from nuclear weapon testing or occupation of 
 Hiroshima/Nagasaki        
Categorical 0.96 0.71 0.00 0.44 0.74 2.40 6.45 
Trendf 1.03 0.90 0.00 0.44 0.74 2.45 8.48 
Use of personal pesticides, like creams, sprays or flea collars        Categorical 0.98 1.25 0.08 0.33 0.68 2.15 12.96 
Trendf 0.97 0.91 0.26 0.33 0.72 2.32 9.89 
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       Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
Use of pesticides on your clothing or bedding        Categorical 0.96 1.44 0.13 0.34 0.69 2.34 19.45 
Trendf 0.96 0.92 0.23 0.39 0.71 2.26 10.27 
Exhaust from heaters or generators (e.g., kerosene heaters, 
 tent heaters)        
Categorical 0.95 0.81 0.18 0.32 0.72 2.28 6.32 
Trendf 0.96 0.74 0.25 0.39 0.73 2.21 6.45 
Exposure to diesel and/or other petrochemical fumes        Categorical 0.93 0.77 0.16 0.30 0.70 2.34 5.35 
Trendf 0.94 0.75 0.25 0.35 0.69 2.39 5.88 
Burning trash or burning feces/manure        Categorical 0.87 0.80 0.15 0.28 0.64 1.96 8.72 
Trendf 0.92 0.82 0.14 0.31 0.70 2.14 8.31 
Exposure to paint, solvents, or petrochemical substances        Categorical 0.92 0.73 0.05 0.33 0.72 2.19 7.09 
Trendf 0.96 0.71 0.12 0.41 0.74 2.45 6.48 
High-intensity radar waves (e.g., as radar operator, radio 
 operator, aviation electrician's mate)        
Categorical 0.96 0.76 0.04 0.34 0.71 2.42 6.79 
Trendf 0.97 0.74 0.18 0.39 0.74 2.42 6.75 
Food contaminated with smoke, oil, or other chemicals        Categorical 0.98 0.74 0.34 0.43 0.75 2.44 6.65 
Trendf 0.97 0.74 0.05 0.41 0.75 2.43 6.38 
Local food other than food provided by the Armed Forces        Categorical 0.91 0.76 0.13 0.31 0.69 2.48 5.04 
Trendf 0.92 0.69 0.18 0.34 0.70 2.52 4.87 
Bathing in or drinking of water contaminated with smoke, oil, 
 dead animals or any chemicals        
Categorical 0.94 0.69 0.13 0.44 0.72 2.31 6.54 
Trendf 0.98 0.73 0.07 0.43 0.77 2.47 6.69 
Heat cramps, heat exhaustion, heat stroke or other heat illness        Categorical 0.89 0.70 0.06 0.36 0.68 2.34 6.89 
Trendf 0.94 0.69 0.15 0.42 0.72 2.37 6.58 
Heard chemical alarms sounding        Categorical 662.87 8140.73 0.34 0.45 0.74 2.39 116708.30 
Trendf 1.33 5.02 0.00 0.43 0.73 2.49 73.20 
Explosion in the air or on the ground within one mile of you 
 (e.g., artillery, rockets, mortars)        
Categorical 0.97 0.94 0.10 0.29 0.67 2.42 7.16 
Trendf 0.97 0.87 0.26 0.36 0.73 2.26 8.91 
Have you suffered a combat-related injury that required medical 
 attention during your deployment?        
Categorical 0.92 0.76 0.08 0.33 0.73 2.29 7.09 
Trendf 0.94 0.69 0.10 0.43 0.74 2.14 6.61 
While you were in WWII, the Korean War, and/or the Vietnam Ware: 
number of days exposed to        
Mixing and application of herbicides        Categorical 0.94 0.70 0.00 0.43 0.75 2.26 6.30 
Trendf 0.98 0.71 0.04 0.46 0.79 2.38 6.46 
Exposure to herbicides in the field        Categorical 0.96 0.72 0.35 0.44 0.76 2.20 6.39 
Trendf 0.99 0.75 0.06 0.43 0.79 2.31 6.62 
        
339 
       Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
Mixing and application of riot control substances        Categorical 0.96 0.70 0.10 0.45 0.75 2.27 6.36 
Trendf 1.00 0.80 0.00 0.44 0.74 2.44 6.24 
Exposure to riot control substances in the field        Categorical 0.98 0.72 0.35 0.45 0.75 2.42 6.58 
Trendf 0.98 0.73 0.00 0.46 0.76 2.47 6.42 
Mixing and application of burning agents        Categorical 0.93 0.70 0.11 0.40 0.75 2.22 6.85 
Trendf 0.96 0.71 0.02 0.45 0.77 2.27 6.70 
Exposure to burning agents in the field        Categorical 0.92 0.70 0.25 0.33 0.72 2.23 6.89 
Trendf 0.97 0.74 0.08 0.40 0.73 2.49 6.36 
While you were in the Korean War, the Vietnam War, and/or the Gulf 
Ware: number of days exposed to        
Microwave radiation        Categorical 1.00 0.76 0.33 0.46 0.75 2.52 6.37 
Trendf 0.98 0.76 0.05 0.44 0.74 2.32 6.51 
While you were in the Vietnam Ware: number of days exposed to        Mixing and application of Agent Orange        Categorical 0.98 0.76 0.07 0.42 0.77 2.48 6.51 
Trendf 1.01 0.79 0.07 0.43 0.76 2.51 6.88 
Exposure to Agent Orange in the field        Categorical 0.97 0.86 0.17 0.27 0.72 2.47 6.42 
Trendf 1.03 0.87 0.21 0.35 0.76 2.63 6.46 
While you were in the Gulf Ware: number of days exposed to        Use of depleted uranium (DU) for munitions or armor        Categorical 1.07 0.63 0.43 0.43 0.73 2.26 2.26 
Trendf 1.06 0.62 0.44 0.44 0.75 2.44 2.44 
CARC (Chemical Agent Resistant Compound) paint        Categorical 0.93 0.56 0.43 0.43 0.69 2.26 2.26 
Trendf 0.94 0.58 0.44 0.44 0.69 2.37 2.37 
Scud missile explosion in the air or on the ground within one 
 mile of you        
Categorical 0.95 0.85 0.42 0.42 0.59 3.44 3.44 
Trendf 0.91 0.66 0.43 0.43 0.63 2.68 2.68 
Smoke from oil well fires        Categorical 0.93 0.59 0.39 0.39 0.71 2.13 2.13 
Trendf 0.93 0.54 0.43 0.43 0.65 2.09 2.09 
Exposure to nerve gas (e.g., during munitions destruction)        Categorical 0.97 0.88 0.34 0.34 0.60 3.47 3.47 
Trendf 0.95 0.62 0.43 0.43 0.67 2.25 2.25 
High levels of dust/sand        Categorical 1.11 1.56 0.19 0.19 0.50 6.41 6.41 
Trendf 1.14 1.50 0.23 0.23 0.60 6.13 6.13 
Ground level fumigation        Categorical 0.83 0.52 0.21 0.21 0.68 2.13 2.13 
Trendf 0.85 0.37 0.44 0.44 0.70 1.68 1.68 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CARC, Chemical Agent 
Resistant Compound; DU, depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; U.S., United States of America; VA, Department of Veterans Affairs; WWII, 
World War II. 
aWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups or, for exposures queried only 
in reference to deployment to the Gulf War, modeled with a linear term that was centered at age 60—the median age among all 
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 cases), war/operation of longest deployment, not missing covariate data (conditional on most recent ALS diagnosis, site of 
symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time 
from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, 
and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in 
GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of 
symptom onset, time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from 
diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score [modeled with a 
restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]). 95% CIs 
were calculated with robust variance estimates. 
bUsed within-category medians that were calculated using all cases. 
cReference category excluded for linear trend test. 
dReference category included for linear trend test. 
eThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a 
separate question: World War II (defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined 
as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period from August 3, 1964, to May 7, 
1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). 
fUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5). Reference category included 
for linear trend test.  
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 Table G.6. Summary statistics for the untruncated overall stabilized inverse probability weightsa for 
models in Appendix G, Table G.12. 
      Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
While you were in WWII, the Korean War, the Vietnam War, and/or 
the Gulf Warb: did you feel ill from exposure to        
Manufacture, testing, or use of chemical protective gear (for 
 mustard gas, tear gas, etc.) Do not include training        
Categorical 0.94 0.73 0.03 0.41 0.73 2.39 6.56 
Trendc 1.57 5.55 0.00 0.41 0.68 2.99 66.45 
Ionizing radiation from nuclear weapon testing or occupation of 
 Hiroshima/Nagasaki        
Categorical 0.97 0.71 0.35 0.47 0.76 2.40 6.45 
Trendc 0.99 0.74 0.00 0.43 0.76 2.46 6.49 
Use of personal pesticides, like creams, sprays or flea collars        Categorical 0.93 0.66 0.08 0.32 0.71 2.38 4.18 
Trendc 0.96 0.74 0.29 0.37 0.74 2.37 6.08 
Use of pesticides on your clothing or bedding        Categorical 0.92 0.72 0.22 0.36 0.70 2.38 6.27 
Trendc 0.95 0.84 0.22 0.39 0.72 2.29 8.28 
Exhaust from heaters or generators (e.g., kerosene heaters, 
 tent heaters)        
Categorical 0.95 0.75 0.14 0.36 0.72 2.22 6.13 
Trendc 0.95 0.72 0.15 0.42 0.74 2.26 6.33 
Exposure to diesel and/or other petrochemical fumes        Categorical 0.91 0.71 0.25 0.31 0.68 2.32 5.09 
Trendc 0.93 0.70 0.26 0.34 0.69 2.24 5.91 
Burning trash or burning feces/manure        Categorical 0.91 0.84 0.25 0.32 0.65 2.30 8.72 
Trendc 0.93 0.84 0.23 0.35 0.67 2.25 8.82 
Exposure to paint, solvents, or petrochemical substances        Categorical 0.95 0.76 0.04 0.39 0.71 2.28 6.56 
Trendc 0.96 0.73 0.12 0.42 0.74 2.23 6.93 
High-intensity radar waves (e.g., as radar operator, radio 
 operator, aviation electrician's mate)        
Categorical 0.97 0.79 0.15 0.34 0.72 2.42 6.70 
Trendc 0.97 0.75 0.19 0.39 0.74 2.45 6.89 
Food contaminated with smoke, oil, or other chemicals        Categorical 0.94 0.72 0.15 0.39 0.73 2.43 6.45 
Trendc 0.98 0.74 0.05 0.41 0.74 2.51 6.42 
Local food other than food provided by the Armed Forces        Categorical 0.96 0.74 0.14 0.35 0.73 2.48 5.26 
Trendc 0.96 0.76 0.31 0.38 0.73 2.43 5.93 
Bathing in or drinking of water contaminated with smoke, oil, 
 dead animals or any chemicals        
Categorical 0.93 0.69 0.08 0.43 0.72 2.25 6.48 
Trendc 0.96 0.70 0.04 0.45 0.75 2.34 6.37 
Heat cramps, heat exhaustion, heat stroke or other heat illness        Categorical 0.93 0.79 0.11 0.36 0.71 2.45 6.94 
Trendc 0.96 0.77 0.12 0.38 0.71 2.58 7.02 
Heard chemical alarms sounding        Categorical 1.01 0.88 0.34 0.44 0.75 2.42 8.77 
Trendc 1.04 1.23 0.00 0.40 0.73 2.58 12.43 
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       Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
Explosion in the air or on the ground within one mile of you 
 (e.g., artillery, rockets, mortars)        
Categorical 0.94 0.79 0.03 0.26 0.67 2.60 5.05 
Trendc 0.95 0.78 0.14 0.33 0.71 2.34 5.66 
While you were in WWII, the Korean War, and/or the Vietnam Warb: 
did you feel ill from exposure to        
Mixing and application of herbicides        Categorical 61.37 854.35 0.35 0.45 0.76 2.43 12083.25 
Trendc 0.97 0.71 0.00 0.44 0.79 2.33 6.32 
Exposure to herbicides in the field        Categorical 0.93 0.71 0.05 0.40 0.76 2.17 6.41 
Trendc 0.96 0.73 0.10 0.42 0.77 2.23 6.47 
Mixing and application of riot control substances        Categorical 0.97 0.71 0.36 0.45 0.76 2.42 6.36 
Trendc 0.98 0.72 0.00 0.45 0.77 2.43 6.39 
Exposure to riot control substances in the field        Categorical 0.93 0.69 0.04 0.44 0.74 2.17 6.45 
Trendc 0.98 0.72 0.00 0.46 0.75 2.53 6.47 
Mixing and application of burning agents        Categorical 0.92 0.69 0.21 0.40 0.75 2.21 6.85 
Trendc 0.95 0.71 0.15 0.41 0.76 2.26 6.95 
Exposure to burning agents in the field        Categorical 0.93 0.74 0.24 0.35 0.74 2.35 7.16 
Trendc 0.94 0.71 0.19 0.38 0.75 2.34 6.86 
While you were in the Korean War, the Vietnam War, and/or the Gulf 
Warb: did you feel ill from exposure to        
Microwave radiation        Categorical 0.97 0.75 0.11 0.44 0.73 2.34 6.35 
Trendc 0.99 0.76 0.07 0.45 0.73 2.36 6.39 
While you were in the Vietnam Warb: did you feel ill from exposure 
to        
Mixing and application of Agent Orange        Categorical 1.02 0.78 0.34 0.43 0.78 2.54 6.51 
Trendc 1.01 0.79 0.24 0.42 0.79 2.52 6.61 
Exposure to Agent Orange in the field        Categorical 1.04 0.98 0.17 0.28 0.71 2.68 6.54 
Trendc 1.05 0.93 0.22 0.37 0.75 2.42 6.77 
While you were in the Gulf Warb: did you feel ill from exposure to        Use of depleted uranium (DU) for munitions or armor        Categorical 1.07 0.64 0.43 0.43 0.73 2.30 2.30 
Trendc 1.06 0.62 0.44 0.44 0.74 2.36 2.36 
CARC (Chemical Agent Resistant Compound) paint        Categorical 0.96 0.59 0.43 0.43 0.65 2.26 2.26 
Trendc 0.94 0.58 0.44 0.44 0.67 2.34 2.34 
Scud missile explosion in the air or on the ground within one 
 mile of you        
Categorical 0.95 0.85 0.42 0.42 0.59 3.44 3.44 
Trendc 0.97 0.93 0.43 0.43 0.60 3.74 3.74 
Smoke from oil well fires        Categorical 0.94 0.60 0.39 0.39 0.71 2.13 2.13 
Trendc 0.93 0.54 0.42 0.42 0.64 2.06 2.06 
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       Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
Exposure to nerve gas (e.g., during munitions destruction)        Categorical 0.97 0.88 0.34 0.34 0.60 3.46 3.46 
Trendc 0.96 0.77 0.35 0.35 0.58 2.84 2.84 
High levels of dust/sand        Categorical 1.20 0.81 0.28 0.28 0.96 2.73 2.73 
Trendc 1.02 0.70 0.27 0.27 0.71 2.80 2.80 
Ground level fumigation        Categorical 0.84 0.55 0.21 0.21 0.68 2.25 2.25 
Trendc 0.87 0.42 0.34 0.34 0.74 1.78 1.78 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CARC, Chemical Agent 
Resistant Compound; DU, depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic 
Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; VA, Department of Veterans Affairs; WWII, World War II. 
aWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups or, for exposures queried only 
in reference to deployment to the Gulf War, modeled with a linear term that was centered at age 60—the median age among all 
cases), war/operation of longest deployment, not missing covariate data (conditional on most recent ALS diagnosis, site of 
symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time 
from diagnosis to enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, 
and 44.19 months based on percentiles of the distribution in the Registry cases not missing covariate data]), and participating in 
GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of 
symptom onset, time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from 
diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline ALSFRS-R score [modeled with a 
restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]). 95% CIs 
were calculated with robust variance estimates. 
bThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a 
separate question: World War II (defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined 
as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period from August 3, 1964, to May 7, 
1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). 
cUsed ordinal scores (0, 1, 2). Reference category included for linear trend test. 
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 Table G.7. Summary statistics for the untruncated overall stabilized inverse probability weightsa for 
models in Appendix G, Table G.13. 
      Percentiles 
Variable Mean Standard Deviation Min 5 50 95 Max 
Total number of theaters of operation for the Vietnam Warb               
Categorical 0.95 1.04 0.12 0.26 0.65 2.46 15.39 
Trendc 1.02 0.81 0.05 0.43 0.77 2.60 6.59 
Total length (years) of deployment to all theaters of operation for the 
Vietnam Warb        
Categorical 0.94 0.88 0.12 0.26 0.65 2.45 8.04 
Trendc 1.01 0.75 0.36 0.42 0.78 2.48 6.40 
End of most recent period of deployment to the Vietnam War (year)b        Categorical 0.94 1.07 0.06 0.22 0.65 2.45 12.55 
Trendc 1.09 1.21 0.04 0.30 0.72 2.88 8.90 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; GENEVA, Genes and 
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; VA, Department of Veterans Affairs. 
aWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data 
(conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical 
Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
bThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a 
separate question: World War II (defined as the period from December 7, 1941, to December 31, 1946), the Korean War (defined 
as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period from August 3, 1964, to May 7, 
1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also 
asked "Ever deployed..." to the following countries where each country was asked about with a separate question: Grenada, 
Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
cUsed within-category medians that were calculated using all cases. Individuals in the categories labeled "Not deployed to any 
war/operation" and "Not deployed to the Vietnam War" were excluded for the linear trend test. 
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 Table G.8. Summary statistics for the untruncated overall stabilized inverse probability weightsa for 
models in Appendix G, Table G.14. 
      Percentiles 
Did you have direct contact with/were you exposed to Mean Standard Deviation Min 5 50 95 Max 
Mixing and application of Agent Orangeb 1.00 0.77 0.20 0.43 0.77 2.53 6.46 
Exposure to Agent Orange in the fieldb 1.05 0.99 0.16 0.32 0.72 2.50 6.74 
Mixing and application of other herbicides 0.99 0.76 0.02 0.42 0.77 2.46 6.28 
Exposure to other herbicides in the field 0.99 0.77 0.34 0.40 0.77 2.29 6.37 
Manufacture, testing, or use of chemical protective gear (for mustard gas, tear 
gas, etc.) Do not include training 1.00 0.77 0.29 0.41 0.74 2.42 6.59 
Ionizing radiation from nuclear weapon testing 1.00 0.78 0.35 0.43 0.75 2.48 6.47 
Microwave radiation 1.01 0.78 0.26 0.45 0.78 2.42 6.35 
Use of personal pesticides, like creams, sprays or flea collars 1.00 0.78 0.22 0.36 0.73 2.56 6.23 
Use of pesticides on your clothing or bedding 0.99 0.80 0.25 0.40 0.74 2.41 6.65 
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters) 0.98 0.77 0.24 0.35 0.70 2.47 6.32 
Exposure to diesel and/or other petrochemical fumes 1.00 0.76 0.20 0.43 0.74 2.34 5.97 
Burning trash or burning feces/manure 1.03 0.90 0.32 0.36 0.77 2.80 7.28 
Exposure to paint, solvents, or petrochemical substances 1.00 0.80 0.23 0.44 0.72 2.39 6.81 
High-intensity radar waves (e.g., as radar operator, radio operator, aviation 
electrician's mate) 1.01 0.80 0.22 0.38 0.75 2.38 6.55 
Food contaminated with smoke, oil, or other chemicals 1.02 0.81 0.20 0.38 0.77 2.49 6.37 
Local food other than food provided by the Armed Forces 1.00 0.80 0.32 0.42 0.75 2.40 6.08 
Bathing in or drinking of water contaminated with smoke, oil, dead animals or 
any chemicals 1.00 0.77 0.27 0.41 0.75 2.42 6.27 
Heat cramps, heat exhaustion, heat stroke or other heat illness 1.00 0.78 0.25 0.39 0.72 2.58 6.28 
Heard chemical alarms sounding 1.00 0.75 0.35 0.41 0.75 2.42 6.32 
Explosion in the air or on the ground within one mile of you (e.g., artillery, 
rockets, mortars) 1.03 0.89 0.20 0.33 0.74 2.45 6.07 
Mixing and application of riot control substances 1.01 0.77 0.20 0.43 0.77 2.49 6.38 
Exposure to riot control substances in the field 1.01 0.76 0.20 0.45 0.75 2.40 6.31 
Mixing and application of burning agents 0.98 0.76 0.32 0.40 0.76 2.30 6.69 
Exposure to burning agents in the field 0.98 0.75 0.28 0.40 0.72 2.35 6.53 
Have you suffered a combat-related injury that required medical attention during 
your deployment? 1.01 0.98 0.26 0.35 0.74 2.73 6.97 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; GENEVA, Genes and 
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; VA, Department of Veterans Affairs. 
aWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data 
(conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical 
Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
bRepeated from Appendix G, Table G.4.
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 Table G.9. Summary statistics for the untruncated overall stabilized inverse probability weightsa for 
models in Appendix G, Table G.15. 
      Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
Total number of preventive vaccinations received by injection (shots) or by 
mouth while inside or outside the U.S.        
Categorical 0.95 0.87 0.13 0.31 0.67 2.02 6.35 
Trendb 0.97 0.71 0.33 0.42 0.78 2.29 5.64 
Number of days exposed to        Mixing and application of Agent Orangec        Categorical 0.98 0.76 0.07 0.42 0.77 2.48 6.51 
Trendd 1.01 0.79 0.07 0.43 0.76 2.51 6.88 
Exposure to Agent Orange in the fieldc        Categorical 0.97 0.86 0.17 0.27 0.72 2.47 6.42 
Trendd 1.03 0.87 0.21 0.35 0.76 2.63 6.46 
Mixing and application of other herbicides        Categorical 20.18 223.76 0.20 0.43 0.77 2.46 2610.47 
Trendd 1.02 0.78 0.01 0.44 0.79 2.54 6.48 
Exposure to other herbicides in the field        Categorical 0.99 0.78 0.25 0.37 0.77 2.32 6.44 
Trendd 1.03 0.83 0.08 0.37 0.79 2.51 6.62 
Manufacture, testing, or use of chemical protective gear (for mustard gas, 
 tear gas, etc.) Do not include training        
Categorical 1.00 0.79 0.17 0.41 0.74 2.51 6.59 
Trendd 1.03 0.80 0.00 0.42 0.78 2.49 6.47 
Ionizing radiation from nuclear weapon testing        Categorical 1.01 0.77 0.35 0.43 0.76 2.48 6.47 
Trendd 1.02 0.80 0.11 0.43 0.77 2.55 6.63 
Microwave radiation        Categorical 1.03 0.80 0.33 0.46 0.78 2.48 6.30 
Trendd 1.01 0.78 0.14 0.44 0.78 2.44 6.42 
Use of personal pesticides, like creams, sprays or flea collars        Categorical 1.01 0.90 0.21 0.36 0.73 2.58 8.24 
Trendd 1.01 0.79 0.28 0.40 0.74 2.51 6.44 
Use of pesticides on your clothing or bedding        Categorical 0.97 0.68 0.18 0.38 0.76 2.37 4.67 
Trendd 1.00 0.78 0.30 0.40 0.75 2.37 6.71 
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)        Categorical 0.96 0.75 0.25 0.35 0.70 2.43 6.41 
Trendd 0.98 0.76 0.30 0.38 0.73 2.40 6.56 
Exposure to diesel and/or other petrochemical fumes        Categorical 0.99 0.76 0.20 0.43 0.74 2.40 5.94 
Trendd 1.00 0.73 0.25 0.44 0.73 2.35 6.01 
Burning trash or burning feces/manure        Categorical 0.99 0.87 0.22 0.34 0.77 2.32 7.13 
Trendd 1.02 0.86 0.21 0.34 0.76 2.66 6.91 
Exposure to paint, solvents, or petrochemical substances        Categorical 0.95 0.78 0.23 0.36 0.71 2.26 6.81 
Trendd 0.99 0.79 0.27 0.41 0.71 2.54 6.40 
High-intensity radar waves (e.g., as radar operator, radio operator, 
 aviation electrician's mate)        
Categorical 1.01 0.82 0.27 0.33 0.73 2.35 6.61 
Trendd 1.03 0.81 0.29 0.38 0.74 2.26 6.62 
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       Percentiles 
Exposure Mean Standard Deviation Min 5 50 95 Max 
Food contaminated with smoke, oil, or other chemicals        Categorical 1.04 0.81 0.33 0.41 0.77 2.45 6.42 
Trendd 1.05 0.85 0.10 0.41 0.78 2.59 6.27 
Local food other than food provided by the Armed Forces        Categorical 0.90 0.65 0.12 0.32 0.74 2.20 4.08 
Trendd 0.95 0.67 0.27 0.39 0.71 2.43 4.42 
Bathing in or drinking of water contaminated with smoke, oil, dead 
 animals or any chemicals        
Categorical 1.02 0.78 0.33 0.46 0.75 2.45 6.35 
Trendd 1.03 0.80 0.14 0.41 0.76 2.46 6.47 
Heat cramps, heat exhaustion, heat stroke or other heat illness        Categorical 0.97 0.76 0.12 0.40 0.71 2.46 6.28 
Trendd 0.99 0.73 0.28 0.43 0.76 2.48 6.28 
Heard chemical alarms sounding        Categorical 0.99 0.75 0.24 0.38 0.74 2.42 6.32 
Trendd 1.02 0.77 0.01 0.44 0.76 2.55 6.55 
Explosion in the air or on the ground within one mile of you (e.g., artillery, 
 rockets, mortars)        
Categorical 0.99 1.00 0.12 0.25 0.72 2.52 9.24 
Trendd 1.02 0.92 0.22 0.37 0.80 2.41 8.13 
Mixing and application of riot control substances        Categorical 1.01 0.76 0.36 0.44 0.77 2.49 6.38 
Trendd 1.04 0.79 0.00 0.44 0.79 2.56 6.54 
Exposure to riot control substances in the field        Categorical 1.02 0.77 0.34 0.41 0.76 2.45 6.45 
Trendd 1.03 0.80 0.01 0.42 0.77 2.49 6.36 
Mixing and application of burning agents        Categorical 1.00 0.76 0.33 0.43 0.77 2.47 6.49 
Trendd 1.00 0.77 0.04 0.42 0.78 2.46 6.57 
Exposure to burning agents in the field        Categorical 0.98 0.77 0.29 0.38 0.70 2.34 6.40 
Trendd 1.02 0.82 0.15 0.40 0.76 2.52 6.25 
Have you suffered a combat-related injury that required medical attention 
 during your deployment?        
Categorical 0.97 0.87 0.17 0.31 0.73 2.65 6.97 
Trendd 1.00 0.80 0.07 0.40 0.74 2.54 6.67 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; GENEVA, Genes and 
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; U.S., United States of America; VA, Department of 
Veterans Affairs. 
aWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data 
(conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical 
Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
bUsed within-category medians that were calculated using all cases. Reference category included for linear trend test. 
cRepeated from Appendix G, Table G.5. 
dUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5). Reference category included 
for linear trend test. 
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 Table G.10. Summary statistics for the untruncated overall stabilized inverse probability weightsa for 
models in Appendix G, Table G.16. 
      Percentiles 
Did you feel ill from exposure to Mean Standard Deviation Min 5 50 95 Max 
Mixing and application of Agent Orangeb        Categorical 1.02 0.78 0.34 0.43 0.78 2.54 6.51 
Trendc 1.01 0.79 0.24 0.42 0.79 2.52 6.61 
Exposure to Agent Orange in the fieldb        Categorical 1.04 0.98 0.17 0.28 0.71 2.68 6.54 
Trendc 1.05 0.93 0.22 0.37 0.75 2.42 6.77 
Mixing and application of other herbicides        Categorical > 20000 > 20000 0.35 0.43 0.77 2.51 > 20000 
Trendc 97.39 928.58 0.00 0.36 0.66 2.17 10532.48 
Exposure to other herbicides in the field        Categorical 1.02 0.79 0.34 0.41 0.78 2.32 6.37 
Trendc 1.01 0.80 0.23 0.38 0.78 2.36 6.54 
Manufacture, testing, or use of chemical protective gear (for 
mustard gas, tear gas, etc.) Do not include training        
Categorical 0.99 0.77 0.17 0.41 0.75 2.42 6.59 
Trendc 1.02 0.80 0.01 0.42 0.77 2.53 6.66 
Ionizing radiation from nuclear weapon testing        Categorical 1.01 0.77 0.35 0.43 0.76 2.48 6.47 
Trendc 1.02 0.80 0.11 0.43 0.77 2.55 6.63 
Microwave radiation        Categorical 1.01 0.78 0.22 0.42 0.76 2.38 6.25 
Trendc 1.02 0.79 0.24 0.45 0.80 2.42 6.36 
Use of personal pesticides, like creams, sprays or flea collars        Categorical 0.98 0.76 0.24 0.37 0.74 2.64 5.82 
Trendc 1.00 0.76 0.28 0.41 0.75 2.56 5.98 
Use of pesticides on your clothing or bedding        Categorical 1.00 0.88 0.26 0.38 0.71 2.43 6.23 
Trendc 1.00 0.83 0.28 0.34 0.75 2.43 6.53 
Exhaust from heaters or generators (e.g., kerosene heaters, 
tent heaters)        
Categorical 0.98 0.77 0.25 0.35 0.69 2.42 6.28 
Trendc 0.99 0.76 0.30 0.42 0.72 2.38 6.27 
Exposure to diesel and/or other petrochemical fumes        Categorical 0.99 0.78 0.21 0.42 0.75 2.50 5.70 
Trendc 1.00 0.78 0.20 0.45 0.71 2.41 6.28 
Burning trash or burning feces/manure        Categorical 1.01 0.87 0.26 0.39 0.75 2.77 7.08 
Trendc 1.03 0.87 0.34 0.38 0.76 2.78 6.99 
Exposure to paint, solvents, or petrochemical substances        Categorical 0.98 0.76 0.24 0.38 0.72 2.33 6.40 
Trendc 0.99 0.76 0.29 0.44 0.72 2.39 6.53 
High-intensity radar waves (e.g., as radar operator, radio 
operator, aviation electrician's mate)        
Categorical 1.00 0.80 0.20 0.33 0.74 2.42 6.51 
Trendc 1.02 0.81 0.26 0.38 0.73 2.36 6.58 
Food contaminated with smoke, oil, or other chemicals        Categorical 1.03 0.84 0.22 0.38 0.77 2.45 6.26 
Trendc 1.06 0.86 0.10 0.41 0.77 2.59 6.29 
Local food other than food provided by the Armed Forces        Categorical 0.99 0.76 0.14 0.42 0.74 2.42 5.90 
Trendc 1.02 0.85 0.21 0.42 0.75 2.43 6.51 
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       Percentiles 
Did you feel ill from exposure to Mean Standard Deviation Min 5 50 95 Max 
Bathing in or drinking of water contaminated with smoke, oil, 
dead animals or any chemicals        
Categorical 0.97 0.74 0.12 0.37 0.72 2.38 6.23 
Trendc 1.01 0.76 0.09 0.40 0.78 2.48 6.23 
Heat cramps, heat exhaustion, heat stroke or other heat illness        Categorical 0.97 0.76 0.13 0.41 0.70 2.42 6.33 
Trendc 1.00 0.79 0.26 0.41 0.73 2.53 6.48 
Heard chemical alarms sounding        Categorical 1.00 0.74 0.35 0.43 0.77 2.42 6.32 
Trendc 1.01 0.77 0.21 0.42 0.76 2.52 6.47 
Explosion in the air or on the ground within one mile of you 
(e.g., artillery, rockets, mortars)        
Categorical 1.02 0.89 0.20 0.32 0.71 2.86 5.80 
Trendc 1.01 0.88 0.19 0.33 0.75 2.52 6.14 
Mixing and application of riot control substances        Categorical 1.01 0.76 0.36 0.44 0.77 2.49 6.38 
Trendc 1.04 0.79 0.00 0.44 0.79 2.56 6.54 
Exposure to riot control substances in the field        Categorical 0.98 0.76 0.07 0.41 0.74 2.40 6.31 
Trendc 1.02 0.77 0.03 0.46 0.77 2.43 6.37 
Mixing and application of burning agents        Categorical 0.98 0.77 0.26 0.40 0.76 2.30 6.69 
Trendc 0.99 0.78 0.25 0.41 0.77 2.44 6.78 
Exposure to burning agents in the field        Categorical 0.99 0.85 0.29 0.36 0.72 2.38 6.63 
Trendc 1.00 0.77 0.32 0.38 0.72 2.44 6.41 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; GENEVA, Genes and 
Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; VA, Department of Veterans Affairs. 
aWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data 
(conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical 
Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
bRepeated from Appendix G, Table G.6. 
cUsed ordinal scores (0, 1, 2). Reference category included for linear trend test. 
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 Table G.11. Dose-response for military exposures and amyotrophic lateral sclerosis survival in GENEVAa. 
  Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Number of anthrax vaccine shots received prior to reference date           0 (Median = 0) 353 8,486 483 18,957 1.00 Referent 1.00 Referent 1.00 Referent 
1-2 (1) 8 206 10 382 1.48 0.71, 3.05 1.59 0.75, 3.37 1.18 0.69, 2.03 
> 2 (4) 8 170 14 670 0.99 0.47, 2.06 1.11 0.50, 2.47 0.72 0.32, 1.62 
Missing 51  75        Trendg     1.01 0.85, 1.21 1.04 0.86, 1.26 0.90 0.71, 1.14 Prior to reference date, number of years involved in testing, transporting or 
spraying herbicides for military purposes           
0 (0) 325 7,357 440 16,184 1.00 Referent 1.00 Referent 1.00 Referent 
1-2 (1) 6 162 12 594 0.59 0.26, 1.34 0.60 0.26, 1.36 0.94 0.39, 2.30 
> 2 (10) < 5 188 5 257 1.56 0.55, 4.41 1.56 0.55, 4.44 1.31 0.87, 1.96 
Missing 85  125        Trendg     1.03 0.93, 1.15 1.04 0.93, 1.15 1.04 0.96, 1.12 Year in which pyridostigmine bromide pills taken           Never taken pyridostigmine bromide pills 379 9,072 523 20,649 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 1971 (1969.5) 5 120 9 449 0.81 0.30, 2.22 0.83 0.30, 2.27 0.82 0.13, 5.17 
> 1971 (1991.0) < 5 123 < 5 123 1.23 0.49, 3.09 1.62 0.58, 4.54 3.65 2.32, 5.76 
Missing 33  47        Trend (IQR = 21)g, h     
i i i i 2.27 0.60, 8.64 
Total days taken pyridostigmine bromide pills           0 (0) 379 9,072 523 20,649 1.00 Referent 1.00 Referent 1.00 Referent 
1-11 (4) < 5 125 5 198 0.74 0.30, 1.82 0.80 0.32, 1.97 1.03 0.24, 4.41 
> 11 (60) < 5 36 5 275 3.28 0.88, 12.20 4.77 1.21, 18.88 3.05 1.59, 5.82 
Missing 35  49        Trendg     1.02 1.00, 1.04 1.03 1.00, 1.05 0.99 0.72, 1.37 Number of pills taken in an average day on days pyridostigmine bromide pills 
taken           
0 (0) 379 9,072 523 20,649 1.00 Referent 1.00 Referent 1.00 Referent 
1 (1) < 5 38 6 287 2.22 0.76, 6.46 2.56 0.88, 7.44 1.36 0.15, 12.76 
> 1 (2) < 5 123 < 5 123 0.60 0.15, 2.45 0.70 0.17, 2.99 2.78 1.17, 6.60 
Missing 35  50        Trendg     0.96 0.56, 1.64 1.05 0.60, 1.84 1.45 1.11, 1.88 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Total number of pyridostigmine bromide pills taken           0 (0) 379 9,072 523 20,649 1.00 Referent 1.00 Referent 1.00 Referent 
1-22 (14) < 5 155 6 308 0.78 0.25, 2.47 0.89 0.27, 2.91 2.07 0.82, 5.20 
> 22 (60) 5 139 9 472 3.35 0.89, 12.57 4.85 1.22, 19.34 3.13 1.63, 5.99 
Missing 32  44        Trend (33)g, j     1.75 0.84, 3.63 2.20 1.02, 4.73 7.13 1.26, 40.18 Prior to reference date, number of times visited or resided in the island of Guam, 
the islands of New Guinea, or the Kii Peninsula of Japan           
0 (0) 347 8,190 480 18,911 1.00 Referent 1.00 Referent 1.00 Referent 
1 (1) 35 848 45 1,634 1.20 0.84, 1.70 1.20 0.84, 1.71 0.99 0.70, 1.40 
2 (2) 9 272 14 679 0.80 0.41, 1.55 0.81 0.41, 1.60 0.87 0.50, 1.52 
3 (3) 8 124 13 531 0.80 0.39, 1.62 0.86 0.42, 1.75 0.96 0.52, 1.75 
4 (4) 5 81 6 165 1.09 0.44, 2.66 1.19 0.48, 3.00 0.97 0.54, 1.75 
> 4 (6) 6 218 9 465 0.65 0.29, 1.46 0.66 0.29, 1.52 0.95 0.47, 1.91 
Missing 10  15        Trendg     0.95 0.86, 1.05 0.96 0.87, 1.06 1.06 0.96, 1.16 Prior to reference date, total amount of time (months) spent in the island of 
Guam, the islands of New Guinea, or the Kii Peninsula of Japan, excluding time 
periods between age at first and last visits when you didn’t visit or reside in the 
island of Guam, the islands of New Guinea, or the Kii Peninsula of Japan 
          
0 (0.00) 347 8,190 480 18,911 1.00 Referent 1.00 Referent 1.00 Referent 
> 0-3 (0.10) 42 1,006 53 1,857 1.19 0.86, 1.64 1.22 0.87, 1.72 1.10 0.82, 1.47 
> 3-6 (5.14) 10 252 16 729 0.69 0.37, 1.31 0.74 0.39, 1.41 1.05 0.44, 2.51 
> 6 (20.00) 13 346 20 949 0.81 0.46, 1.41 0.82 0.46, 1.44 0.98 0.62, 1.55 
Missing 8  13        Trend (5.90)g, j     0.92 0.78, 1.08 0.92 0.78, 1.09 0.96 0.83, 1.11 While you were in WWII, the Korean War, the Vietnam War, and/or the Gulf 
Wark:           
Total number of preventive vaccinations received by injection (shots) or by 
 mouth while inside or outside the U.S.           
0 (0) 43 1,119 56 2,208 1.00 Referent 1.00 Referent 1.00 Referent 
1-10 (5) 46 1,170 67 2,844 0.91 0.59, 1.43 0.95 0.60, 1.48 1.19 0.65, 2.17 
11-20 (14) 20 573 25 984 1.13 0.65, 1.97 1.22 0.69, 2.16 1.15 0.62, 2.11 
> 20 (66) 15 295 23 919 0.87 0.47, 1.61 0.87 0.47, 1.61 0.95 0.48, 1.87 
Missing 44  57             Trend (13)g, j     0.98 0.87, 1.10 0.97 0.87, 1.09 0.96 0.87, 1.07 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
While you were in WWII, the Korean War, the Vietnam War, and/or the Gulf 
Wark: number of days exposed to           
Manufacture, testing, or use of chemical protective gear (for mustard gas, 
 tear gas, etc.) Do not include training           
Not exposed 154 3,735 208 8,109 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 22 < 5 22 1.81 0.42, 7.76 1.66 0.39, 7.14 1.95 0.37, 10.25 
> 5 < 5 73 7 377 0.68 0.20, 2.24 0.83 0.23, 2.96 0.40 0.05, 3.42 
Missing 9  11        Trendl     0.59 0.23, 1.52 0.64 0.23, 1.79 1.11 0.17, 7.15 Ionizing radiation from nuclear weapon testing or occupation of 
 Hiroshima/Nagasaki           
Not exposed 153 3,911 209 8,450 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 17 < 5 76 1.18 0.28, 4.91 1.42 0.33, 6.01 1.00 0.13, 7.97 
6-30 < 5 1 < 5 1 58.10 3.32, 1016.77 45.88 2.37, 888.40 68.14 9.66, 480.65 
> 30 0 0 0 0 i i i i i i 
Missing 12  15        Trendm     1.23 1.06, 1.42 1.22 1.05, 1.42 1.04 0.71, 1.54 Use of personal pesticides, like creams, sprays or flea collars           Not exposed 111 2,781 152 6,155 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 7 119 9 292 1.61 0.73, 3.54 1.72 0.78, 3.82 0.87 0.47, 1.61 
6-30 7 134 8 207 1.59 0.69, 3.65 1.52 0.66, 3.51 1.36 0.92, 2.01 
> 30 34 860 48 1,944 1.13 0.75, 1.72 1.16 0.76, 1.77 0.92 0.50, 1.68 
Missing 9  11        Trendl     1.05 0.88, 1.25 1.06 0.88, 1.26 0.95 0.75, 1.22 Use of pesticides on your clothing or bedding           Not exposed 114 3,090 159 6,770 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 11 204 14 443 1.58 0.81, 3.09 1.52 0.78, 2.98 1.31 0.78, 2.19 
> 30 25 471 34 1,138 1.46 0.90, 2.35 1.41 0.87, 2.29 1.34 0.65, 2.76 
Missing 18  21        Trendl     1.19 0.98, 1.46 1.18 0.96, 1.44 1.07 0.78, 1.47 Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)           Not exposed 102 2,484 140 5,525 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 13 296 18 717 1.00 0.54, 1.85 0.97 0.52, 1.81 0.66 0.28, 1.57 
> 30 35 782 49 1,908 0.97 0.65, 1.45 1.00 0.66, 1.51 0.90 0.63, 1.30 
Missing 18  21        Trendl     0.99 0.84, 1.18 1.01 0.84, 1.20 0.96 0.82, 1.13 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Exposure to diesel and/or other petrochemical fumes           Not exposed 57 1,372 75 2,890 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 5 111 8 344 0.82 0.32, 2.07 0.88 0.34, 2.27 0.45 0.13, 1.53 
6-30 9 146 14 535 0.95 0.45, 1.97 0.93 0.45, 1.95 0.82 0.30, 2.25 
> 30 84 2,120 117 4,749 1.01 0.70, 1.46 1.05 0.73, 1.52 1.10 0.69, 1.75 
Missing 13  14        Trendl     1.01 0.87, 1.18 1.03 0.88, 1.20 1.06 0.88, 1.27 Burning trash or burning feces/manure           Not exposed 108 2,691 144 5,635 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 11 224 11 224 2.15 1.10, 4.21 2.01 1.02, 3.96 1.33 0.78, 2.27 
6-30 8 171 13 548 0.75 0.36, 1.56 0.70 0.33, 1.46 0.55 0.26, 1.15 
> 30 30 787 47 2,168 1.10 0.69, 1.76 1.10 0.69, 1.76 0.90 0.57, 1.41 
Missing 11  13        Trendl     1.00 0.82, 1.21 1.00 0.82, 1.21 0.94 0.78, 1.15 Exposure to paint, solvents, or petrochemical substances           Not exposed 110 2,730 143 5,461 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 16 297 25 1,008 0.80 0.46, 1.38 0.81 0.47, 1.41 1.01 0.64, 1.60 
> 30 29 835 47 2,256 0.71 0.47, 1.09 0.74 0.48, 1.15 0.54 0.33, 0.88 
Missing 13  13        Trendl     0.89 0.75, 1.07 0.91 0.76, 1.09 0.81 0.67, 0.99 High-intensity radar waves (e.g., as radar operator, radio operator, aviation 
 electrician's mate)           
Not exposed 117 3,026 158 6,377 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 6 154 7 237 1.00 0.43, 2.34 1.19 0.49, 2.85 1.50 0.94, 2.39 
> 30 28 655 38 1,449 1.18 0.76, 1.84 1.26 0.81, 1.96 1.28 0.84, 1.96 
Missing 17  25        Trendl     1.08 0.90, 1.31 1.11 0.92, 1.34 1.11 0.93, 1.34 Food contaminated with smoke, oil, or other chemicals           Not exposed or ≤ 5 132 3,339 183 7,462 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 9 219 13 532 0.92 0.46, 1.87 0.84 0.41, 1.71 0.62 0.31, 1.23 
Missing 27  32        Trendl     1.03 0.73, 1.45 0.98 0.69, 1.40 0.83 0.61, 1.12 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Local food other than food provided by the Armed Forces           Not exposed 85 1,881 108 3,741 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 22 653 33 1,614 0.86 0.53, 1.39 0.84 0.52, 1.37 0.80 0.53, 1.22 
6-30 20 463 31 1,329 0.77 0.46, 1.28 0.76 0.45, 1.26 0.53 0.33, 0.88 
> 30 32 859 45 1,849 0.86 0.55, 1.34 0.88 0.56, 1.40 0.64 0.42, 0.99 
Missing 9  11        Trendl     0.94 0.78, 1.14 0.95 0.78, 1.16 0.78 0.63, 0.96 Bathing in or drinking of water contaminated with smoke, oil, dead animals or 
 any chemicals           
Not exposed 131 3,186 174 6,641 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 7 131 10 357 0.97 0.45, 2.13 0.96 0.44, 2.09 0.94 0.37, 2.40 
> 30 5 57 10 445 0.79 0.31, 2.01 0.78 0.31, 1.97 0.63 0.17, 2.30 
Missing 25  34        Trendl     0.92 0.63, 1.35 0.91 0.62, 1.34 0.91 0.54, 1.54 Heat cramps, heat exhaustion, heat stroke or other heat illness           Not exposed 129 3,162 172 6,645 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 14 275 21 875 1.30 0.73, 2.32 1.36 0.76, 2.44 1.03 0.60, 1.77 
6-30 9 283 17 916 0.58 0.29, 1.17 0.58 0.29, 1.17 0.43 0.20, 0.92 
> 30 11 253 12 312 2.31 1.20, 4.42 2.33 1.20, 4.53 1.95 1.13, 3.38 
Missing 5  6        Trendl     1.24 0.93, 1.66 1.23 0.92, 1.66 1.03 0.70, 1.51 Heard chemical alarms sounding           Not exposed or ≤ 5 156 3,762 212 8,307 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 5 128 9 447 0.68 0.27, 1.68 0.91 0.33, 2.46 0.28 0.15, 0.52 
Missing 7  7        Trendl     0.56 0.26, 1.20 0.61 0.28, 1.36 0.16 0.06, 0.39 Explosion in the air or on the ground within one mile of you (e.g., artillery, 
 rockets, mortars)           
Not exposed 49 1,349 71 3,154 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 27 678 33 1,196 1.74 1.06, 2.87 1.68 1.01, 2.78 1.73 1.09, 2.75 
6-30 25 403 37 1,377 1.29 0.78, 2.14 1.18 0.70, 1.99 1.55 0.96, 2.50 
> 30 56 1,433 73 2,761 1.22 0.81, 1.83 1.19 0.79, 1.79 1.16 0.73, 1.86 
Missing 11  14        Trendl     1.01 0.87, 1.19 1.01 0.86, 1.18 0.97 0.81, 1.16 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Have you suffered a combat-related injury that required medical attention 
 during your deployment?           
Not exposed 126 2,958 175 6,965 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 17 490 21 823 1.05 0.62, 1.81 1.04 0.60, 1.79 0.94 0.63, 1.38 
6-30 7 225 10 442 0.86 0.39, 1.87 0.81 0.37, 1.78 0.92 0.43, 1.94 
> 30 13 294 16 507 1.28 0.71, 2.30 1.20 0.66, 2.19 0.90 0.36, 2.28 
Missing 5  6        Trendl     1.09 0.85, 1.40 1.06 0.82, 1.37 0.94 0.66, 1.36 While you were in WWII, the Korean War, and/or the Vietnam Wark: number 
of days exposed to           
Mixing and application of herbicides           Not exposed 150 3,661 201 7,744 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 6 < 5 6 3.33 0.42, 26.46 2.08 0.22, 19.57 2.39 1.30, 4.39 
6-30 < 5 16 < 5 16 2.08 0.28, 15.54 2.09 0.28, 15.66 1.36 0.94, 1.95 
> 30 < 5 65 < 5 65 2.31 0.53, 10.03 1.98 0.44, 8.85 3.81 1.83, 7.94 
Missing 10  11        Trendl     1.47 0.81, 2.66 1.38 0.75, 2.53 1.51 1.02, 2.25 Exposure to herbicides in the field           Not exposed or ≤ 5 123 2,991 162 6,134 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 5 106 6 198 1.36 0.54, 3.41 1.20 0.47, 3.06 1.13 0.65, 1.97 
Missing 36  48        Trendl     1.32 0.84, 2.07 1.26 0.79, 2.01 1.01 0.54, 1.88 Mixing and application of riot control substances           Not exposed 159 3,911 211 8,084 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 6 < 5 6 4.99 0.62, 40.15 4.28 0.53, 34.47 3.51 1.77, 6.98 
6-30 < 5 3 < 5 3 4.13 0.47, 36.33 5.62 0.62, 50.86 5.22 2.76, 9.88 
> 30 0 0 0 0 i i i i i i 
Missing 3  3        Trendm     1.09 0.97, 1.22 1.11 0.99, 1.25 1.58 1.25, 2.00 Exposure to riot control substances in the field           Not exposed or ≤ 5 155 3,728 204 7,675 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 6 193 8 352 0.93 0.40, 2.15 0.98 0.42, 2.27 0.78 0.38, 1.58 
Missing 3  4        Trendl     1.01 0.58, 1.76 1.03 0.59, 1.80 0.49 0.30, 0.79 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Mixing and application of burning agents           Not exposed 145 3,601 195 7,594 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 30 8 94 8 94 2.40 1.11, 5.21 2.61 1.20, 5.64 1.75 1.20, 2.55 
> 30 5 99 6 190 1.95 0.72, 5.34 2.13 0.79, 5.77 2.51 0.99, 6.33 
Missing 6  7        Trendl     1.45 0.99, 2.12 1.51 1.03, 2.20 1.77 1.14, 2.75 Exposure to burning agents in the field           Not exposed 134 3,286 175 6,610 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 8 167 14 596 0.59 0.28, 1.21 0.61 0.29, 1.26 0.38 0.17, 0.82 
> 5 11 319 15 649 0.94 0.49, 1.81 0.98 0.51, 1.89 0.69 0.40, 1.19 
Missing 11  12        Trendl     0.84 0.56, 1.24 0.86 0.58, 1.28 0.76 0.64, 0.90 While you were in the Korean War, the Vietnam War, and/or the Gulf Wark: 
number of days exposed to           
Microwave radiation           Not exposed or ≤ 5 109 2,810 153 6,369 1.00 Referent 1.00 Referent 1.00 Referent 
> 5 9 223 12 472 1.17 0.57, 2.40 1.17 0.57, 2.41 1.17 0.66, 2.09 
Missing 23  29        Trendl     1.04 0.75, 1.46 1.04 0.74, 1.46 0.97 0.75, 1.26 While you were in the Vietnam Wark: number of days exposed to           Mixing and application of Agent Orange           Not exposed 91 2,145 128 5,050 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 3 < 5 63 0.61 0.08, 4.50 NA NA 0.23 0.01, 3.42 
6-30 < 5 46 < 5 142 1.04 0.23, 4.70 NA NA 0.83 0.14, 4.84 
> 30 < 5 59 < 5 59 1.31 0.31, 5.53 NA NA 0.65 0.37, 1.12 
Missing 8  10        Trendl     1.10 0.61, 2.00 NA NA 0.91 0.51, 1.62 Exposure to Agent Orange in the field           Not exposed 40 841 51 1,729 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 7 200 12 602 0.58 0.25, 1.32 NA NA 0.56 0.28, 1.13 
6-30 7 128 10 342 0.92 0.38, 2.22 NA NA 0.73 0.25, 2.11 
> 30 22 408 35 1,442 0.82 0.47, 1.43 NA NA 0.70 0.40, 1.23 
Missing 28  37        Trendl     0.96 0.76, 1.21 NA NA 0.87 0.68, 1.11 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
While you were in the Gulf Wark: number of days exposed to           Use of depleted uranium (DU) for munitions or armor           Not exposed or ≤ 30 5 213 10 671 1.00 Referent 1.00 Referent 1.00 Referent 
> 30 < 5 43 < 5 213 1.03 0.09, 11.80 NA NA 0.93 0.18, 4.90 
Missing 2  3        Trendl     0.88 0.29, 2.64 NA NA 0.92 0.44, 1.90 CARC (Chemical Agent Resistant Compound) paint           Not exposed 5 205 10 663 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 0 0 0 0 i i NA NA i i 
6-30 < 5 27 < 5 27 i i NA NA i i 
> 30 0 0 < 5 170 i i NA NA i i 
Missing 2  3        Trendl     0.50 0.07, 3.44 NA NA 0.50 0.21, 1.20 Scud missile explosion in the air or on the ground within one mile of you           Not exposed 4 153 9 593 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 78 < 5 172 36.01 0.66, 1973.21 NA NA 6.09 0.89, 41.58 
6-30 0 0 < 5 94 i i NA NA i i 
> 30 0 0 0 0 i i NA NA i i 
Missing 2  3        Trendl     1.28 0.01, 248.17 NA NA 2.08 0.06, 68.13 Smoke from oil well fires           Not exposed 5 206 5 206 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 27 < 5 214 i i NA NA i i 
6-30 0 0 < 5 240 i i NA NA i i 
> 30 0 0 < 5 169 i i NA NA i i 
Missing 2  3        Trendl     
i i NA NA i i 
Exposure to nerve gas (e.g., during munitions destruction)           Not exposed 7 246 11 593 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 0 0 < 5 93 i i NA NA i i 
6-30 0 0 < 5 94 i i NA NA i i 
> 30 0 0 < 5 94 i i NA NA i i 
Missing 1  2        Trendl     
i i NA NA i i 
           
           
           
           
           
           
 
358 
   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
High levels of dust/sand           Not exposed < 5 86 < 5 86 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 < 5 55 < 5 138 i i NA NA i i 
6-30 0 0 < 5 264 i i NA NA i i 
> 30 < 5 111 7 455 i i NA NA i i 
Missing 1  1        Trendl     1.39 0.41, 4.73 NA NA 0.91 0.36, 2.31 Ground level fumigation           Not exposed 6 204 9 468 1.00 Referent 1.00 Referent 1.00 Referent 
≤ 5 0 0 < 5 93 i i NA NA i i 
6-30 0 0 < 5 83 i i NA NA i i 
> 30 0 0 < 5 188 i i NA NA i i 
Missing 2  3        Trendl         i i NA NA i i 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CARC, Chemical Agent Resistant Compound; CI, confidence interval; DU, 
depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; HR, hazard ratio; IP, inverse 
probability; IQR, interquartile range; NA, not applicable; PM, person-months; U.S., United States of America; VA, Department of Veterans Affairs; WWII, World War II. 
aFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) they died before the interview (i.e., the interview was 
completed by a proxy after the case died; n = 7). 
bAdjusted for age (modeled with indicator variables corresponding to 5-year groups or, for exposures queried only in reference to deployment to the Gulf War, modeled with a 
linear term that was centered at age 60—the median age among all cases). 
cAdjusted for age (modeled with indicator variables corresponding to 5-year groups), war/operation of longest deployment, and the pairwise interaction between war/operation of 
longest deployment and the natural logarithm of time since diagnosis. 
dWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups or, for exposures queried only in reference to deployment to the Gulf War, 
modeled with a linear term that was centered at age 60—the median age among all cases), war/operation of longest deployment, not missing covariate data (conditional on most 
recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to 
enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the 
Registry cases not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS 
diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the 
Registry [months; modeled with a linear term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the 
distribution in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
ePerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 2013). 
fHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
gUsed within-category medians that were calculated using all cases. 
hScaled the HR to an IQR-unit increase in the exposure variable. IQRs were calculated using all cases except those in the reference category. Reference category excluded for 
linear trend test. 
iUnable to estimate HR and 95% CI. 
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 jScaled the HR to an IQR-unit increase in the exposure variable. IQRs were calculated using all cases except those in the reference category. Reference category included for 
linear trend test. 
kThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). 
lUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5) and scaled the HR to a 20 day increase in the exposure variable. Reference 
category included for linear trend test. 
mUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5). HR corresponds to a one day increase in the exposure variable. Reference 
category included for linear trend test. 
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 Table G.12. Feel ill from military exposures and amyotrophic lateral sclerosis survival in GENEVAa. 
  Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
While you were in WWII, the Korean War, the Vietnam War, and/or the Gulf 
Warg: did you feel ill from exposure to           
Manufacture, testing, or use of chemical protective gear (for mustard gas, 
 tear gas, etc.) Do not include training           
Not exposed 154 3,735 208 8,109 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 44 < 5 107 14.77 3.53, 61.88 15.09 3.70, 61.61 7.57 3.55, 16.12 
Yes < 5 52 6 386 0.38 0.09, 1.59 0.43 0.10, 1.84 0.23 0.03, 1.75 
Missing 9  10        Trendh     0.78 0.44, 1.37 0.83 0.47, 1.50 0.59 0.26, 1.31 Ionizing radiation from nuclear weapon testing or occupation of 
 Hiroshima/Nagasaki           
Not exposed 153 3,911 209 8,450 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 18 < 5 77 1.78 0.55, 5.77 2.18 0.66, 7.18 1.43 0.34, 5.93 
Yes 0 0 0 0 i i i i i i 
Missing 12  15        Trendh     1.78 0.55, 5.77 2.18 0.66, 7.18 1.04 0.15, 6.98 Use of personal pesticides, like creams, sprays or flea collars           Not exposed 111 2,781 152 6,155 1.00 Referent 1.00 Referent 1.00 Referent 
No 42 1,083 54 2,018 1.33 0.90, 1.96 1.34 0.90, 1.98 0.91 0.63, 1.32 
Yes < 5 66 5 131 1.14 0.41, 3.14 1.26 0.45, 3.55 0.48 0.07, 3.24 
Missing 11  17        Trendh     1.22 0.89, 1.67 1.25 0.91, 1.72 1.05 0.70, 1.59 Use of pesticides on your clothing or bedding           Not exposed 114 3,090 159 6,770 1.00 Referent 1.00 Referent 1.00 Referent 
No 29 539 39 1,307 1.42 0.91, 2.21 1.37 0.87, 2.14 0.87 0.49, 1.55 
Yes < 5 63 5 203 1.23 0.38, 4.01 1.21 0.37, 3.96 0.53 0.07, 3.95 
Missing 22  25        Trendh     1.29 0.90, 1.85 1.26 0.87, 1.82 1.09 0.59, 2.02 Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)           Not exposed 102 2,484 140 5,525 1.00 Referent 1.00 Referent 1.00 Referent 
No 44 1,090 56 2,093 1.16 0.80, 1.70 1.16 0.79, 1.70 0.95 0.68, 1.34 
Yes 6 105 14 745 0.50 0.22, 1.16 0.51 0.22, 1.21 0.44 0.14, 1.40 
Missing 16  18        Trendh     0.90 0.68, 1.18 0.90 0.68, 1.20 0.80 0.56, 1.14 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Exposure to diesel and/or other petrochemical fumes           Not exposed 57 1,372 75 2,890 1.00 Referent 1.00 Referent 1.00 Referent 
No 78 1,925 107 4,165 0.97 0.67, 1.40 1.01 0.69, 1.46 1.00 0.63, 1.59 
Yes 18 437 25 1,020 1.34 0.76, 2.36 1.39 0.78, 2.46 1.20 0.63, 2.31 
Missing 15  21        Trendh     1.10 0.83, 1.44 1.12 0.85, 1.48 1.06 0.79, 1.43 Burning trash or burning feces/manure           Not exposed 108 2,691 144 5,635 1.00 Referent 1.00 Referent 1.00 Referent 
No 40 1,103 58 2,562 1.06 0.71, 1.58 1.04 0.69, 1.55 0.76 0.51, 1.14 
Yes 9 126 13 436 1.43 0.69, 2.96 1.36 0.65, 2.81 0.83 0.29, 2.37 
Missing 11  13        Trendh     1.13 0.83, 1.53 1.10 0.81, 1.50 0.86 0.62, 1.19 Exposure to paint, solvents, or petrochemical substances           Not exposed 110 2,730 143 5,461 1.00 Referent 1.00 Referent 1.00 Referent 
No 38 1,017 60 2,763 0.78 0.54, 1.15 0.81 0.55, 1.19 0.84 0.59, 1.21 
Yes 5 100 7 242 0.81 0.32, 2.05 0.89 0.34, 2.31 0.68 0.38, 1.22 
Missing 15  18        Trendh     0.83 0.60, 1.13 0.86 0.62, 1.18 0.82 0.62, 1.08 High-intensity radar waves (e.g., as radar operator, radio operator, aviation 
 electrician's mate)           
Not exposed 117 3,026 158 6,377 1.00 Referent 1.00 Referent 1.00 Referent 
No 34 800 42 1,423 1.29 0.86, 1.93 1.40 0.93, 2.12 1.37 0.95, 1.98 
Yes < 5 15 < 5 92 1.46 0.19, 11.13 1.52 0.20, 11.62 2.37 0.79, 7.10 
Missing 16  26        Trendh     1.28 0.87, 1.88 1.38 0.94, 2.04 1.38 0.98, 1.95 Food contaminated with smoke, oil, or other chemicals           Not exposed 130 3,291 181 7,414 1.00 Referent 1.00 Referent 1.00 Referent 
No 7 151 8 230 1.44 0.65, 3.16 1.43 0.64, 3.19 1.01 0.49, 2.08 
Yes < 5 76 6 310 0.61 0.19, 1.96 0.54 0.17, 1.77 0.14 0.02, 1.13 
Missing 28  33        Trendh     0.92 0.59, 1.45 0.88 0.56, 1.39 0.65 0.36, 1.16 Local food other than food provided by the Armed Forces           Not exposed 85 1,881 108 3,741 1.00 Referent 1.00 Referent 1.00 Referent 
No 68 1,688 98 4,141 0.89 0.63, 1.25 0.88 0.62, 1.24 0.73 0.53, 1.02 
Yes 8 328 12 627 0.66 0.31, 1.43 0.66 0.31, 1.43 0.45 0.22, 0.89 
Missing 7  10        Trendh     0.85 0.65, 1.12 0.85 0.65, 1.12 0.66 0.50, 0.86 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Bathing in or drinking of water contaminated with smoke, oil, dead animals or 
 any chemicals           
Not exposed 131 3,186 174 6,641 1.00 Referent 1.00 Referent 1.00 Referent 
No 10 169 13 411 1.27 0.65, 2.49 1.24 0.63, 2.43 1.43 0.59, 3.49 
Yes < 5 15 < 5 250 0.30 0.04, 2.20 0.29 0.04, 2.17 0.49 0.13, 1.93 
Missing 26  37        Trendh     0.87 0.52, 1.45 0.85 0.51, 1.43 1.17 0.72, 1.90 Heat cramps, heat exhaustion, heat stroke or other heat illness           Not exposed 129 3,162 172 6,645 1.00 Referent 1.00 Referent 1.00 Referent 
No 7 198 8 292 1.57 0.68, 3.61 1.62 0.69, 3.78 1.31 0.65, 2.64 
Yes 27 613 41 1,751 1.06 0.69, 1.65 1.07 0.69, 1.66 0.79 0.46, 1.34 
Missing 5  7        Trendh     1.05 0.85, 1.30 1.05 0.85, 1.30 0.95 0.74, 1.20 Heard chemical alarms sounding           Not exposed 154 3,722 206 7,944 1.00 Referent 1.00 Referent 1.00 Referent 
No 7 169 15 810 0.60 0.28, 1.30 0.69 0.30, 1.57 0.46 0.20, 1.04 
Yes 0 0 0 0 i i i i i i 
Missing 7  7        Trendh     0.60 0.28, 1.30 0.69 0.30, 1.57 0.75 0.29, 1.94 Explosion in the air or on the ground within one mile of you (e.g., artillery, 
 rockets, mortars)           
Not exposed 49 1,349 71 3,154 1.00 Referent 1.00 Referent 1.00 Referent 
No 101 2,336 133 4,920 1.28 0.89, 1.84 1.24 0.86, 1.79 1.23 0.84, 1.80 
Yes 9 189 13 521 2.57 1.18, 5.57 2.48 1.13, 5.46 2.67 1.53, 4.66 
Missing 9  11        Trendh     1.41 1.03, 1.93 1.37 0.99, 1.89 1.44 1.02, 2.02 While you were in WWII, the Korean War, and/or the Vietnam Warg: did you 
feel ill from exposure to           
Mixing and application of herbicides           Not exposed 150 3,661 201 7,744 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 87 < 5 87 2.41 0.85, 6.87 2.03 0.69, 6.02 2.19 1.12, 4.28 
Yes 0 0 0 0 i i i i i i 
Missing 10  11        Trendh     2.41 0.85, 6.87 2.03 0.69, 6.02 1.54 0.96, 2.47 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Exposure to herbicides in the field           Not exposed 120 2,839 159 5,982 1.00 Referent 1.00 Referent 1.00 Referent 
No 10 304 10 304 1.68 0.85, 3.31 1.71 0.85, 3.45 1.25 0.87, 1.78 
Yes 0 0 < 5 92 i i i i i i 
Missing 34  46        Trendh     1.08 0.60, 1.91 1.02 0.57, 1.82 1.14 0.80, 1.61 Mixing and application of riot control substances           Not exposed 159 3,911 211 8,084 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 9 < 5 9 4.54 1.01, 20.42 4.83 1.08, 21.61 4.87 2.80, 8.49 
Yes 0 0 0 0 i i i i i i 
Missing 3  3        Trendh     4.54 1.01, 20.42 4.83 1.08, 21.61 3.63 1.82, 7.24 Exposure to riot control substances in the field           Not exposed 152 3,654 200 7,537 1.00 Referent 1.00 Referent 1.00 Referent 
No 6 165 8 325 1.09 0.47, 2.53 1.13 0.49, 2.64 0.69 0.36, 1.32 
Yes < 5 102 < 5 165 0.75 0.22, 2.58 0.78 0.23, 2.66 0.44 0.13, 1.43 
Missing < 5  < 5        Trendh     0.93 0.57, 1.52 0.96 0.59, 1.56 0.75 0.41, 1.38 Mixing and application of burning agents           Not exposed 145 3,601 195 7,594 1.00 Referent 1.00 Referent 1.00 Referent 
No 10 173 11 263 1.97 0.98, 3.96 2.21 1.10, 4.45 1.54 1.07, 2.20 
Yes < 5 20 < 5 20 3.65 1.09, 12.27 3.35 1.00, 11.26 2.97 0.96, 9.26 
Missing 6  7        Trendh     1.94 1.21, 3.10 1.97 1.24, 3.13 2.13 1.22, 3.72 Exposure to burning agents in the field           Not exposed 134 3,286 175 6,610 1.00 Referent 1.00 Referent 1.00 Referent 
No 19 451 24 842 0.95 0.57, 1.58 0.99 0.59, 1.64 0.68 0.45, 1.04 
Yes < 5 61 6 275 0.63 0.20, 2.03 0.66 0.21, 2.12 0.09 0.01, 0.70 
Missing 8  11        Trendh     0.88 0.60, 1.29 0.90 0.61, 1.33 0.60 0.39, 0.91 While you were in the Korean War, the Vietnam War, and/or the Gulf Warg: 
did you feel ill from exposure to           
Microwave radiation           Not exposed 108 2,792 151 6,261 1.00 Referent 1.00 Referent 1.00 Referent 
No 9 227 12 475 1.21 0.59, 2.47 1.20 0.58, 2.47 1.19 0.71, 1.98 
Yes 0 0 < 5 91 i i i i i i 
Missing 24  30        Trendh     0.97 0.51, 1.84 0.95 0.50, 1.82 1.02 0.62, 1.69 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
While you were in the Vietnam Warg: did you feel ill from exposure to           Mixing and application of Agent Orange           Not exposed 91 2,145 128 5,050 1.00 Referent 1.00 Referent 1.00 Referent 
No 5 87 7 242 1.01 0.40, 2.54 NA NA 0.63 0.30, 1.32 
Yes 0 0 0 0 i i NA NA i i 
Missing 8  10        Trendh     1.01 0.40, 2.54 NA NA 0.61 0.32, 1.15 Exposure to Agent Orange in the field           Not exposed 40 841 51 1,729 1.00 Referent 1.00 Referent 1.00 Referent 
No 31 636 49 2,045 0.77 0.47, 1.27 NA NA 0.75 0.46, 1.22 
Yes 5 59 9 352 0.85 0.32, 2.26 NA NA 0.65 0.19, 2.27 
Missing 28  36        Trendh     0.84 0.56, 1.25 NA NA 0.70 0.45, 1.08 While you were in the Gulf Warg: did you feel ill from exposure to           Use of depleted uranium (DU) for munitions or armor           Not exposed 5 213 8 495 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 43 5 389 0.35 0.04, 3.39 NA NA 0.45 0.09, 2.26 
Yes 0 0 0 0 i i NA NA i i 
Missing 2  3        Trendh     0.35 0.04, 3.39 NA NA 0.47 0.10, 2.25 CARC (Chemical Agent Resistant Compound) paint           Not exposed 5 205 10 663 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 27 < 5 197 0.63 0.04, 9.88 NA NA 0.61 0.09, 4.39 
Yes 0 0 0 0 i i NA NA i i 
Missing 2  3        Trendh     0.63 0.04, 9.88 NA NA 0.58 0.08, 4.41 Scud missile explosion in the air or on the ground within one mile of you           Not exposed < 5 153 9 593 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 78 < 5 172 36.01 0.66, 1973.21 NA NA 6.09 0.89, 41.58 
Yes 0 0 < 5 94 i i NA NA i i 
Missing 2  3        Trendh     2.78 0.40, 19.22 NA NA 2.02 0.59, 6.90 Smoke from oil well fires           Not exposed 5 206 5 206 1.00 Referent 1.00 Referent 1.00 Referent 
No 0 0 < 5 232 i i NA NA i i 
Yes < 5 27 5 391 i i NA NA i i 
Missing 2  3        Trendh     0.17 0.02, 1.39 NA NA 0.13 0.03, 0.51 
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   Deaths Total Adjustedb Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf HRf 95% CIf 
Exposure to nerve gas (e.g., during munitions destruction)           Not exposed 7 246 11 593 1.00 Referent 1.00 Referent 1.00 Referent 
No 0 0 < 5 94 i i NA NA i i 
Yes 0 0 < 5 187 i i NA NA i i 
Missing 1  2        Trendh     
i i NA NA i i 
High levels of dust/sand           Not exposed < 5 86 < 5 86 1.00 Referent 1.00 Referent 1.00 Referent 
No < 5 165 12 857 i i NA NA i i 
Yes 0 0 0 0 i i NA NA i i 
Missing 1  1        Trendh     
i i NA NA i i 
Ground level fumigation           Not exposed 6 204 9 468 1.00 Referent 1.00 Referent 1.00 Referent 
No 0 0 < 5 282 i i NA NA i i 
Yes 0 0 < 5 83 i i NA NA i i 
Missing 2  3        Trendh         i i NA NA i i 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CARC, Chemical Agent Resistant Compound; CI, confidence interval; DU, 
depleted uranium; GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; Gulf, 1990-1991 Persian Gulf; HR, hazard ratio; IP, inverse 
probability; NA, not applicable; PM, person-months; VA, Department of Veterans Affairs; WWII, World War II. 
aFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) they died before the interview (i.e., the interview was 
completed by a proxy after the case died; n = 7). 
bAdjusted for age (modeled with indicator variables corresponding to 5-year groups or, for exposures queried only in reference to deployment to the Gulf War, modeled with a 
linear term that was centered at age 60—the median age among all cases). 
cAdjusted for age (modeled with indicator variables corresponding to 5-year groups), war/operation of longest deployment, and the pairwise interaction between war/operation of 
longest deployment and the natural logarithm of time since diagnosis. 
dWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups or, for exposures queried only in reference to deployment to the Gulf War, 
modeled with a linear term that was centered at age 60—the median age among all cases), war/operation of longest deployment, not missing covariate data (conditional on most 
recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to 
enrollment in the Registry [months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the 
Registry cases not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS 
diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the 
Registry [months; modeled with a linear term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the 
distribution in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
ePerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 2013). 
fHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
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 gThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). 
hUsed ordinal scores (0, 1, 2). Reference category included for linear trend test. 
iUnable to estimate HR and 95% CI. 
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 Table G.13. Military deployments to the Vietnam Wara and amyotrophic lateral sclerosis survival in GENEVAb. 
  Deaths Total Adjustedc IP-weightedd 
Variable No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Total number of theaters of operation for the Vietnam War         Not deployed to any war/operationg 250 5,790 348 13,683 1.00 Referent 1.00 Referent 
Not deployed to the Vietnam War 75 1,980 102 4,247 0.95 0.71, 1.28 0.68 0.43, 1.07 
1 (Median = 1) 76 1,792 101 3,754 1.13 0.86, 1.49 1.18 0.87, 1.60 
2 (2) 16 374 31 1,579 0.58 0.35, 0.98 0.69 0.35, 1.34 
> 2 (3) 11 276 12 355 1.58 0.85, 2.92 1.30 0.92, 1.86 
Missing 18  22      Trendh     0.92 0.66, 1.28 1.01 0.74, 1.39 Total length (years) of deployment to all theaters of operation for the Vietnam War         Not deployed to any war/operationg 250 5,790 348 13,683 1.00 Referent 1.00 Referent 
Not deployed to the Vietnam War 75 1,980 102 4,247 0.96 0.71, 1.28 0.69 0.44, 1.08 
≤ 1 (0.91) 56 1,268 75 2,809 1.14 0.84, 1.56 1.27 0.96, 1.69 
> 1-2 (1.11) 29 800 44 1,932 0.82 0.55, 1.21 0.71 0.48, 1.06 
> 2-3 (2.12) 11 236 14 501 1.50 0.81, 2.79 1.33 0.89, 1.97 
> 3 (5.90) 5 114 8 331 0.65 0.27, 1.59 0.44 0.09, 2.03 
Missing 20  25      Trendh     0.94 0.79, 1.12 1.00 0.83, 1.20 End of most recent period of deployment to the Vietnam War (year)         Not deployed to any war/operationg 250 5,790 348 13,683 1.00 Referent 1.00 Referent 
Not deployed to the Vietnam War 75 1,980 102 4,247 0.95 0.71, 1.28 0.68 0.43, 1.06 
≤ 1965 (1964.0) 8 214 9 307 1.07 0.52, 2.18 1.77 0.78, 4.04 
1966-1967 (1967.0) 21 453 26 811 1.23 0.76, 1.99 1.24 0.82, 1.88 
1968-1969 (1969.0) 30 665 49 2,147 0.77 0.52, 1.14 0.58 0.26, 1.29 
1970-1971 (1970.0) 31 778 41 1,587 1.14 0.77, 1.68 1.43 1.05, 1.94 
1972-1973 (1972.0) 6 177 10 498 0.96 0.42, 2.18 0.88 0.39, 1.98 
> 1973 (1974.5) 5 132 6 224 1.62 0.65, 4.03 1.37 0.54, 3.45 
Missing 20  25      Trendh         1.00 0.89, 1.12 1.11 0.95, 1.30 
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI, confidence interval; GENEVA, Genes and Environmental Exposures in 
Veterans with Amyotrophic Lateral Sclerosis; HR, hazard ratio; IP, inverse probability; PM, person-months. 
aThe GENEVA study questionnaire asked "Were you deployed to..." the Vietnam War (defined as the period from August 3, 1964, to May 7, 1975). 
bFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) they died before the interview (i.e., the interview was 
completed by a proxy after the case died; n = 7). 
cAdjusted for age (modeled with indicator variables corresponding to 5-year groups). 
dWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data (conditional on most recent ALS diagnosis, site of 
symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry 
[months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing 
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 covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, 
time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear 
term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]). 95% CIs 
were calculated with robust variance estimates. 
ePerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 2013). 
fHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
gThe GENEVA study questionnaire asked "Were you deployed to..." the following wars where each war was asked about with a separate question: World War II (defined as the 
period from December 7, 1941, to December 31, 1946), the Korean War (defined as the period from June 27, 1950, to January 31, 1955), the Vietnam War (defined as the period 
from August 3, 1964, to May 7, 1975), and the Persian Gulf War (defined as the period from August 2, 1990, to December 31, 1991). The questionnaire also asked "Ever 
deployed..." to the following countries where each country was asked about with a separate question: Grenada, Lebanon, Panama, Somalia, Bosnia, Kosovo, Rwanda, 
Afghanistan, and Iraq/Persian Gulf region (Gulf War II). 
hUsed within-category medians that were calculated using all cases. Individuals in the categories labeled "Not deployed to any war/operation" and "Not deployed to the Vietnam 
War" were excluded for the linear trend test. 
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 Table G.14. Military exposures during deployment to the Vietnam Wara and amyotrophic lateral sclerosis survival in GENEVAb. 
  Deaths Total Adjustedc IP-weightedd 
Did you have direct contact with/were you exposed to No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Mixing and application of Agent Orangeg         No 91 2,145 128 5,050 1.00 Referent 1.00 Referent 
Yes 6 127 8 283 1.11 0.47, 2.61 0.63 0.33, 1.22 
Missing 7  9      Exposure to Agent Orange in the fieldg         No 40 841 51 1,729 1.00 Referent 1.00 Referent 
Yes 39 795 63 2,668 0.73 0.46, 1.17 0.62 0.39, 0.99 
Missing 25  31      Mixing and application of other herbicides         No 96 2,336 136 5,494 1.00 Referent 1.00 Referent 
Yes < 5 29 < 5 29 3.19 0.73, 13.81 1.90 1.14, 3.17 
Missing 5  6      Exposure to other herbicides in the field         No 67 1,588 96 3,898 1.00 Referent 1.00 Referent 
Yes 7 159 7 159 1.89 0.85, 4.23 1.40 0.90, 2.17 
Missing 30  42      Manufacture, testing, or use of chemical protective gear (for mustard gas, tear gas, etc.) Do 
not include training         
No 96 2,291 136 5,473 1.00 Referent 1.00 Referent 
Yes < 5 59 5 123 1.22 0.43, 3.43 0.75 0.11, 5.09 
Missing 4  4      Ionizing radiation from nuclear weapon testing         No 94 2,337 132 5,354 1.00 Referent 1.00 Referent 
Yes < 5 2 < 5 61 0.98 0.13, 7.24 1.02 0.10, 10.37 
Missing 9  11      Microwave radiation         No 78 2,020 113 4,786 1.00 Referent 1.00 Referent 
Yes 9 214 13 554 1.02 0.50, 2.09 1.06 0.62, 1.83 
Missing 17  19      Use of personal pesticides, like creams, sprays or flea collars         No 61 1,471 88 3,653 1.00 Referent 1.00 Referent 
Yes 40 984 53 1,981 1.18 0.78, 1.78 0.82 0.54, 1.23 
Missing 3  4      Use of pesticides on your clothing or bedding         No 63 1,655 93 4,061 1.00 Referent 1.00 Referent 
Yes 30 580 41 1,422 1.09 0.69, 1.73 0.78 0.47, 1.29 
Missing 11  11      
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   Deaths Total Adjustedc IP-weightedd 
Did you have direct contact with/were you exposed to No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)         No 66 1,648 94 3,840 1.00 Referent 1.00 Referent 
Yes 32 656 45 1,711 1.15 0.74, 1.80 0.91 0.56, 1.47 
Missing 6  6      Exposure to diesel and/or other petrochemical fumes         No 30 795 39 1,535 1.00 Referent 1.00 Referent 
Yes 72 1,631 103 4,042 0.89 0.57, 1.40 1.03 0.58, 1.83 
Missing 2  3      Burning trash or burning feces/manure         No 52 1,206 75 3,016 1.00 Referent 1.00 Referent 
Yes 49 1,238 66 2,609 1.17 0.78, 1.78 0.96 0.65, 1.44 
Missing 3  4      Exposure to paint, solvents, or petrochemical substances         No 67 1,635 89 3,416 1.00 Referent 1.00 Referent 
Yes 30 739 49 2,205 0.76 0.49, 1.18 0.76 0.49, 1.19 
Missing 7  7      High-intensity radar waves (e.g., as radar operator, radio operator, aviation electrician's mate)         No 68 1,671 95 3,807 1.00 Referent 1.00 Referent 
Yes 25 578 33 1,213 1.14 0.70, 1.86 1.23 0.78, 1.93 
Missing 11  17      Food contaminated with smoke, oil, or other chemicals         No 79 1,973 113 4,637 1.00 Referent 1.00 Referent 
Yes 9 168 13 480 0.92 0.44, 1.90 0.63 0.30, 1.35 
Missing 16  19      Local food other than food provided by the Armed Forces         No 47 1,094 64 2,462 1.00 Referent 1.00 Referent 
Yes 55 1,320 78 3,107 1.00 0.67, 1.49 0.76 0.51, 1.14 
Missing 2  3      Bathing in or drinking of water contaminated with smoke, oil, dead animals or any chemicals         No 80 1,965 107 4,079 1.00 Referent 1.00 Referent 
Yes 9 122 17 736 0.67 0.33, 1.37 0.56 0.22, 1.45 
Missing 15  21      Heat cramps, heat exhaustion, heat stroke or other heat illness         No 72 1,696 100 3,915 1.00 Referent 1.00 Referent 
Yes 30 718 42 1,657 1.15 0.74, 1.81 0.92 0.58, 1.45 
Missing 2  3      
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   Deaths Total Adjustedc IP-weightedd 
Did you have direct contact with/were you exposed to No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Heard chemical alarms sounding         No 99 2,389 137 5,422 1.00 Referent 1.00 Referent 
Yes < 5 11 5 226 0.61 0.15, 2.54 0.85 0.26, 2.72 
Missing 3  3      Explosion in the air or on the ground within one mile of you (e.g., artillery, rockets, mortars)         No 23 543 36 1,575 1.00 Referent 1.00 Referent 
Yes 78 1,867 106 4,083 1.20 0.74, 1.94 1.06 0.65, 1.74 
Missing 3  3      Mixing and application of riot control substances         No 102 2,466 143 5,713 1.00 Referent 1.00 Referent 
Yes < 5 6 < 5 6 4.93 0.58, 41.68 3.69 1.64, 8.34 
Missing 1  1      Exposure to riot control substances in the field         No 95 2,223 132 5,181 1.00 Referent 1.00 Referent 
Yes 8 249 11 472 0.88 0.41, 1.87 0.57 0.31, 1.05 
Missing 1  2      Mixing and application of burning agents         No 89 2,168 128 5,236 1.00 Referent 1.00 Referent 
Yes 11 177 12 268 2.13 1.08, 4.23 1.76 1.24, 2.49 
Missing 4  5      Exposure to burning agents in the field         No 78 1,917 109 4,396 1.00 Referent 1.00 Referent 
Yes 21 480 30 1,159 0.91 0.55, 1.52 0.64 0.38, 1.09 
Missing 5  6      Have you suffered a combat-related injury that required medical attention during your 
deployment?         
No 76 1,657 111 4,470 1.00 Referent 1.00 Referent 
Yes 25 739 31 1,174 1.08 0.66, 1.77 0.81 0.42, 1.54 
Missing 3   3           
Abbreviation: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI, confidence interval; GENEVA, Genes and Environmental Exposures in 
Veterans with Amyotrophic Lateral Sclerosis; HR, hazard ratio; IP, inverse probability; PM, person-months. 
aThe GENEVA study questionnaire asked "Were you deployed to..." the Vietnam War (defined as the period from August 3, 1964, to May 7, 1975). 
bFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) they died before the interview (i.e., the interview was 
completed by a proxy after the case died; n = 7). 
cAdjusted for age (modeled with indicator variables corresponding to 5-year groups). 
dWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data (conditional on most recent ALS diagnosis, site of 
symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry 
[months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing 
 
372 
 covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, 
time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear 
term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]). 95% CIs 
were calculated with robust variance estimates. 
ePerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 2013). 
fHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
gRepeated from Table 5.5. 
  
 
373 
 Table G.15. Dose-response for military exposures during deployment to the Vietnam Wara and amyotrophic lateral sclerosis survival in 
GENEVAb. 
  Deaths Total Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Total number of preventive vaccinations received by injection (shots) or by mouth while inside or 
outside the U.S.         
0 (Median = 0) 23 656 33 1,470 1.00 Referent 1.00 Referent 
1-10 (6) 29 709 40 1,541 1.38 0.78, 2.45 1.36 0.83, 2.21 
11-20 (14) 15 363 17 516 1.82 0.90, 3.71 1.74 1.06, 2.85 
> 20 (68) 14 249 22 872 1.19 0.60, 2.36 1.25 0.65, 2.39 
Missing 23  33      Trend (IQR = 15)g     1.00 0.88, 1.15 1.00 0.89, 1.14 Number of days exposed to         Mixing and application of Agent Orangeh         Not exposed 91 2,145 128 5,050 1.00 Referent 1.00 Referent 
≤ 5 < 5 3 < 5 63 0.61 0.08, 4.50 0.23 0.01, 3.42 
6-30 < 5 46 < 5 142 1.04 0.23, 4.70 0.83 0.14, 4.84 
> 30 < 5 59 < 5 59 1.31 0.31, 5.53 0.65 0.37, 1.12 
Missing 8  10      Trendi     1.10 0.61, 2.00 0.91 0.51, 1.62 Exposure to Agent Orange in the fieldh         Not exposed 40 841 51 1,729 1.00 Referent 1.00 Referent 
≤ 5 7 200 12 602 0.58 0.25, 1.32 0.56 0.28, 1.13 
6-30 7 128 10 342 0.92 0.38, 2.22 0.73 0.25, 2.11 
> 30 22 408 35 1,442 0.82 0.47, 1.43 0.70 0.40, 1.23 
Missing 28  37      Trendi     0.96 0.76, 1.21 0.87 0.68, 1.11 Mixing and application of other herbicides         Not exposed 96 2,336 136 5,494 1.00 Referent 1.00 Referent 
≤ 5 < 5 6 < 5 6 j j 2.37 0.89, 6.29 
6-30 < 5 16 < 5 16 2.22 0.29, 16.81 1.15 0.67, 1.98 
> 30 < 5 6 < 5 6 5.83 0.67, 51.05 4.19 1.72, 10.24 
Missing 5  6      Trendi     2.17 0.92, 5.14 1.88 1.14, 3.10 
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   Deaths Total Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Exposure to other herbicides in the field         Not exposed 67 1,588 96 3,898 1.00 Referent 1.00 Referent 
≤ 5 < 5 93 < 5 93 1.15 0.27, 4.87 1.23 0.66, 2.30 
6-30 < 5 15 < 5 15 2.34 0.29, 18.67 1.44 0.77, 2.67 
> 30 < 5 32 < 5 32 2.51 0.73, 8.62 1.74 0.86, 3.49 
Missing 31  43      Trendi     1.51 0.90, 2.53 1.39 1.00, 1.93 Manufacture, testing, or use of chemical protective gear (for mustard gas, tear gas, etc.) Do not 
include training         
Not exposed 96 2,291 136 5,473 1.00 Referent 1.00 Referent 
≤ 5 < 5 22 < 5 22 1.59 0.37, 6.87 1.83 0.38, 8.88 
6-30 < 5 36 < 5 101 0.99 0.24, 4.13 0.22 0.02, 2.71 
> 30 0 0 0 0 j j j j 
Missing 4  4      Trendi     1.04 0.22, 4.83 0.25 0.02, 3.96 Ionizing radiation from nuclear weapon testing         Not exposed 94 2,337 132 5,354 1.00 Referent 1.00 Referent 
≤ 5 < 5 2 < 5 61 0.98 0.13, 7.24 1.02 0.10, 10.15 
6-30 0 0 0 0 j j j j 
> 30 0 0 0 0 j j j j 
Missing 9  11      Trendk     0.99 0.51, 1.93 1.01 0.46, 2.21 Microwave radiation         Not exposed or ≤ 5 79 2,038 115 4,895 1.00 Referent 1.00 Referent 
> 5 8 196 11 445 1.10 0.52, 2.32 1.14 0.62, 2.10 
Missing 17  19      Trendi     1.03 0.74, 1.45 0.96 0.74, 1.25 Use of personal pesticides, like creams, sprays or flea collars         Not exposed 61 1,471 88 3,653 1.00 Referent 1.00 Referent 
≤ 30 9 159 11 312 1.49 0.70, 3.15 1.32 0.87, 1.98 
> 30 30 774 41 1,618 1.07 0.68, 1.69 0.66 0.40, 1.08 
Missing 4  5      Trendi     1.03 0.85, 1.24 0.85 0.69, 1.05 
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   Deaths Total Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Use of pesticides on your clothing or bedding         Not exposed 63 1,655 93 4,061 1.00 Referent 1.00 Referent 
≤ 30 7 147 9 293 1.19 0.51, 2.76 1.13 0.67, 1.90 
> 30 23 433 31 1,037 1.13 0.68, 1.86 0.71 0.38, 1.32 
Missing 11  12      Trendi     1.07 0.87, 1.32 0.88 0.68, 1.15 Exhaust from heaters or generators (e.g., kerosene heaters, tent heaters)         Not exposed 66 1,648 94 3,840 1.00 Referent 1.00 Referent 
≤ 30 10 211 14 538 0.98 0.50, 1.93 0.64 0.25, 1.66 
> 30 21 414 29 1,047 1.27 0.75, 2.15 1.10 0.71, 1.70 
Missing 7  8      Trendi     1.11 0.89, 1.38 1.03 0.84, 1.26 Exposure to diesel and/or other petrochemical fumes         Not exposed 30 795 39 1,535 1.00 Referent 1.00 Referent 
≤ 30 9 187 16 727 0.61 0.29, 1.32 0.59 0.25, 1.39 
> 30 62 1,425 86 3,296 0.95 0.60, 1.50 1.13 0.63, 2.01 
Missing 3  4      Trendi     1.03 0.85, 1.24 1.09 0.88, 1.37 Burning trash or burning feces/manure         Not exposed 52 1,206 75 3,016 1.00 Referent 1.00 Referent 
≤ 5 9 219 9 219 1.67 0.79, 3.53 1.20 0.72, 2.00 
6-30 8 171 10 298 1.14 0.53, 2.44 0.79 0.41, 1.50 
> 30 30 787 44 1,936 1.09 0.67, 1.77 1.00 0.62, 1.60 
Missing 5  7      Trendi     1.02 0.83, 1.24 0.99 0.81, 1.22 Exposure to paint, solvents, or petrochemical substances         Not exposed 67 1,635 89 3,416 1.00 Referent 1.00 Referent 
≤ 30 12 232 18 704 0.89 0.47, 1.69 1.14 0.68, 1.91 
> 30 18 508 31 1,502 0.69 0.40, 1.18 0.57 0.32, 1.04 
Missing 7  7      Trendi     0.89 0.71, 1.11 0.83 0.65, 1.06 High-intensity radar waves (e.g., as radar operator, radio operator, aviation electrician's mate)         Not exposed 68 1,671 95 3,807 1.00 Referent 1.00 Referent 
≤ 30 5 146 5 146 1.35 0.53, 3.45 1.51 0.81, 2.81 
> 30 19 425 27 1,060 1.09 0.63, 1.88 1.27 0.76, 2.13 
Missing 12  18      Trendi     1.04 0.83, 1.32 1.11 0.89, 1.37 
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   Deaths Total Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Food contaminated with smoke, oil, or other chemicals         Not exposed or ≤ 5 80 1,979 114 4,642 1.00 Referent 1.00 Referent 
> 5 8 163 12 475 0.81 0.38, 1.74 0.60 0.30, 1.21 
Missing 16  19      Trendi     0.99 0.67, 1.45 0.84 0.64, 1.11 Local food other than food provided by the Armed Forces         Not exposed 47 1,094 64 2,462 1.00 Referent 1.00 Referent 
≤ 5 13 417 21 1,107 0.85 0.44, 1.63 0.78 0.48, 1.25 
6-30 16 346 21 693 0.90 0.49, 1.63 0.61 0.34, 1.10 
> 30 25 546 35 1,295 1.18 0.71, 1.96 0.84 0.46, 1.51 
Missing 3  4      Trendi     1.08 0.87, 1.34 0.90 0.70, 1.16 Bathing in or drinking of water contaminated with smoke, oil, dead animals or any chemicals         Not exposed or ≤ 30 84 2,031 114 4,369 1.00 Referent 1.00 Referent 
> 30 5 57 10 445 0.71 0.28, 1.82 0.62 0.21, 1.82 
Missing 15  21      Trendi     0.85 0.57, 1.27 0.82 0.49, 1.36 Heat cramps, heat exhaustion, heat stroke or other heat illness         Not exposed 72 1,696 100 3,915 1.00 Referent 1.00 Referent 
≤ 5 11 241 15 581 1.31 0.68, 2.54 1.06 0.63, 1.81 
6-30 8 224 15 765 0.63 0.30, 1.33 0.45 0.20, 1.03 
> 30 11 253 12 312 2.25 1.14, 4.43 1.92 1.12, 3.28 
Missing 2  3      Trendi     1.26 0.94, 1.70 1.12 0.81, 1.54 Heard chemical alarms sounding         Not exposed 99 2,389 137 5,422 1.00 Referent 1.00 Referent 
≤ 5 < 5 3 < 5 140 0.56 0.08, 4.15 0.58 0.08, 4.41 
6-30 < 5 8 < 5 8 2.47 0.32, 18.94 1.88 1.12, 3.16 
> 30 0 0 < 5 79 j j j j 
Missing 3  3      Trendi     0.53 0.11, 2.52 1.34 0.53, 3.38 Explosion in the air or on the ground within one mile of you (e.g., artillery, rockets, mortars)         Not exposed 23 543 36 1,575 1.00 Referent 1.00 Referent 
≤ 5 20 548 24 890 1.61 0.85, 3.06 1.52 0.85, 2.71 
6-30 16 258 26 1,059 1.02 0.52, 2.00 1.23 0.66, 2.31 
> 30 40 1,014 53 1,993 1.15 0.67, 1.96 0.94 0.54, 1.66 
Missing 5  6      Trendi     0.99 0.81, 1.21 0.88 0.72, 1.08 
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   Deaths Total Adjustedc IP-weightedd 
Exposure No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Mixing and application of riot control substances         Not exposed 102 2,466 143 5,713 1.00 Referent 1.00 Referent 
≤ 5 < 5 6 < 5 6 4.93 0.58, 41.68 3.72 1.62, 8.53 
6-30 0 0 0 0 j j j j 
> 30 0 0 0 0 j j j j 
Missing 1  1      Trendk     1.70 0.84, 3.47 1.55 1.18, 2.03 Exposure to riot control substances in the field         Not exposed or ≤ 5 97 2,279 135 5,301 1.00 Referent 1.00 Referent 
> 5 6 193 8 352 0.96 0.41, 2.25 0.86 0.42, 1.77 
Missing 1  2      Trendi     1.01 0.58, 1.77 0.54 0.32, 0.89 Mixing and application of burning agents         Not exposed or ≤ 5 91 2,196 130 5,263 1.00 Referent 1.00 Referent 
> 5 9 149 10 240 1.96 0.93, 4.15 1.66 1.15, 2.38 
Missing 4  5      Trendi     1.35 0.88, 2.07 1.39 1.09, 1.76 Exposure to burning agents in the field         Not exposed 78 1,917 109 4,396 1.00 Referent 1.00 Referent 
≤ 5 7 136 12 484 0.66 0.30, 1.45 0.38 0.14, 1.02 
> 5 11 319 15 649 0.96 0.49, 1.88 0.74 0.44, 1.27 
Missing 8  9      Trendi     0.84 0.55, 1.27 0.80 0.66, 0.97 Have you suffered a combat-related injury that required medical attention during your 
deployment?         
Not exposed 76 1,657 111 4,470 1.00 Referent 1.00 Referent 
≤ 5 13 399 15 553 1.10 0.58, 2.09 1.01 0.63, 1.61 
6-30 5 187 7 323 0.87 0.34, 2.25 1.02 0.50, 2.07 
> 30 7 153 9 297 1.26 0.55, 2.89 0.75 0.21, 2.72 
Missing 3  3      Trendi         1.08 0.76, 1.52 0.83 0.48, 1.43 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI, confidence interval; GENEVA, Genes and Environmental Exposures in 
Veterans with Amyotrophic Lateral Sclerosis; HR, hazard ratio; IP, inverse probability; IQR, interquartile range; U.S., United States of America; VA, Department of Veterans 
Affairs. 
aThe GENEVA study questionnaire asked "Were you deployed to..." the Vietnam War (defined as the period from August 3, 1964, to May 7, 1975). 
bFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) they died before the interview (i.e., the interview was 
completed by a proxy after the case died; n = 7). 
cAdjusted for age (modeled with indicator variables corresponding to 5-year groups). 
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 dWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data (conditional on most recent ALS diagnosis, site of 
symptom onset, time from symptom onset to diagnosis [months; modeled with the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry 
[months; modeled with a restricted, quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases not missing 
covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical Center, most recent ALS diagnosis, site of symptom onset, 
time from symptom onset to diagnosis [months; modeled with linear, quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear 
term], and baseline ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution in GENEVA cases]). 95% CIs 
were calculated with robust variance estimates. 
ePerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 2013). 
fHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
gUsed within-category medians that were calculated using all cases. Scaled the HR to an IQR-unit increase in the exposure variable. IQRs were calculated using all cases except 
those in the reference category. Reference category included for linear trend test. 
hRepeated from Appendix G, Table G.11. 
iUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5) and scaled the HR to a 20 day increase in the exposure variable. Reference 
category included for linear trend test. 
jUnable to estimate HR and 95% CI. 
kUsed category midpoints (0, 3, 18) or 50% above the lower bound of the highest category (46.5) and scaled the HR to a one day increase in the exposure variable. Reference 
category included for linear trend test. 
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 Table G.16. Feel ill from military exposures during deployment to the Vietnam Wara and amyotrophic 
lateral sclerosis survival in GENEVAb. 
  Deaths Total Adjustedc IP-weightedd 
Did you feel ill from exposure to No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Mixing and application of Agent Orangeg         Not exposed 91 2,145 128 5,050 1.00 Referent 1.00 Referent 
No 5 87 7 242 1.01 0.40, 2.54 0.63 0.30, 1.32 
Yes 0 0 0 0 h h h h 
Missing 8  10      Trendi     1.01 0.40, 2.54 0.61 0.32, 1.15 Exposure to Agent Orange in the fieldg         Not exposed 40 841 51 1,729 1.00 Referent 1.00 Referent 
No 31 636 49 2,045 0.77 0.47, 1.27 0.75 0.46, 1.22 
Yes 5 59 9 352 0.85 0.32, 2.26 0.65 0.19, 2.27 
Missing 28  36      Trendi     0.84 0.56, 1.25 0.70 0.45, 1.08 Mixing and application of other herbicides         Not exposed 96 2,336 136 5,494 1.00 Referent 1.00 Referent 
No < 5 29 < 5 29 3.19 0.73, 13.81 1.00 0.59, 1.70 
Yes 0 0 0 0 h h h h 
Missing 5  6      Trendi     3.19 0.73, 13.81 2.39 1.43, 4.00 Exposure to other herbicides in the field         Not exposed 67 1,588 96 3,898 1.00 Referent 1.00 Referent 
No 7 159 7 159 1.89 0.85, 4.23 1.45 0.98, 2.13 
Yes 0 0 0 0 h h h h 
Missing 30  42      Trendi     1.89 0.85, 4.23 1.39 0.89, 2.17 Manufacture, testing, or use of chemical protective gear (for 
mustard gas, tear gas, etc.) Do not include training         
Not exposed 96 2,291 136 5,473 1.00 Referent 1.00 Referent 
No < 5 7 < 5 7 15.53 2.97, 81.16 10.01 3.71, 27.03 
Yes < 5 52 < 5 116 0.63 0.15, 2.61 0.13 0.02, 1.04 
Missing 4  4      Trendi     0.95 0.53, 1.73 0.70 0.25, 1.93 Ionizing radiation from nuclear weapon testing         Not exposed 94 2,337 132 5,354 1.00 Referent 1.00 Referent 
No < 5 2 < 5 61 0.98 0.13, 7.24 1.02 0.10, 10.15 
Yes 0 0 0 0 h h h h 
Missing 9  11      Trendi     0.98 0.13, 7.24 1.02 0.10, 10.75 Microwave radiation         Not exposed 78 2,020 113 4,786 1.00 Referent 1.00 Referent 
No 8 201 11 449 1.06 0.50, 2.28 1.22 0.72, 2.08 
Yes 0 0 < 5 91 h h h h 
Missing 18  20      Trendi     0.87 0.43, 1.74 0.99 0.59, 1.67 Use of personal pesticides, like creams, sprays or flea collars         Not exposed 61 1,471 88 3,653 1.00 Referent 1.00 Referent 
No 35 920 43 1,522 1.28 0.83, 1.98 0.94 0.62, 1.42 
Yes < 5 22 < 5 87 0.83 0.20, 3.43 0.22 0.03, 1.73 
Missing 6  11      Trendi     1.15 0.80, 1.67 0.85 0.58, 1.25 
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   Deaths Total Adjustedc IP-weightedd 
Did you feel ill from exposure to No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Use of pesticides on your clothing or bedding         Not exposed 63 1,655 93 4,061 1.00 Referent 1.00 Referent 
No 24 445 32 1,057 1.08 0.67, 1.77 0.80 0.46, 1.39 
Yes < 5 61 < 5 202 0.70 0.17, 2.92 0.21 0.02, 1.90 
Missing 15  16      Trendi     0.99 0.66, 1.50 0.69 0.42, 1.12 Exhaust from heaters or generators (e.g., kerosene heaters, 
tent heaters)         
Not exposed 66 1,648 94 3,840 1.00 Referent 1.00 Referent 
No 26 564 33 1,163 1.40 0.86, 2.28 1.21 0.84, 1.74 
Yes 5 77 10 448 0.76 0.30, 1.93 0.46 0.10, 2.02 
Missing 7  8      Trendi     1.05 0.75, 1.47 0.84 0.53, 1.35 Exposure to diesel and/or other petrochemical fumes         Not exposed 30 795 39 1,535 1.00 Referent 1.00 Referent 
No 57 1,279 80 3,057 0.89 0.56, 1.41 1.06 0.59, 1.89 
Yes 14 334 19 729 1.11 0.57, 2.15 1.16 0.52, 2.59 
Missing 3  7      Trendi     1.01 0.73, 1.41 1.05 0.72, 1.54 Burning trash or burning feces/manure         Not exposed 52 1,206 75 3,016 1.00 Referent 1.00 Referent 
No 39 1,103 51 2,078 1.18 0.76, 1.82 1.00 0.68, 1.48 
Yes 9 126 13 436 1.35 0.65, 2.83 0.87 0.30, 2.50 
Missing 4  6      Trendi     1.17 0.85, 1.60 0.97 0.67, 1.40 Exposure to paint, solvents, or petrochemical substances         Not exposed 67 1,635 89 3,416 1.00 Referent 1.00 Referent 
No 24 629 40 1,886 0.75 0.46, 1.21 0.90 0.58, 1.41 
Yes < 5 96 5 155 1.06 0.38, 2.97 0.64 0.36, 1.12 
Missing 9  11      Trendi     0.85 0.57, 1.26 0.85 0.62, 1.16 High-intensity radar waves (e.g., as radar operator, radio 
operator, aviation electrician's mate)         
Not exposed 68 1,671 95 3,807 1.00 Referent 1.00 Referent 
No 24 562 29 944 1.30 0.79, 2.14 1.32 0.85, 2.07 
Yes < 5 15 < 5 92 1.50 0.19, 11.61 3.04 0.79, 11.70 
Missing 11  19      Trendi     1.29 0.81, 2.04 1.38 0.90, 2.11 Food contaminated with smoke, oil, or other chemicals         Not exposed 79 1,973 113 4,637 1.00 Referent 1.00 Referent 
No 6 108 7 187 1.31 0.55, 3.15 0.92 0.47, 1.77 
Yes < 5 20 5 253 0.50 0.12, 2.09 0.12 0.01, 1.13 
Missing 17  20      Trendi     0.85 0.50, 1.46 0.58 0.30, 1.13 Local food other than food provided by the Armed Forces         Not exposed 47 1,094 64 2,462 1.00 Referent 1.00 Referent 
No 49 1,113 67 2,537 1.06 0.70, 1.62 0.89 0.59, 1.33 
Yes 5 167 9 467 0.74 0.28, 1.94 0.52 0.25, 1.07 
Missing 3  5      Trendi     0.97 0.70, 1.34 0.70 0.49, 1.00 
         
         
         
         
381 
   Deaths Total Adjustedc IP-weightedd 
Did you feel ill from exposure to No. PMe No. PMe HRf 95% CIf HRf 95% CIf 
Bathing in or drinking of water contaminated with smoke, oil, 
dead animals or any chemicals         
Not exposed 80 1,965 107 4,079 1.00 Referent 1.00 Referent 
No 8 107 11 348 1.12 0.52, 2.38 1.25 0.52, 3.00 
Yes < 5 15 < 5 250 0.26 0.04, 1.95 0.48 0.13, 1.73 
Missing 15  23      Trendi     0.76 0.43, 1.33 0.99 0.63, 1.54 Heat cramps, heat exhaustion, heat stroke or other heat 
illness         
Not exposed 72 1,696 100 3,915 1.00 Referent 1.00 Referent 
No 7 198 7 198 1.98 0.83, 4.71 1.62 0.92, 2.85 
Yes 23 520 34 1,400 1.08 0.66, 1.76 0.85 0.51, 1.41 
Missing 2  4      Trendi     1.06 0.84, 1.35 0.94 0.73, 1.21 Heard chemical alarms sounding         Not exposed 99 2,389 137 5,422 1.00 Referent 1.00 Referent 
No < 5 11 5 226 0.61 0.15, 2.54 0.52 0.12, 2.26 
Yes 0 0 0 0 h h h h 
Missing 3  3      Trendi     0.61 0.15, 2.54 0.86 0.27, 2.77 Explosion in the air or on the ground within one mile of you 
(e.g., artillery, rockets, mortars)         
Not exposed 23 543 36 1,575 1.00 Referent 1.00 Referent 
No 71 1,703 96 3,674 1.16 0.71, 1.89 1.03 0.63, 1.69 
Yes 6 136 8 301 2.65 0.98, 7.16 2.72 1.26, 5.88 
Missing 4  5      Trendi     1.35 0.87, 2.09 1.27 0.78, 2.07 Mixing and application of riot control substances         Not exposed 102 2,466 143 5,713 1.00 Referent 1.00 Referent 
No < 5 6 < 5 6 4.93 0.58, 41.68 3.72 1.62, 8.53 
Yes 0 0 0 0 h h h h 
Missing 1  1      Trendi     4.93 0.58, 41.68 3.72 1.66, 8.34 Exposure to riot control substances in the field         Not exposed 95 2,223 132 5,181 1.00 Referent 1.00 Referent 
No 5 147 7 307 1.00 0.40, 2.53 0.62 0.36, 1.05 
Yes < 5 102 < 5 165 0.71 0.20, 2.52 0.47 0.15, 1.44 
Missing 1  2      Trendi     0.89 0.53, 1.49 0.66 0.39, 1.12 Mixing and application of burning agents         Not exposed 89 2,168 128 5,236 1.00 Referent 1.00 Referent 
No 9 158 10 249 2.10 0.99, 4.47 1.82 1.22, 2.72 
Yes < 5 19 < 5 19 2.27 0.53, 9.84 1.56 0.98, 2.49 
Missing 4  5      Trendi     1.74 1.04, 2.93 1.54 1.15, 2.07 Exposure to burning agents in the field         Not exposed 78 1,917 109 4,396 1.00 Referent 1.00 Referent 
No 18 420 22 730 1.09 0.63, 1.89 0.85 0.54, 1.35 
Yes < 5 61 6 275 0.66 0.20, 2.12 0.10 0.01, 0.75 
Missing 5  8      Trendi         0.94 0.63, 1.40 0.65 0.40, 1.04 
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; CI, confidence interval; 
GENEVA, Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis; HR, hazard ratio; IP, inverse 
probability; U.S., United States of America; VA, Department of Veterans Affairs. 
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 aThe GENEVA study questionnaire asked "Were you deployed to..." the Vietnam War (defined as the period from August 3, 
1964, to May 7, 1975). 
bFourteen ALS cases were excluded from this analysis because (1) they were missing data on date of diagnosis (n = 7) or (2) 
they died before the interview (i.e., the interview was completed by a proxy after the case died; n = 7). 
cAdjusted for age (modeled with indicator variables corresponding to 5-year groups). 
dWeights were adjusted for age (modeled with indicator variables corresponding to 5-year groups), not missing covariate data 
(conditional on most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with 
the natural logarithm of a linear term], and time from diagnosis to enrollment in the Registry [months; modeled with a restricted, 
quadratic spline with knots at 7.72, 13.24, 23.06, and 44.19 months based on percentiles of the distribution in the Registry cases 
not missing covariate data]), and participating in GENEVA (conditional on race/ethnicity, being a current patient of a VA Medical 
Center, most recent ALS diagnosis, site of symptom onset, time from symptom onset to diagnosis [months; modeled with linear, 
quadratic, and cubic terms], time from diagnosis to enrollment in the Registry [months; modeled with a linear term], and baseline 
ALSFRS-R score [modeled with a restricted, quadratic spline with knots at 12, 34, and 44 based on percentiles of the distribution 
in GENEVA cases]). 95% CIs were calculated with robust variance estimates. 
ePerson-months calculated for time on study (i.e., the difference between the date of interview and the date of death or July 25, 
2013). 
fHRs and 95% CIs correspond to time since diagnosis accounting for late entry into the risk set at the date of interview. 
gRepeated from Appendix G, Table G.12. 
hUnable to estimate HR and 95% CI. 
iUsed ordinal scores (0, 1, 2). Reference category included for linear trend test.
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